
<html lang="en"     class="pb-page"  data-request-id="475f4d35-90bb-478a-8e69-a066e0647d79"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.1c00679;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of IACS-9779 and IACS-70465 as Potent Inhibitors Targeting Indoleamine 2,3-Dioxygenase 1 (IDO1) Apoenzyme" /></meta><meta name="dc.Creator" content="Matthew M.  Hamilton" /></meta><meta name="dc.Creator" content="Faika  Mseeh" /></meta><meta name="dc.Creator" content="Timothy J.  McAfoos" /></meta><meta name="dc.Creator" content="Paul G.  Leonard" /></meta><meta name="dc.Creator" content="Naphtali J.  Reyna" /></meta><meta name="dc.Creator" content="Angela L.  Harris" /></meta><meta name="dc.Creator" content="Alan  Xu" /></meta><meta name="dc.Creator" content="Michelle  Han" /></meta><meta name="dc.Creator" content="Michael J.  Soth" /></meta><meta name="dc.Creator" content="Barbara  Czako" /></meta><meta name="dc.Creator" content="Jay P.  Theroff" /></meta><meta name="dc.Creator" content="Pijus K.  Mandal" /></meta><meta name="dc.Creator" content="Jason P.  Burke" /></meta><meta name="dc.Creator" content="Brett  Virgin-Downey" /></meta><meta name="dc.Creator" content="Alessia  Petrocchi" /></meta><meta name="dc.Creator" content="Dana  Pfaffinger" /></meta><meta name="dc.Creator" content="Norma E.  Rogers" /></meta><meta name="dc.Creator" content="Connor A.  Parker" /></meta><meta name="dc.Creator" content="Simon S.  Yu" /></meta><meta name="dc.Creator" content="Yongying  Jiang" /></meta><meta name="dc.Creator" content="Stephan  Krapp" /></meta><meta name="dc.Creator" content="Alfred  Lammens" /></meta><meta name="dc.Creator" content="Graham  Trevitt" /></meta><meta name="dc.Creator" content="Martin R.  Tremblay" /></meta><meta name="dc.Creator" content="Keith  Mikule" /></meta><meta name="dc.Creator" content="Keith  Wilcoxen" /></meta><meta name="dc.Creator" content="Jason B.  Cross" /></meta><meta name="dc.Creator" content="Philip  Jones" /></meta><meta name="dc.Creator" content="Joseph R.  Marszalek" /></meta><meta name="dc.Creator" content="Richard T.  Lewis" /></meta><meta name="dc.Description" content="Indoleamine 2,3-dioxygenase 1 (IDO1), a heme-containing enzyme that mediates the rate-limiting step in the metabolism of l-tryptophan to kynurenine, has been widely explored as a potential immunoth..." /></meta><meta name="Description" content="Indoleamine 2,3-dioxygenase 1 (IDO1), a heme-containing enzyme that mediates the rate-limiting step in the metabolism of l-tryptophan to kynurenine, has been widely explored as a potential immunoth..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="July 22, 2021" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.1c00679" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00679" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.1c00679" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00679" /></link>
        
    
    

<title>Discovery of IACS-9779 and IACS-70465 as Potent Inhibitors Targeting Indoleamine 2,3-Dioxygenase 1 (IDO1) Apoenzyme | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.1c00679" /></meta><meta property="og:title" content="Discovery of IACS-9779 and IACS-70465 as Potent Inhibitors Targeting Indoleamine 2,3-Dioxygenase 1 (IDO1) Apoenzyme" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0029.jpeg" /></meta><meta property="og:description" content="Indoleamine 2,3-dioxygenase 1 (IDO1), a heme-containing enzyme that mediates the rate-limiting step in the metabolism of l-tryptophan to kynurenine, has been widely explored as a potential immunotherapeutic target in oncology. We developed a class of inhibitors with a conformationally constrained bicyclo[3.1.0]hexane core. These potently inhibited IDO1 in a cellular context by binding to the apoenzyme, as elucidated by biochemical characterization and X-ray crystallography. A SKOV3 tumor model was instrumental in differentiating compounds, leading to the identification of IACS-9779 (62) and IACS-70465 (71). IACS-70465 has excellent cellular potency, a robust pharmacodynamic response, and in a human whole blood assay was more potent than linrodostat (BMS-986205). IACS-9779 with a predicted human efficacious once daily dose below 1 mg/kg to sustain &gt;90% inhibition of IDO1 displayed an acceptable safety margin in rodent toxicology and dog cardiovascular studies to support advancement into preclinical safety evaluation for human development." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.1c00679"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00679">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.1c00679&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.1c00679&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.1c00679&amp;href=/doi/10.1021/acs.jmedchem.1c00679" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, XXXX</span><span class="cit-fg-issue">, XXX</span><span class="cit-fg-pageRange">, XXX-XXX</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/0/0" title="Return to Articles ASAP" id="returnToASAP" class="content-navigation__btn--return"><span>RETURN TO ARTICLES ASAP</span></a><a href="/doi/10.1021/acs.jmedchem.1c00608" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.1c00701" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of IACS-9779 and IACS-70465 as Potent Inhibitors Targeting Indoleamine 2,3-Dioxygenase 1 (IDO1) Apoenzyme</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Matthew M. Hamilton</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Matthew M. Hamilton</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">IACS (Institute for Applied Cancer Science), University of Texas, MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#8fe2e2e7eee2e6e3fbe0e1cfe2ebeee1ebeafdfce0e1a1e0fde8"><span class="__cf_email__" data-cfemail="503d3d38313d393c243f3e103d34313e343522233f3e7e3f2237">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Matthew+M.++Hamilton">Matthew M. Hamilton</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-1703-1685" title="Orcid link">https://orcid.org/0000-0002-1703-1685</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Faika Mseeh</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Faika Mseeh</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">IACS (Institute for Applied Cancer Science), University of Texas, MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Faika++Mseeh">Faika Mseeh</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Timothy J. McAfoos</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Timothy J. McAfoos</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">IACS (Institute for Applied Cancer Science), University of Texas, MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Timothy+J.++McAfoos">Timothy J. McAfoos</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Paul G. Leonard</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Paul G. Leonard</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">IACS (Institute for Applied Cancer Science), University of Texas, MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Paul+G.++Leonard">Paul G. Leonard</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Naphtali J. Reyna</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Naphtali J. Reyna</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">IACS (Institute for Applied Cancer Science), University of Texas, MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Naphtali+J.++Reyna">Naphtali J. Reyna</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Angela L. Harris</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Angela L. Harris</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">TRACTION (Translational Research to Advance Therapeutics and Innovation in Oncology), University of Texas, MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Angela+L.++Harris">Angela L. Harris</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Alan Xu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Alan Xu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">IACS (Institute for Applied Cancer Science), University of Texas, MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Alan++Xu">Alan Xu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Michelle Han</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michelle Han</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">IACS (Institute for Applied Cancer Science), University of Texas, MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michelle++Han">Michelle Han</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Michael J. Soth</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michael J. Soth</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">IACS (Institute for Applied Cancer Science), University of Texas, MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michael+J.++Soth">Michael J. Soth</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-2649-5537" title="Orcid link">https://orcid.org/0000-0002-2649-5537</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Barbara Czako</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Barbara Czako</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">IACS (Institute for Applied Cancer Science), University of Texas, MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Barbara++Czako">Barbara Czako</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-3357-7514" title="Orcid link">https://orcid.org/0000-0002-3357-7514</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jay P. Theroff</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jay P. Theroff</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">IACS (Institute for Applied Cancer Science), University of Texas, MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jay+P.++Theroff">Jay P. Theroff</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Pijus K. Mandal</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Pijus K. Mandal</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">IACS (Institute for Applied Cancer Science), University of Texas, MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Pijus+K.++Mandal">Pijus K. Mandal</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jason P. Burke</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jason P. Burke</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">IACS (Institute for Applied Cancer Science), University of Texas, MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jason+P.++Burke">Jason P. Burke</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Brett Virgin-Downey</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Brett Virgin-Downey</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">IACS (Institute for Applied Cancer Science), University of Texas, MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Brett++Virgin-Downey">Brett Virgin-Downey</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Alessia Petrocchi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Alessia Petrocchi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">IACS (Institute for Applied Cancer Science), University of Texas, MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Alessia++Petrocchi">Alessia Petrocchi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dana Pfaffinger</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dana Pfaffinger</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">IACS (Institute for Applied Cancer Science), University of Texas, MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dana++Pfaffinger">Dana Pfaffinger</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Norma E. Rogers</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Norma E. Rogers</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">IACS (Institute for Applied Cancer Science), University of Texas, MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Norma+E.++Rogers">Norma E. Rogers</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Connor A. Parker</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Connor A. Parker</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">IACS (Institute for Applied Cancer Science), University of Texas, MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Connor+A.++Parker">Connor A. Parker</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Simon S. Yu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Simon S. Yu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">IACS (Institute for Applied Cancer Science), University of Texas, MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Simon+S.++Yu">Simon S. Yu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yongying Jiang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yongying Jiang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">IACS (Institute for Applied Cancer Science), University of Texas, MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yongying++Jiang">Yongying Jiang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Stephan Krapp</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Stephan Krapp</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Proteros Biostructures GmbH, Bunsenstr. 7a, D-82152 Martinsried, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Stephan++Krapp">Stephan Krapp</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Alfred Lammens</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Alfred Lammens</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Proteros Biostructures GmbH, Bunsenstr. 7a, D-82152 Martinsried, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Alfred++Lammens">Alfred Lammens</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Graham Trevitt</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Graham Trevitt</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">XenoGesis Ltd, BioCity Nottingham, Pennyfoot Street, Nottingham, Nottinghamshire NG1 1GF, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Graham++Trevitt">Graham Trevitt</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Martin R. Tremblay</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Martin R. Tremblay</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Tesaro Inc., 1000 Winter Street, Waltham, Massachusetts 02451 United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Martin+R.++Tremblay">Martin R. Tremblay</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Keith Mikule</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Keith Mikule</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Tesaro Inc., 1000 Winter Street, Waltham, Massachusetts 02451 United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Keith++Mikule">Keith Mikule</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Keith Wilcoxen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Keith Wilcoxen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Tesaro Inc., 1000 Winter Street, Waltham, Massachusetts 02451 United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Keith++Wilcoxen">Keith Wilcoxen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jason B. Cross</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jason B. Cross</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">IACS (Institute for Applied Cancer Science), University of Texas, MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jason+B.++Cross">Jason B. Cross</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Philip Jones</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Philip Jones</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">IACS (Institute for Applied Cancer Science), University of Texas, MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Philip++Jones">Philip Jones</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Joseph R. Marszalek</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Joseph R. Marszalek</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">TRACTION (Translational Research to Advance Therapeutics and Innovation in Oncology), University of Texas, MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Joseph+R.++Marszalek">Joseph R. Marszalek</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Richard T. Lewis</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Richard T. Lewis</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">IACS (Institute for Applied Cancer Science), University of Texas, MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Richard+T.++Lewis">Richard T. Lewis</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00679&amp;href=/doi/10.1021%2Facs.jmedchem.1c00679" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, XXXX</span><span class="cit-issue">, XXX</span><span class="cit-pageRange">, XXX-XXX</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">July 22, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>13 April 2021</li><li><span class="item_label"><b>Published</b> online</span>22 July 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.1c00679" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00679</a></div><div class="article_header-article-copyright"><strong>© 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D1%26pageCount%3D28%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DMatthew%2BM.%2BHamilton%252C%2BFaika%2BMseeh%252C%2BTimothy%2BJ.%2BMcAfoos%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D0%26issueNum%3D0%26contentID%3Dacs.jmedchem.1c00679%26title%3DDiscovery%2Bof%2BIACS-9779%2Band%2BIACS-70465%2Bas%2BPotent%2BInhibitors%2BTargeting%2BIndoleamine%2B2%252C3-Dioxygenase%2B1%2B%2528IDO1%2529%2BApoenzyme%26numPages%3D28%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D28%26publicationDate%3DJuly%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.1c00679"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">384</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.1c00679" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of IACS-9779 and IACS-70465 as Potent Inhibitors Targeting Indoleamine 2,3-Dioxygenase 1 (IDO1) Apoenzyme&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Matthew&quot;,&quot;last_name&quot;:&quot;M. Hamilton&quot;},{&quot;first_name&quot;:&quot;Faika&quot;,&quot;last_name&quot;:&quot;Mseeh&quot;},{&quot;first_name&quot;:&quot;Timothy&quot;,&quot;last_name&quot;:&quot;J. McAfoos&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;G. Leonard&quot;},{&quot;first_name&quot;:&quot;Naphtali&quot;,&quot;last_name&quot;:&quot;J. Reyna&quot;},{&quot;first_name&quot;:&quot;Angela&quot;,&quot;last_name&quot;:&quot;L. Harris&quot;},{&quot;first_name&quot;:&quot;Alan&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;Michelle&quot;,&quot;last_name&quot;:&quot;Han&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;J. Soth&quot;},{&quot;first_name&quot;:&quot;Barbara&quot;,&quot;last_name&quot;:&quot;Czako&quot;},{&quot;first_name&quot;:&quot;Jay&quot;,&quot;last_name&quot;:&quot;P. Theroff&quot;},{&quot;first_name&quot;:&quot;Pijus&quot;,&quot;last_name&quot;:&quot;K. Mandal&quot;},{&quot;first_name&quot;:&quot;Jason&quot;,&quot;last_name&quot;:&quot;P. Burke&quot;},{&quot;first_name&quot;:&quot;Brett&quot;,&quot;last_name&quot;:&quot;Virgin-Downey&quot;},{&quot;first_name&quot;:&quot;Alessia&quot;,&quot;last_name&quot;:&quot;Petrocchi&quot;},{&quot;first_name&quot;:&quot;Dana&quot;,&quot;last_name&quot;:&quot;Pfaffinger&quot;},{&quot;first_name&quot;:&quot;Norma&quot;,&quot;last_name&quot;:&quot;E. Rogers&quot;},{&quot;first_name&quot;:&quot;Connor&quot;,&quot;last_name&quot;:&quot;A. Parker&quot;},{&quot;first_name&quot;:&quot;Simon&quot;,&quot;last_name&quot;:&quot;S. Yu&quot;},{&quot;first_name&quot;:&quot;Yongying&quot;,&quot;last_name&quot;:&quot;Jiang&quot;},{&quot;first_name&quot;:&quot;Stephan&quot;,&quot;last_name&quot;:&quot;Krapp&quot;},{&quot;first_name&quot;:&quot;Alfred&quot;,&quot;last_name&quot;:&quot;Lammens&quot;},{&quot;first_name&quot;:&quot;Graham&quot;,&quot;last_name&quot;:&quot;Trevitt&quot;},{&quot;first_name&quot;:&quot;Martin&quot;,&quot;last_name&quot;:&quot;R. Tremblay&quot;},{&quot;first_name&quot;:&quot;Keith&quot;,&quot;last_name&quot;:&quot;Mikule&quot;},{&quot;first_name&quot;:&quot;Keith&quot;,&quot;last_name&quot;:&quot;Wilcoxen&quot;},{&quot;first_name&quot;:&quot;Jason&quot;,&quot;last_name&quot;:&quot;B. Cross&quot;},{&quot;first_name&quot;:&quot;Philip&quot;,&quot;last_name&quot;:&quot;Jones&quot;},{&quot;first_name&quot;:&quot;Joseph&quot;,&quot;last_name&quot;:&quot;R. Marszalek&quot;},{&quot;first_name&quot;:&quot;Richard&quot;,&quot;last_name&quot;:&quot;T. Lewis&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;07&quot;,&quot;day&quot;:&quot;22&quot;,&quot;issue&quot;:&quot;0&quot;,&quot;volume&quot;:&quot;0&quot;,&quot;pages&quot;:&quot;&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.1c00679&quot;},&quot;abstract&quot;:&quot;Indoleamine 2,3-dioxygenase 1 (IDO1), a heme-containing enzyme that mediates the rate-limiting step in the metabolism of l-tryptophan to kynurenine, has been widely explored as a potential immunotherapeutic target in oncology. We developed a class of inhibitors with a conformationally constrained bicyclo[3.1.0]hexane core. These potently inhibited IDO1 in a cellular context by binding to the apoenzyme, as elucidated by biochemical characterization and X-ray crystallography. A SKOV3 tumor model was instrumental in differentiating compounds, leading to the identification of IACS-9779 (62) and IACS-70465 (71). IACS-70465 has excellent cellular potency, a robust pharmacodynamic response, and in a human whole blood assay was more potent than linrodostat (BMS-986205). IACS-9779 with a predicted human efficacious once daily dose below 1 mg/kg to sustain &gt;90% inhibition of IDO1 displayed an acceptable safety margin in rodent toxicology and dog cardiovascular studies to support advancement into preclinical safety eval&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00679&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00679" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00679&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00679" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00679&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00679" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00679&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00679&amp;href=/doi/10.1021/acs.jmedchem.1c00679" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.1c00679" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.1c00679" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00679&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.1c00679%26sid%3Dliteratum%253Aachs%26pmid%3D34292726%26genre%3Darticle%26aulast%3DHamilton%26date%3D2021%26atitle%3DDiscovery%2Bof%2BIACS-9779%2Band%2BIACS-70465%2Bas%2BPotent%2BInhibitors%2BTargeting%2BIndoleamine%2B2%252C3-Dioxygenase%2B1%2B%2528IDO1%2529%2BApoenzyme%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D0%26issue%3D0%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292460" title="Bioinorganic chemistry">Bioinorganic chemistry</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291880" title="Crystal structure">Crystal structure</a>,</li><li><a href="/action/doSearch?ConceptID=290795" title="Quinolines">Quinolines</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/0/0" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/medium/jm1c00679_0029.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00679&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Indoleamine 2,3-dioxygenase 1 (IDO1), a heme-containing enzyme that mediates the rate-limiting step in the metabolism of <span class="smallcaps smallerCapital">l</span>-tryptophan to kynurenine, has been widely explored as a potential immunotherapeutic target in oncology. We developed a class of inhibitors with a conformationally constrained bicyclo[3.1.0]hexane core. These potently inhibited IDO1 in a cellular context by binding to the apoenzyme, as elucidated by biochemical characterization and X-ray crystallography. A SKOV3 tumor model was instrumental in differentiating compounds, leading to the identification of IACS-9779 (<b>62</b>) and IACS-70465 (<b>71</b>). IACS-70465 has excellent cellular potency, a robust pharmacodynamic response, and in a human whole blood assay was more potent than linrodostat (BMS-986205). IACS-9779 with a predicted human efficacious once daily dose below 1 mg/kg to sustain >90% inhibition of IDO1 displayed an acceptable safety margin in rodent toxicology and dog cardiovascular studies to support advancement into preclinical safety evaluation for human development.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82786" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82786" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The tryptophan–kynurenine–aryl hydrocarbon receptor (Trp–KYN–AhR) pathway plays a major role in immune regulation by promoting immune tolerance via suppression of local T cell responses under physiological (e.g., maternal–fetal tolerance) and pathophysiological (e.g., tumor immune evasion) conditions.<a onclick="showRef(event, 'ref1 ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3">(1−3)</a><span class="smallcaps smallerCapital">l</span>-Tryptophan (Trp) is metabolized in a tissue-specific manner by the rate-limiting heme-containing enzymes indoleamine 2,3-dioxygenase (IDO1 and IDO2) and tryptophan 2,3-dioxygenase (TDO) to generate <i>N</i>-formylkynurenine (NFK), which is subsequently hydrolyzed to kynurenine (KYN) and formate.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> The active site heme is essential for dioxygenase activity and although these enzymes catalyze the same reaction and contain similar heme active sites, IDO and TDO are distinct enzymes sharing only 10% sequence identity.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> IDO1 has been shown to play an aberrant role in cancer development. It can be expressed by tumor cells and by myeloid cells surrounding the tumor, and IDO1 transcription in vivo is mainly regulated by interferon-γ (IFNγ).<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> IDO1-mediated Trp catabolism and KYN accumulation in the tumor microenvironment exert a profound inhibitory effect on T cells, leading to an immunosuppressive response and tumor immune evasion.<a onclick="showRef(event, 'ref3 ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref3 ref6 ref7">(3,6,7)</a> Increased levels of IDO expression in tumors have been shown to correlate with a lower presence of tumor-infiltrating lymphocytes (TILs), a high percentage of T<sub>reg</sub> cells, and a worse disease outcome.<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7,8)</a> The maintenance of an active immune response in the tumor microenvironment is expected to be an effective strategy for disease mitigation.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Tumor biology, however, is frequently adapted to exploit the control systems, which keep the immune system under control, and thereby evade surveillance and an appropriate T-cell response to the aberrant cell growth. Recent exploration of the role of IDO1 in this process has suggested activation of IDO1 as a potential means of tumor escape from a variety of cancer immunotherapy agents, including those that seek to control the PD1-PDL1 axis.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Based on these results, we and several other groups have invested significant efforts to develop IDO1 inhibitors amenable for cancer treatment.</div><div class="NLM_p">At the inception of our IDO1 inhibitor program, a survey of the literature revealed several chemical classes of disclosed IDO1 inhibitors (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a> presents a few that were of interest to us).<a onclick="showRef(event, 'ref11 ref12 ref13 ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref11 ref12 ref13 ref14 ref15">(11−15)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/medium/jm1c00679_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Known inhibitors of hIDO1.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00679&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Since then, numerous IDO1 inhibitors have been developed and evaluated preclinically, including those represented in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a> and <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>. Eight IDO1 inhibitors have entered clinical trials in combination with chemotherapeutics, checkpoint inhibitors, and vaccines.<a onclick="showRef(event, 'ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref16 ref17">(16,17)</a> Among the clinical candidates were navoximod <b>1</b> (NewLink Genetics),<a onclick="showRef(event, 'ref11 ref20'); return false;" href="javascript:void(0);" class="ref ref11 ref20">(11,20)</a> epacadostat <b>2</b> (Incyte Corp.),<a onclick="showRef(event, 'ref12 ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref12 ref18 ref19">(12,18,19)</a> PF-06840003 <b>3</b> (iTeos Therapeutics/Pfizer),<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> and linrodostat <b>6</b> (BMS-986205; Flexus Biosciences, Inc./Bristol-Myers Squibb, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).<a onclick="showRef(event, 'ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref21 ref22">(21,22)</a> Epacadostat, the most advanced compound in clinical development, showed promising anticancer activity in its early phase I/II trials, but disappointingly failed in subsequent pivotal phase III trial due to the lack of efficacy.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Consequently, 27 trials including those of the inhibitors mentioned above have been terminated, suspended, or withdrawn.<a onclick="showRef(event, 'ref16 ref23'); return false;" href="javascript:void(0);" class="ref ref16 ref23">(16,23)</a> Since the second half of 2018, several new phase I/II trials have been initiated; however, it appears that only one agent, linrodostat (BMS-986205), has entered into a phase III trial (bladder cancer).<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/medium/jm1c00679_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Apo-IDO1 inihibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00679&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/medium/jm1c00679_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Holo-IDO1 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00679&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The mechanism of action of these inhibitors on IDO1 has now been presented in multiple reports, and it has been shown that compounds can display four distinct mechanisms of binding. Type I, II, and III inhibitors bind to the holoenzyme encompassing the substrate pocket (pocket A) and pockets B and C above the heme. Type IV inhibitors bind to the apoenzyme devoid of the heme prosthetic group, still occupying pocket A and filling pocket D exposed by the absence of the heme.<a onclick="showRef(event, 'ref21 ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref21 ref24 ref25">(21,24,25)</a> For example, linrodostat <b>6</b> (BMS-986205) and similar compounds (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) have been suggested by either crystal structure, docking, or modeling to bind to the IDO1 apoenzyme and have been classified as type IV inhibitors.<a onclick="showRef(event, 'ref21 ref24 ref26 ref32 ref33 ref34 ref35 ref36 ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref21 ref24 ref26 ref32 ref33 ref34 ref35 ref36 ref37 ref38">(21,24,26,32−38)</a> These inhibitors all contain a <i>para</i>-haloaryl moiety that binds in pocket A, make a crucial hydrogen bond with Ser-167, and have a middle core that spans the space of the absent heme with an attachment to a lipophilic aryl group that binds in pocket D. Linrodostat<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> and the close analogs <b>7</b><a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> (reversed amide of linrodostat) and <b>8</b><a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> (benzimidazole isostere of linrodostat) were based on a cyclohexyl core with a direct attachment to the fluoroquinoline. Linrodostat <b>6</b> is apparently still in clinical trials<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> and the phase 1/2A trial of <b>7</b> (BMS-986242) was terminated.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Inhibitors <b>9</b> to <b>13</b> all contain the 4-halo aniline amide similar to linrodostat but with varying cores and lipophilic moieties binding in pocket D. Eli Lilly’s inhibitor <b>12</b> (LY-3391916) entered the clinic but the trial was terminated.<a onclick="showRef(event, 'ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref16 ref17">(16,17)</a></div><div class="NLM_p">Furthermore, epacadostat, and the inhibitors illustrated in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a> have been suggested to occupy the active site of the holo-IDO1 enzyme and are considered type II or III binders, depending on their preference for ferric or ferrous iron states of the heme. Specifically, compounds <b>14–17</b> have been implied to coordinate to the iron of the heme: the 3-N nitrogen of the benzimidazole of <b>14</b><a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> by docking, 7-N nitrogen of the imidazolothiazole of <b>15</b><a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> by a crystal structure, the hydroxyamidine of <b>16</b><a onclick="showRef(event, 'ref24 ref29'); return false;" href="javascript:void(0);" class="ref ref24 ref29">(24,29)</a> by modeling in epacadostat’s crystal structure, and the 1-N nitrogen of the imidazopyridine <b>17</b><a onclick="showRef(event, 'ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref30 ref31">(30,31)</a> (independently developed by our group and also by Iomet/Merck) by a crystal structure (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). Imidazopyridine <b>17</b> and the other heme-binding IDO1 compounds <b>1</b>, <b>2</b>, and <b>3</b> display inhibition of IDO1 activity in the purified IDO1 holoenzyme and in the cellular context (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/medium/jm1c00679_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Crystal structure of <b>17</b> bound to human IDO1 showing key interactions in the binding pocket (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7M7D">7M7D</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00679&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Enzymatic and Cellular IDO1 Inhibition</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">liver microsomal CI<sub>int</sub> (mL/min/kg)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">hIDO1 RFMS IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a><sup>,</sup><a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">HeLa hIDO1 IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">rat</th><th class="colsep0 rowsep0" align="center">human</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">14</td><td class="colsep0 rowsep0" align="left">210 ± 60 (3)</td><td class="colsep0 rowsep0" align="left">39</td><td class="colsep0 rowsep0" align="left">11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="left">3.5 ± 1.1 (58)</td><td class="colsep0 rowsep0" align="left">11 ± 9 (174)</td><td class="colsep0 rowsep0" align="left">32</td><td class="colsep0 rowsep0" align="left">12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="left">216 ± 79 (2)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">7.2</td><td class="colsep0 rowsep0" align="left">2.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="left">>50,000 ± 0 (2)</td><td class="colsep0 rowsep0" align="left">9.1 ± 2.2 (4)</td><td class="colsep0 rowsep0" align="left">884</td><td class="colsep0 rowsep0" align="left">681</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="left">>16,000</td><td class="colsep0 rowsep0" align="left">108 ± 12 (2)</td><td class="colsep0 rowsep0" align="left">455</td><td class="colsep0 rowsep0" align="left">44</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17R</b><a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">68 ± 7(3)</td><td class="colsep0 rowsep0" align="left">61 ± 32 (16)</td><td class="colsep0 rowsep0" align="left">37</td><td class="colsep0 rowsep0" align="left">21</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17</b></td><td class="colsep0 rowsep0" align="left">24 ± 47 (5)</td><td class="colsep0 rowsep0" align="left">26 ± 9(34)</td><td class="colsep0 rowsep0" align="left">42 ± 10 (4)</td><td class="colsep0 rowsep0" align="left">22 ± 2 (4)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18</b></td><td class="colsep0 rowsep0" align="left">>50,000</td><td class="colsep0 rowsep0" align="left">145</td><td class="colsep0 rowsep0" align="left">526</td><td class="colsep0 rowsep0" align="left">227</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19</b></td><td class="colsep0 rowsep0" align="left">>16,000</td><td class="colsep0 rowsep0" align="left">32 ± 5 (3)</td><td class="colsep0 rowsep0" align="left">170</td><td class="colsep0 rowsep0" align="left">115</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="left">>16,000</td><td class="colsep0 rowsep0" align="left">28 ± 4 (3)</td><td class="colsep0 rowsep0" align="left">137</td><td class="colsep0 rowsep0" align="left">171</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="left">>50,000</td><td class="colsep0 rowsep0" align="left">9.9 ± 2.3 (4)</td><td class="colsep0 rowsep0" align="left">956</td><td class="colsep0 rowsep0" align="left">316</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="left">>50,000</td><td class="colsep0 rowsep0" align="left">1.6 ± 0.7 (3)</td><td class="colsep0 rowsep0" align="left">14</td><td class="colsep0 rowsep0" align="left">23</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Average ± standard deviation (number of measurements).</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Enzymatic assay; RFMS, rapid-fire mass spectrometry.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a></p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">Racemate of 17.</p></div></div></div><div class="NLM_p last">At the initiation of our program to identify novel IDO1 inhibitors, the unique mechanism of the type IV inhibitors had not yet been reported. Interestingly, we noticed that compounds <b>4</b> and <b>5</b>, unlike compounds <b>1</b>, <b>2</b>, and <b>3</b> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), showed no activity against the purified IDO1 enzyme, but were potent inhibitors of IDO1 activity in the cellular context (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Herein we describe our mechanistic studies and structural biology confirming their mode of inhibition, and the drug discovery efforts to identify <b>62</b> (IACS-9779) and <b>71</b> (IACS-70465) as potent and selective inhibitors targeting the IDO1 apoenzyme.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75545" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75545" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Identification of the [3.1.0] Bicyclic Scaffold</h3><div class="NLM_p">Based on the structures of <b>4</b> and <b>5</b>, we prepared several concept compounds (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>) and in hindsight they have structural similarity to the subsequently disclosed inhibitors summarized in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>. <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> highlights their comparison to the inhibitors in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>. It was evident that <b>4</b>, <b>5</b>, and <b>18</b> suffered from metabolic instability and <b>19</b> and <b>20</b> had only a modest improvement (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Interestingly, one stereoisomer of <b>21</b> and <b>22</b> was significantly more metabolically stable. The cis isomer <b>22</b>, where the fused [3.1.0] bicyclic scaffold is forced into a boat conformation, infers that this orientation provides additional stability.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/medium/jm1c00679_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Proposed concept compounds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00679&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">We hypothesized that <b>21</b> and <b>22</b> (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) with a conformational constraint in the form of a [3.1.0] bicycle might offer a benefit, and potentially also improve the off-target pharmacology profile of these relatively lipophilic molecules by restricting the number of accessible conformations.<a onclick="showRef(event, 'ref41 ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref41 ref42 ref43">(41−43)</a> We also proposed in the concept compounds <b>21</b> and <b>22</b>, two additional changes with respect to compound <b>5</b>; reversing the amide and introducing a substituent at the methylene linker. The benzoyl amide was a logical modification to avoid potential metabolic release of 4-chloroaniline and the assessment of the potential for genotoxicity in that event.<a onclick="showRef(event, 'ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref44 ref45">(44,45)</a> The introduction of an ethyl substituent on the methylene linker was anticipated to minimize the metabolic cleavage of the amide bond by providing additional steric hindrance.<a onclick="showRef(event, 'ref46 ref47'); return false;" href="javascript:void(0);" class="ref ref46 ref47">(46,47)</a> The single-digit nM hIDO1 cellular potency and low microsomal intrinsic clearance of compound <b>22</b> were supportive of our structural modifications. This molecule was cell permeable and had a 12.8 h half-life in mouse plasma.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> Compounds <b>21</b> and <b>22</b> were used in mechanistic studies and this framework became our starting point for further optimization.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Compounds <b>21</b> and <b>22</b> Block Heme Incorporation into IDO1 Apoenzyme</h3><div class="NLM_p">The mode of inhibition of IDO1 was characterized in human HeLa cells expressing IDO1 after IFNγ induction using tool compounds <b>4</b>, <b>21</b>, <b>22</b>, and epacadostat <b>2</b>. It is well described that IDO1 expression and enzymatic activity are tightly regulated at multiple levels within the cell.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> At the transcriptional level, IDO1 expression is robustly induced in response to inflammation and infection, with IFNγ representing the most potent stimulus for IDO1 gene expression in vitro and in vivo.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> In fact, IFN-γ treatment can induce IDO1 expression in many cells.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> Catabolites of IDO1 products, such as KYN, can also promote IDO1 transcription by binding and activating the aryl hydrocarbon receptor (AhR) in a positive feedback loop. Once transcribed and translated into the IDO1 apoprotein, the heme cofactor must be incorporated to form the heme-containing holoenzyme, and activation of IDO1 requires the reduction of ferric (Fe<sup>3+</sup>) heme to the active ferrous (Fe<sup>2+</sup>) heme-IDO1 state, facilitating Trp and O<sub>2</sub> binding.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> IDO1 can be post-translationally modified by Src family kinases that phosphorylate Tyr115 and Tyr253, ultimately leading to IDO1 proteasomal degradation by associating with the suppressor of cytokine signaling 3 (SOCS3).<a onclick="showRef(event, 'ref49 ref52 ref53'); return false;" href="javascript:void(0);" class="ref ref49 ref52 ref53">(49,52,53)</a> In order to assess the effect of <b>21</b> and <b>22</b> on IDO1 transcription, translation, and degradation, we measured the endogeneous and recombinant human IDO1 activity and the protein level in cells after induction of IDO1 expression in the absence or presence of IDO1 inhibitors. Compounds <b>21</b>, <b>4</b>, and <b>2</b> inhibited IFN-γ-induced IDO1 activity without altering the IDO1 protein levels in HeLa cells (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). These results indicated these inhibitors did not modulate endogeneous IDO1 gene transcription or IDO1 protein stability.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/medium/jm1c00679_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Effect of compound treatment on cellular IDO1 activity and protein level. HeLa cells stimulated with 10 ng/mL of IFN-γ in the absence or the presence of IDO1 inhibitors (1 μM) for 24 h. IDO1 Activity (NFK_AUC) is the cellular production of NFK measured from aliquots of harvested cell conditioned media analyzed via RFMS [NFK_AUC is the area under the curve and is the integration of the total ion count peak intensities from the relative abundance of NFK in the mass spectrometry (MS) signal]. All compounds significantly (<i>p</i> < 0.01) inhibited cellular NFK production as compared to their absence. Western-blot analysis of cell lysates for expression levels of IDO1 protein (HSP90 as control). These are representative results from at least two independent test occasions performed in triplicate.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00679&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Next, we evaluated the ability of <b>22</b> to block heme incorporation into the newly expressed IDO1 apoenzyme. We hypothesized that if <b>22</b> blocked heme incorporation, induction of IDO1 expression in the presence of a compound would lead to newly synthesize IDO1 protein devoid of the heme prosthetic group, and the cell lysates would show IDO1 expression, but no IDO1 activity. In addition, we reasoned that exogeneous addition of hemin to the cell lysate would allow reconstitution of the apoenzyme into the active holoenzyme, and IDO1 activity would be restored in the cell lysate. First, we established a stable recombinant HEK293 cell line expressing tetracycline-inducible human IDO1, then we induced expression of human IDO1 in cells by doxycycline (1 μg/mL) treatment in the absence (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>A) or presence of <b>22</b> (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>B) for a period of 24 h. The cell lysates were incubated for 30 min under three different conditions: (1) the absence of hemin, (2) the presence of hemin, and (3) the presence of hemin plus <b>22</b>. We observed by Western-blot similar levels of IDO1 expression in lysates of cells induced with doxycycline in the absence or presence of <b>22</b> (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>C). The lysates from the cells induced in the absence of <b>22</b> (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>A) displayed similar activities under the three described conditions above, (condition 1 vs 2, <i>p</i> < 0.05). However, IDO1 activity was significantly lower in lysates of cells induced in the presence of <b>22</b> (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>B), but the addition of hemin to the cell lysate completely restored the IDO1 activity (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>B, condition 1 vs 2, <i>p</i> < 0.01). However, coaddition of hemin and <b>22</b> showed reduced recovery of IDO1 activity (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>B, conditions 2 vs 3, <i>p</i> < 0.01), suggesting competition between <b>22</b> and hemin for binding to the newly synthesized IDO1 apoenzyme. In summary, these results indicate that the presence of <b>22</b> during IDO1 synthesis blocked heme incorporation into the apoenzyme, addition of hemin to cell lysates containing the newly synthesized IDO1 apoenzyme can reconstitute and restore IDO1 activity, and <b>22</b> appears to compete with hemin for binding to the IDO1 apoenzyme during the holoenzyme reconstitution.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/medium/jm1c00679_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Compound <b>22</b> competes against heme incorporation into newly synthesized IDO1 protein. HEK293 cells were stimulated with doxycycline (1 ng/mL) in the absence (<b>7A</b>) or presence (<b>7B</b>) of <b>22</b> (1 μM). IDO1 activity in the cell lysates was assessed in (1) the absence of hemin (black), (2) the presence of hemin (3 μM, red), or (3) the presence of hemin (3 μM) plus <b>22</b> (1 μM) (blue). (<b>7C</b>) Western-blot analysis for IDO1 protein expression in the absence (1) or presence (2) of <b>22</b> (HSP90 as control). (<b>7D</b>) Activity of purified low heme-IDO1 in the presence of increasing concentrations of hemin and <b>22</b>. These are representative results from at least two independent test occasions performed in triplicates.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00679&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In order to further validate our hypothesis, we first purified a batch of His-tagged human IDO1 protein containing very low levels of heme incorporation (<5% heme content). Next, the activity of the low heme-IDO1 was measured in the absence or presence of increasing concentrations of hemin. Addition of hemin promoted a dose-dependent increase in low heme-IDO1 activity (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>D). Finally, we performed competition studies by assessing the hemin-dependent recovery of low heme-IDO1 activity in the presence of increasing concentrations of compound <b>22</b> (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>D). Addition of <b>22</b> inhibited the hemin-induced IDO1 activation in a dose-dependent manner, further indicating that the hemin and <b>22</b> compete for binding to the purified low-heme IDO1 enzyme.</div><div class="NLM_p">In order to directly assess the binding of <b>22</b> to IDO1 apoenzyme, we conducted thermal shift assays using the purified recombinant His-tagged low-heme human IDO1 protein (<5% heme content) in the absence or presence of IDO1 inhibitors. The thermal stability profile of the purified low heme-IDO1 protein was evaluated via differential scanning fluorimetry (DSF) methodology (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A,B), showing a melting temperature (<i>T</i><sub>m</sub>) of 55.5 °C in the absence of compound. <i>T</i><sub>m</sub> of the low heme-IDO1 protein was significantly increased in the presence of <b>22</b> (2.5 °C shift, <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>B), and as we expected, epacadostat <b>2</b> did not induce a significant increase in the low heme-IDO1 protein thermal stability (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A). It is well documented that epacadostat binds to the IDO1 holoenzyme via a key interaction with the heme cofactor.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> These results further indicate that <b>22</b>, unlike epacadostat, occupies the heme-binding site of IDO1 apoenzyme, blocks incorporation of the essential heme cofactor after IDO1 translation, and thereby inhibits IDO1 activity.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/medium/jm1c00679_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0009.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Compound <b>22</b> binds and promotes thermal stability of purified low-heme content IDO1 enzyme. (A) DSF profile of purified low heme-IDO1 protein in the presence of DMSO (control, red) or 50 μM of epacadostat (blue), displaying an unchanged <i>T</i><sub>m</sub> value of 55.5 °C under both treatment. (B) DSF profile of purified low heme-IDO1 protein in the presence of DMSO (control, red) or 50 μM of <b>22</b> (blue). IDO1 melting temperature (<i>T</i><sub>m</sub>) values showed a significant (<i>p</i> < 0.01) shift from 55.5 to 58 °C. <i>T</i><sub>m</sub> values were calculated by averaging the results from at least four independent test occasions.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00679&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> X-ray Crystallography Studies Confirmed the Binding Mode of Compound <b>22</b> to IDO1 Apoenzyme</h3><div class="NLM_p">In order to elucidate the binding mode of IDO1–inhibitor complexes, the crystal structure was determined by cocrystallization of IDO1 with <b>22</b> (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>A). Interestingly, soaking the high-heme enzyme IDO1 crystals (75% heme content) with <b>22</b> (4 mM addition of <b>22</b> to the hanging drop containing the IDO crystal) promoted a slow loss of the characteristic red coloration of the IDO1 crystals over a 24 h period at 20 °C, indicating a gradual displacement of the heme cofactor from the crystals. Unfortunately, the resulting crystals did not diffract well. Alternatively, high-heme IDO1 protein was mixed with the compound in the protein buffer and incubated overnight to allow for displacement of the heme cofactor, prior to cocrystallization of the protein with the bound inhibitor. X-ray diffraction of the crystals thus obtained showed <b>22</b> to be occupying the apoenzyme of IDO1, which implies a favorable trapping of the apoenzyme after in situ loss of the heme cofactor from the holoenzyme.</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/medium/jm1c00679_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0010.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. (A) Crystal structure of <b>22</b> bound to human IDO1 showing key interactions in the binding pocket (purple, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7B1O">7B1O</a>). (B) Crystal structure of <b>22</b> (light purple) superposed with the crystal structure of the IDO1 holoenzyme with <b>17</b> (yellow, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7M7D">7M7D</a>) with the heme (teal) depicted using a surface representation, to show the volume occupied by heme in the IDO1 holoenzyme.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00679&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A superposition of <b>22</b> overlaid with the crystal structure of <b>17</b> (previously shown to bind to the IDO1 holoenzyme, <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>) illustrates how <b>17</b> directly engages the iron of the heme, whereas <b>22</b> can only bind to the apo form of the protein (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>B), presumably by competing with the incorporation of heme. Overall, the protein fold of the apoprotein is consistent with that observed for the holoenzyme. However, we observe a difference in the conformation of Phe270 side chain, which adopts a distinct rotamer conformation that interacts with the quinoline, with the Cα proton of this phenylalanine making an arene–proton interaction with the quinoline. This quinoline moiety is projected into a largely lipophilic cavity of pocket D exposed by the absence of the heme. On the opposite face of the quinoline group, Leu342 side chain makes an additional arene–proton interaction with <b>22</b>.</div><div class="NLM_p">It is worth noting that the rotamer conformation of Phe270 that allows for this interaction with the quinoline is not accessible in the heme-bound holoenzyme as it would sterically clash with the heme cofactor. The crystal structure revealed a number of additional interactions between <b>22</b> and the apoprotein (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>A). The quinoline nitrogen makes a hydrogen bond with the side chain of Arg343 and a second direct hydrogen bond is found between the hydroxyl side chain of Ser167 and the amide N–H of the compound.</div><div class="NLM_p">The bicyclo[3.1.0]hexane scaffold occupies a hydrophobic region vacated by the displaced heme cofactor between Ala264 and Tyr126 on one side of the core scaffold and Phe214 on the other side. The axially disposed equatorial hydrogen of the  3-carbon of the bicyclo[3.1.0]hexane scaffold in a boat conformation is directed at the center of Phe214 phenyl ring, making a further arene–proton interaction between the compound and the protein. The amide linker extends into the bottom of the substrate pocket of the enzyme, with the chlorobenzene group occupying the tryptophan-binding pocket (pocket A).</div><div class="NLM_p last">The binding mode for <b>22</b> is most similar to the crystal structures reported for other type IV inhibitors: analog of linrodostat <b>6</b> (FXB-001116, BMS-116, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6AZW">6AZW</a>),<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> analog of Merck compound <b>10</b> (3-chloro-<i>N</i>-(3-{(2<i>S</i>)-1-[(4-fluorophenyl)amino]-1-oxopropan-2-yl}bicyclo[1.1.1]pentan-1-yl)benzamide, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6V52">6V52</a>),<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> and analog of Merck compound <b>9</b> (3-chloro-<i>N</i>-{4-[1-(propylcarbamoyl)cyclobutyl]phenyl}benzamide PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6WJY">6WJY</a>).<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> These molecules span between pocket A and pocket D of the IDO1 protein. The BMS-116 inhibitor in particular also has a quinoline group occupying pocket D and makes the same direct hydrogen bond interaction with Arg343 as we observed for <b>22</b>. BMS-116 has a cyclohexane core with a nitrogen linkage to the quinoline that occupies a similar part of the pocket to our bicyclo[3.1.0]hexane core. In pocket A, BMS-116 has a 4-cyanophenyl group, which overlaps with the chlorobenzene in <b>22</b> and although the amide in the linker is reversed, the amide still makes a hydrogen bond interaction with Ser167. The X-ray structure confirms that <b>22</b> binds to the apoenzyme form of IDO1.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Metabolic Stability of <b>22</b></h3><div class="NLM_p">The metabolic profile of <b>22</b>, characterized in mouse, rat, and human liver microsomes, indicated that the main metabolite observed was N-oxidation of the quinoline moiety. The crystal structure of <b>22</b> reveals potential space in the pocket D region of the protein, available in the vicinity of the quinoline moiety to accommodate substituents on the benzo-fused ring. <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> summarizes the SAR investigated to improve the metabolic stability. The fluoro substituent at the 6-position <b>24</b> resulted in an unmeasurably low-intrinsic liver microsomal clearance, ameliorating the susceptibility of the quinoline nitrogen toward N-oxidation. Interestingly, placement of fluorine at the 7 position, of the quinoline, <b>28</b>, was somewhat less impactful on metabolic stability. As with compounds <b>21</b> and <b>22</b>, there was a distinct difference between the diastereoisomers with respect to their potency and microsomal stability.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Quinoline Ether Exploration</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/medium/jm1c00679_0023.gif" alt="" id="GRAPHIC-d7e1586-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="bottom" class="colsep0"><th class="colsep0 rowsep0" align="center" valign="bottom">compound</th><th class="colsep0 rowsep0" align="center" valign="bottom">(<b>3</b>)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" valign="bottom">(<b>6</b>)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" valign="bottom">X</th><th class="colsep0 rowsep0" align="center" valign="bottom">R<sub>1</sub></th><th class="colsep0 rowsep0" align="center" valign="bottom">R<sub>2</sub></th><th class="colsep0 rowsep0" align="center" valign="bottom">HeLa hIDO1 IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" valign="bottom">HLM<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a> CLint (mL/min/kg)</th><th class="colsep0 rowsep0" align="center" valign="bottom">CYP 3A4<sub>m</sub><a class="ref internalNav" href="#t2fn4" aria-label="d">d</a>; IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" valign="bottom">clog <i>P</i></th><th class="colsep0 rowsep0" align="center" valign="bottom">hPPB (%)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a>,<a class="ref internalNav" href="#t2fn5" aria-label="e">e</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="left">e</td><td class="colsep0 rowsep0" align="left">e</td><td class="colsep0 rowsep0" align="left">C</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">9.9 ± 2.3 (4)</td><td class="colsep0 rowsep0" align="left">316</td><td class="colsep0 rowsep0" align="left">1.1 ± 0.4 (2)</td><td class="colsep0 rowsep0" align="left">5.03</td><td class="colsep0 rowsep0" align="left">99.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="left">a</td><td class="colsep0 rowsep0" align="left">e</td><td class="colsep0 rowsep0" align="left">C</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">1.6 ± 0.7 (3)</td><td class="colsep0 rowsep0" align="left">23</td><td class="colsep0 rowsep0" align="left">3.3 ± 0.02 (2)</td><td class="colsep0 rowsep0" align="left">5.03</td><td class="colsep0 rowsep0" align="left">99.7 ± 0.2 (3)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23</b></td><td class="colsep0 rowsep0" align="left">e</td><td class="colsep0 rowsep0" align="left">e</td><td class="colsep0 rowsep0" align="left">C</td><td class="colsep0 rowsep0" align="left">6-F</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">6.1 ± 1.1 (4)</td><td class="colsep0 rowsep0" align="left">493</td><td class="colsep0 rowsep0" align="left">1.4</td><td class="colsep0 rowsep0" align="left">5.17</td><td class="colsep0 rowsep0" align="left">99.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24</b></td><td class="colsep0 rowsep0" align="left">a</td><td class="colsep0 rowsep0" align="left">e</td><td class="colsep0 rowsep0" align="left">C</td><td class="colsep0 rowsep0" align="left">6-F</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">1 ± 0.3 (3)</td><td class="colsep0 rowsep0" align="left">0</td><td class="colsep0 rowsep0" align="left">>5 ± 0 (2)</td><td class="colsep0 rowsep0" align="left">5.17</td><td class="colsep0 rowsep0" align="left">100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25</b></td><td class="colsep0 rowsep0" align="left">e</td><td class="colsep0 rowsep0" align="left">e</td><td class="colsep0 rowsep0" align="left">C</td><td class="colsep0 rowsep0" align="left">6-F</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">334 ± 0 (1)</td><td class="colsep0 rowsep0" align="left">227</td><td class="colsep0 rowsep0" align="left">2.1</td><td class="colsep0 rowsep0" align="left">4.24</td><td class="colsep0 rowsep0" align="left">99.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>26</b></td><td class="colsep0 rowsep0" align="left">a</td><td class="colsep0 rowsep0" align="left">a</td><td class="colsep0 rowsep0" align="left">C</td><td class="colsep0 rowsep0" align="left">6-F</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">14 ± 3 (2)</td><td class="colsep0 rowsep0" align="left">38</td><td class="colsep0 rowsep0" align="left">1.9</td><td class="colsep0 rowsep0" align="left">4.24</td><td class="colsep0 rowsep0" align="left">99.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27</b></td><td class="colsep0 rowsep0" align="left">a</td><td class="colsep0 rowsep0" align="left">e</td><td class="colsep0 rowsep0" align="left">C</td><td class="colsep0 rowsep0" align="left">6-F</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">4.2 ± 1.1 (3)</td><td class="colsep0 rowsep0" align="left">39</td><td class="colsep0 rowsep0" align="left">6.7 ± 0.8 (2)</td><td class="colsep0 rowsep0" align="left">4.24</td><td class="colsep0 rowsep0" align="left">100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>28</b></td><td class="colsep0 rowsep0" align="left">a</td><td class="colsep0 rowsep0" align="left">e</td><td class="colsep0 rowsep0" align="left">C</td><td class="colsep0 rowsep0" align="left">7-F</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">1.4</td><td class="colsep0 rowsep0" align="left">32</td><td class="colsep0 rowsep0" align="left">5.4</td><td class="colsep0 rowsep0" align="left">5.17</td><td class="colsep0 rowsep0" align="left">100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>29</b></td><td class="colsep0 rowsep0" align="left">a</td><td class="colsep0 rowsep0" align="left">e</td><td class="colsep0 rowsep0" align="left">5-N</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">18 ± 6 (5)</td><td class="colsep0 rowsep0" align="left">14</td><td class="colsep0 rowsep0" align="left">13</td><td class="colsep0 rowsep0" align="left">4.20</td><td class="colsep0 rowsep0" align="left">95</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>30</b></td><td class="colsep0 rowsep0" align="left">a</td><td class="colsep0 rowsep0" align="left">e</td><td class="colsep0 rowsep0" align="left">6-N</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">23</td><td class="colsep0 rowsep0" align="left">54</td><td class="colsep0 rowsep0" align="left">18</td><td class="colsep0 rowsep0" align="left">3.81</td><td class="colsep0 rowsep0" align="left">98.9</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">The orientation [equatorial (e) or axial (a)] of the substituents at the 3- and 6-positions of the bicycle core.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">Average ± standard deviation (number of measurements).</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last">HLM, human liver microsomes.</p></div><div class="footnote" id="t2fn4"><sup><sup>d</sup></sup><p class="last">Midazolam was the probe substrate for this assay.</p></div><div class="footnote" id="t2fn5"><sup><sup>e</sup></sup><p class="last">Human plasma protein binding.</p></div></div></div><div class="NLM_p last">Apparent from the crystal structure of <b>22</b>, the bicyclo[3.1.0]hexane system is constrained in a pseudoboat conformation. The placement of the quinolinoxy substituent in the axial position appears to be the preferred binding geometry for the apoenzyme. The diastereoisomers represented by <b>21</b> and <b>23</b> with the quinolinoxy disposed pseudoequatorially are still accommodated, albeit with a 5-fold loss of potency. Fortunately, the more potent isomer is also the more metabolically stable. Removal of the ethyl substituent resulted in a loss of metabolic stability (<b>27</b> vs <b>24</b> and <b>25</b> vs <b>23</b>, <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Despite the lower clog <i>P</i>, the removal did not afford a measurable change in plasma protein binding and also resulted in a reduction in potency. Compound <b>24</b> was well absorbed with a long half-life and good bioavailability when orally dosed to mice at 10 mg/kg (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>), but the clog <i>P</i> and plasma-protein binding were very high. The protein binding was modulated by lowering the clog <i>P</i> via the incorporation of an additional nitrogen (<b>29</b> or <b>30</b>, <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>), but the cost was a 10-fold loss in potency compared to <b>22</b>.</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Species Differences within the IDO1 Binding Pocket</h3><div class="NLM_p">Despite the good pharmacokinetic (PK) and human IDO1 potency of <b>24</b>, the physical properties of the quinoline series were less than desirable (hPPB 100% and clog <i>P</i> 5.17). To evaluate other promising compounds in vivo, we initially used the murine CT26 syngeneic mouse model similar to that used for the evaluation of epacadostat <b>2</b>.<a onclick="showRef(event, 'ref54 ref55'); return false;" href="javascript:void(0);" class="ref ref54 ref55">(54,55)</a> When comparing <b>2</b>, our type III inhibitor <b>17</b> and a representative type IV inhibitor <b>31</b> (analog with improved hPPB, <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>, PK <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>) in the model, we obtained the expected results with <b>2</b> and <b>17</b> [10% ± 7% (<i>n</i> = 10) KYN % of vehicle control, for both compounds]; however, we observed not only a significant variation in KYN levels in the vehicle-treated cohort [11 ± 7 μM (<i>n</i> = 65)] but <b>31</b> [53% ± 31% (<i>n</i> = 8) KYN % of vehicle control] and other compounds did not perform nearly as well as <b>2</b> and <b>17</b>. Our concern was the challenge to deliver a sufficient concentration of unbound drug to the tumor tissue to cover the murine IC<sub>90</sub> due to not only the high protein binding of this class of compounds but also the significant shift in IDO1 potency we observed between our murine PANC02 (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>) and human HeLa cellular assays.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> In our effort to find an alternative replacement for the quinoline or quinazoline, we also considered moieties that possessed a lower species shift in potency.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Diverse Set of IDO1 Inhibitors and Their Species Shift</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/medium/jm1c00679_0025.gif" alt="" id="GRAPHIC-d7e2062-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char="±">HeLa hIDO1 IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">PANCO<sub>2</sub> mIDO1 IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">species shift<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">HLM<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a> CLint (mL/min/kg)</th><th class="colsep0 rowsep0" align="center">CYP 3A4<sub>m</sub><a class="ref internalNav" href="#t3fn4" aria-label="d">d</a>; IC<sub>50</sub>(μM)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">clog <i>P</i></th><th class="colsep0 rowsep0" align="center">hPPB (%)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a><sup>,</sup><a class="ref internalNav" href="#t3fn5" aria-label="e">e</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="char" char="±">11 ± 9 (174)</td><td class="colsep0 rowsep0" align="left">74 ± 30 (56)</td><td class="colsep0 rowsep0" align="char" char=".">7</td><td class="colsep0 rowsep0" align="char" char=".">12</td><td class="colsep0 rowsep0" align="left">28 ± 5 (6)</td><td class="colsep0 rowsep0" align="left">0.02</td><td class="colsep0 rowsep0" align="left">97.2 ± 0.1 (3)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23</b></td><td class="colsep0 rowsep0" align="char" char="±">6.1 ± 1.1 (4)</td><td class="colsep0 rowsep0" align="left">76</td><td class="colsep0 rowsep0" align="char" char=".">12</td><td class="colsep0 rowsep0" align="char" char=".">490</td><td class="colsep0 rowsep0" align="left">1.4</td><td class="colsep0 rowsep0" align="left">5.17</td><td class="colsep0 rowsep0" align="left">99.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>29</b></td><td class="colsep0 rowsep0" align="char" char="±">18 ± 6 (5)</td><td class="colsep0 rowsep0" align="left">1200</td><td class="colsep0 rowsep0" align="char" char=".">69</td><td class="colsep0 rowsep0" align="char" char=".">14</td><td class="colsep0 rowsep0" align="left">13</td><td class="colsep0 rowsep0" align="left">4.20</td><td class="colsep0 rowsep0" align="left">95</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31</b></td><td class="colsep0 rowsep0" align="char" char="±">6.9 ± 2.2 (6)</td><td class="colsep0 rowsep0" align="left">2200</td><td class="colsep0 rowsep0" align="char" char=".">320</td><td class="colsep0 rowsep0" align="char" char=".">17</td><td class="colsep0 rowsep0" align="left">>17</td><td class="colsep0 rowsep0" align="left">3.79</td><td class="colsep0 rowsep0" align="left">98.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32</b></td><td class="colsep0 rowsep0" align="char" char="±">6.2 ± 2 (3)</td><td class="colsep0 rowsep0" align="left">1300</td><td class="colsep0 rowsep0" align="char" char=".">210</td><td class="colsep0 rowsep0" align="char" char=".">13</td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">3.03</td><td class="colsep0 rowsep0" align="left">95.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33</b></td><td class="colsep0 rowsep0" align="char" char="±">8.4 ± 1.5 (6)</td><td class="colsep0 rowsep0" align="left">570 ± 48 (2)</td><td class="colsep0 rowsep0" align="char" char=".">68</td><td class="colsep0 rowsep0" align="char" char=".">0.7</td><td class="colsep0 rowsep0" align="left">>17</td><td class="colsep0 rowsep0" align="left">4.15</td><td class="colsep0 rowsep0" align="left">96.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>34</b></td><td class="colsep0 rowsep0" align="char" char="±">19 ± 8 (8)</td><td class="colsep0 rowsep0" align="left">106 ± 18 (2)</td><td class="colsep0 rowsep0" align="char" char=".">6</td><td class="colsep0 rowsep0" align="char" char=".">6.5</td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">3.99</td><td class="colsep0 rowsep0" align="left">95.4 ± 2.8 (1)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>35</b></td><td class="colsep0 rowsep0" align="char" char="±">69 ± 12 (2)</td><td class="colsep0 rowsep0" align="left">230</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char=".">2.0</td><td class="colsep0 rowsep0" align="left">31</td><td class="colsep0 rowsep0" align="left">3.81</td><td class="colsep0 rowsep0" align="left">91.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>38</b></td><td class="colsep0 rowsep0" align="char" char="±">2.6 ± 2.2 (10)</td><td class="colsep0 rowsep0" align="left">23 ± 21 (3)</td><td class="colsep0 rowsep0" align="char" char=".">9</td><td class="colsep0 rowsep0" align="char" char=".">8.3</td><td class="colsep0 rowsep0" align="left">1.3</td><td class="colsep0 rowsep0" align="left">4.68</td><td class="colsep0 rowsep0" align="left">99.4</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Average ± standard deviation (number of measurements).</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">Ratio of PANCO IC<sub>50</sub>/HeLa IC<sub>50</sub>.</p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last">HLM, human liver microsomes.</p></div><div class="footnote" id="t3fn4"><sup><sup>d</sup></sup><p class="last">Midazolam was the probe substrate for this assay.</p></div><div class="footnote" id="t3fn5"><sup><sup>e</sup></sup><p class="last">Human plasma protein binding.</p></div></div></div><div class="NLM_p">Sequence comparison between human and mouse IDO1 proteins identified several amino acid differences in the compound binding site. In order to understand and potentially predict shifts of compound potency across species, the amino acid sequence of the human IDO1 protein was aligned with those of other species (see <a href="/doi/suppl/10.1021/acs.jmedchem.1c00679/suppl_file/jm1c00679_si_001.pdf" class="ext-link">Supporting Information</a>, Table S6) and a homology model was constructed. The residues (Y126, V130, S167, and F163; key interactions from the X-ray crystal structure) that line the indole-binding pocket of the natural substrate, tryptophan, are conserved across species, including S167, which forms a hydrogen bond with the amide NH of <b>22</b>. However, we observed side chain variations across species in the vicinity of the heme-binding pocket, where the quinoline moiety of <b>22</b> binds (pocket D). The human to mouse sequence changes were: V269I, F273L, and L342V resulting in a distinct binding pocket in the murine enzyme.</div><div class="NLM_p">To assess the impact of IDO1 amino acid sequence differences across species on inhibitor potency, we screened compounds against the PANC02 murine cell line in comparison to the HeLa human cell line assay. The results for a representative group of molecules are presented in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>. These hydrophobic steric changes in the vicinity of the compound-binding site resulted in sensitivity to the substitution pattern of the moiety occupying pocket D. The human IDO1 tolerated a diversity of substituents; however, the mouse protein was significantly more sensitive. From this exploration, <b>38</b> (benzimidazole) and <b>34</b> (triazole) had the best overall balance of potency, ancillary pharmacology, and species shifts that were deemed manageable from a translational perspective. Of the two compounds, <b>38</b> had better mouse PK (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). Initial SAR of the benzimidazole series is presented in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Mouse PK Profile of the Selected Compounds</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">PK parameter<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char="±"><b>24</b></th><th class="colsep0 rowsep0" align="center" char="±"><b>31</b></th><th class="colsep0 rowsep0" align="center" char="±"><b>34</b></th><th class="colsep0 rowsep0" align="center" char="±"><b>38</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CI (L/h/kg)<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="±">0.014 ± 0.002</td><td class="colsep0 rowsep0" align="char" char="±">0.007 ± 0.001</td><td class="colsep0 rowsep0" align="char" char="±">0.28 ± 0.05</td><td class="colsep0 rowsep0" align="char" char="±">0.15 ± 0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>V</i><sub>ss</sub><a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="±">0.27 ± 001</td><td class="colsep0 rowsep0" align="char" char="±">0.31 ± 0.04</td><td class="colsep0 rowsep0" align="char" char="±">1.04 ± 0.10</td><td class="colsep0 rowsep0" align="char" char="±">0.8 ± 0.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>1/2</sub> (terminal h)<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="±">15 ± 3</td><td class="colsep0 rowsep0" align="char" char="±">33 ± 12</td><td class="colsep0 rowsep0" align="char" char="±">2.7 ± 0.7</td><td class="colsep0 rowsep0" align="char" char="±">3.9 ± 1.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>Inf</sub> (h·μM)<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="±">51 ± 7</td><td class="colsep0 rowsep0" align="char" char="±">106 ± 25</td><td class="colsep0 rowsep0" align="char" char="±">2.8 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">4.9 ± 0.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (μM)<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char="±">51 ± 4</td><td class="colsep0 rowsep0" align="char" char="±">44 ± 3</td><td class="colsep0 rowsep0" align="char" char="±">1.5 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">19.0 ± 0.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>F</i> (%)</td><td class="colsep0 rowsep0" align="char" char="±">146 ± 81</td><td class="colsep0 rowsep0" align="char" char="±">62 ± 4</td><td class="colsep0 rowsep0" align="char" char="±">22 ± 17</td><td class="colsep0 rowsep0" align="char" char="±">127 ± 10</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Each dose done in triplicate.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">IV (0.3mpk).</p></div><div class="footnote" id="t4fn3"><sup><sup>c</sup></sup><p class="last">po (10 mpk).</p></div></div></div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Initial Benzimidazole Series SAR</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/medium/jm1c00679_0026.gif" alt="" id="GRAPHIC-d7e2537-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center">X</th><th class="colsep0 rowsep0" align="center">HeLa hIDO1 IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">PANCO<sub>2</sub> mIDO1 IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">HLM<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a> CLint (mL/min/kg)</th><th class="colsep0 rowsep0" align="center">CYP 2C9 IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">hERG (FP)<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a> IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">hERG safety margin<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center" char=".">clog <i>P</i></th><th class="colsep0 rowsep0" align="center" char=".">hPPB (%)<a class="ref internalNav" href="#t5fn5" aria-label="e">e</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>36</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">C</td><td class="colsep0 rowsep0" align="left">6.3 ± 2 (4)</td><td class="colsep0 rowsep0" align="left">108</td><td class="colsep0 rowsep0" align="char" char=".">13.5</td><td class="colsep0 rowsep0" align="left">7.8</td><td class="colsep0 rowsep0" align="char" char=".">0.78</td><td class="colsep0 rowsep0" align="char" char=".">120</td><td class="colsep0 rowsep0" align="char" char=".">4.54</td><td class="colsep0 rowsep0" align="char" char=".">98</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>37</b></td><td class="colsep0 rowsep0" align="left">4-F</td><td class="colsep0 rowsep0" align="left">C</td><td class="colsep0 rowsep0" align="left">7.0 ± 1 (5)</td><td class="colsep0 rowsep0" align="left">134 ± 31 (2)</td><td class="colsep0 rowsep0" align="char" char=".">19</td><td class="colsep0 rowsep0" align="left">3.9</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">140</td><td class="colsep0 rowsep0" align="char" char=".">4.68</td><td class="colsep0 rowsep0" align="char" char=".">99</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>38</b></td><td class="colsep0 rowsep0" align="left">5-F</td><td class="colsep0 rowsep0" align="left">C</td><td class="colsep0 rowsep0" align="left">2.6 ± 2.2 (10)</td><td class="colsep0 rowsep0" align="left">23 ± 21 (3)</td><td class="colsep0 rowsep0" align="char" char=".">8.3</td><td class="colsep0 rowsep0" align="left">0.71</td><td class="colsep0 rowsep0" align="char" char=".">0.18</td><td class="colsep0 rowsep0" align="char" char=".">69</td><td class="colsep0 rowsep0" align="char" char=".">4.68</td><td class="colsep0 rowsep0" align="char" char=".">99.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>39</b></td><td class="colsep0 rowsep0" align="left">6-F</td><td class="colsep0 rowsep0" align="left">C</td><td class="colsep0 rowsep0" align="left">3.8 ± 0.4 (8)</td><td class="colsep0 rowsep0" align="left">23 ± 4 (4)</td><td class="colsep0 rowsep0" align="char" char=".">11.8</td><td class="colsep0 rowsep0" align="left">4.2</td><td class="colsep0 rowsep0" align="char" char=".">5.4</td><td class="colsep0 rowsep0" align="char" char=".">1400</td><td class="colsep0 rowsep0" align="char" char=".">4.68</td><td class="colsep0 rowsep0" align="char" char=".">98.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>40</b></td><td class="colsep0 rowsep0" align="left">7-F</td><td class="colsep0 rowsep0" align="left">C</td><td class="colsep0 rowsep0" align="left">5.2 ± 0.6 (3)</td><td class="colsep0 rowsep0" align="left">97</td><td class="colsep0 rowsep0" align="char" char=".">16.3</td><td class="colsep0 rowsep0" align="left">2.1</td><td class="colsep0 rowsep0" align="char" char=".">2.1</td><td class="colsep0 rowsep0" align="char" char=".">400</td><td class="colsep0 rowsep0" align="char" char=".">4.68</td><td class="colsep0 rowsep0" align="char" char=".">99.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>41</b></td><td class="colsep0 rowsep0" align="left">5-CN</td><td class="colsep0 rowsep0" align="left">C</td><td class="colsep0 rowsep0" align="left">73 ± 14 (2)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">5.5</td><td class="colsep0 rowsep0" align="left">4.6</td><td class="colsep0 rowsep0" align="char" char=".">0.15</td><td class="colsep0 rowsep0" align="char" char=".">2.1</td><td class="colsep0 rowsep0" align="char" char=".">4.4</td><td class="colsep0 rowsep0" align="char" char=".">99.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>42</b></td><td class="colsep0 rowsep0" align="left">4,6-F<sub>2</sub></td><td class="colsep0 rowsep0" align="left">C</td><td class="colsep0 rowsep0" align="left">7 ± 0.9 (4)</td><td class="colsep0 rowsep0" align="left">65</td><td class="colsep0 rowsep0" align="char" char=".">6.6</td><td class="colsep0 rowsep0" align="left">3.06 ± 0.01 (2)</td><td class="colsep0 rowsep0" align="char" char=".">1.9</td><td class="colsep0 rowsep0" align="char" char=".">270</td><td class="colsep0 rowsep0" align="char" char=".">4.83</td><td class="colsep0 rowsep0" align="char" char=".">99.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>43</b></td><td class="colsep0 rowsep0" align="left">5,7-F<sub>2</sub></td><td class="colsep0 rowsep0" align="left">C</td><td class="colsep0 rowsep0" align="left">6.2 ± 2.4 (2)</td><td class="colsep0 rowsep0" align="left">67</td><td class="colsep0 rowsep0" align="char" char=".">5.5</td><td class="colsep0 rowsep0" align="left">1.6 ± 0.2 (2)</td><td class="colsep0 rowsep0" align="char" char=".">0.57</td><td class="colsep0 rowsep0" align="char" char=".">92</td><td class="colsep0 rowsep0" align="char" char=".">4.83</td><td class="colsep0 rowsep0" align="char" char=".">99.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44</b></td><td class="colsep0 rowsep0" align="left">6,7-F<sub>2</sub></td><td class="colsep0 rowsep0" align="left">C</td><td class="colsep0 rowsep0" align="left">4 ± 0.8 (4)</td><td class="colsep0 rowsep0" align="left">45 ± 20 (2)</td><td class="colsep0 rowsep0" align="char" char=".">18</td><td class="colsep0 rowsep0" align="left">1.9 ± 0.1 (2)</td><td class="colsep0 rowsep0" align="char" char=".">5.4</td><td class="colsep0 rowsep0" align="char" char=".">1400</td><td class="colsep0 rowsep0" align="char" char=".">4.83</td><td class="colsep0 rowsep0" align="char" char=".">99.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>45</b></td><td class="colsep0 rowsep0" align="left">5,6-F<sub>2</sub></td><td class="colsep0 rowsep0" align="left">C</td><td class="colsep0 rowsep0" align="left">4.6 ± 2.9 (4)</td><td class="colsep0 rowsep0" align="left">20 ± 8 (2)</td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="left">2.2 ± 0.2 (2)</td><td class="colsep0 rowsep0" align="char" char=".">5.0</td><td class="colsep0 rowsep0" align="char" char=".">110</td><td class="colsep0 rowsep0" align="char" char=".">4.83</td><td class="colsep0 rowsep0" align="char" char=".">99.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>46</b></td><td class="colsep0 rowsep0" align="left">5,6-CI<sub>2</sub></td><td class="colsep0 rowsep0" align="left">C</td><td class="colsep0 rowsep0" align="left">12 ± 4.8 (9)</td><td class="colsep0 rowsep0" align="left">72 ± 24 (4)</td><td class="colsep0 rowsep0" align="char" char=".">3.8</td><td class="colsep0 rowsep0" align="left">2.1 ± 0.3 (2)</td><td class="colsep0 rowsep0" align="char" char=".">9.6</td><td class="colsep0 rowsep0" align="char" char=".">800</td><td class="colsep0 rowsep0" align="char" char=".">5.75</td><td class="colsep0 rowsep0" align="char" char=".">100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>47</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">4-N</td><td class="colsep0 rowsep0" align="left">68</td><td class="colsep0 rowsep0" align="left">1024</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="left">8.0<a class="ref internalNav" href="#t5fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">3.65</td><td class="colsep0 rowsep0" align="char" char=".">91.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>48</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">5-N</td><td class="colsep0 rowsep0" align="left">22 ± 2.8 (5)</td><td class="colsep0 rowsep0" align="left">240</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left">0.18</td><td class="colsep0 rowsep0" align="char" char=".">0.059</td><td class="colsep0 rowsep0" align="char" char=".">2.7</td><td class="colsep0 rowsep0" align="char" char=".">3.32</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>49</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">6-N</td><td class="colsep0 rowsep0" align="left">30 ± 3.1 (3)</td><td class="colsep0 rowsep0" align="left">1824</td><td class="colsep0 rowsep0" align="char" char=".">8.8</td><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="char" char=".">1.2</td><td class="colsep0 rowsep0" align="char" char=".">40</td><td class="colsep0 rowsep0" align="char" char=".">3.32</td><td class="colsep0 rowsep0" align="char" char=".">96.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>50</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">7-N</td><td class="colsep0 rowsep0" align="left">33</td><td class="colsep0 rowsep0" align="left">236</td><td class="colsep0 rowsep0" align="char" char=".">16</td><td class="colsep0 rowsep0" align="left">5.1</td><td class="colsep0 rowsep0" align="char" char=".">11</td><td class="colsep0 rowsep0" align="char" char=".">330</td><td class="colsep0 rowsep0" align="char" char=".">3.69</td><td class="colsep0 rowsep0" align="char" char=".">96.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>51</b></td><td class="colsep0 rowsep0" align="left">5-F</td><td class="colsep0 rowsep0" align="left">7-N</td><td class="colsep0 rowsep0" align="left">19 ± 11 (4)</td><td class="colsep0 rowsep0" align="left">194 ± 5 (2)</td><td class="colsep0 rowsep0" align="char" char=".">0.46</td><td class="colsep0 rowsep0" align="left">2.7 ± 0.2 (2)</td><td class="colsep0 rowsep0" align="char" char=".">2.1</td><td class="colsep0 rowsep0" align="char" char=".">110</td><td class="colsep0 rowsep0" align="char" char=".">3.83</td><td class="colsep0 rowsep0" align="char" char=".">65.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>52</b></td><td class="colsep0 rowsep0" align="left">5-CN</td><td class="colsep0 rowsep0" align="left">7-N</td><td class="colsep0 rowsep0" align="left">343 ± 52 (2)</td><td class="colsep0 rowsep0" align="left">1573</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="left">>30 ± 0 (2)</td><td class="colsep0 rowsep0" align="char" char=".">0.69</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">3.55</td><td class="colsep0 rowsep0" align="char" char=".">99.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>53</b></td><td class="colsep0 rowsep0" align="left">6-CN</td><td class="colsep0 rowsep0" align="left">4-N</td><td class="colsep0 rowsep0" align="left">357 ± 13 (2)</td><td class="colsep0 rowsep0" align="left">1837</td><td class="colsep0 rowsep0" align="char" char=".">4.5</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="char" char=".">5.2</td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">3.51</td><td class="colsep0 rowsep0" align="char" char=".">96.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>54</b></td><td class="colsep0 rowsep0" align="left">5,6-F<sub>2</sub></td><td class="colsep0 rowsep0" align="left">C</td><td class="colsep0 rowsep0" align="left">19 ± 3 (2)</td><td class="colsep0 rowsep0" align="left">33 ± 2 (2)</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="left">6.2</td><td class="colsep0 rowsep0" align="char" char=".">4.8</td><td class="colsep0 rowsep0" align="char" char=".">250</td><td class="colsep0 rowsep0" align="char" char=".">3.89</td><td class="colsep0 rowsep0" align="char" char=".">99.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>55</b></td><td class="colsep0 rowsep0" align="left">5,6-F<sub>2</sub></td><td class="colsep0 rowsep0" align="left">C</td><td class="colsep0 rowsep0" align="left">471</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="left">4.3</td><td class="colsep0 rowsep0" align="char" char=".">0.46</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">5.39</td><td class="colsep0 rowsep0" align="char" char=".">99.8</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">Average ± standard deviation (number of measurements).</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">HLM, human liver microsomes.</p></div><div class="footnote" id="t5fn3"><sup><sup>c</sup></sup><p class="last">(FP), hERG florescence polarization assay.</p></div><div class="footnote" id="t5fn4"><sup><sup>d</sup></sup><p class="last">Safety margin is the ratio of hERG (FP) IC<sub>50</sub>/HeLa IC<sub>50</sub>.</p></div><div class="footnote" id="t5fn5"><sup><sup>e</sup></sup><p class="last">Human plasma protein binding.</p></div><div class="footnote" id="t5fn6"><sup><sup>f</sup></sup><p class="last">Compound 35 also had CYP 2d6 = 0.20 μM.</p></div></div></div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Initial SAR of the Benzimidazole Series</h3><div class="NLM_p">The benzimidazole series was further optimized for metabolic stability and its ancillary pharmacology profile, in particular the safety margin between hERG and HeLa potencies. The inhibition of the hERG (human ether-a-go-go gene) potassium channel is associated with QT interval prolongation (measured on an electrocardiogram, ECG) and the potentially lethal ventricular tachycardia torsades de pointes (TdP).<a onclick="showRef(event, 'ref57 ref58'); return false;" href="javascript:void(0);" class="ref ref57 ref58">(57,58)</a> The safety margin determined by the ratio of the hERG IC<sub>50</sub> to the Hela IC<sub>50</sub> was used as a comparator to rank order compounds for further evaluation.<a onclick="showRef(event, 'ref59 ref60 ref61'); return false;" href="javascript:void(0);" class="ref ref59 ref60 ref61">(59−61)</a> Initially, activity against hERG was assessed using a fluorescence polarization-binding assay (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>), and subsequent electrophysiological readouts of hERG channel function were measured for key compounds via Q-Patch and Manual Patch clamp assays (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>).</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Benzimidazole Selection</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/medium/jm1c00679_0027.gif" alt="" id="GRAPHIC-d7e3225-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">R<sub>1</sub></th><th class="colsep0 rowsep0" align="center">R<sub>2</sub><a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">R<sub>3</sub></th><th class="colsep0 rowsep0" align="center">HeLa hIDO1 IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">hERG (FP)<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a><sup>,</sup><a class="ref internalNav" href="#t6fn3" aria-label="c">c</a> IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">hERG (QP)<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a><sup>,</sup><a class="ref internalNav" href="#t6fn4" aria-label="d">d</a> IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">hERG (MP)<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a><sup>,</sup><a class="ref internalNav" href="#t6fn5" aria-label="e">e</a> IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">hERG safety margin<a class="ref internalNav" href="#t6fn6" aria-label="f">f</a></th><th class="colsep0 rowsep0" align="center">hPPB (%)<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a><sup>,</sup><a class="ref internalNav" href="#t6fn7" aria-label="g">g</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>56</b></td><td class="colsep0 rowsep0" align="left">6-F</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">4-CI</td><td class="colsep0 rowsep0" align="left">2.8 ± 1.1 (2)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">9.9</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">99.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>39A</b></td><td class="colsep0 rowsep0" align="left">6-F</td><td class="colsep0 rowsep0" align="left">Et(R)</td><td class="colsep0 rowsep0" align="left">4-CI</td><td class="colsep0 rowsep0" align="left">2.2</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>39B</b></td><td class="colsep0 rowsep0" align="left">6-F</td><td class="colsep0 rowsep0" align="left">Et(S)</td><td class="colsep0 rowsep0" align="left">4-CI</td><td class="colsep0 rowsep0" align="left">8.4 ± 1.9 (8)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">14</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">99.2 ± 0.1 (2)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>57</b></td><td class="colsep0 rowsep0" align="left">6-F, 2-Me</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">4-CI</td><td class="colsep0 rowsep0" align="left">9.2 ± 2.8 (4)</td><td class="colsep0 rowsep0" align="left">2.05 ± 0.01 (2)</td><td class="colsep0 rowsep0" align="left">21</td><td class="colsep0 rowsep0" align="left">1.1<a class="ref internalNav" href="#t6fn8" aria-label="h">h</a></td><td class="colsep0 rowsep0" align="left">120</td><td class="colsep0 rowsep0" align="left">99.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>58</b></td><td class="colsep0 rowsep0" align="left">6-CI</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">4-CI</td><td class="colsep0 rowsep0" align="left">3.4 ± 0.3 (2)</td><td class="colsep0 rowsep0" align="left">2.3</td><td class="colsep0 rowsep0" align="left">>30 ± 0 (2)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">99.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>59</b></td><td class="colsep0 rowsep0" align="left">6-CN</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">4-CI</td><td class="colsep0 rowsep0" align="left">8.8 ± 1.9 (4)</td><td class="colsep0 rowsep0" align="left">5.3</td><td class="colsep0 rowsep0" align="left">5.6</td><td class="colsep0 rowsep0" align="left">1.1<a class="ref internalNav" href="#t6fn8" aria-label="h">h</a></td><td class="colsep0 rowsep0" align="left">120</td><td class="colsep0 rowsep0" align="left">98.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>60</b></td><td class="colsep0 rowsep0" align="left">6-CI</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">4-CN</td><td class="colsep0 rowsep0" align="left">52 ± 13 (2)</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">2.1</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">98.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>61</b></td><td class="colsep0 rowsep0" align="left">6-CN</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">4-CN</td><td class="colsep0 rowsep0" align="left">35 ± 5.8 (2)</td><td class="colsep0 rowsep0" align="left">1.2</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">96.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>62</b></td><td class="colsep0 rowsep0" align="left">5,6 F<sub>2</sub></td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">4-CI</td><td class="colsep0 rowsep0" align="left">1.7 ± 0.6 (20)</td><td class="colsep0 rowsep0" align="left">2.4 ± 0.3 (3)</td><td class="colsep0 rowsep0" align="left">11</td><td class="colsep0 rowsep0" align="left">0.79 ± 0.22 (3)<a class="ref internalNav" href="#t6fn9" aria-label="i">i</a></td><td class="colsep0 rowsep0" align="left">470</td><td class="colsep0 rowsep0" align="left">99.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>63</b></td><td class="colsep0 rowsep0" align="left">5,6 F<sub>2</sub></td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">3-F, 4-CI</td><td class="colsep0 rowsep0" align="left">3.9 ± 1.6 (4)</td><td class="colsep0 rowsep0" align="left">2.5</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">0.95</td><td class="colsep0 rowsep0" align="left">240</td><td class="colsep0 rowsep0" align="left">99.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>64</b></td><td class="colsep0 rowsep0" align="left">5,6 F<sub>2</sub></td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">4-CN</td><td class="colsep0 rowsep0" align="left">4.4 ± 1.2 (10)</td><td class="colsep0 rowsep0" align="left">1.1</td><td class="colsep0 rowsep0" align="left">1.4</td><td class="colsep0 rowsep0" align="left">0.43<a class="ref internalNav" href="#t6fn7" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="left">96.6 ± 0.2 (2)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>65</b></td><td class="colsep0 rowsep0" align="left">5,6 F<sub>2</sub></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">4-CI</td><td class="colsep0 rowsep0" align="left">5.3 ± 1.2 (8)</td><td class="colsep0 rowsep0" align="left">0.52 ± 0.03 (2)</td><td class="colsep0 rowsep0" align="left">>30</td><td class="colsep0 rowsep0" align="left">0.53 ± 0.29 (2)<a class="ref internalNav" href="#t6fn8" aria-label="h">h</a><sup>,</sup><a class="ref internalNav" href="#t6fn9" aria-label="i">i</a></td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="left">99.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>66</b></td><td class="colsep0 rowsep0" align="left">5,6 F<sub>2</sub></td><td class="colsep0 rowsep0" align="left">Me<sub>2</sub><a class="ref internalNav" href="#t6fn10" aria-label="j">j</a></td><td class="colsep0 rowsep0" align="left">4-CI</td><td class="colsep0 rowsep0" align="left">8.3 ± 0.89 (4)</td><td class="colsep0 rowsep0" align="left">1.6 ± 0.6 (2)</td><td class="colsep0 rowsep0" align="left">12</td><td class="colsep0 rowsep0" align="left">1.4<a class="ref internalNav" href="#t6fn8" aria-label="h">h</a></td><td class="colsep0 rowsep0" align="left">260</td><td class="colsep0 rowsep0" align="left">99.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>67</b></td><td class="colsep0 rowsep0" align="left">5,6 F<sub>2</sub></td><td class="colsep0 rowsep0" align="left">cProp</td><td class="colsep0 rowsep0" align="left">4-CI</td><td class="colsep0 rowsep0" align="left">3.6 ± 0.72 (4)</td><td class="colsep0 rowsep0" align="left">0.56</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">99.2 ± 0.2 (2)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>68</b></td><td class="colsep0 rowsep0" align="left">5,6 F<sub>2</sub></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">4-CN</td><td class="colsep0 rowsep0" align="left">33 ± 6.2 (6)</td><td class="colsep0 rowsep0" align="left">1.3</td><td class="colsep0 rowsep0" align="left">0.74</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">94.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>69</b></td><td class="colsep0 rowsep0" align="left">5,6 F<sub>2</sub></td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">426 ± 144 (2)</td><td class="colsep0 rowsep0" align="left">48</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">86.1</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">R<sub>2</sub> enantiomer chirally synthesized, (R) (S) designation assigned from potency.</p></div><div class="footnote" id="t6fn2"><sup><sup>b</sup></sup><p class="last">Average ± standard deviation (number of measurements).</p></div><div class="footnote" id="t6fn3"><sup><sup>c</sup></sup><p class="last">(FP) fluorescence polarization. hERG-binding assay.</p></div><div class="footnote" id="t6fn4"><sup><sup>d</sup></sup><p class="last">(QP) Q-patch electrophysiology hERG assay.</p></div><div class="footnote" id="t6fn5"><sup><sup>e</sup></sup><p class="last">(MP) manual patch clamp hERG assay.</p></div><div class="footnote" id="t6fn6"><sup><sup>f</sup></sup><p class="last">Safety margin is the ratio of hERG (MP)/HeLa.</p></div><div class="footnote" id="t6fn7"><sup><sup>g</sup></sup><p class="last">Human plasma protein binding.</p></div><div class="footnote" id="t6fn8"><sup><sup>h</sup></sup><p class="last">Precipitation at 30 μM.</p></div><div class="footnote" id="t6fn9"><sup><sup>i</sup></sup><p class="last">Precipitation at 10 and 30 μM.</p></div><div class="footnote" id="t6fn10"><sup><sup>j</sup></sup><p class="last">Gem dimethyl.</p></div></div></div><div class="NLM_p last">The unsubstituted benzimidazole <b>36</b> with a hERG safety margin of 120 was the starting point for this series (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). Of the single substituents, a fluorine at the 6 position <b>39</b> had the best hERG safety margin and also conferred an improved CYP 2C9 inhibition profile (CYP 3A4 midazolam and testosterone substrates and 2D6 were also monitored but 2C9 was usually the most sensitive unless noted). Furthermore, the 6,7 and the 5,6 difluoro substitutions (<b>44</b> and <b>45</b>) significantly improved the hERG safety margin. Plasma protein binding was reduced by lowering the clog <i>P</i> via the incorporation of an additional nitrogen into the ring between the 4–7 positions to afford the corresponding imidazopyridines. However, those substitutions also reduced the hIDO1 potency. A range of additional analogs were explored but offered no substantial improvements. The ethyl substitution was removed in <b>54</b>, which reduced the clog <i>P</i> an order of magnitude but did not lower the PPB nor the hERG and also resulted in a 4-fold reduction of the hIDO1potency.</div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Benzimidazole Selection by SKOV3</h3><div class="NLM_p">In order to progress the benzimidazole series, it was necessary to confirm target engagement (TE) in vivo. The CT26 syngeneic tumor model described earlier was replaced with the SKOV3 model (a human tumor xenograft, which naturally expresses high levels of hIDO1 endogenously). This model offered a better signal to noise ratio with less interanimal variability, and allowed the measurement of TE against the more therapeutically relevant human IDO1 sequence. The in vivo experiments were designed to measure only TE and not inhibition of tumor growth, due to the absence of an innate immune system.<a onclick="showRef(event, 'ref62 ref63'); return false;" href="javascript:void(0);" class="ref ref62 ref63">(62,63)</a> This model, of necessity, does not have an intact immune system, which mechanistically, is absolutely required in order to observe an immune-mediated antitumor response. Hence tumor growth inhibition or regression was not an expected outcome in this model following intervention via the IDO mechanism. Tumor TE was assessed by measuring KYN concentrations in tumor samples collected after oral compound administration [per os (po)] to mice. The percent of vehicle control of tumor KYN production was used as a pharmacodynamic (PD) biomarker of IDO1 inhibition, and epacadostat <b>2</b> was used as a benchmark. TE was assessed after compound treatment (po, 125 mg/kg, QD 5 days, tumor collected 24 h after last dose) relative to a vehicle-dosed control cohort (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>).</div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/medium/jm1c00679_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0011.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. In vivo modulation of tumor KYN production after compound administration (po) using SKOV3 xenograft mouse model. Compounds were dosed as follows: (a) 125 mg/kg, po, QD, 5 days, tumor collected 4 h after last dose; (b) 125 mg/kg, po, QD, 5 days, tumor collected 24 h after last dose; (c) 3 mg/kg, po, tumor collected 24 h after single dose; (d) 50 mg/kg, po, tumor collected 24 h after single dose; (e) 125 mg/kg, po, BID, 5 days, tumor collected 24 h after last dose. Each symbol represents an individual animal, and at least five vehicle-treated animals per study was used as control. Tumor samples were harvested at 4 or 24 h after last dose for KYN quantification. For each study, the average of tumor KYN concentration in the vehicle control was used to calculate the percent inhibition of IDO1 in treated animals. Means ± standard error of the mean (SEM) are represented. po (oral administration); QD (once daily dose). Statistical <i>t</i>-test was performed and there was no statistical difference between <b>6(b)</b> and <b>62(a)</b>, <b>62(b)</b> and <b>71(c)</b> but there was between <b>6(b)</b> and <b>71(d)</b>, <i>p</i> = 0.012.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00679&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">From the initial benzimidazole SAR (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>), monosubstitutions at the 6 position and disubstitutions at the 5,6 position were chosen for further exploration. The racemic 6-fluoro <b>39</b> was separated by chiral SFC. The more potent enantiomer (<b>39A</b>, <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>) was confirmed as the R configuration based on its chiral synthesis (<b>56</b>, described in the chemistry section). Additional compounds were resynthesized homochirally as the R enantiomer. The hERG safety margin was also calculated using the hERG manual patch clamp data. Within the monofluoro- and cyano-substituted benzimidazoles (<b>56–61</b>), 6-CN <b>59</b> was the only compound that exhibited good TE but the hERG safety margin was low compared to the disubstituted benzimidazoles (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Tables <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a>, <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>).</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Benzimidazole Selection, SKOV3 TE</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char="±">tumor [compound] (μM)<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char="±">plasma [compound] (μM)<a class="ref internalNav" href="#t7fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">mPPB (%)<a class="ref internalNav" href="#t7fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center" char="±">HeLa hIDO1 IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t7fn5" aria-label="e">e</a></th><th class="colsep0 rowsep0" align="center" char="±">tumor TE (%)<a class="ref internalNav" href="#t7fn6" aria-label="f">f</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="char" char="±">3.2 ± 0.7 (4)</td><td class="colsep0 rowsep0" align="char" char="±">0.1 ± 0.1 (4)</td><td class="colsep0 rowsep0" align="left">96.4</td><td class="colsep0 rowsep0" align="char" char="±">11 ± 9 (174)</td><td class="colsep0 rowsep0" align="char" char="±">32 ± 5 (4)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="char" char="±">0.9 ± 0.5 (8)</td><td class="colsep0 rowsep0" align="char" char="±">0.02 ± 0.01 (8)</td><td class="colsep0 rowsep0" align="left">99.1</td><td class="colsep0 rowsep0" align="char" char="±">0.42 ± 0.11 (19)</td><td class="colsep0 rowsep0" align="char" char="±">25 ± 5 (7)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17</b></td><td class="colsep0 rowsep0" align="char" char="±">0.7 ± 0.1 (4)</td><td class="colsep0 rowsep0" align="char" char="±">0.1 ± 0 (4)</td><td class="colsep0 rowsep0" align="left">93.8 ± 1.9 (3)</td><td class="colsep0 rowsep0" align="char" char="±">26 ± 8 (34)</td><td class="colsep0 rowsep0" align="char" char="±">86 ± 10 (4)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>56(a)</b></td><td class="colsep0 rowsep0" align="char" char="±">2.3 ± 0.7 (3)</td><td class="colsep0 rowsep0" align="char" char="±">0.6 ± 0.4 (3)</td><td class="colsep0 rowsep0" align="left">99.5</td><td class="colsep0 rowsep0" align="char" char="±">2.8 ± 1.1 (2)</td><td class="colsep0 rowsep0" align="char" char="±">83 ± 23 (3)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>57(b)</b></td><td class="colsep0 rowsep0" align="char" char="±">0.1 ± 0.1 (4)</td><td class="colsep0 rowsep0" align="char" char="±">0.01 ± 0 (1)</td><td class="colsep0 rowsep0" align="left">99.2</td><td class="colsep0 rowsep0" align="char" char="±">9.2 ± 2.8 (4)</td><td class="colsep0 rowsep0" align="char" char="±">102 ± 10 (4)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>58(b)</b></td><td class="colsep0 rowsep0" align="char" char="±">0.6 ± 0.5 (6)</td><td class="colsep0 rowsep0" align="char" char="±">0.5 ± 0.2 (6)</td><td class="colsep0 rowsep0" align="left">99.2</td><td class="colsep0 rowsep0" align="char" char="±">3.4 ± 0.3 (2)</td><td class="colsep0 rowsep0" align="char" char="±">70 ± 7 (6)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>59(b)</b></td><td class="colsep0 rowsep0" align="char" char="±">12 ± 3 (4)</td><td class="colsep0 rowsep0" align="char" char="±">10.1 ± 3 (4)</td><td class="colsep0 rowsep0" align="left">98.7</td><td class="colsep0 rowsep0" align="char" char="±">8.8 ± 1.9 (4)</td><td class="colsep0 rowsep0" align="char" char="±">19 ± 4 (4)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>62(a)</b></td><td class="colsep0 rowsep0" align="char" char="±">32 ± 12 (6)</td><td class="colsep0 rowsep0" align="char" char="±">35 ± 9.2 (6)</td><td class="colsep0 rowsep0" align="left">99.3</td><td class="colsep0 rowsep0" align="char" char="±">1.7 ± 0.6 (20)</td><td class="colsep0 rowsep0" align="char" char="±">11 ± 4 (6)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>62(b)</b></td><td class="colsep0 rowsep0" align="char" char="±">3.4 ± 3 (9)</td><td class="colsep0 rowsep0" align="char" char="±">1.4 ± 1.5 (9)</td><td class="colsep0 rowsep0" align="left">99.3</td><td class="colsep0 rowsep0" align="char" char="±">1.7 ± 0.6 (20)</td><td class="colsep0 rowsep0" align="char" char="±">18 ± 3 (7)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>63(b)</b></td><td class="colsep0 rowsep0" align="char" char="±">11 ± 6 (4)</td><td class="colsep0 rowsep0" align="char" char="±">4.1 ± 1.2 (4)</td><td class="colsep0 rowsep0" align="left">99</td><td class="colsep0 rowsep0" align="char" char="±">3.9 ± 1.6 (4)</td><td class="colsep0 rowsep0" align="char" char="±">10 ± 2 (4)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>64(a)</b></td><td class="colsep0 rowsep0" align="char" char="±">52 ± 16 (3)</td><td class="colsep0 rowsep0" align="char" char="±">49.3 ± 6.6 (3)</td><td class="colsep0 rowsep0" align="left">97.1</td><td class="colsep0 rowsep0" align="char" char="±">4.4 ± 1.2 (10)</td><td class="colsep0 rowsep0" align="char" char="±">6 ± 2 (3)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>65(b)</b></td><td class="colsep0 rowsep0" align="char" char="±">5.1 ± 2.5 (6)</td><td class="colsep0 rowsep0" align="char" char="±">2.8 ± 1.6 (6)</td><td class="colsep0 rowsep0" align="left">98.9</td><td class="colsep0 rowsep0" align="char" char="±">5.3 ± 1.2 (8)</td><td class="colsep0 rowsep0" align="char" char="±">26 ± 4 (6)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>70(b)</b></td><td class="colsep0 rowsep0" align="char" char="±">2.1 ± 2.3 (6)</td><td class="colsep0 rowsep0" align="char" char="±">0.3 ± 0.1 (6)</td><td class="colsep0 rowsep0" align="left">99.01</td><td class="colsep0 rowsep0" align="char" char="±">0.69 ± 0.16 (11)</td><td class="colsep0 rowsep0" align="char" char="±">21 ± 3 (6)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>71(c)</b></td><td class="colsep0 rowsep0" align="char" char="±">0.5 ± 0 (4)</td><td class="colsep0 rowsep0" align="char" char="±">0.06 ± 0.02 (4)</td><td class="colsep0 rowsep0" align="left">99.01</td><td class="colsep0 rowsep0" align="char" char="±">0.60 ± 0.06 (6)</td><td class="colsep0 rowsep0" align="char" char="±">33 ± 4 (4)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>71(d)</b></td><td class="colsep0 rowsep0" align="char" char="±">0.7 ± 0.2 (7)</td><td class="colsep0 rowsep0" align="char" char="±">1.9 ± 1.1 (7)</td><td class="colsep0 rowsep0" align="left">99.01</td><td class="colsep0 rowsep0" align="char" char="±">0.60 ± 0.06 (6)</td><td class="colsep0 rowsep0" align="char" char="±">9 ± 1 (7)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>72(c)</b></td><td class="colsep0 rowsep0" align="char" char="±">0.5 ± 0.1 (4)</td><td class="colsep0 rowsep0" align="char" char="±">0.01 ± 0.004 (4)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="±">0.92 ± 0.24 (6)</td><td class="colsep0 rowsep0" align="char" char="±">102 ± 3 (4)</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last">Description (a–e) in <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>.</p></div><div class="footnote" id="t7fn2"><sup><sup>b</sup></sup><p class="last">Compound concentration in tumor [average ± standard deviation (<i>n</i>)].</p></div><div class="footnote" id="t7fn3"><sup><sup>c</sup></sup><p class="last">Compound concentration in plasma [average ±standard deviation (<i>n</i>)].</p></div><div class="footnote" id="t7fn4"><sup><sup>d</sup></sup><p class="last">Mouse plasma protein binding [average ±standard deviation (<i>n</i>)].</p></div><div class="footnote" id="t7fn5"><sup><sup>e</sup></sup><p class="last">Average ± standard deviation (<i>n</i>).</p></div><div class="footnote" id="t7fn6"><sup><sup>f</sup></sup><p class="last">TE in tumor [% of vehicle control ± SEM, (<i>n</i>)].</p></div></div></div><div class="NLM_p">The 5,6-difluorobenzimidazole <b>45</b> (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>) was synthesized homochirally (<b>62</b>) (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>), had the best safety margin, and in the SKOV3 model, it displayed robust TE from good tumor exposure (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>, <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>). However, the hERG activity was still a potential concern and other modifications were explored. Addition of a 3-fluoro (<b>63</b>), replacement of the 4-chloro with a 4-nitrile (<b>64</b>), and the ethyl (R<sub>2</sub>) truncated to a methyl (<b>65</b>) resulted in molecules with excellent TE (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>, <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>), but none of these molecules offered any advantage or an increase in the safety margin over <b>62</b> (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). Other modifications including the R<sub>2</sub> gem-dimethyl (<b>66</b>), R<sub>2</sub> cyclopropyl (<b>67</b>), combination of the R<sub>2</sub> methyl with the 4-nitrile (<b>68</b>), and the phenyl replaced with a propellane (<b>69</b>) lack optimal safety margins or the potency (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>).</div><div class="NLM_p">Considering our crystal structures of <b>22</b> and <b>17</b>, it was apparent that the hydrogen bond to the Ser-167 was significant. We postulated that the difference in the HeLa potency between <b>62</b> and <b>6</b> might be due to our reversal of the amide bond and by switching it back we may improve the potency and the hERG safety margin. To do this, we considered the very close analog <b>65</b>. Q-patch hERG data for <b>65</b> indicated an apparently improved margin. Hence, the reverse amide of <b>65</b> was synthesized, compound <b>70</b> (<a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>). After the fact, we received the manual patch clamp data for <b>62</b> and <b>65</b> and the compounds were actually very similar. Compound <b>70</b> (IACS-70099) had improved PK exposure over <b>62</b> (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>), robust TE (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>), potency less than 1 nM (<i>n</i> of 11), and despite the similar hERG potencies, the improved HeLa potency increased the safety margin (<a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>) compared to <b>62</b>. It is interesting to note that the decrease in potency of the amide-reversed <b>65</b> compared to <b>70</b> was not observed for <b>7</b> (BMS-986242), the corresponding matched analog of linrodostat <b>6</b>, both of which were reported as equipotent (2 nM).<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a></div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Lead-Optimized Compounds</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/medium/jm1c00679_0028.gif" alt="" id="GRAPHIC-d7e4409-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">whole blood<a class="ref internalNav" href="#t8fn12" aria-label="l">l</a></th><th class="rowsep1 colsep0" colspan="2" align="center">SKOV3 PK/PD<a class="ref internalNav" href="#t8fn13" aria-label="m">m</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">HeLa hIDO1 IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">PANCO<sub>2</sub> mIDO1 IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">HLM<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a> CI<sub>int</sub> (mL/min/kg)</th><th class="colsep0 rowsep0" align="center">CYP 2C9 IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">hERG (FP)<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a><sup>,</sup><a class="ref internalNav" href="#t8fn3" aria-label="c">c</a> IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">hERG (QP)<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a><sup>,</sup><a class="ref internalNav" href="#t8fn4" aria-label="d">d</a> IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">hERG (MP)<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a><sup>,</sup><a class="ref internalNav" href="#t8fn5" aria-label="e">e</a> IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">hERG safety margin<a class="ref internalNav" href="#t8fn6" aria-label="f">f</a></th><th class="colsep0 rowsep0" align="center">hPPB (%)<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a><sup>,</sup><a class="ref internalNav" href="#t8fn7" aria-label="g">g</a></th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub></th><th class="colsep0 rowsep0" align="center">IC<sub>90</sub></th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub></th><th class="colsep0 rowsep0" align="center">IC<sub>90</sub></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="left">11 ± 9 (174)</td><td class="colsep0 rowsep0" align="left">74 ± 30 (56)</td><td class="colsep0 rowsep0" align="char" char=".">12</td><td class="colsep0 rowsep0" align="left">7.8 ± 2 (5)</td><td class="colsep0 rowsep0" align="left">>36 ± 0 (4)<a class="ref internalNav" href="#t8fn11" aria-label="k">k</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">3300</td><td class="colsep0 rowsep0" align="left">97.2 ± 0.1 (3)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left">0.42 ± 0.11 (19)</td><td class="colsep0 rowsep0" align="left">1.6 ± 0.5 (13)</td><td class="colsep0 rowsep0" align="char" char=".">28</td><td class="colsep0 rowsep0" align="left">1.4</td><td class="colsep0 rowsep0" align="left">4.2 ± 1.3 (3)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">2.4<a class="ref internalNav" href="#t8fn8" aria-label="h">h</a></td><td class="colsep0 rowsep0" align="left">6400</td><td class="colsep0 rowsep0" align="left">100.0</td><td class="colsep0 rowsep0" align="left">26</td><td class="colsep0 rowsep0" align="left">260</td><td class="colsep0 rowsep0" align="left">5.8</td><td class="colsep0 rowsep0" align="left">52</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17</b></td><td class="colsep0 rowsep0" align="left">26 ± 8 (34)</td><td class="colsep0 rowsep0" align="left">23 ± 7 (20)</td><td class="colsep0 rowsep0" align="char" char=".">22</td><td class="colsep0 rowsep0" align="left">23 ± 6 (6)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">>30 ± 0 (2)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">>1200</td><td class="colsep0 rowsep0" align="left">91.6 ± 0.7 (4)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>62</b></td><td class="colsep0 rowsep0" align="left">1.7 ± 0.6 (20)</td><td class="colsep0 rowsep0" align="left">14 ± 5 (11)</td><td class="colsep0 rowsep0" align="char" char=".">8.5</td><td class="colsep0 rowsep0" align="left">1.8 ± 0.6 (2)</td><td class="colsep0 rowsep0" align="left">2.4 ± 0.3 (3)</td><td class="colsep0 rowsep0" align="left">11</td><td class="colsep0 rowsep0" align="left">0.79 ± 0.22 (3)<a class="ref internalNav" href="#t8fn8" aria-label="h">h</a></td><td class="colsep0 rowsep0" align="left">465</td><td class="colsep0 rowsep0" align="left">99.4</td><td class="colsep0 rowsep0" align="left">116</td><td class="colsep0 rowsep0" align="left">1047</td><td class="colsep0 rowsep0" align="left">166</td><td class="colsep0 rowsep0" align="left">1497</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>70</b></td><td class="colsep0 rowsep0" align="left">0.69 ± 0.16 (11)</td><td class="colsep0 rowsep0" align="left">1.0 ± 0.2 (11)</td><td class="colsep0 rowsep0" align="char" char=".">19</td><td class="colsep0 rowsep0" align="left">1.9</td><td class="colsep0 rowsep0" align="left">3.6 ± 0.8 (2)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">1.0<a class="ref internalNav" href="#t8fn9" aria-label="i">i</a></td><td class="colsep0 rowsep0" align="left">1400</td><td class="colsep0 rowsep0" align="left">99.0</td><td class="colsep0 rowsep0" align="left">46</td><td class="colsep0 rowsep0" align="left">411</td><td class="colsep0 rowsep0" align="left">85</td><td class="colsep0 rowsep0" align="left">762</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>71</b></td><td class="colsep0 rowsep0" align="left">0.60 ± 0.06 (6)</td><td class="colsep0 rowsep0" align="left">2.0 ± 0.2 (2)</td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="left">6.2</td><td class="colsep0 rowsep0" align="left">>44 ± 0 (4)<a class="ref internalNav" href="#t8fn10" aria-label="j">j</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">>3<a class="ref internalNav" href="#t8fn8" aria-label="h">h</a></td><td class="colsep0 rowsep0" align="left">>5000</td><td class="colsep0 rowsep0" align="left">99.0</td><td class="colsep0 rowsep0" align="left">14</td><td class="colsep0 rowsep0" align="left">124</td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="left">228</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>72</b></td><td class="colsep0 rowsep0" align="left">0.92 ± 0.24 (6)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">17</td><td class="colsep0 rowsep0" align="left">0.91</td><td class="colsep0 rowsep0" align="left">1.0</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">1100</td><td class="colsep0 rowsep0" align="left">99.97</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup><sup>a</sup></sup><p class="last">Average ± standard deviation (number of measurements).</p></div><div class="footnote" id="t8fn2"><sup><sup>b</sup></sup><p class="last">Human liver microsomes.</p></div><div class="footnote" id="t8fn3"><sup><sup>c</sup></sup><p class="last">(FP) fluorescence polarization hERG-binding assay.</p></div><div class="footnote" id="t8fn4"><sup><sup>d</sup></sup><p class="last">(QP) Q-patch electrophysiology hERG assay.</p></div><div class="footnote" id="t8fn5"><sup><sup>e</sup></sup><p class="last">(MP) manual patch clamp hERG assay, each dose <i>n</i> ≥ 2 current measurements.</p></div><div class="footnote" id="t8fn6"><sup><sup>f</sup></sup><p class="last">Safety margin is the ratio of hERG (MP) or available hERG data/HeLa IC<sub>50</sub>.</p></div><div class="footnote" id="t8fn7"><sup><sup>g</sup></sup><p class="last">Human plasma protein binding.</p></div><div class="footnote" id="t8fn8"><sup><sup>h</sup></sup><p class="last">Precipitation observed at 10 and 30 μM.</p></div><div class="footnote" id="t8fn9"><sup><sup>i</sup></sup><p class="last">Precipitation observed at 30 μM.</p></div><div class="footnote" id="t8fn10"><sup><sup>j</sup></sup><p class="last">Four measurements, two at 44 and two at >44 μM.</p></div><div class="footnote" id="t8fn11"><sup><sup>k</sup></sup><p class="last">Four measurements, two at 36 and two at >36 μM.</p></div><div class="footnote" id="t8fn12"><sup><sup>l</sup></sup><p class="last">Human whole blood assay data from <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>.</p></div><div class="footnote" id="t8fn13"><sup><sup>m</sup></sup><p class="last">SKOV3 PK/PD data from <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>.</p></div></div></div><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. Mouse PK Profile of the Selected Compounds</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">PK parameter<a class="ref internalNav" href="#t9fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char="±"><b>2</b></th><th class="colsep0 rowsep0" align="center" char="±"><b>6</b></th><th class="colsep0 rowsep0" align="center" char="±"><b>17</b></th><th class="colsep0 rowsep0" align="center" char="±"><b>62</b></th><th class="colsep0 rowsep0" align="center" char="±"><b>70</b></th><th class="colsep0 rowsep0" align="center" char="±"><b>71</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Cl (L/h/Kg)<a class="ref internalNav" href="#t9fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="±">3.2 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="±">2.0 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="±">1.4 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="±">1.04 ± 0.09</td><td class="colsep0 rowsep0" align="char" char="±">0.45 ± 0.02</td><td class="colsep0 rowsep0" align="char" char="±">0.21 ± 0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>V</i><sub>ss</sub><a class="ref internalNav" href="#t9fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="±">7.5 ± 0.9</td><td class="colsep0 rowsep0" align="char" char="±">4.5 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">2.1 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="±">3.1 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="±">1.61 ± 0.07</td><td class="colsep0 rowsep0" align="char" char="±">1.55 ± 0.02</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>1/2</sub> (terminal h)<a class="ref internalNav" href="#t9fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="±">1.6 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">1.57 ± 0.05</td><td class="colsep0 rowsep0" align="char" char="±">0.848 ± 0.05</td><td class="colsep0 rowsep0" align="char" char="±">2.1 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="±">2.49 ± 0.07</td><td class="colsep0 rowsep0" align="char" char="±">5.3 ± 0.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>Inf</sub> (h·μM)<a class="ref internalNav" href="#t9fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="±">0.21 ± 0.01</td><td class="colsep0 rowsep0" align="char" char="±">0.37 ± 0.03</td><td class="colsep0 rowsep0" align="char" char="±">0.45 ± 0..07</td><td class="colsep0 rowsep0" align="char" char="±">0.67 ± 0.06</td><td class="colsep0 rowsep0" align="char" char="±">1.61 ± 0.09</td><td class="colsep0 rowsep0" align="char" char="±">3.3 ± 0.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (μM)<a class="ref internalNav" href="#t9fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char="±">2 ± 2</td><td class="colsep0 rowsep0" align="char" char="±">4.1 ± 0.1</td><td class="colsep0 rowsep0" align="char" char="±">7 ± 2</td><td class="colsep0 rowsep0" align="char" char="±">1.5 ± 0.1</td><td class="colsep0 rowsep0" align="char" char="±">8.6 ± 0.9</td><td class="colsep0 rowsep0" align="char" char="±">5.2 ± 2.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>F</i> (%)</td><td class="colsep0 rowsep0" align="char" char="±">50 ± 13</td><td class="colsep0 rowsep0" align="char" char="±">39 ± 5</td><td class="colsep0 rowsep0" align="char" char="±">132 ± 20</td><td class="colsep0 rowsep0" align="char" char="±">89 ± 38</td><td class="colsep0 rowsep0" align="char" char="±">82 ± 11</td><td class="colsep0 rowsep0" align="char" char="±">48 ± 6</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t9fn1"><div class="footnote" id="t9fn1"><sup><sup>a</sup></sup><p class="last">Each dose done in triplicate.</p></div><div class="footnote" id="t9fn2"><sup><sup>b</sup></sup><p class="last">IV (0.3 mpk).</p></div><div class="footnote" id="t9fn3"><sup><sup>c</sup></sup><p class="last">po (10 mpk).</p></div></div></div><div class="NLM_p">A crystal structure was also obtained for <b>70</b> showing binding of the inhibitor spanning between pockets A and D of IDO1, similar to the previously described compound <b>22</b>. Reversing the amide, the N–H of compound <b>70</b> maintains the hydrogen bond with Ser167 with the chlorophenyl group in the tryptophan pocket (pocket A) and the bicyclo[3.1.0]hexane core occupying the hydrophobic region between Phe214, Phe270 and His346. The direct link from the bicyclo[3.1.0]hexane core to the benzimidazole in <b>70</b>, instead of an oxygen-linked quinoline, allows the benzimidazole to orient 90° relative to the quinoline of <b>22</b> (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>). This orientation of the benzimidazole group appears to be better tolerated by mouse IDO1 resulting in only a small, 1.4-fold, species shift between human and mouse IDO1 (<a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>).</div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/medium/jm1c00679_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0012.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Crystal structure of <b>70</b> (light purple, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7M63">7M63</a>) superposed with the crystal structure of <b>22</b> (green).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00679&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In addition, we wanted to advance a compound without a hERG liability. We revisited the quinoline series and considered reversing the amide of compound <b>24</b> (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, mouse PK <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). However, to have a direct comparison to <b>70</b> and the use of a common intermediate, the R<sub>2</sub> methyl substitution analog was synthesized, compound <b>71</b> (IACS-70465). The absolute configuration of the eutomer was not confirmed (assigned based on the SFC elution order). The potency of <b>71</b>, was consistently less than 1 nM (<i>n</i> of 6, <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>), had excellent PK (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>), robust TE even at 3 mg/kg (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>, <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>), and did not have a measurable hERG signal in the fluorescence polarization nor the manual patch clamp assays (<a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>).</div><div class="NLM_p">As mentioned earlier, we were still concerned with the stability of the aniline amides and considered the isostere similar to Merck’s series, compound <b>8</b>. We synthesized a series of benzimidazole isosteres with the ether-linked 6-fluoroquinoline moiety.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> Compound <b>72</b>, (<a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>), is a representative molecule that was taken into the SKOV3 model but did not show TE as compared to <b>71</b> at 3 mg/kg (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a> and <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>).</div><div class="NLM_p">The TE of the compounds from <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>, and compound <b>8</b> are compared with linrodostat <b>6</b> and two type III inhibitors, epacadostat <b>2</b> and imidazopyridine <b>17</b> (data in <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>, <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>). The heme-binding inhibitor-dosed BID were not as efficacious as the apoenzyme inhibitor-dosed QD. These two compounds have higher clearances and shorter half lives in mice (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>) but they are also less potent in our HeLa cellular assay (<a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>).</div><div class="NLM_p">The SKOV3 tumor xenograft model in a mouse lacking an intact immune system may not be clinically predictive<a onclick="showRef(event, 'ref16 ref62 ref63'); return false;" href="javascript:void(0);" class="ref ref16 ref62 ref63">(16,62,63)</a> and a comparison between different structural classes of inhibitors with this model may not be informative (catalytic and signaling activity and inadvertent AhR agonism).<a onclick="showRef(event, 'ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref16 ref17">(16,17)</a> However, within our class of type IV inhibitors, differentiation using this model proved beneficial. Most of the compounds exhibited tumor TE, except for <b>56</b>, <b>57</b>, and <b>72</b> (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>, <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>). Of interest was <b>64</b>; dosed QD, it exhibited the best TE, but was not advanced because of its poor hERG safety margin. The more potent <b>71</b> was dosed only once at 50 mg/kg with the same resulting efficacy as linrodostat <b>6</b> at half the dose (QD 5 days), and TE was observed even at 3 mg/kg. Considering this, the isostere <b>72</b> was dosed at only 3 mg/kg but no TE was observed.</div><div class="NLM_p last">Finally, <b>62</b> (<b>IACS-9779</b>), its close analog <b>70</b> (<b>IACS-70099</b>), and <b>71</b> (<b>IACS-70465</b>) displayed the best hIDO1 potencies and hERG safety margin among all the permutations that we profiled, had good PK and bioavailability (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>), and consistently showed robust TE and good tumor exposure (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>, <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Tables <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a>). These were advanced to additional studies.</div></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Whole Blood Assay of <b>62</b> (IACS-9779), <b>70</b> (IACS-70099), <b>71</b> (IACS-70465), and <b>6</b> (Linrodostat)</h3><div class="NLM_p">To assess the impact of the high level of plasma protein binding on compound potency under physiological conditions, we profiled the leading compounds using a human whole blood assay (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>). We observed a decrease in potency for all of the inhibitors as compared to their HeLa potencies (<a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>). The potency differential between linrodostat and IACS-9779 was maintained, IACS-70099 was comparable, but IACS-70465 appeared to be the most potent.</div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/medium/jm1c00679_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0013.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Human whole blood assay. Fresh human peripheral blood was collected from volunteers, treated with DMSO control or increasing concentration of compounds, and stimulated with LPS/IFNγ for 24 h. Plasma samples were then collected for KYN quantification. The percent inhibition of KYN production was determined relative to the DMSO control, and compound potency was calculated: IC<sub>50</sub>: and IC<sub>90</sub>: values reported in <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>. The results are representative of three independent test occasions performed in duplicate.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00679&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> SKOV3 Comparison of <b>62</b> (IACS-9779), <b>70</b> (IACS-70099), <b>71</b> (IACS-70465), and <b>6</b> (Linrodostat)</h3><div class="NLM_p">Next, we used the SKOV3 xenograft model to establish a PK and PD relationship between our molecules and <b>6</b> (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>, <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>). Animals were treated for 5 days with each compound at doses ranging from 10 to 125 mg/kg via oral administration (po). Once daily (QD) for the IACS compounds, and twice daily (BID) for linrodostat (BID to compensate for its higher clearance and shorter half-life in the mouse). Plasma and tumor samples were collected after the last dose. The PK/PD relationship was established by correlating compound plasma exposure against the percent inhibition of tumor KYN relative to vehicle control animals. The relationship for IACS-9779 was consistent with the ex vivo human blood assay (IC<sub>90</sub>: 1047 nM), giving an estimated IC<sub>90</sub> of 1497 nM. In this SKOV3 study, IACS-70099 was less potent than linrodostat but was similar to IACS-9779. Due to its improved potency and PK, IACS-70465 was only dosed for a single day unlike the 5 days of dosing with the other compounds and still out performed IACS-9779 and IACS-70099 (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>, <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>). However, due to its single QD dose, it did not achieve the same response as linrodostat dosed BID for 5 days.</div><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/medium/jm1c00679_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0014.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Compound PK/PD relationship. The concentrations of KYN in tumor and compound in plasma samples were derived from in vivo studies using a human SKOV3 xenograft model after administration of compounds at doses ranging from 10 to 125 mg/kg: IACS-9779 (po, QD, 5 days) and linrodostat (po, BID, 5 days), IACS-70099 (po, QD, 5 days), and IACS-70465 (po, single dose). Plasma and tumor samples were collected at 12 h after the last dose for linrodostat, or 24 h after the last dose for IACS-9779, IACS-70099, and IACS-70465. Compound-mediated inhibition of tumor KYN was calculated relative to vehicle-treated animals (vehicle tumor [KYN] = 96 ± 36 μM). Each symbol represents a treated mouse. Estimated tumor PD: IC<sub>50</sub>: and IC<sub>90</sub>: values reported in <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00679&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">For a direct comparison to linrodostat and epacadostat in an identical dosing experiment, we performed an additional PKPD study in the SKOV-3 model with IACS-9779-dosed BID (<a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">Table <a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">10</a></a>). A 75 mg/kg BID dose of IACS-9779 gave equivalent (>90%) suppression of KYN to either a 125 mg/kg BID dose of linrodostat, or a high dose of 200 mg/kg of epacadostat 12 h after the second dose. It is worth noting that the recent clinical candidate BMS-986242(<b>7</b>),<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> which is more structurally similar to IACS-9779 than to linrodostat <b>6</b>, also had an observed improvement of its PD effect.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a></div><div class="NLM_table-wrap" id="tbl10"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 10. PKPD Comparison</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="±" /></col><col align="char" char="." /></col><col align="char" char="±" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char=".">BID Dose (mpk)</th><th class="colsep0 rowsep0" align="center" char="±">tumor [compound] μM</th><th class="colsep0 rowsep0" align="center" char=".">tumor target inhibition (%)</th><th class="colsep0 rowsep0" align="center" char="±">plasma [compound] μM</th><th class="colsep0 rowsep0" align="center" char=".">plasma target inhibition (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">epacodostat</td><td class="colsep0 rowsep0" align="char" char=".">200</td><td class="colsep0 rowsep0" align="char" char="±">5.0 ± 2.6</td><td class="colsep0 rowsep0" align="char" char=".">82.9</td><td class="colsep0 rowsep0" align="char" char="±">0.69 ± 0.77</td><td class="colsep0 rowsep0" align="char" char=".">57.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BMS-986205</td><td class="colsep0 rowsep0" align="char" char=".">125</td><td class="colsep0 rowsep0" align="char" char="±">0.61 ± 0.21</td><td class="colsep0 rowsep0" align="char" char=".">88</td><td class="colsep0 rowsep0" align="char" char="±">0.06 ± 0.06</td><td class="colsep0 rowsep0" align="char" char=".">62</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IACS-9779</td><td class="colsep0 rowsep0" align="char" char=".">75</td><td class="colsep0 rowsep0" align="char" char="±">17 ± 5.3</td><td class="colsep0 rowsep0" align="char" char=".">95.4</td><td class="colsep0 rowsep0" align="char" char="±">33 ± 2.1</td><td class="colsep0 rowsep0" align="char" char=".">61</td></tr></tbody></table></div></div><div class="NLM_p">There is an apparent shift in the IC<sub>90</sub> of IACS-9779 as compared to linrodostat; however, there is a caveat with this comparison because of the differences in QD and BID dosing (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>). Despite this, the PK profile of IACS-9779 in the mouse allowed for a similar TE in tumors at almost half the dose. The PK of IACS-9779 in other preclinical species was superior to the mouse, and resulted in excellent human PK projections using allometric scaling or IVIVE (in vitro–in vivo extrapolation) methods (<a class="ref showTableEvent internalNav" data-ID="tbl11" href="#tbl11">Table <a class="ref showTableEvent internalNav" data-ID="tbl11" href="#tbl11">11</a></a>). Modeling of these parameters predicts that the compound should achieve a steady state concentration with a low <i>C</i><sub>max</sub>/<i>C</i><sub>min</sub> ratio, and permit constant coverage of the IC<sub>90</sub> from a predicted QD human dose of 50 mg (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>); half of the tolerated dose reportedly used in the clinic for the BMS compound.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> The IC<sub>90</sub> values were used to evaluate the therapeutic margin with respect to findings in ancillary pharmacological profiling in vitro and subsequent in vivo tolerability studies.</div><figure id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/medium/jm1c00679_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0015.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. IACS-9779 human prediction of dose escalation over 10 half lives.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00679&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl11"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 11. Species PK of IACS-9779</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="6" align="center">species</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">human<a class="ref internalNav" href="#t11fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">PK parameters</th><th class="colsep0 rowsep0" align="center">mouse</th><th class="colsep0 rowsep0" align="center">rat</th><th class="colsep0 rowsep0" align="center">dog</th><th class="colsep0 rowsep0" align="center">monkey</th><th class="colsep0 rowsep0" align="center">prediction A</th><th class="colsep0 rowsep0" align="center">prediction B</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Cl (L/h/kg)</td><td class="colsep0 rowsep0" align="left">1.04</td><td class="colsep0 rowsep0" align="left">0.025</td><td class="colsep0 rowsep0" align="left">0.075</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left"><i>0.018</i></td><td class="colsep0 rowsep0" align="left"><i>0.012</i></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Vd<sub>ss</sub> (L/kg)</td><td class="colsep0 rowsep0" align="left">3.1</td><td class="colsep0 rowsep0" align="left">1.48</td><td class="colsep0 rowsep0" align="left">1.42</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left"><i>1.03</i></td><td class="colsep0 rowsep0" align="left"><i>0.87</i></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="left">2.1</td><td class="colsep0 rowsep0" align="left">53.8</td><td class="colsep0 rowsep0" align="left">12.9</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left"><i>40</i></td><td class="colsep0 rowsep0" align="left"><i>50</i></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>F</i> (%)</td><td class="colsep0 rowsep0" align="left">89</td><td class="colsep0 rowsep0" align="left">77</td><td class="colsep0 rowsep0" align="left">68</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left"><i>>50</i></td><td class="colsep0 rowsep0" align="left"><i>99</i></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">microsomal Clint (mL/min/kg)</td><td class="colsep0 rowsep0" align="left">37.8</td><td class="colsep0 rowsep0" align="left">9.7</td><td class="colsep0 rowsep0" align="left">13.3</td><td class="colsep0 rowsep0" align="left">61.4</td><td class="colsep0 rowsep0" colspan="2" align="center">8.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="left">2.41</td><td class="colsep0 rowsep0" align="left">4.28</td><td class="colsep0 rowsep0" align="left">4.33</td><td class="colsep0 rowsep0" align="left">0.55</td><td class="colsep0 rowsep0" colspan="2" align="center">3.39</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hepatocyte CLint (mL/min/kg)</td><td class="colsep0 rowsep0" align="left">231</td><td class="colsep0 rowsep0" align="left">0</td><td class="colsep0 rowsep0" align="left">36.7</td><td class="colsep0 rowsep0" align="left">24</td><td class="colsep0 rowsep0" colspan="2" align="center">4.78</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="left">1.18</td><td class="colsep0 rowsep0" align="left">>24</td><td class="colsep0 rowsep0" align="left">4.33</td><td class="colsep0 rowsep0" align="left">3.75</td><td class="colsep0 rowsep0" colspan="2" align="center">12.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">plasma protein binding (%)</td><td class="colsep0 rowsep0" align="left">>99</td><td class="colsep0 rowsep0" align="left">>99</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" colspan="2" align="center">>99</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t11fn1"><div class="footnote" id="t11fn1"><sup><sup>a</sup></sup><p class="last">A: Based on allometric scaling from mouse, rat, and dog (IV) data. B: IVIVE method by XenoGesis.</p></div></div></div></div><div id="sec2_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Safety Studies</h3><div class="NLM_p">Dose range finding toxicity characterization of IACS-9779 and IACS-70099 was performed in a 7-day (po, QD) rat study (<a class="ref showTableEvent internalNav" data-ID="tbl12" href="#tbl12">Table <a class="ref showTableEvent internalNav" data-ID="tbl12" href="#tbl12">12</a></a>). A low dose (20 mg/kg) of IACS-9779 achieved a <i>C</i><sub>max</sub> in plasma above 25 μM [area under the curve (AUC) > 400 μM·h (NOAEL)], which is 16× that of the predicted IDO1 IC<sub>90</sub> coverage (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>). At a high dose (200 mg/kg), IACS-9779 achieved a coverage in plasma at 87 μM (AUC > 1700 μM·h) with minimal events (<a class="ref showTableEvent internalNav" data-ID="tbl12" href="#tbl12">Table <a class="ref showTableEvent internalNav" data-ID="tbl12" href="#tbl12">12</a></a>). IACS-70099 at a high dose (500 mg/kg), more than twice that of IACS-9779, achieved only a tenth of the exposure, resulted in serious toxicological events, was significantly worse than IACS-9779 and linrodostat, and was discontinued. In a separate safety pharmacology cardiovascular (CV) dog study, a 10 mg/kg dose of IACS-9779 achieving a <i>C</i><sub>max</sub> of 23 μM in plasma was well tolerated, without measurable QTc prolongation, and 15× margin above the predicted IDO1 IC<sub>90</sub> coverage. A 20 mg/kg dose with a plasma concentration at 43 μM <i>C</i><sub>max</sub> was associated with ≤16% prolongation of QT/QTc interval and with transient emesis that resolved. All other CV parameters were within normal ranges. IACS-70099 displayed normal responses up to 30 mg/kg.</div><div class="NLM_table-wrap" id="tbl12"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 12. Rat Dose Range Finding Toxicity of IACS-9779</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">compound</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">parameters</th><th class="colsep0 rowsep0" align="center">IACS-9779</th><th class="colsep0 rowsep0" align="center">IACS-70099<a class="ref internalNav" href="#t12fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">linrodostat</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">high-dose mpk</td><td class="colsep0 rowsep0" align="left">200</td><td class="colsep0 rowsep0" align="left">500</td><td class="colsep0 rowsep0" align="left">250</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC projection μM·h</td><td class="colsep0 rowsep0" align="left">6600</td><td class="colsep0 rowsep0" align="left">277–689</td><td class="colsep0 rowsep0" align="left">95–245</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ALT</td><td class="colsep0 rowsep0" align="left">↑</td><td class="colsep0 rowsep0" align="left">↑↑</td><td class="colsep0 rowsep0" align="left">↑</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">bilirubin</td><td class="colsep0 rowsep0" align="left">no change</td><td class="colsep0 rowsep0" align="left">↑↑</td><td class="colsep0 rowsep0" align="left">↑</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">RBC, HGB, HCT</td><td class="colsep0 rowsep0" align="left">no change</td><td class="colsep0 rowsep0" align="left">↓↓, ↓↓, ↓↓</td><td class="colsep0 rowsep0" align="left">↓RBC only</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">reticulocytes</td><td class="colsep0 rowsep0" align="left">↓↓</td><td class="colsep0 rowsep0" align="left">↓↓</td><td class="colsep0 rowsep0" align="left">↑</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">bone marrow smear</td><td class="colsep0 rowsep0" align="left">50% ↓ erythroid cell</td><td class="colsep0 rowsep0" align="left">50% ↓ myeloid cell; 70% ↓ erythroid cells; 2.5-fold ↑ lymphoid cell</td><td class="colsep0 rowsep0" align="left">no change</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">gross lesion</td><td class="colsep0 rowsep0" align="left">none visible</td><td class="colsep0 rowsep0" align="left">bilateral enlarged adrenal gland in 3/5 animals; dark red diffuse ovary noted 3/5 animals</td><td class="colsep0 rowsep0" align="left">none visible</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">body weight (high dose)</td><td class="colsep0 rowsep0" align="left">decrease</td><td class="colsep0 rowsep0" align="left">decrease</td><td class="colsep0 rowsep0" align="left">decrease</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">high-dose mortality</td><td class="colsep0 rowsep0" align="left">1 death</td><td class="colsep0 rowsep0" align="left">2 deaths</td><td class="colsep0 rowsep0" align="left">2 deaths</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t12fn1"><div class="footnote" id="t12fn1"><sup><sup>a</sup></sup><p class="last">Strong inhibition for OATP1B1/OATP1B3/BRCP; modest rate inhibition for BSEP.</p></div></div></div><div class="NLM_p">The late identification of IACS-70465 resulted in it not being profiled in any safety studies prior to the termination of the program. Its performance appears to be superior to IACS-9779 in the HeLa cellular and whole blood assays as well as in in vivo studies. However, a dose range finding toxicological study would be necessary to clearly differentiate it from IACS-9779.</div><div class="NLM_p last">IACS-9779 has a clog <i>D</i> of 4.82 based on a calculated p<i>K</i><sub>a</sub> of 5.6, and low thermodynamic solubility in buffered aqueous media (7 ng/mL at pH 6.7 and 28 ng/mL at pH 5.1). It has excellent passive cell permeability; <i>P</i><sub>app</sub> 21 × 10<sup>6</sup>/cm·s<sup>–1</sup> as measured in a confluent monolayer of MDCK MDR1 expressing cells, and it is not a P-gp substrate. The compound was also selective with no measured activity against TDO (IC<sub>50</sub> > 10 μM, at least three independent test occasions). These physical properties are similar to linrodostat. It is well absorbed upon oral administration to mice, rats, or dogs, and has excellent PK (<a class="ref showTableEvent internalNav" data-ID="tbl11" href="#tbl11">Table <a class="ref showTableEvent internalNav" data-ID="tbl11" href="#tbl11">11</a></a>).</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i26">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64615" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64615" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">The bicyclo[3.1.0]hexane core provided a conformationally constrained scaffold with axial and equatorial substitutions (at the 3 and 6 carbons, respectively) that offer a preferred geometry for optimal IDO1 inhibition as measured by the reduction of KYN with a RFMS technique in lysates from a human HeLa cell line. The crystal structures of compounds <b>17</b>, <b>22</b>, and <b>70</b> revealed that <b>17</b> was a type III inhibitor and <b>22</b> and <b>70</b> were type IV inhibitors of IDO1. Biochemistry experiments elucidated the mechanism of IDO1 inhibition by <b>22</b> to be via engagement with the apoenzyme. A protein sequence homology study across species showed the conservation of pocket A and modest changes in the vicinity of the pocket D. Variations in the substitution pattern of the inhibitor in the vicinity of this region resulted in significant shifts in potency between the human and mouse enzyme; the human receptor being more tolerant to a diversity of modifications than the mouse. The benzimidazole moiety provided potency in both mouse and human enzymes with a minimal species shift. Extensive SAR produced potent molecules with excellent PK and tumor TE. Compounds <b>62</b> (IACS-9779), <b>70</b> (IACS70099), and <b>71</b> (IACS-70465) displayed the best combinations of potency and hERG safety margin and had consistent TE with good tumor exposure. IACS-70099 did not progress due to toxicology and the profiling of IACS-70465 was not completed due to termination of the program. IACS-9779 had a better safety profile in a preliminary rat toxicology study than did IACS-70099. From human PK projections of IACS-9779 based on allometric scaling and IVIVE methods, a calculated QD dose of below 1 mg/kg was postulated to be efficacious, sustain exposure at the IDO1 IC<sub>90</sub>, and provide an adequate safety margin based on rat toxicology. In a CV dog study, IACS-9779 was tolerated without QTc prolongation up to 20 mg/kg offering a 15× therapeutic index with respect to the hIDO1 IC<sub>90</sub>. The predicted human PK of IACS-9779 indicates suitability for a QD dosing regimen with a low plasma peak-trough ratio. We independently elucidated the mechanism of action of a series of type IV IDO1 inhibitors, and upon recognizing the potential of this mode of action, optimized our leads to culminate in the identification of IACS-9779, a potent and selective IDO inhibitor suitable for human evaluation. In light of the current state of stalled and terminated clinical trials, the utility of IDO1 inhibition in the oncology setting is in question. Linrodostat’s phase III trial appears to be still active, as is recruiting for a phase I trial of KHK-2455 (structure undisclosed). Perhaps, when the results of these trials are disclosed, the clinical utility of an IDO1 inhibitor will be better defined.<a onclick="showRef(event, 'ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref16 ref17">(16,17)</a></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i27">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83148" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83148" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The starting bicyclo[3.1.0]hexane core <b>73</b> was synthesized according to known procedures.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> Briefly, 3-cyclopentene-1-ol protected with TBDPS-Cl is cyclopropanated with ethyl 2-diazoacetate, and then hydrolyzed to give the starting acid.</div><div class="NLM_p">Acid <b>73</b> was converted to aldehyde <b>74</b> via the Weinreb Amide and reduction with DIBAL-H. Condensation with <i>tert</i>-butyl sulfinamide formed the intermediate imine <b>75</b>, which was either alkylated with a Grignard reagent or reduced with lithium aluminum hydride (LAH). Sulfinamide <b>76R</b><sub><b>1</b></sub> was globally deprotected to give the amino alkyl bicyclo[3.1.0]hexane alcohol, which was amidated without purification. Standard amide-coupling conditions using EDCI or HATU work but some esterification occurs as a side product, the yield can be increased by coupling with the NHS ester of the benzoic acid. The crude amide alcohol was subjected to flash silica gel chromatography to isolate the two major diastereomers, <b>77R</b><sub><b>1</b></sub> and <b>78R</b><sub><b>1</b></sub>, which can be differentially identified by NOSEY NMR experiments that display the interaction or the absence thereof between the protons on the 3 and 6 carbons of the bicyclo[3.1.0]hexane system (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>).</div><figure id="sch1" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/medium/jm1c00679_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0016.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Hydroxy Bicyclo[3.1.0]hexane Diastereomers<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00679&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Regents and conditions: (a) MeNHOMe·HCl, DMAP, DIEA, EDCI, DCM; (b) DIBAL-H, PhMe; (c) 2-methylpropane-2-sulfinamide, CuSO<sub>4</sub>, DCM; (d) R<sub>1</sub>MgBr, THF; (e) LAH, THF; (f) HCl/Dioxane, MeOH; (g) R<sub>2</sub>COOH, DIEA, HATU, DMF or EDCI, HOBT, DIEA, DCM.</p></p></figure><div class="NLM_p">Initially, the preferred diastereomer was undetermined and both isomers were taken forward to make final compounds (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). Depending on availability of reagents, the final compounds were synthesized by several methods. The quinolines were synthesized through nucleophilic aromatic substitutions (S<sub>N</sub>Ar) with retention of configuration (<b>21–23, 25–30</b>) or through a Mitsunobu reaction with inversion (<b>24</b>). In the synthesis of the benzimidazoles, alcohol <b>77R</b><sub><b>1</b></sub> was activated with mesyl chloride (<b>79R</b><sub><b>1</b></sub>) and displaced inverting the carbon center to produce a more potent isomer (<b>36–70</b>).</div><figure id="sch2" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/medium/jm1c00679_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0017.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Quinolines and Symmetric Benzimidazoles<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00679&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (h<sub>a</sub>) 4-bromoquinoline, NaH, DMSO or KOtBu, THF; (h<sub>b</sub>) polymer-TPP, quinolin-4-ol, DTAB, THF; (i) MsCl, TEA DCM; (j) Benzimidazole, K<sub>2</sub>CO<sub>3</sub>, DMF.</p></p></figure><div class="NLM_p">In the synthesis of benzimidazoles with unsymmetrical substitutions, the two products could usually be separated by prep-HPLC and identified by NOESY experiments. For inseparable products, the benzimidazoles were synthesized by azide nucleophilic displacement (<b>80R</b><sub><b>1</b></sub>) of the mesylate <b>79R</b><sub><b>1</b></sub>, reduction to the amine <b>81R</b><sub><b>1</b></sub>, S<sub>N</sub>Ar with the appropriate fluoro-nitro-aryl/heteroaryl compound <b>82R</b><sub><b>1</b></sub><b>(R</b><sub><b>3</b></sub><b>)</b>, reduction, and cyclization to the benzimidazole in one pot with iron and formic acid (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>).<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a></div><figure id="sch3" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/medium/jm1c00679_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0018.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Unsymmetrical Benzimidazoles<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00679&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (k) NaN<sub>3</sub>, DMF; (l) polymer-TPP, THF, H<sub>2</sub>O; (m) 2-fluoronitrobenzene, K<sub>2</sub>CO<sub>3</sub>, THF, (n) Fe, HCOOH, IPA.</p></p></figure><div class="NLM_p">Based on the crystal structure of <b>22</b>, it was determined that the R enantiomeric center of <b>83</b> should be the more potent isomer. The diastereomeric chiral amine <b>83</b>, as illustrated in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>, was synthesized from an asymmetric Grignard addition to chiral <i>t</i>-Bu-sulfinimine <b>75(S)</b> as developed by Ellman and co-workers.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> Following literature examples, condensation of aldehyde <b>74</b> with (<i>S</i>)-<i>t</i>-Bu-sulfinamide in the presence of anhydrous copper sulfate gave imine <b>75(S)</b> in moderate yield. Grignard addition to imine <b>75(S)</b> gave sulfinamide <b>76R</b><sub><b>1</b></sub><b>(R)</b>, which upon further removal of the <i>t</i>-Bu-sulfinyl auxiliary under mild acid conditions provided chiral amine <b>83R</b><sub><b>1</b></sub><b>(R)</b>.</div><figure id="sch4" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/medium/jm1c00679_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0019.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Diastereomeric Chiral Bicyclo[3.1.0]hexane Amine<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00679&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (<i>S</i>)-2-methylpropane-2-sulfinamide, CuSO<sub>4</sub>, DCM; (b) R<sub>1</sub>MgBr, THF; (o) HCl/Dioxane, MeOH.</p></p></figure><div class="NLM_p">Intermediate <b>83R</b><sub><b>1</b></sub><b>(R)</b> was used in the synthesis of compound <b>56</b>, which proved to be equipotent to <b>39A</b>, the more potent isomer obtained from SFC separation of racemic <b>39</b>, in a human IDO1 HeLa cellular assay (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). This synthesis proved to be very robust for gaining access to the chiral amine <b>83R</b><sub><b>1</b></sub><b>(R)</b>.</div><div class="NLM_p">To confirm the chirality of the newly formed (R) stereocenter, a Mosher’s amide analysis was utilized (<a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>).<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> Comparing the NMRs of the resulting (S) and (R) Mosher amides <b>84</b> and <b>85</b> showed a nice correlation of the shielding effect of the phenyl group from the Mosher’s amide. Calculating the ΔδSR of key NMR proton shifts established chemically that starting from the (<i>S</i>)-sulfinamide gave the desired (<i>R</i>) stereoisomer.</div><figure id="sch5" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/medium/jm1c00679_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0020.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Mosher Amide Analysis<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00679&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Regents and conditions: (a) DIEA, ClCOMTPA, DCM.</p></p></figure><div class="NLM_p">The reversed amides <b>70</b> and <b>71</b> were initially synthesized from the same common intermediate <b>88</b> (<a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>). The starting aldehyde <b>74</b> was converted to the methyl ketone <b>86</b> via the Grignard and Dess–Martin oxidation. The ketone was homologated to the corresponding carboxylic acid <b>88</b> through the Wittig, acid hydrolysis, and Pinnick oxidation. Then, through chemistry previously described, the racemic versions of <b>70</b> and <b>71</b> were synthesized. The enantiomers were separated by SFC and the assignment of stereo chemistry was based on the order of elution precedently set by the SFC separation of <b>39</b>, and were not absolutely confirmed. The synthesis of the benzimidazole isostere <b>72</b> (<a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>) used the carboxylic acid <b>72(Et)H</b> (prepared through an analogous scheme, <a href="/doi/suppl/10.1021/acs.jmedchem.1c00679/suppl_file/jm1c00679_si_001.pdf" class="ext-link">Supporting Information</a>) that was coupled with the diamine and cyclized using tosic acid.</div><figure id="sch6" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/medium/jm1c00679_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0021.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Common Intermediate, Reversed Amides<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00679&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (p) 0 °C, THF, MeMgBr; (q) 0 °C, DCM(wet) DMP; (r) −13 °C Ph<sub>3</sub>PCH<sub>2</sub>OMe·Cl, THF, LHMDS; (s) PPTS, dioxane, H<sub>2</sub>O, 70 °C; (t) 0 °C, tBuOH, CH<sub>3</sub>(CH<sub>3</sub>)C═CHCH<sub>3</sub>, NaClO<sub>2</sub>, KH<sub>2</sub>PO<sub>4</sub>, H<sub>2</sub>O; (u) Pyridine, EtOAc, T3P; (v) THF, TBAF, 50 °C. (w) 0 °C, NaH, DMF.</p></p></figure><figure id="sch7" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/medium/jm1c00679_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0022.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Benzimidazole Synthesis<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00679&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (x) pyridine, EtOAc, T3P, 65 °C; (y) PhMe, pTsOH, 110 °C.</p></p></figure></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i35">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28763" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28763" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> Synthesis Methods</h3><div class="NLM_p">The inhibitors described were synthesized by employing standard chemical transformations. Starting materials and reagents were purchased from commercial suppliers such as Sigma-Aldrich, Alfa Aesar, TCI, Combi-Block, Enamine, or Acros and were used without further purification unless otherwise indicated. Anhydrous solvents [e.g., tetrahydrofuran (THF), dimethylformamide (DMF), DMA, dimethyl sulfoxide (DMSO), MeOH, dichloromethane (DCM), and toluene] were purchased from Sigma-Aldrich and used directly. Purification of final compounds was performed by column chromatography utilizing a Biotage system applying Biotage SNAP columns with Biotage KP-Sil silica or Biotage Zip Si columns with Biotage KP-Sil silica or a Teledyne ISCO system with RediSep Rf normal phase silica cartridges. Some compounds were purified by preparative HPLC using a Waters Autopurify system with a Waters Xbridge Prep C18 5 μm OBD, 19 mm × 150 mm or 50 mm × 100 mm column, and a SQ detector mass spectrometer with electrospray ionization (ESI) ionization. The identity of all compounds with reported biological activity was confirmed by NMR spectroscopy and low-resolution mass spectrometry, and for selected analogs, high-resolution mass spectrometry (HRMS). Purity of all compounds with reported biological activity was >95% and was determined by ultraperformance liquid chromatography (UPLC). HRMS data were collected for leading compounds <b>22</b> and <b>62</b> (as well as <b>24</b>, <b>31</b>, <b>34</b>, <b>38</b>, <b>39</b>, <b>39A</b>, <b>39B</b>, <b>46</b>, <b>56</b>, <b>59</b>, <b>62</b>, and <b>64;</b><a href="/doi/suppl/10.1021/acs.jmedchem.1c00679/suppl_file/jm1c00679_si_001.pdf" class="ext-link">Supporting Information</a>). NMR spectra were recorded on Bruker instruments operating at 300, 500, or 600 MHz. NMR spectra were obtained as CDCl<sub>3</sub>, CD<sub>3</sub>OD, D<sub>2</sub>O, (CD<sub>3</sub>)<sub>2</sub>SO, (CD<sub>3</sub>)<sub>2</sub>CO, C<sub>6</sub>D<sub>6</sub>, or CD<sub>3</sub>CN solutions (reported in ppm), using tetramethylsilane (0.00 ppm) or residual solvent (CDCl<sub>3</sub>, 7.26 ppm; CD<sub>3</sub>OD, 3.31 ppm; D<sub>2</sub>O, 4.79 ppm; (CD<sub>3</sub>)<sub>2</sub>SO, 2.50 ppm; (CD<sub>3</sub>)<sub>2</sub>CO, 2.05 ppm; C<sub>6</sub>D<sub>6</sub>, 7.16 ppm; and CD<sub>3</sub>CN, 1.94 ppm) as the reference standard. Low-resolution mass spectra were obtained on either a Waters H class UPLC with a Waters Acquity UPLC BEH C18 1.7 μm, 2.1 mm × 50 mm column, UV detection between 200 and 400 nm, evaporating light scattering detection, and a SQ detector mass spectrometer with ESI ionization or a Water I class UPLC with a Waters Acquity UPLC CSH C18 1.7 μm, 2.1 mm × 50 mm column, UV detection at 254 and 290 nm, evaporating light scattering detection, and a SQ detector 2 mass spectrometer with ESI. HRMS were obtained on a Waters Acquity I-Class UPLC coupled to a LTQ-Orbitrap Elite mass spectrometer. The injection volume was 5 μL. Chromatographic separation was performed on a Waters Acquity UPLC BEH C18 1.7 μm, 2.1 mm × 50 mm column, at a flow rate of 0.5 mL/min. The mobile phases were 0.1% acetic acid in water (solvent A) and 0.1% acetic acid in acetonitrile (solvent B). The gradient had a total run time of 18 min and was as follows: 0–2 min 5% B; 2–12 min from 5 to 65% B; 12–14 min from 65 to 95% B; 14–16 min at 95% B; 16–16.1 min from 95 to 5% B; and 16.1–18 min at 5% B. The column temperature was kept at 40 °C. The samples were analyzed using the positive ESI mode. The ESI source temperature was set at 375 °C, the capillary temperature at 320 °C, and the electrospray voltage at 4.1 kV. Sheath and auxiliary gases were of 45 arbitrary unit and 10 arbitrary unit, respectively. Calculator Plugins were used for structure property prediction and calculation (clog <i>P</i>), Marvin 16.8.15, 2016, ChemAxon (<a href="http://www.chemaxon.com" class="extLink">http://www.chemaxon.com</a>), and used in ChemCart, version 6.0.1, <a href="http://www.deltasoftinc.com" class="extLink">http://www.deltasoftinc.com</a>.</div><div id="sec5_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 4-Chloro-<i>N</i>-(1-((1<i>R</i>,3<i>r</i>,5<i>S</i>,6<i>r</i>)-3-(Quinolin-4-yloxy)bicyclo[3.1.0]hexan-6-yl)propyl)benzamide (<b>21</b>)</h4><div id="sec5_1_1_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i38" class="anchor-spacer"></div><h5 class="article-section__title" id="_i38"> (1<i>R</i>,5<i>S</i>)-3-((<i>tert</i>-Butyldiphenylsilyl)oxy)-<i>N</i>-methoxy-<i>N</i>-methylbicyclo[3.1.0]hexane-6-carboxamide (Step a)</h5><div class="NLM_p last">To a solution of (1<i>R</i>,5<i>S</i>)-3-((<i>tert</i>-butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexane-6-carboxylic acid <b>74a</b> (20 g, 53 mmol) in DCM (200 mL) were added DMAP (<i>N</i>,<i>N</i>-dimethylpyridin-4-amine) (1.3 g, 11 mmol) and <i>N</i>,<i>O</i>-dimethylhydroxylamine hydrochloride (7.7 g, 79 mmol), and the partially dissolved mixture was chilled in an ice/water bath for 5 min. To the mixture was added <i>N</i>,<i>N</i>-diisopropylethylamine, Hunig’s base (DIEA) (10 g, 79 mmol), stirred for 5 min and then EDC (N1-((ethylimino)methylene)-N3,N3-dimethylpropane-1,3-diamine hydrochloride) (15 g, 79 mmol) was added and the mixture was allowed to warm to room temperature (RT) overnight. The slightly cloudy solution was diluted with a mixture of DCM and hexane (10%) and washed with HCl (0.1 M, 200 mL), NaOH (0.1 M, 200 mL), water (200 mL), and brine (200 mL). The aqueous layers were extracted with DCM (1 × 30 mL). The DCM layers were combined, dried over MgSO<sub>4</sub>, filtered, and concentrated as a colorless slightly cloudy oil. The residue was dissolved in minimal DCM and purified via silica gel chromatography (0–30% EtOAc in hexanes) to give the title compound <b>74a</b> (22.4 g, 50 mmol, 96% yield) as a colorless semisolid/viscous. MS (ES<sup>+</sup>) C<sub>25</sub>H<sub>33</sub>NO<sub>3</sub>Si calculated 423; found 424 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>): δ 7.69–7.60 (m, 4H), 7.45–7.40 (m, 2H), 7.40–7.32 (m, 4H), 4.40–3.90 (m, 1H), 3.79–3.50 (m, 3H), 3.29–3.07 (m, 3H), 2.86–1.42 (m, 7H), 1.10–1.00 (m, 9H).</div></div><div id="sec5_1_1_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i39" class="anchor-spacer"></div><h5 class="article-section__title" id="_i39"> (1<i>R</i>,5<i>S</i>)-3-((<i>tert</i>-Butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexane-6-carbaldehyde (Step b, <b>74</b>)</h5><div class="NLM_p last">To a solution of (1<i>R</i>,5<i>S</i>)-3-((<i>tert</i>-butyldiphenylsilyl)oxy)-<i>N</i>-methoxy-<i>N</i>-methylbicyclo[3.1.0] hexane-6-carboxamide <b>74a</b> (22.4 g, 52.9 mmol) in dry toluene (260 mL) at −78 °C was added DIBAL-H (1 M in toluene, 58 mL, 58 mmol) dropwise over 17 min, and the resulting colorless solution was stirred at −78 °C for 3.5 h. To the reaction at −78 °C was added EtOAc (135 mL) and allowed to warm in an ice bath for 15 min. To the reaction was added water (2.4 mL) and stirred for 5 min, 15% aqueous NaOH (2.6 mL) and stirred for 5 min, and then water (6 mL), and the reaction was allowed to warm to RT for 30 min. To the stirring reaction was added MgSO<sub>4</sub> and allowed stir at RT overnight. The reaction was filtered and the filtrate was washed with (150 mL/each) saturated NH<sub>4</sub>Cl, water, and saturated NaCl, dried over MgSO<sub>4</sub>, filtered, and concentrated. The residue was purified via flash chromatography (0–30% EtOAc in hexanes) to give <b>74</b> (17.6 g, 48.4 mmol, 92% yield). MS (ES<sup>+</sup>) C<sub>23</sub>H<sub>28</sub>O<sub>2</sub>Si calculated 364; found 387 [M + Na]<sup>+</sup>. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>): δ 9.31–8.88 (m, 1H), 7.65–7.59 (m, 4H), 7.46–7.40 (m, 2H), 7.39–7.34 (m, 4H), 4.41–3.79 (m, 1H), 2.54–2.20 (m, 1H), 2.09–1.97 (m, 3H), 1.96–1.86 (m, 3H), 1.11–0.98 (m, 9H).</div></div><div id="sec5_1_1_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i40" class="anchor-spacer"></div><h5 class="article-section__title" id="_i40"> <i>N</i>-((<i>E</i>)-((1<i>R</i>,5<i>S</i>)-3-((<i>tert</i>-Butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexan-6-yl)methylene)-2-methylpropane-2-sulfinamide (Step c, <b>75</b>)</h5><div class="NLM_p last">To a solution of (1<i>R</i>,5<i>S</i>)-3-((<i>tert</i>-butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexane-6-carbaldehyde <b>74</b> (13 g, 36 mmol) in DCM (72 mL) were added 2-methylpropane-2-sulfinamide (8.7 g, 72 mmol) and anhydrous copper(II) sulfate (5.7 g, 36 mmol) and the resulting mixture was stirred at RT overnight. The reaction was filtered through Celite, concentrated, and purified via flash chromatography (0–15% EtOAc in hexanes) to give <b>75</b> (14.5 g, 31 mmol, 86% yield). MS (ES<sup>+</sup>) C<sub>27</sub>H<sub>37</sub>NO<sub>2</sub>SSi calculated 467; found 468 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>): δ 7.75 (d, <i>J</i> = 7.1 Hz, 1H), 7.65–7.59 (m, 4H), 7.45–7.40 (m, 2H), 7.40–7.34 (m, 4H), 4.38–3.92 (m, 1H), 2.59–2.19 (m, 1H), 2.13–1.40 (m, 6H), 1.22–1.10 (m, 9H), 1.08–0.98 (m, 9H).</div></div><div id="sec5_1_1_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i41" class="anchor-spacer"></div><h5 class="article-section__title" id="_i41"> <i>N</i>-(1-((1<i>R</i>,5<i>S</i>)-3-((<i>tert</i>-Butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexan-6-yl)propyl)-2-methylpropane-2-sulfinamide (Step d, <b>76Et</b>)</h5><div class="NLM_p last">To a cooled −78 °C solution of <i>N</i>-((<i>E</i>)-((1<i>R</i>,5<i>S</i>)-3-((<i>tert</i>-butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexan-6-yl)methylene)-2-methylpropane-2-sulfinamide <b>75</b> (8 g, 17 mmol) in THF (64 mL) was added EtMgBr (23 mL of 3 M solution in diethylether, 68 mmol). The resulting mixture was stirred at −78 °C for ∼5 min, removed from the cooling bath, and allowed to warm to RT overnight. The reaction was cooled in ice and quenched with saturated NH<sub>4</sub>Cl (150 mL) and stirred for 1 h. The mixture was diluted with DCM (200 mL) and the organic layer was separated. The aqueous layer was extracted with DCM. The organic layers were combined, washed with saturated NaCl, dried over MgSO<sub>4</sub>, filtered, and concentrated to give <b>76Et</b> (7.8 g, 16 mmol), which was used directly in the next step. MS (ES<sup>+</sup>) C<sub>29</sub>H<sub>43</sub>NO<sub>2</sub>SSi calculated 497; found 498[M + H]<sup>+</sup>. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>): δ 7.66–7.58 (m, 4H), 7.45–7.39 (m, 2H), 7.39–7.32 (m, 4H), 4.35–3.85 (m, 1H), 3.21–2.49 (m, 1H), 2.40–0.78 (m, 31H).</div></div><div id="sec5_1_1_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i42" class="anchor-spacer"></div><h5 class="article-section__title" id="_i42"> (1<i>R</i>,5<i>S</i>)-6-(1-Aminopropyl)bicyclo[3.1.0]hexan-3-ol (Step f)</h5><div class="NLM_p last">To a solution of <i>N</i>-(1-((1<i>R</i>,5<i>S</i>)-3-((<i>tert</i>-butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexan-6-yl)propyl)-2-methylpropane-2-sulfinamide (3.2 g, 6.4 mmol) in MeOH (50 mL) cooled in an ice bath was added HCl in MeOH [prepared immediately before use by the addition of AcCl (18.3 mL, 257 mmol) into MeOH (25 mL) cooled in an ice bath and stirred for 5 min]. The reaction was removed from the ice bath and stirred at RT overnight. The reaction was concentrated and the residual solvent was azeotroped with ACN and toluene (3×) to give the title compound, HCl salt, off white solid, and used as is immediately. MS (ES<sup>+</sup>) C<sub>9</sub>H<sub>17</sub>NO calculated 155; found 156 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_1_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i43" class="anchor-spacer"></div><h5 class="article-section__title" id="_i43"> 4-Chloro-<i>N</i>-(1-((1<i>R</i>,3<i>r</i>,5<i>S</i>,6<i>r</i>)-3-hydroxybicyclo[3.1.0]hexan-6-yl)propyl)benzamide (Step g, <b>77Et</b>)</h5><div class="NLM_p last">The crude (1<i>R</i>,5<i>S</i>)-6-(1-aminopropyl)bicyclo[3.1.0]hexan-3-ol hydrochloride was diluted with DCM (50.0 mL) and to this were added DIEA (5.6 mL, 32 mmol), HOBT (1.6 g, 9.6 mmol), 4-chlorobenzoic acid (1.1 g, 7.1 mmol), and EDC (1.4 g, 7.1 mmol). The reaction was stirred at RT for 4 days. The reaction was diluted with DCM and washed with NaOH (0.25 M), citric acid (0.25 M), water, and brine. The aqueous washes were extracted with DCM once. The organic layers were combined, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, concentrated, and purified by flash chromatography [0–50% of EtOAc/IPA (8:2) in hexanes] to give <b>77Et</b>, as the first eluting diastereomer, (776 mg, 2.6 mmol, 4% yield) white solid. MS (ES<sup>+</sup>) C<sub>16</sub>H<sub>20</sub>ClNO<sub>2</sub> calculated 293; found 294 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD): δ 7.79 (d, <i>J</i> = 8.6 Hz, 2H), 7.46 (d, <i>J</i> = 8.5 Hz, 2H), 4.32–4.27 (m, 1H), 3.29–3.25 (m, 1H), 2.12–1.97 (m, 2H), 1.80–1.58 (m, 4H), 1.36–1.24 (m, 2H), 1.24–1.20 (m, 1H), 0.96 (t, <i>J</i> = 7.4 Hz, 3H).</div></div><div id="sec5_1_1_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i44" class="anchor-spacer"></div><h5 class="article-section__title" id="_i44"> 4-Chloro-<i>N</i>-(1-((1<i>R</i>,3<i>r</i>,5<i>S</i>,6<i>r</i>)-3-(quinolin-4-yloxy)bicyclo[3.1.0]hexan-6-yl)propyl)benzamide (Step h, <b>21</b>)</h5><div class="NLM_p last">To a solution of 4-chloro-<i>N</i>-(1-((1<i>R</i>,3<i>r</i>,5<i>S</i>,6<i>r</i>)-3-hydroxybicyclo[3.1.0]hexan-6-yl)propyl)benzamide <b>77Et</b> (49 mg, 0.17 mmol) in DMSO (0.34 mL) under nitrogen was added sodium hydride (60% in mineral oil, 15 mg, 0.38 mmol) and the mixture was stirred at RT for 30 min until gas evolution ceased. To the resulting yellow mixture was added 4-bromoquinoline (43 mg, 0.21 mmol), and the reaction was stirred at 80 °C overnight. To the mixture was added 2 drops of a saturated NH<sub>4</sub>Cl. The mixture was filtered (0.2 μM Whatman syringe filter), rinsed with DMSO (3 × 0.3 mL), and the filtrate was purified by mass-triggered preparative HPLC (mobile phase: A = 0.1% TFA/H<sub>2</sub>O, B = 0.1% TFA/MeCN; gradient: B = 20–50%; 12 min; column: C18) to give <b>21</b> as a glassy yellow solid (55 mg, 62%). MS (ES<sup>+</sup>) C<sub>25</sub>H<sub>25</sub>ClN<sub>2</sub>O<sub>2</sub> calculated  420; found, 421 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>): δ 8.95 (d, <i>J</i> = 6.42 Hz, 1H), 8.48 (d, <i>J</i> = 7.93 Hz, 1H), 8.41 (d, <i>J</i> = 8.69 Hz, 1H), 8.16–8.11 (m, 1H), 8.10–8.05 (m, 1H), 7.92 (ddd, <i>J</i> = 8.40, 7.08, 1.13 Hz, 1H), 7.80–7.75 (m, 2H), 7.48–7.43 (m, 2H), 7.40 (d, <i>J</i> = 6.80 Hz, 1H), 5.49 (t, <i>J</i> = 6.61 Hz, 1H), 3.45–3.37 (m, 1H), 2.60–2.48 (m, 2H), 2.31–2.21 (m, 2H), 1.82–1.73 (m, 1H), 1.73–1.65 (m, 1H), 1.63–1.58 (m, 1H), 1.55 (td, <i>J</i> = 5.85, 3.40 Hz, 1H), 1.27 (dt, <i>J</i> = 9.06, 3.21 Hz, 1H), 0.97 (t, <i>J</i> = 7.36 Hz, 3H).</div></div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> 4-Chloro-<i>N</i>-(1-((1<i>R</i>,3<i>s</i>,5<i>S</i>,6<i>r</i>)-3-(quinolin-4-yloxy)bicyclo[3.1.0]hexan-6-yl) propyl)benzamide (<b>22</b>)</h4><div id="sec5_1_2_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i46" class="anchor-spacer"></div><h5 class="article-section__title" id="_i46"> 4-Chloro-<i>N</i>-(1-((1<i>R</i>,3<i>s</i>,5<i>S</i>,6<i>r</i>)-3-hydroxybicyclo[3.1.0]hexan-6-yl)propyl)benzamide (Step g, <b>78Et</b>)</h5><div class="NLM_p last">From the flash chromatography purification of step g as described above for compound <b>77Et</b>, the title compound <b>78Et</b> was isolated as the second eluting diastereomer (0.21 g, 0.71 mmol, 11% yield) as a white solid. MS (ES<sup>+</sup>) C<sub>16</sub>H<sub>20</sub>ClNO<sub>2</sub> calculated  293; found 294 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD): δ 7.78 (d, <i>J</i> = 8.6 Hz, 2H), 7.46 (d, <i>J</i> = 8.6 Hz, 2H), 3.95–3.87 (m, 1H), 3.26–3.18 (m, 1H), 2.09 (ddd, <i>J</i> = 24.4, 12.6, 7.1 Hz, 2H), 1.75–1.55 (m, 4H), 1.35–1.23 (m, 2H), 0.94 (t, <i>J</i> = 7.4 Hz, 3H), 0.71 (dt, <i>J</i> = 9.3, 3.2 Hz, 1H).</div></div><div id="sec5_1_2_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i47" class="anchor-spacer"></div><h5 class="article-section__title" id="_i47"> 4-Chloro-<i>N</i>-(1-((1<i>R</i>,3<i>s</i>,5<i>S</i>,6<i>r</i>)-3-(quinolin-4-yloxy)bicyclo[3.1.0]hexan-6-yl)propyl)benzamide (Step h, <b>22</b>)</h5><div class="NLM_p last">To a solution of 4-chloro-<i>N</i>-(1-((1<i>R</i>,3<i>s</i>,5<i>S</i>,6<i>r</i>)-3-hydroxybicyclo[3.1.0]hexan-6-yl)propyl)benzamide <b>78Et</b> (27 mg, 0.084 mmol) in DMSO (0.17 mL) under nitrogen was added sodium hydride (60% in mineral oil, 8.1 mg, 0.20 mmol) and the mixture was stirred at RT for 30 min. To the resulting yellow mixture was added 4-bromoquinoline (25 mg, 0.12 mmol), and the resulting mixture was stirred at 80 °C overnight. To the mixture was added two drops of a saturated NH<sub>4</sub>Cl. The mixture was filtered (0.2 μM Whatman syringe filter), rinsed with DMSO (3 × 0.3 mL), and the filtrate was purified by mass-triggered preparative HPLC (mobile phase: A = 0.1% TFA/H<sub>2</sub>O, B = 0.1% TFA/MeCN; gradient: B = 20–50%; 12 min; column: C18) to give <b>22</b> (32.9 mg, 73%). HRMS (ES<sup>+</sup>) C<sub>25</sub>H<sub>25</sub>ClN<sub>2</sub>O<sub>2</sub> calculated 421.1677 [M + H]<sup>+</sup>; found 421.1671 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD): δ 8.94 (d, <i>J</i> = 6.80 Hz, 1H), 8.45 (d, <i>J</i> = 7.93 Hz, 1H), 8.34 (d, <i>J</i> = 8.69 Hz, 1H), 8.14–8.09 (m, 1H), 8.08–8.04 (m, 1H), 7.88 (ddd, <i>J</i> = 8.21, 6.89, 1.13 Hz, 1H), 7.84–7.79 (m, 2H), 7.50–7.47 (m, 2H), 7.46 (d, <i>J</i> = 6.80 Hz, 1H), 5.17 (quin, <i>J</i> = 6.89 Hz, 1H), 3.41 (qd, <i>J</i> = 8.62, 5.85 Hz, 1H), 2.61–2.65 (m, 1H), 2.56 (dd, <i>J</i> = 13.41, 6.99 Hz, 1H), 2.28–2.18 (m, 2H), 1.83–1.75 (m, 1H), 1.75–1.67 (m, 1H), 1.64 (td, <i>J</i> = 6.04, 3.40 Hz, 1H), 1.56 (td, <i>J</i> = 6.04, 3.40 Hz, 1H), 1.00 (t, <i>J</i> = 7.37 Hz, 3H), 0.90 (dt, <i>J</i> = 8.69, 3.40 Hz, 1H).</div></div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> 4-Chloro-<i>N</i>-((<i>R</i>)-1-((1<i>R</i>,3<i>S</i>,5<i>S</i>,6<i>r</i>)-3-(5,6-difluoro-1<i>H</i>-benzo[<i>d</i>]imidazole-1-yl)bicyclo[3.1.0]hexan-6-yl)propyl)benzamide (<b>62</b>)</h4><div id="sec5_1_3_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i49" class="anchor-spacer"></div><h5 class="article-section__title" id="_i49"> (<i>S</i>)-<i>N</i>-((<i>E</i>)-((1<i>R</i>,5<i>S</i>,6<i>r</i>)-3-((<i>tert</i>-Butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexan-6-yl)methylene)-2-methylpropane-2-sulfinamide (Step c, <b>75(S</b>))</h5><div class="NLM_p last">(1<i>R</i>,5<i>S</i>,6<i>r</i>)-3-((<i>tert</i>-Butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexane-6-carbaldehyde <b>74</b> (26.5 g, 72.7 mmol) was dissolved in DCM (73 mL) and (<i>S</i>)-2-methylpropane-2-sulfinamide (17.6 g, 145 mmol) along with copper(II) sulfate (11.6 g, 72.7 mmol) were added. The solution was stirred at RT overnight. The solution was filtered through Celite, concentrated, and purified by flash chromatography (5–20% EtOAc in hexanes) to give <b>75(S)</b> (29 g, 63 mmol, 86% yield), and C<sub>27</sub>H<sub>37</sub>NO<sub>2</sub>SSi calculated 467; found  468 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.62–7.52 (m, 4H), 7.50–7.37 (m, 7H), 4.35 (t, <i>J</i> = 6.2 Hz, 1H), 2.10–1.98 (m, 2H), 1.97–1.90 (m, 2H), 1.88–1.55 (m, 3H), 1.10 (s, 9H), 1.02 (s, 9H).</div></div><div id="sec5_1_3_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i50" class="anchor-spacer"></div><h5 class="article-section__title" id="_i50"> (<i>S</i>)-<i>N</i>-((1<i>R</i>)-1-((1<i>R</i>,5<i>S</i>)-3-((<i>tert</i>-Butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexan-6-yl)propyl)-2-methylpropane-2-sulfinamide (Step d, <b>76Et(R)</b>)</h5><div class="NLM_p last">To a cooled −78 °C solution of (<i>S</i>,<i>E</i>)-<i>N</i>-(((1<i>R</i>,5<i>S</i>)-3-((<i>tert</i>-butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexan-6-yl)methylene)-2-methylpropane-2-sulfinamide <b>75(S)</b> (29.6 g, 63.2 mmol) in THF (126 mL) was added ethylmagnesium bromide (31.6 mL, 95 mmol). The resulting mixture was stirred at −78 °C for ∼5 min, removed from the bath, and allowed to warm to RT overnight. The reaction was slowly poured into a mixture of ice and saturated NH<sub>4</sub>Cl (150 mL) and stirred for until the ice melted. The mixture was diluted with EtOAc (400 mL) and the product extracted into the organic layer. The aqueous layer was extracted with EtOAc and the organic layers were combined, washed with saturated NaCl, dried over MgSO<sub>4</sub>, filtered, and concentrated to give <b>76Et(R)</b> (32 g, 65 mmol, 103% yield) as a clear very viscous oil/semisolid/gum. MS (ES<sup>+</sup>) C<sub>29</sub>H<sub>43</sub>NO<sub>2</sub>SSi calculated 497; found 498 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (600 MHz, DMSO): δ 7.65–7.52 (m, 4H), 7.51–7.34 (m, 6H), 4.91–4.73 (m, 1H), 4.33–4.22 (m, 1H), 2.40 (dt, <i>J</i> = 11.2, 5.6 Hz, 1H), 1.94–1.83 (m, 2H), 1.78–1.67 (m, 2H), 1.66–1.39 (m, 2H), 1.37–1.17 (m, 2H), 1.16–1.04 (m, 9H), 1.02–0.89 (m, 12H), 0.85–0.76 (m, 1H).</div></div><div id="sec5_1_3_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i51" class="anchor-spacer"></div><h5 class="article-section__title" id="_i51"> 4-Chloro-<i>N</i>-((<i>R</i>)-1-((1<i>R</i>,3<i>R</i>,5<i>S</i>,6<i>r</i>)-3-hydroxybicyclo[3.1.0]hexan-6-yl)propyl)benzamide (Step f and g, <b>77Et(R)</b>)</h5><div class="NLM_p last">To a cooled 0 °C solution of (<i>S</i>)-<i>N</i>-((1<i>R</i>)-1-((1<i>R</i>,5<i>S</i>)-3-((<i>tert</i>-butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexan-6-yl)propyl)-2-methylpropane-2-sulfinamide <b>76Et(R)</b> (32 g, 65 mmol) in MeOH (200 mL) was added HCl (4 M in MeOH, 4 equiv) freshly prepared by the slow addition of acetyl chloride (18.4 mL, 260 mmol) to MeOH (70 mL) at 0 °C, stirred for 15 min, and then transferred using a syringe, and the resulting mixture was stirred at 0 °C for 10 min, ice bath removed, and kept at RT for 3 h. The reaction was cooled in an ice bath, slowly basified with DIEA (57 mL, 320 mmol), concentrated, and dried under house vacuum overnight. The reaction was resuspended in DMF (200 mL), DIEA (23 mL, 130 mmol) and 2,5-dioxopyrrolidin-1-yl 4-chlorobenzoate (17 g, 68 mmol) were added, and the reaction was stirred at RT overnight. The reaction was diluted with EtOAc (500 mL) and washed with 0.25 M NaOH (400 mL), 0.25 M HCl (400 mL), water (300 mL), and brine (200 mL). The aqueous layers were extracted with EtOAc (1 × 500, 1 × 200 mL), the organic layers were combined, dried over MgSO<sub>4</sub>, filtered, and concentrated to give the crude product as a yellow solid, 35 g. The crude (a mixture of the TBDPS intermediate and the desired alcohol) was dissolved in THF (25 mL), cooled in an ice bath, and TBAF (1 M in THF, 70 mL, 70 mmol) was added dropwise. The reaction was stirred at 0 °C for 5 min then at RT overnight. The reaction was concentrated, diluted in THF (10 mL), and more TBAF (30 mL) was added. The reaction was heated at 40 °C overnight. The reaction was poured into ice water and extracted with EtOAc (3 × 200 mL). The organic layers were washed with brine, combined, dried over MgSO<sub>4</sub>, filtered, and concentrated to give the crude desired product as a yellow semi solid. The material was diluted with toluene (100 mL), heated to reflux, and allowed to cool to RT overnight. The solid was filtered off, washed with toluene (3 × 10 mL), hexanes (3 × 20 mL), and dried over house vacuum to give a mixture of cis alcohol (<b>78Et(R)</b>) to trans alcohol (<b>77Et(R)</b>) ∼ 10:1 as a white solid (2.7 g). The filtrate was concentrated to give a yellow semisolid (30.5 g) that was dissolved in DCM/MeOH, supported on silica gel and purified by flash chromatography in two batches [either 10–70% or 10–60% of a solution of EtOAc/IPA (8:2) in hexanes] to give <b>77Et(R)</b> as the first eluting chiral diastereomer (9.6 g, 33 mmol, 50% yield) as a white solid. MS (ES<sup>+</sup>) C<sub>16</sub>H<sub>20</sub>ClNO<sub>2</sub> calculated 293; found 294 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO): δ 8.34 (d, <i>J</i> = 8.7 Hz, 1H), 7.89 (d, <i>J</i> = 8.7 Hz, 2H), 7.52 (d, <i>J</i> = 8.6 Hz, 2H), 4.42 (d, <i>J</i> = 2.8 Hz, 1H), 4.17 (td, <i>J</i> = 6.4, 2.6 Hz, 1H), 3.28–3.19 (m, 1H), 1.97–1.84 (m, 2H), 1.67–1.52 (m, 4H), 1.27 (dt, <i>J</i> = 9.1, 3.2 Hz, 1H), 1.23–1.11 (m, 2H), 0.87 (t, <i>J</i> = 7.4 Hz, 3H).</div></div><div id="sec5_1_3_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i52" class="anchor-spacer"></div><h5 class="article-section__title" id="_i52"> 2,5-Dioxopyrrolidin-1-yl 4-Chlorobenzoate</h5><div class="NLM_p last">To a 500 mL round bottom flask were added 4-chlorobenzoic acid (50 g, 319 mmol), bis(2,5-dioxopyrrolidin-1-yl) carbonate (90 g, 351 mmol), DMAP (0.975 g, 7.98 mmol), and then DMF (319 mL). The resulting mixture was stirred at 40 °C overnight. The reaction mixture was poured into ice water (∼500 mL water, ∼200 mL of ice) and the resulting mixture was stirred until the ice melted. The white solid was filtered off, washed with water, 0.25 M HCl (100 mL), 0.25 M NaOH (100 mL), water, hexanes, ethyl ether, hexanes, dried over house vacuum for 1 h, and dried in a lyophilizer to give (73 g, 288 mmol, 90% yield) as a white solid. MS (ES<sup>+</sup>) C<sub>11</sub>H<sub>8</sub>ClNO<sub>4</sub> calculated 253; found 139 [M – NHS]<sup>+</sup>. <sup>1</sup>H NMR (600 MHz, DMSO): δ 8.11 (d, <i>J</i> = 8.1 Hz, 2H), 7.75 (d, <i>J</i> = 8.1 Hz, 2H), 2.90 (s, 4H).</div></div><div id="sec5_1_3_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i53" class="anchor-spacer"></div><h5 class="article-section__title" id="_i53"> (1<i>R</i>,3<i>R</i>,5<i>S</i>,6<i>r</i>)-6-((<i>R</i>)-1-(4-Chlorobenzamido)propyl)bicyclo[3.1.0]hexan-3-yl Methanesulfonate (Step i, <b>79Et(R)</b>)</h5><div class="NLM_p last">To a solution of 4-chloro-<i>N</i>-((<i>R</i>)-1-((1<i>R</i>,3<i>r</i>,5<i>S</i>,6<i>r</i>)-3-hydroxybicyclo[3.1.0]hexan-6-yl)propyl)benzamide <b>77Et(R)</b> (9.6 g, 33 mmol) in DCM (100 mL) cooled in an ice bath were added TEA (9.1 mL, 65 mmol) and Ms-Cl (3.8 mL, 49 mmol, dropwise) and the resulting mixture was stirred in the ice bath for 5 min then at RT for 2 h. The reaction was cooled in an ice bath diluted with DCM and quenched with 1 M HCl. The reaction was mixed, separated, and the aqueous layer extracted with EtOAc twice. The organic layers were washed with water and saturated NaCl, combined, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give <b>79EtR</b> (13 g, 35 mmol, 108% yield) as a clear semisolid. MS (ES<sup>+</sup>) C<sub>17</sub>H<sub>22</sub>ClNO<sub>4</sub>S calculated 371; found  372 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.39 (d, <i>J</i> = 8.6 Hz, 1H), 7.89 (d, <i>J</i> = 8.8 Hz, 2H), 7.53 (d, <i>J</i> = 8.8 Hz, 2H), 5.13 (t, <i>J</i> = 6.5 Hz, 1H), 3.34–3.23 (m, 1H), 3.12 (s, 3H), 2.32–2.14 (m, 2H), 2.04–1.85 (m, 2H), 1.74–1.51 (m, 2H), 1.38–1.26 (m, 2H), 1.01–0.93 (m, 1H), 0.88 (t, <i>J</i> = 7.4 Hz, 3H).</div></div><div id="sec5_1_3_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i54" class="anchor-spacer"></div><h5 class="article-section__title" id="_i54"> 4-Chloro-<i>N</i>-((<i>R</i>)-1-((1<i>R</i>,3<i>S</i>,5<i>S</i>,6<i>r</i>)-3-(5,6-difluoro-1<i>H</i>-benzo[<i>d</i>]imidazole-1-yl)bicyclo[3.1.0]hexan-6-yl)propyl)benzamide (Step j, <b>62</b>, IACS-9779)</h5><div class="NLM_p last">To a suspension of (1<i>R</i>,3<i>R</i>,5<i>S</i>,6<i>r</i>)-6-((<i>R</i>)-1-(4-chlorobenzamido)propyl)bicyclo[3.1.0]hexan-3-yl methanesulfonate <b>79Et(R)</b> (12.1 g, 32.5 mmol) in dioxane (100 mL) were added 5,6-difluoro-1<i>H</i>-benzo[<i>d</i>]imidazole (12.5 g, 81 mmol) and cesium carbonate (26.5 g, 81 mmol) and the resulting mixture was stirred at 65 °C for 1 day. The reaction was concentrated, diluted with DMF (100 mL), and heated at 65 °C for 4.5 h. The reaction was poured into ice water, stirred, and warmed to RT. The mixture was diluted with EtOAc and the desired product was extracted into the organic phase. The aqueous layer was extracted twice with EtOAc. The organic layers were washed with brine, combined, dried over MgSO<sub>4</sub>, filtered, and concentrated to give a yellow semisolid (30 g). The crude was supported on silica gel and purified twice in two batches. The first flash chromatography purifications were with increasing concentrations of a solution of EtOAc/IPA (8:2) or EtOAc/IPA/MeOH/NH<sub>4</sub>OH (80:20:2:2) in hexanes (5–50%) and the second was with increasing concentrations of a solution of DCM/MeOH/NH<sub>4</sub>OH (90:10:1) in DCM (5–50%). The first batch was crystallized from EtOH to give 4.4 g of the desired product as a white solid. The impure chromatography fractions from both batches were combined with the filtrate from the first batch crystallization, purified by flash chromatography, and combined with the pure material from the second batch to produce 5.7 g of the desired product. The combined total of <b>62</b> was 9.4 g (22 mmol, 67% yield). The title compound <b>62</b> (IACS-9779) was also synthesized by WuXi Apptec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China, EW10144-31-P1. HRMS (ES<sup>+</sup>) C<sub>23</sub>H<sub>22</sub>ClF<sub>2</sub>N<sub>3</sub>O calculated  430.1492 [M + H]<sup>+</sup>; found 430.1488 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (600 MHz, DMSO): δ 8.43 (s, 1H), 8.32 (d, <i>J</i> = 8.6 Hz, 1H), 7.90 (d, <i>J</i> = 8.3 Hz, 2H), 7.84 (dd, <i>J</i> = 10.9, 7.3 Hz, 1H), 7.69 (dd, <i>J</i> = 11.2, 7.4 Hz, 1H), 7.55 (d, <i>J</i> = 8.4 Hz, 2H), 4.65–4.55 (m, 1H), 3.47–3.37 (m, 1H), 2.38–2.31 (m, 1H), 2.29–2.12 (m, 3H), 1.72–1.61 (m, <i>J</i> = 6.8 Hz, 2H), 1.52–1.35 (m, 2H), 1.14 (dt, <i>J</i> = 7.3, 3.4 Hz, 1H), 0.92 (t, <i>J</i> = 7.4 Hz, 3H).</div></div></div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> Compounds <b>84</b> and <b>85</b></h3><div id="sec5_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> (1<i>R</i>)-1-((1<i>R</i>,5<i>S</i>)-3-((<i>tert</i>-Butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexan-6-yl)propan-1-amine (<b>83Et(R)</b>)</h4><div class="NLM_p last">To a cooled (0 °C) solution of (<i>S</i>)-<i>N</i>-((1<i>R</i>)-1-((1<i>R</i>,5<i>S</i>)-3-((<i>tert</i>-butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexan-6-yl)propyl)-2-methylpropane-2-sulfinamide <b>76Et(R)</b> (13.56 g, 27.2 mmol) in methanol (272 mL) was added HCl (4 M in dioxane, 34.0 mL, 136 mmol) dropwise. The solution was stirred at RT for 2 h. The solution was cooled to 0 °C and Hunig’s base (23.79 mL, 136 mmol) was added to quench. The solution was concentrated under pressure, taken up in EtOAc, washed with water, and the organics were collected, dried, and concentrated under pressure to the title compound <b>83Et(R)</b> (9.52 g, 24.18 mmol, 89% yield) and used directly as crude in the next step. MS (ES<sup>+</sup>) C<sub>25</sub>H<sub>35</sub>NOSi calculated 393; found 377 in <i>m</i>/<i>z</i> [M-NH<sub>2</sub>]<sup>+</sup>.</div></div><div id="sec5_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> (2<i>R</i>)-<i>N</i>-((1<i>R</i>)-1-((1<i>R</i>,5<i>S</i>,6<i>r</i>)-3-((<i>tert</i>-Butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexan-6-yl)propyl)-3,3,3-trifluoro-2-methoxy-2-phenylpropanamide (<b>84</b>)</h4><div class="NLM_p last">To a solution of (1<i>R</i>)-1-((1<i>R</i>,5<i>S</i>,6<i>r</i>)-3-((<i>tert</i>-butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexan-6-yl)propan-1-amine <b>83Et(R)</b> (5 mg, 0.013 mmol) in DCM (127 μL) were added (<i>S</i>)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoyl chloride (3.53 mg, 0.014 mmol) and Hunig’s base (3.33 μL, 0.019 mmol) and the resulting mixture was stirred at 25 °C for 15 min. The mixture was diluted with DCM (3 mL), H<sub>2</sub>O (2 mL) was added, and the layers were separated. The aqueous phase was extracted with DCM (3 × 3 mL), the combined organic layers were washed with saturated NaCl, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The title compound <b>84</b> was used without further purification. MS (ES<sup>+</sup>) C<sub>35</sub>H<sub>42</sub>F<sub>3</sub>NO<sub>3</sub>Si calculated  609; found 610 in <i>m</i>/<i>z</i> [M + H]<sup>+</sup>. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.65–7.63 (m, 5H), 7.51–7.49 (m, 10H), 4.26 (t, <i>J</i> = 6.3 Hz, 1H), 3.72 (s, 3H), 3.16–3.12 (m, 1H), 1.91–1.83 (m, 2H), 1.67–1.65 (m, 3H), 1.59–1.57 (m, 2H), 1.46 (dt, <i>J</i> = 9.1, 3.2 Hz, 1H), 1.25–1.22 (m, 1H), 1.19–1.18 (m, 1H), 0.99 (s, 9H), 0.73 (t, <i>J</i> = 7.4 Hz, 3H).</div></div><div id="sec5_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> (2<i>S</i>)-<i>N</i>-((1<i>R</i>)-1-((1<i>R</i>,5<i>S</i>,6<i>r</i>)-3-((<i>tert</i>-Butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexan-6-yl)propyl)-3,3,3-trifluoro-2-methoxy-2-phenylpropanamide (<b>85</b>)</h4><div class="NLM_p last">To a solution of (1<i>R</i>)-1-((1<i>R</i>,5<i>S</i>,6<i>r</i>)-3-((<i>tert</i>-butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexan-6-yl)propan-1-amine <b>83Et(R)</b> (5 mg, 0.013 mmol) in DCM (127 μL) were added (<i>R</i>)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoyl chloride (3.53 mg, 0.014 mmol) and Hunig’s base (3.33 μL, 0.019 mmol) and the resulting mixture was stirred at 25 °C for 15 min. The mixture was diluted with DCM (3 mL), H<sub>2</sub>O (2 mL) was added, and the layers were separated. The aqueous phase was extracted with DCM (3 × 3 mL), the combined organic layers were washed with saturated NaCl, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The title compound <b>85</b> was used without further purification. MS (ES<sup>+</sup>) C<sub>35</sub>H<sub>42</sub>F<sub>3</sub>NO<sub>3</sub>Si calculated 609; found 610 in <i>m</i>/<i>z</i> [M + H]<sup>+</sup>. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.22 (d, <i>J</i> = 8.8 Hz, 1H), 7.64–7.62 (m, 5H), 7.52–7.48 (m, 10H), 4.25 (t, <i>J</i> = 6.3 Hz, 1H), 3.72 (s, 3H), 3.63–3.57 (m, 1H), 3.15–3.08 (m, 2H), 1.91–1.81 (m, 2H), 1.66–1.62 (m, 3H), 1.57 (dd, <i>J</i> = 14.2, 6.7 Hz, 1H), 1.14–1.11 (m, 1H), 0.94 (s, 9H), 0.88 (t, <i>J</i> = 7.3 Hz, 3H).</div></div><div id="sec5_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> <i>N</i>-(4-Chlorophenyl)-2-((1<i>R</i>,3<i>s</i>,5<i>S</i>,6<i>r</i>)-3-(5,6-difluoro-1<i>H</i>-benzo[<i>d</i>]imidazole-1-yl)bicyclo[3.1.0]hexan-6-yl)propanamide (<b>70</b>)</h4><div id="sec5_2_4_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i60" class="anchor-spacer"></div><h5 class="article-section__title" id="_i60"> (1<i>R</i>,5<i>S</i>)-3-((<i>tert</i>-Butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexane-6-carbaldehyde, (<b>74ml</b>, Mother Liquor)</h5><div class="NLM_p last">(1<i>R</i>,3<i>s</i>,5<i>S</i>,6<i>r</i>)-3-((<i>tert</i>-butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexane-6-carbaldehyde, the cis isomer, can be crystalized from crude aldehyde. The crude aldehyde mixture of diastereomers (450 g) was heated to 50 °C with stirring (∼30 min) in hexanes (700 mL) to give an orange solution (total volume 1300 mL). The solution was concentrated under reduced pressure until crystallization began. The mixture was then allowed to cool to RT over 8 h, and then cooled to 4 °C for 3 days. The mixture was filtered and the resulting solid was washed with hexanes to give a white crystalline solid, predominantly the cis isomer (218.6 g), which may be recrystallized from warm methanol. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 8.92 (d, <i>J</i> = 5.2 Hz, 1H), 7.66–7.58 (m, 4H), 7.46–7.41 (m, 2H), 7.40–7.35 (m, 4H), 3.95–3.83 (m, 1H), 2.10–1.99 (m, 2H), 1.97–1.87 (m, 4H), 1.34 (dt, <i>J</i> = 5.2, 2.5 Hz, 1H), 1.03 (s, 9H). The mother liquor (<b>ml</b>) was concentrated to give the title compound <b>74ml</b> as an orange oil (230.6 g), and used as is in the next step. The NMR mixture of diastereomers (not a complete integration): <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 9.26 (d, <i>J</i> = 4.7 Hz, 0.46H), 9.04 (d, <i>J</i> = 6.3 Hz, 0.21H), 8.92 (d, <i>J</i> = 5.3 Hz, 0.17H), 7.69–7.57 (m, 4H), 7.48–7.33 (m, 6H), 4.44–4.37 (m, 0.23H), 4.36–4.31 (m, 0.55H), 3.94–3.86 (m, 0.19H), 2.49 (dt, <i>J</i> = 4.9, 2.5 Hz, 0.51H), 2.27–2.14 (m, 0.88H), 2.09–1.88 (m, 4.53H), 1.57 (td, <i>J</i> = 8.0, 6.1 Hz, 0.23H), 1.34 (dt, <i>J</i> = 5.2, 2.5 Hz, 0.2H), 1.11–0.97 (m, 9H).</div></div><div id="sec5_2_4_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i61" class="anchor-spacer"></div><h5 class="article-section__title" id="_i61"> 1-((1<i>R</i>,3<i>r</i>,5<i>S</i>,6<i>r</i>)-3-((<i>tert</i>-Butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexan-6-yl)ethanol (<b>86p</b>, Step p)</h5><div class="NLM_p last">To a cooled 0 °C solution of (1<i>R</i>,3<i>r</i>,5<i>S</i>,6<i>r</i>)-3-((<i>tert</i>-butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexane-6-carbaldehyde <b>74ml</b> (100 g, 274 mmol) in THF (300 mL) was added methylmagnesium bromide (110 mL, 329 mmol). The resulting mixture was stirred at 0 °C for 3 h, saturated NH<sub>4</sub>Cl (20 mL) was added slowly at 0 °C, and the layers were separated. The aqueous phase was extracted with EtOAc (3 × 50 mL), the combined organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The title product <b>86p</b>, as a yellow oil, was used without further purification. MS (ES<sup>+</sup>) C<sub>24</sub>H<sub>32</sub>O<sub>2</sub>Si calculated 380; found 363 [M – OH]<sup>+</sup>.</div></div><div id="sec5_2_4_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i62" class="anchor-spacer"></div><h5 class="article-section__title" id="_i62"> 1-((1<i>R</i>,3<i>r</i>,5<i>S</i>,6<i>r</i>)-3-((<i>tert</i>-Butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexan-6-yl)ethanone (<b>86</b>, Step q)</h5><div class="NLM_p last">To a cooled 0 °C solution of <b>86p</b> (104 g, 273 mmol) in DCM (wet) (364 mL) was added DMP (139 g, 328 mmol) portion wise. The resulting mixture was stirred at 25 °C for 3 h. The reaction mixture was cooled to 0 °C, saturated NaHCO<sub>3</sub> (20 mL) was added slowly, an equal volume of Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> was also added, the mixture was allowed to stir for 30 min, and the layers were separated. The aqueous phase was extracted with DCM (3 × 50 mL), the combined organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified via a silica gel plug eluting with DCM to give the title compound <b>86</b> (83 g, 80%) as a pale orange liquid, and was used without further purification. MS (ES<sup>+</sup>) C<sub>24</sub>H<sub>30</sub>O<sub>2</sub>Si calculated 378; found 379 [M + H]<sup>+</sup>.</div></div><div id="sec5_2_4_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i63" class="anchor-spacer"></div><h5 class="article-section__title" id="_i63"> <i>tert</i>-Butyl(((1<i>R</i>,3<i>r</i>,5<i>S</i>,6<i>r</i>)-6-((<i>E</i>)-1-methoxyprop-1-en-2-yl)bicyclo[3.1.0]hexan-3-yl)oxy)diphenylsilane (<b>87</b>, Step r)</h5><div class="NLM_p last">To a −13 °C solution of (methoxymethyl)triphenylphosphonium chloride (5.23 g, 15.3 mmol) in THF (21.8 mL) was added LHMDS (14.8 mL, 14.8 mmol) and the resulting mixture was stirred at 2–5 °C for 1 h. A solution of <b>86</b> (3.3 g, 8.72 mmol) in THF (7.3 mL) was added dropwise over 30 min and the reaction was stirred at 25 °C for 12 h. 1 M HCl (5 mL) was added, and the layers were separated. The aqueous phase was extracted with EtOAc (3 × 20 mL), the combined organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified via silica gel chromatography (5–20% EtOAc in hexanes) to give the title compound <b>87</b> (1.96 g, 4.82 mmol, 55.3% yield) as a colorless liquid. MS (ES<sup>+</sup>) C<sub>26</sub>H<sub>34</sub>O<sub>2</sub>Si calculated 406; found 407 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (600 MHz, DMSO): δ 7.60–7.55 (m, 4H), 7.48–7.41 (m, 6H), 5.93–5.72 (m, 1H), 4.37–3.88 (m, 1H), 3.52–3.36 (m, 3H), 1.98–1.88 (m, 2H), 1.82–1.65 (m, 2H), 1.46–1.10 (m, 5H), 1.05–0.65 (m, 10H).</div></div><div id="sec5_2_4_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i64" class="anchor-spacer"></div><h5 class="article-section__title" id="_i64"> 2-((1<i>R</i>,3<i>r</i>,5<i>S</i>,6<i>r</i>)-3-((<i>tert</i>-Butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexan-6-yl)propanal (<b>88s</b>, Step s)</h5><div class="NLM_p last">To a solution of <b>87</b> (7.5 g, 18.4 mmol) in dioxane (52.7 mL) were added PPTS (5.10 g, 20.3 mmol) and water (8.8 mL) and the resulting mixture was stirred at 70 °C for 12 h. The volatiles were removed under reduced pressure. The reaction mixture was diluted with EtOAc (30 mL) and washed with H<sub>2</sub>O (2 × 50 mL). The layers were separated, and the organic layer was washed with brine (2 × 50 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure to give the title compound <b>88s</b> as a pale yellow oil, and was used without further purification.</div></div><div id="sec5_2_4_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i65" class="anchor-spacer"></div><h5 class="article-section__title" id="_i65"> 2-((1<i>R</i>,3<i>r</i>,5<i>S</i>,6<i>r</i>)-3-((<i>tert</i>-Butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexan-6-yl)propanoic Acid (<b>88</b>, Step t)</h5><div class="NLM_p last">To a cooled 0 °C solution of <b>88s</b> (7.24 g, 18.44 mmol) in <i>t</i>BuOH (138 mL) and 2-methyl-2-butene (39.1 mL, 369 mmol) was added dropwise as freshly prepared solution of sodium chlorite (3.34 g, 36.9 mmol) and potassium dihydrogenphosphate (5.02 g, 36.9 mmol) in water (46.1 mL). The resulting mixture was stirred at 0 °C for 2 h, then allowed to warm to 25 °C with vigorous stirring for 12 h. Brine (150 mL) was added, and the layers were separated. The aqueous phase was extracted with DCM (3 × 75 mL), the combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified via silica gel chromatography (0–5% MeOH in DCM) to give the title compound <b>88</b> (6.7 g, 16.4 mmol, 89% yield) as a colorless liquid. MS (ES<sup>–</sup>) C<sub>25</sub>H<sub>32</sub>O<sub>3</sub>Si calculated 408; found 407 [M – H]<sup>−</sup>. <sup>1</sup>H NMR (600 MHz, DMSO): δ 11.94 (s, 1H), 7.65–7.60 (m, 2H), 7.59–7.52 (m, 4H), 7.49–7.35 (m, 4H), 4.30–3.88 (m, 1H), 1.97–1.36 (m, 4H), 1.31–1.16 (m, 1H), 1.17–1.07 (m, 7H), 1.06–0.90 (m, 7H), 0.89–0.80 (m, 1H).</div></div><div id="sec5_2_4_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i66" class="anchor-spacer"></div><h5 class="article-section__title" id="_i66"> 2-((1<i>R</i>,5<i>S</i>,6<i>r</i>)-3-((<i>tert</i>-Butyldiphenylsilyl)oxy)bicyclo[3.1.0]hexan-6-yl)-<i>N</i>-(4-chlorophenyl)propanamide (<b>89/90u</b>, Step u)</h5><div class="NLM_p last">To a solution of <b>88</b> (800 mg, 1.95 mmol) and pyridine (0.47 mL, 5.87 mmol) in EtOAc (20 mL) was added T3P (2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane 2,4,6-trioxide, 50% in EtOAc, 2.9 mL, 2.9 mmol) and the resulting mixture was stirred at RT for 0.5 h. To this mixture, 4-chloroaniline (275 mg, 2.15 mmol) was added and the mixture was stirred at RT for 12 h. The mixture was quenched with 10% Na<sub>2</sub>CO<sub>3</sub> (30 mL) and extracted with EtOAc (2 × 50 mL). Combined organics were washed with brine (2 × 30 mL), dried over MgSO<sub>4</sub>, filtered, and concentrated to give the crude product. The residue was purified via silica gel chromatography (2–20% EtOAc in hexanes) to give the title compound <b>88/90u</b> (735 mg, 1.42 mmol, 72% yield) as a white solid. MS (ES<sup>+</sup>) C<sub>31</sub>H<sub>36</sub>ClNO<sub>2</sub>Si calculated 518; found 519 [M + H]<sup>+</sup>. The product was used without further purification.</div></div><div id="sec5_2_4_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i67" class="anchor-spacer"></div><h5 class="article-section__title" id="_i67"> <i>N</i>-(4-Chlorophenyl)-2-((1<i>R</i>,3<i>r</i>,5<i>S</i>,6<i>r</i>)-3-hydroxybicyclo[3.1.0]hexan-6-yl)propanamide (<b>89</b>) and <i>N</i>-(4-Chlorophenyl)-2-((1<i>R</i>,3<i>s</i>,5<i>S</i>,6<i>r</i>)-3-hydroxybicyclo[3.1.0]hexan-6-yl)propanamide (<b>90</b>, Step v)</h5><div class="NLM_p last">To a solution of <b>88/90u</b> (1.6 g, 3.1 mmol) in THF (2 mL) was added a solution of TBAF in THF (1 M, 10.0 mL, 10.0 mmol) and the resulting mixture was stirred at 50 °C for 24 h. The reaction mixture was diluted with EtOAc (50 mL), 5% HCl (15 mL) was added, and the layers were separated. The aqueous phase was extracted with EtOAc (3 × 10 mL), the combined organic layers were washed with water (20 mL), followed by brine (20 mL), dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified via silica gel chromatography (10–80% EtOAc in hexane) to give the title compound <b>89</b> as the first eluting diastereomer (220 mg, 0.786 mmol, 25.5% yield) as a clear oil. MS (ES<sup>+</sup>) C<sub>15</sub>H<sub>18</sub>ClNO<sub>2</sub> calculated 279; found 280 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.66 (s, 1H), 7.55–7.49 (m, 2H), 7.32–7.27 (m, 2H), 4.44 (t, <i>J</i> = 6.4 Hz, 1H), 2.23–2.13 (m, 2H), 1.80–1.75 (m, 2H), 1.70–1.65 (m, 1H), 1.45–1.20 (m, 7H). The title compound <b>90</b> was obtained as the second diastereomer. MS (ES<sup>+</sup>) C<sub>15</sub>H<sub>18</sub>ClNO<sub>2</sub> calculated 279; found 280 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO): δ 9.80 (s, 1H), 7.63 (d, <i>J</i> = 8.9 Hz, 2H), 7.34 (d, <i>J</i> = 8.8 Hz, 2H), 4.49 (d, <i>J</i> = 5.6 Hz, 1H), 3.82–3.73 (m, 1H), 2.01–1.84 (m, 2H), 1.69–1.61 (m, 1H), 1.58–1.44 (m, 2H), 1.25–1.20 (m, 1H), 1.10 (d, <i>J</i> = 6.8 Hz, 3H), 1.06–1.00 (m, 1H), 0.68–0.63 (m, 1H).</div></div><div id="sec5_2_4_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i68" class="anchor-spacer"></div><h5 class="article-section__title" id="_i68"> (1<i>R</i>,3<i>r</i>,5<i>S</i>,6<i>r</i>)-6-(1-((4-Chlorophenyl)amino)-1-oxopropan-2-yl)bicyclo[3.1.0]hexan-3-yl Methanesulfonate (<b>70i</b>, Step i)</h5><div class="NLM_p last">To a solution of <b>89</b> (215 mg, 0.77 mmol) in DCM (5 mL) were added Ms-Cl (0.12 mL, 1.54 mmol) and TEA (0.32 mL, 2.3 mmol) and the resulting mixture was stirred at 0 °C for 2 h. The reaction mixture was diluted with DCM (20 mL), water (10 mL) was added, and the layers were separated. The aqueous phase was extracted with DCM (3 × 10 mL), the combined organic layers were washed with 5% HCl (2 × 10 mL), followed by brine (1 × 10 mL), dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified via silica gel chromatography (20–80% EtOAc in hexane) to give the title compound <b>70i</b> (242 mg, 0.676 mmol, 88% yield) as a clear oil. MS (ES<sup>+</sup>) C<sub>16</sub>H<sub>20</sub>ClNO<sub>4</sub>S calculated 357; found 358 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.55–7.49 (m, 2H), 7.32–7.27 (m, 2H), 5.21 (t, <i>J</i> = 6.4 Hz, 1H), 2.99 (s, 3H), 2.35–2.15 (m, 4H), 1.81–1.71 (m, 1H), 1.48–1.40 (m, 1H), 1.39–1.35 (m, 1H), 1.31 (d, <i>J</i> = 7.0 Hz, 3H), 1.16–1.12 (m, 1H).</div></div><div id="sec5_2_4_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i69" class="anchor-spacer"></div><h5 class="article-section__title" id="_i69"> <i>N</i>-(4-Chlorophenyl)-2-((1<i>R</i>,3<i>s</i>,5<i>S</i>,6<i>r</i>)-3-(5,6-difluoro-1<i>H</i>-benzo[<i>d</i>]imidazol-1-yl)bicyclo[3.1.0]hexan-6-yl)propanamide (70), IACS-70099 (Step j)</h5><div class="NLM_p last">To a solution of <b>70i</b> in 1,4-dioxane (5 mL) were added cesium carbonate and 5,6-difluoro-1<i>H</i>-benzo[<i>d</i>]imidazole and the resulting mixture was stirred at 65 °C for 12 h. The reaction mixture was diluted with EtOAc (15 mL), water (10 mL) was added, and the layers were separated. The aqueous phase was extracted with EtOAc (3 × 10 mL), the combined organic layers were washed with brine, dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified via silica gel chromatography (5–15% 2-propanol in DCM) to give <i>N</i>-(4-chlorophenyl)-2-((1<i>R</i>,3<i>s</i>,5<i>S</i>,6<i>r</i>)-3-(5,6-difluoro-1<i>H</i>-benzo[<i>d</i>]imidazol-1-yl)bicyclo[3.1.0]hexan-6-yl)propanamide (155 mg, 0.373 mmol, 58.0% yield) as a light yellow oil). This was then triturated with ether–hexane (10 mL) to give 70 mg of the white solid of the desired material. NMR data and LC–MS confirmed the identity of the compound. Rest of the mother liquor was then concentrated, and the residue was purified by reverse-phase preparative HPLC (mobile phase: A = 0.1% NH<sub>4</sub>OH/H<sub>2</sub>O, B = 0.1% NH<sub>4</sub>OH/MeCN; gradient: B = 10–100%; 12 min) to give the title compound racemic <b>70</b> (25 mg) as a white solid. MS (ES<sup>+</sup>) C<sub>22</sub>H<sub>20</sub>ClF<sub>2</sub>N<sub>3</sub>O calculated 415; found 416 [M + H] <sup>+</sup>. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.90 (s, 1H), 8.43 (s, 1H), 7.89 (dd, <i>J</i> = 11.0, 7.3 Hz, 1H), 7.73–7.60 (m, 3H), 7.42–7.31 (m, 2H), 4.73–4.59 (m, 1H), 2.33 (dd, <i>J</i> = 12.4, 7.6 Hz, 1H), 2.27–2.12 (m, 3H), 1.86–1.77 (m, 1H), 1.57–1.50 (m, 1H), 1.33 (q, <i>J</i> = 6.7, 5.0 Hz, 1H), 1.21–1.19 (m, 4H). The racemic solid was purified by SFC (Averica Discovery Services, 50 D’Angelo Drive Suite 6 Marlborough MA 01752, AV17301-E1) to give the title compound <b>70</b>. The title compound <b>70</b> was also synthesized by WuXi Apptec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China, EW-10232-17-P1; with similar SFC conditions described for <b>71</b>, <b>IACS-70465</b>.</div></div></div><div id="sec5_2_4_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> <i>N</i>-(4-Chlorophenyl)-2-((1<i>R</i>,3<i>s</i>,5<i>S</i>,6<i>r</i>)-3-((6-fluoroquinolin-4-yl)oxy)bicyclo[3.1.0]hexan-6-yl)propanamide (<b>71</b>), IACS-70465 (Step w)</h4><div class="NLM_p last">To a cooled 0 °C suspension of NaH (14.30 mg, 0.357 mmol) in DMF (1787 μL) was added <b>90</b> (50 mg, 0.179 mmol). The resulting mixture was stirred at 0 °C for 30 min then at 25 °C for an additional 15 min. The solution was cooled to 0 °C and 4-bromo-6-fluoroquinoline (52.5 mg, 0.232 mmol) was added and the resulting mixture was stirred at 25 °C for 3 h. Saturated NH<sub>4</sub>Cl (2 mL) was added, and the layers were separated. The aqueous phase was extracted with DCM (3 × 5 mL), the combined organic layers were washed with saturated NaCl, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified via silica gel chromatography (0–20% MeOH in DCM with 2% TEA) to give the title compound racemic <b>71</b> (58 mg, 0.137 mmol, 76% yield) as an off-white solid. MS (ES<sup>+</sup>) C<sub>24</sub>H<sub>22</sub>ClFN<sub>2</sub>O<sub>2</sub> calculated 424; found  425 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 0.83–0.93 (m, 1H), 1.15–1.24 (m, 3H), 1.30–1.51 (m, 2H), 1.68–1.79 (m, 1H), 1.99–2.13 (m, 2H), 2.39–2.46 (m, 1H), 2.51–2.58 (m, 1H), 5.13–5.25 (m, 1H), 7.31–7.40 (m, 2H), 7.44–7.52 (m, 1H), 7.63–7.72 (m, 2H), 7.85–7.93 (m, 1H), 7.94–8.01 (m, 1H), 8.08–8.20 (m, 1H), 8.89–9.05 (m, 1H), 9.86–9.99 (m, 1H). The racemic solid was purified by SFC (Averica Discovery Services, 50 D’Angelo Drive Suite 6 Marlborough MA 01752, AV18044-E2) to give the title compound <b>71</b>. The title compound <b>71</b> was also synthesized by WuXi Apptec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China, EW118833-13, and separated by SFC (column: DAICEL CHIRALCEL OJ (250 mm × 30 mm, 10 μm); mobile phase: [0.1% NH<sub>4</sub>OH EtOH]; B %: 35–35%, 3–20 min). Compound, <b>71</b>, <b>IACS-70465</b> (41.44 g, 96.55 mmol, 23.70% yield, 99% purity) was obtained as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.87 (s, 1H), 8.66 (d, <i>J</i> = 5.1 Hz, 1H), 8.00 (dd, <i>J</i> = 5.5, 9.0 Hz, 1H), 7.80–7.56 (m, 4H), 7.36 (d, <i>J</i> = 8.4 Hz, 2H), 7.11 (d, <i>J</i> = 5.1 Hz, 1H), 4.89 (quin, <i>J</i> = 7.0 Hz, 1H), 2.41 (br dd, <i>J</i> = 7.2, 12.9 Hz, 1H), 1.97 (dq, <i>J</i> = 5.9, 12.8 Hz, 2H), 1.85–1.73 (m, 1H), 1.51 (br s, 1H), 1.31 (br s, 1H), 1.19 (d, <i>J</i> = 6.6 Hz, 3H), 0.93–0.84 (m, 1H).</div></div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> IDO1 Enzyme Assay</h3><div class="NLM_p last">Inhibition of recombinant human His-tagged IDO1 enzyme (R&D Systems, catalog # 6030-AO) was assessed by measuring the conversion of Trp to NFK using a RFMS system (Agilent Technologies). IDO1 enzyme (1 nM) was incubated in the absence or presence of various concentrations of compounds in assay buffer (40 mM Tris, pH 7.0, 15 μM Tween-20, containing 5 mM sodium ascorbate, 5 μM methylene blue, and 0.5 μM catalase) in a 384-well plate. After 10 min at RT, Trp (6 μM) was added to a final volume of 60 μL per well, and the reaction plate was incubated at RT for 1 h. Reactions were quenched by addition of 30 μL 0.24% formic acid containing 15 μM deuterated Trp-<i>d5</i> as an internal standard. Samples were analyzed via RFMS to quantify NFK (AUC of the  total ion count, TIC) and Trp (AUC of TIC). A C18 cartridge was used with mobile phases of 0.1% formic acid and 80% ACN/0.1% formic acid under isocratic conditions. Dose–response curves were analyzed using IC<sub>50</sub> regression curve fitting (GeneData Screener). Curves were plotted as percent of control and normalized by high controls without inhibitor (100%), and low controls without substrate (0%).</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> Human IDO1 Cell Assay</h3><div class="NLM_p last">The human HeLa cervix carcinoma cell line was obtained from the American Type Culture Collection (ATCC) and maintained in Dulbecco’s modified Eagle medium (DMEM) media containing 10% fetal bovine serum (FBS). Cells (7000/well) were seeded onto a 384-well plate in 50 μL of media and incubated at 37 °C, 5% CO<sub>2</sub> overnight. Cell media were aspirated, fresh media containing 10 ng/mL human IFNγ (R&D Systems) were added, and cells were incubated in the absence or presence of various concentrations of compounds (final 0.5% DMSO) for 24 h at 37 °C, 5% CO<sub>2</sub>. Aliquots of the cell conditioned media were removed from the cell plate, and mixed with an equal volume of 200 mM ZnSO<sub>4</sub> to precipitate media containing protein. Two volumes of acetonitrile were added by mixing, and the samples were then centrifuged at 2250<i>g</i> for 20 min at 4 °C. Aliquots of the supernatant were diluted 1:10 in 0.1% formic acid containing 3 μM of deuterated Trp-<i>d5</i> as an internal standard. Samples were analyzed via RFMS to quantify NFK (AUC of TIC) and Trp (AUC of TIC). A C18 cartridge was used with mobile phases of 0.1% formic acid and 80% ACN/0.1% formic acid under isocratic conditions. Dose–response curves were analyzed using IC<sub>50</sub> regression curve fitting (GeneData Screener). Curves were plotted as percent of control and normalized by high controls without inhibitor (100%), and low controls (0%) containing 1 μM of a potent cell-permeable IDO1 inhibitor (epacadostat). Cell viability was also assessed using the Cell Titer Glo Kit (Promega) following manufacturer’s recommendations.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> Mouse IDO1 Cell Assay</h3><div class="NLM_p last">The murine PANC02 pancreatic ductal adenocarcinoma cell line was routinely maintained in DMEM media containing 10% FBS. Cells (3000/well) were seeded onto a 384-well plate in 50 μL of media and incubated at 37 °C, 5% CO<sub>2</sub> overnight. Cell media were aspirated, fresh media containing 30 ng/mL mouse IFNγ (Gibco Life Technologies, cat# PMC4031) were added, and cells were incubated in the absence or presence of various concentrations of compounds (final 0.5% DMSO) for 48 h at 37 °C, 5% CO<sub>2</sub>. Aliquots of the cell conditioned media were removed from the cell plate, and mixed with an equal volume of 200 mM ZnSO<sub>4</sub> to precipitate media containing protein. Two volumes of acetonitrile were added by mixing, and samples were then centrifuged at 2250G for 20 min at 4 °C. Aliquots of the supernatant were diluted 1:10 in 0.1% formic acid containing 3 μM of deuterated Trp-<i>d5</i> as an internal standard. Samples were analyzed via RFMS to quantify NFK (AUC of TIC) and Trp (AUC of TIC). A C18 cartridge was used with mobile phases of 0.1% formic acid and 80% ACN/0.1% formic acid under isocratic conditions. Dose–response curves were analyzed using IC<sub>50</sub> regression curve fitting (GeneData Screener). Curves were plotted as percent of control and normalized by high controls without inhibitor (100%), and low controls (0%) containing 1 μM of a potent cell permeable IDO1 inhibitor epacadostat. Cell viability was also assessed using the Cell Titer Glo Kit (Promega) following manufacturer’s recommendations.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> TDO Cell Assay</h3><div class="NLM_p last">The human A-172 glioblastoma cell line was obtained from the American Type Culture Collection (ATCC) and maintained in DMEM media containing 10% FBS. Cells (7000/well) were seeded onto a 384-well plate in 50 μL of media and incubated at 37 °C, 5% CO<sub>2</sub> overnight. Cell media were aspirated, fresh media containing 1 mM Trp were added, and cells were incubated in the absence or presence of various concentrations of compounds (final 0.5% DMSO) for 16 h at 37 °C, 5% CO<sub>2</sub>. Aliquots of the cell-conditioned media were removed from the cell plate, and mixed with an equal volume of 200 mM ZnSO<sub>4</sub> to precipitate media containing protein. Two volumes of acetonitrile were added by mixing, and samples were then centrifuged at 2250<i>g</i> for 20 min at 4 °C. Aliquots of the supernatant were diluted 1:10 in 0.1% formic acid containing 3 μM of deuterated Trp-<i>d5</i> as an internal standard. Samples were analyzed via RFMS to quantify NFK (AUC of TIC) and Trp (AUC of TIC). A C18 cartridge was used with mobile phases of 0.1% formic acid and 80% ACN/0.1% formic acid under isocratic conditions. Dose–response curves were analyzed using IC<sub>50</sub> regression curve fitting (GeneData Screener). Curves were plotted as percent of control and normalized by high controls without inhibitor (100%), and low controls (0%) containing 1 μM of a potent cell permeable IDO1 inhibitor (epacadostat). Cell viability was also assessed using the Cell Titer Glo Kit (Promega) following manufacturer’s recommendations.</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> Recombinant Human His-Tagged IDO1 Production</h3><div class="NLM_p last">Human IDO1 was expressed in <i>Escherichia coli</i> BL21 (DE3) in Luria Bertani media supplemented with 100 μg mL<sup>–1</sup> carbenicillin. For protein batches, where high levels of heme incorporation were desired, 1.5 mM δ-aminolevulinic acid was also added to the growth media but this supplement was not included for low-heme IDO1 protein preparations. Once the <i>E. coli</i> culture reached an optical density of 0.7, the temperature was reduced to 18 °C and recombinant protein expression was induced with 0.5 mM IPTG. After overnight incubation, the <i>E. coli</i> cells were harvested by centrifugation and the cell pellet was lyzed in 50 mM HEPES, 500 mM NaCl, and 2 mM TCEP at pH 8.0. The cell lysate was clarified by centrifugation at 20,000 rpm at 4 °C for 1 h and purified by Ni affinity chromatography using 50 mM HEPES, 500 mM NaCl, 500 mM imidazole, and 2 mM TCEP at pH 8.0 as the elution buffer. The IDO1 protein was further purified by size exclusion chromatography using an S200 column pre-equilibrated in 25 MES and 150 mM KCl at pH 6.5. The ratio of the 406 and 280 nm absorbance peaks for the protein was used to determine the heme content, based on the 406:280 ratio of 2.75:1 for 100% heme-bound holoenzyme, as previously described.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> Low levels of heme incorporation contained <5% heme content and high levels contained 75%.</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> Cell Lysate Preparation and IDO1 Activity</h3><div class="NLM_p">The HeLa cell line (ATCC, CCL-2) was cultured in DMEM media containing 10% FBS. HEK293-TetR (GenTarget, SC005-Puro, and GenTarget) were transduced with hIDO1-inducible lentiviral particles (GenTarget, LVP302) following the manufacturer’s protocol, and a bulk stable-inducible HEK293-TetR-IDO1 cell line was generated after selection in DMEM media containing 10% FBS, puromycin (1 μg/mL), and blasticidin (10 μg/mL). Expression of endogeneous human IDO1 in HeLa cells was induced after 10 ng/ml of IFN-γ treatment, and recombinant human IDO1 in HEK293-TetR-IDO1 cells was induced after 1 μg/ml of doxycycline. Expression of IDO1 protein was confirmed via western-blot analysis using a mouse monoclonal antibody against human IDO1 protein (anti-IDO1 [4D2] and Abcam ab55305). Antibody specificity against human IDO1 was confirmed via western-blot analysis of purified human IDO1 protein. HSP90 expression was assessed via western-blot using anti-HSP90 (Millipore), <a href="/doi/suppl/10.1021/acs.jmedchem.1c00679/suppl_file/jm1c00679_si_001.pdf" class="ext-link">Figure S1</a>.</div><div class="NLM_p">HeLa or HEK293-TetR-IDO1 cells were induced with IFN-γ or doxycycline in the absence or presence of IDO1 inhibitors at 37 °C, 0.5% CO<sub>2</sub> for a period of 24 h. Cells were extensively washed with phosphate buffered saline, and cell lysates were prepared by harvesting the cells using the CelLytic-M solution (Sigma-Aldrich, C2978) containing 1× Halt Protease inhibitor cocktail (ThermoFisher, 78429). Cell lysates were diluted in assay buffer (40 mM Tris, pH 7.0, and 15 μM Tween-20) to yield 20–30% enzyme turnover for further studies. Reconstitution of IDO1 apoenzyme to active holoenzyme was achieved by adding increasing concentration of hemin to cell lysates. First, 3 mM hemin (Sigma-Aldrich, 51280) stock solution was prepared in 300 mM triethylamine, and then further diluted in assay buffer as required. Hemin and/or inhibitor were titrated in assay buffer, then combined with either the cell lysate or purified recombinant human His-tagged IDO1 protein for the enzymatic assay.</div><div class="NLM_p last">IDO1 enzymatic activity was assessed by measuring the conversion of Trp to NFK using RFMS. Cell lysates or purified IDO1 enzyme (1 nM) were incubated in the absence or presence of various concentrations of compounds in assay buffer (40 mM Tris, pH 7.0, 15 μM Tween-20, containing 5 mM sodium ascorbate, 5 μM methylene blue, and 0.5 μM catalase) in a 384-well plate. After 10 min at RT, Trp (6 μM) was added to a final volume of 60 μL per well, and the reaction plate was incubated at RT for 1 h. Reactions were quenched by addition of 30 μL 0.24% formic acid containing 15 μM deuterated-Trp-<i>d5</i> as an internal standard, and then sampled on a RFMS instrument using a C18 cartridge, using 80% acetonitrile with 0.1% formic acid for elution. Parent and product ions were monitored for NFK, deuterated Trp, KYN, and Trp. AUC of the TIC of each the compound was integrated using Agilent Mass Hunter software. AUC values for NFK were normalized to deuterated-Trp AUC values and graphed using GraphPad Prism.</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> Whole Blood Assay</h3><div class="NLM_p last">Fresh peripheral blood was collected with 2 h of collection from Bloodworks Northwest (all donors with signed informed consents). The blood was aliquoted (200 μL per well into a 96-well round bottom plate). Serial dilutions of the test compounds were performed initially in DMSO and then in culture medium so that the final DMSO concentration per well becomes 0.1%. Solvent control cultures also contained 0.1% DMSO. The test compounds (<i>n</i> = 4) were added at 12 concentrations to the blood, 15 min prior to the addition of LPS (25 μg/mL) and IFNγ (100 ng/mL). Four replicates were initiated for each concentration of each test compound. The blood was incubated for 24 h at 37 °C and 5% CO<sub>2</sub>. Samples were spun, the plasma removed, and stored at −80 °C until sample analysis via LCMS (described at the PK/PD methodology).</div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> DSF Assay</h3><div class="NLM_p last">Equal volumes of apo-IDO, DMSO or inhibitor, and Sypro Orange (ThermoFisher) were mixed in assay buffer (40 mM Tris, pH 7.0 with 15 μM Tween-20) to achieve final concentrations of 4 μM of enzyme, 0.5% DMSO, and 50 μM of compound, and plates containing the mixture were covered with an optical adhesive film cover (Applied Biosystems), centrifuged at 1000 rpm for 1 min, and incubated for 10 min at 25 °C. Plates were subsequently loaded into a QuantStudio6 real-time PCR instrument (Applied Biosystems), initially incubated at 25 °C for 2 min and thereafter subjected to a temperature gradient from 25 to 99 °C (∼2 °C/10 min) in a step and hold mode with 0.4 °C temperature increments. Fluorescence emission at 586 was monitored and recorded. Protein Thermal Shift software (Applied Biosystems) was used to calculate the first derivative melting temperature.</div></div><div id="sec5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> Animals and Xenograft Models for PK and In Vivo Studies</h3><div class="NLM_p">All PK and in vivo experiments were conducted in accordance with the animal welfare procedures of the Institutional Animal Care and Use Committee (IACUC).</div><div id="sec5_11_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80"> General Formulation Protocol</h4><div class="NLM_p last">Preparation of IV dosing solution in 20% DMSO + 60% PEG400 + 20% water at 0.06 mg/mL: To a 10 mM stock solution of compound (0.06 mL) in a clear vial was added DMSO (0.54 mL). The solution was vortexed for 2 min and PEG400 (1.8 mL) was added. The mixture was vortexed for 2 min, water (0.6 mL) was added, and the solution was vortexed for additional 2 min. Preparation of po dosing solution in 0.5% methyl cellulose (MC) in water at 1 mg/mL: to compound (1) (4.1 mg) in a clean tube was added 0.5% MC in water (4.1 mL). The mixture was vortexed for 2 min, sonicated for 20 min, stirred for 30 min, and homogenized with ULTRA-TURPAX at 4500 rpm for 5 min.</div></div><div id="sec5_11_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> In Vivo Animal Studies</h4><div class="NLM_p last">Protocol number 00000884-RN02 was approved by The University of Texas MD Anderson Cancer Center Institutional Animal Care and Use Committee (IACUC), and adhered to the National Institutes of Health (NIH) guidelines. All mice were housed in state-of-the-art Association for the Assessment and Accreditation for Laboratory Animal Care (AAALAC)-accredited animal research facilities. All animals were maintained under the supervision and care of the veterinarians associated with the Animal Facilities, who oversee a comprehensive and well-executed health surveillance program. Female C57BL/6 mice (strain code: 000664, purchased from Jackson Lab) aged 6–12 weeks and weighing approximately 20–25 g were used for PANC02 studies. Female Balb/c mice (strain code: 028, purchased from Charles River) aged 6–12 weeks and weighing approximately 20–25 g were used for CT26 studies. Female NSG mice (strain code: 005557, purchased from Jackson Lab) aged 6–12 weeks and weighing approximately 20–25 g were used for SKOV3 studies. Animal health was monitored daily by observation and sentinel animal blood sample analysis. Animal experiments were conducted in accordance with the Guideline of IACUC, MDACC. Mice were fed animal diet 5053 from LabDiet ad libitum. PANC02, CT26, or SKOV3 cells were scaled up and then harvested on the day of cell inoculation. For PANC02, each mouse received 5.0 × 10<sup>5</sup> cells in 0.2 mL PBS. For CT26, each mouse received 2.0 × 10<sup>5</sup> cells in 0.2 mL PBS. For SKOV3, cells were diluted 1:1 with Matrigel just before implantation, and each mouse received 2.5 × 10<sup>6</sup> cells in 0.2 mL. Cells were implanted subcutaneously in the right flank. PANC02, CT26, or SKOV3 tumors were monitored by caliper before randomly sorting and dividing into several groups (<i>n</i> = 5–10 mice per group) based on the study design and requirements. Treatment was started from day 14 to 36 days postimplantation, depending on mouse models and requirements of the tumor size. Vehicle controls or IDO inhibitors were given orally using a sterile 1 mL syringe and a 18-gauge gavage needle using formulations as described above.</div></div><div id="sec5_11_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82"> Pharmacokinetics</h4><div class="NLM_p last">The PK study was performed at ChemPartner (No. 5 Building, 998 Halei Road, Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai, China. <a href="http://www.chempartner.com" class="extLink">www.chempartner.com</a>).</div></div><div id="sec5_11_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i83" class="anchor-spacer"></div><h4 class="article-section__title" id="_i83"> Mice</h4><div class="NLM_p last">Female mice (CD1 strain, purchased from Shanghai JH Laboratory Animal Co. LTD) weighing 20–30 g were used for this study. Food and water were made available to all animals ad libitum. The test article was dosed via tail vein and oral gavage, respectively. Blood samples were collected from animals by retro-orbital bleeding into test tubes containing K2EDTA predose and at 0.083, 0.25, 0.5, 1, 2, 4, 8, and 24 h postdose (three animals per time point with three time points collected per animal) into tubes containing the anticoagulant K<sub>2</sub>EDTA. Plasma was separated from the blood by centrifugation at 4 °C and stored at −70 °C until analysis. The test article concentrations in plasma were quantified using a liquid chromatography with the tandem mass spectrometry (LC–MS/MS) method.</div></div><div id="sec5_11_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84"> Rat</h4><div class="NLM_p last">Male rats (SD strain, purchased from Shanghai JH Laboratory Animal Co. LTD) weighing 200–300 g were used for this study. Animals were fasted overnight and fed 4 h postdose. Water was made available ad libitum for all animals. The test article was dosed via dorsal foot vein and via oral gavage, respectively. Blood samples were collected via tail vein from all animals at predose and at 0.083, 0.25, 0.5, 1, 2, 4, 8, and 24 h postdose into tubes containing the anticoagulant K<sub>2</sub>EDTA. Plasma was separated from the blood by centrifugation at 4 °C and stored at −70 °C until analysis. The test article concentrations in plasma were quantified using the LC–MS/MS method.</div></div><div id="sec5_11_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> Dog</h4><div class="NLM_p last">Male Beagle dogs (purchased from Beijing Marshall Biotechnology Co., Ltd) weighing 7–10 kg were used for this study. Animals were fasted overnight and fed 4 h postdose. The test article was administered to dogs via the cephalic vein or via oral gavage. Blood samples were collected via the saphenous vein or cephalic vein from all animals at predose and 0.083, 0.25, 0.5, 1, 2, 4, 8, and 24 h postdose into tubes containing the anticoagulant K<sub>2</sub>EDTA. Plasma was separated from the blood by centrifugation at 4 °C and stored at −70 °C until analysis. The test article concentrations in plasma were quantified using the LC–MS/MS method.</div></div><div id="sec5_11_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86"> Monkey</h4><div class="NLM_p last">Male Cynomolgus monkeys (purchased from Hainan Jingang Biotech. Co., Ltd) weighing 3–5 kg were used for this study. Animals were fasted overnight and fed 4 h postdose. The test article was administered to monkeys via the cephalic vein or via nasal gavage. Blood samples were collected via the saphenous vein or cephalic vein from all animals at predose and 0.083, 0.25, 0.5, 1, 2, 4, 8, and 24 h postdose into tubes containing the anticoagulant K<sub>2</sub>EDTA. Plasma was separated from the blood by centrifugation at 4 °C and stored at −70 °C until analysis. The test article concentration in plasma was quantified using the LC–MS/MS method.</div></div><div id="sec5_11_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i87" class="anchor-spacer"></div><h4 class="article-section__title" id="_i87"> Sample Collection for PK/PD Analysis</h4><div class="NLM_p last">Tumor and plasma were harvested at the desired time point after the last dose. Blood was obtained via the retro-orbital sinus into a Vacutainer K2 EDTA tube to a volume of 250 μL. The Vacutainer vials were centrifuged for 10 min as 2000<i>g</i> without braking. The supernatant (plasma) was carefully aspirated into a microcentrifuge tube and placed onto dry ice prior to storage at −80 °C. Tumor samples from the right flank were obtained and cut into several (at least 5 or 6) approximately 100 mg pieces of comparable size with a scalpel. These pieces are immediately placed into a labeled cryovial and snap frozen in liquid nitrogen prior to storage at −80 °C. KYN and Trp were purchased from Sigma-Aldrich. <span class="smallcaps smallerCapital">l</span>-Kynurenine-<i>d</i>6 (KYN-<i>d</i>6) and <span class="smallcaps smallerCapital">l</span>-tryptophan-<i>d</i>5 (Trp-<i>d</i>5) were purchased from Cambridge Isotope Laboratories. DMSO were purchased from Sigma-Aldrich. Acetonitrile, methanol, isopropanol, water, and formic acid (all LC–MS grade) were obtained from Fisher Chemicals (Fair Lawn, NJ, USA). Blank human plasma samples from healthy donors were purchased from Bioreclamation IVT (Baltimore, MD, USA).</div></div><div id="sec5_11_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i88" class="anchor-spacer"></div><h4 class="article-section__title" id="_i88"> Stock Solutions, Standards, and Quality Controls</h4><div class="NLM_p last">The analyte reference standard (KYN and TRP) stock solutions were prepared at 1.00 mg/mL in water. Working solutions were obtained by diluting stock solutions to 100 μL/mL. KYN-<i>d</i>6 and Trp-<i>d</i>5 internal standard solutions were also prepared in water. Calibration standards and QC samples of KYN and TRP were prepared in acetonitrile in the range from 1 to 200 ng/mL. Calibration standards and QC samples of IACS compounds were prepared in the range from 1 to 1000 ng/mL by spiking work solutions to blank mouse plasma.</div></div><div id="sec5_11_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i89" class="anchor-spacer"></div><h4 class="article-section__title" id="_i89"> Liquid Chromtography</h4><div class="NLM_p last">Quantitative analysis was performed using a Shimadzu Nexera X2 LC system consisting of a binary pump, a column oven, a DAD detector, and an autosampler with a 10 μL injection loop autosampler. The autosampler temperature was set at 4 °C. Chromatographic separation was carried out on a Supelco Ascentis Express RP-Amide column (30 × 2.1 mm, 2.7 μm) for KYN and TRP and on a Supelco Ascentis Express C18 column (20 × 2.1 mm, 2.7 μm) for IACS compounds. The column temperature was maintained at 40 °C. For the analysis of KYN and TRP, mobile phase A was 0.1 acetic acid in water and mobile phase B was 0.1% acetic acid in acetonitrile. The mobile phase was delivered in a gradient mode: 80% B (0–1 min), 80–10% B (1–3 min), 10% B (3–5 min), 10–80% B (5–5.3 min), and 80% B (5.3–10 min). The column temperature was 40 °C, and the flow rate was 0.5 mL/min. For the analysis of IACS compounds, mobile phase A was 0.1 acetic acid in water and mobile phase B was 0.1% acetic acid in acetonitrile. The mobile phase was delivered in a gradient: 5% B (0–0.3 min), 5–95% (0.3–1.3 min), 95% (1.31–1.60 min), and 5% (1.61–2.00 min). Wash solvent 1 was 50% methanol in water and wash solvent 2 was 0.2% formic acid in a mixture of acetonitrile, methanol, isopropanol, and water (50:50:50:50, v/v/v/v).</div></div><div id="sec5_11_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i90" class="anchor-spacer"></div><h4 class="article-section__title" id="_i90"> Mass Spectrometry</h4><div class="NLM_p last">Eluents from column were monitored using an AB Sciex 5500 triple quadrupole mass spectrometer with an ESI source. A mass spectrometer was operated in the positive ion mode and its operation parameters were optimized to maximize its sensitivity by a direct infusion of analytes at 10 ng/mL in an acetonitrile/water (1:2, v/v): ion spray voltage of 5500 V, CAD 8, curtain gas 35, Gas1 35, Gas2 50, and source temperature 400 °C. The MS data were first acquired by a Sciex software Analyst version 1.6.2 and then processed using Sciex software MultiQuant version 3.0.2. KYN, TRP, and IACS compounds were detected in MRM mode and their corresponding mass spectrometry parameters reported. PK parameters were estimated using Phoenix WinNonlin 8.3 software.</div></div><div id="sec5_11_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i91" class="anchor-spacer"></div><h4 class="article-section__title" id="_i91"> Sample Preparation</h4><div class="NLM_p last">For the analysis of KYN and TRP in plasma samples—an aliquot of 25 μL of standards, QC samples, and clinical human plasma samples was manually transferred to a well of a 1 mL 96-DW plate. Two hundred microliters of acetonitrile that was chilled at 4 °C were added to wells using a liquid–liquid handling robot, Biomek FX<sup>P</sup> Automation Workstation. After vortexing for 10 min, samples were centrifuged at 4000 rpm and 4 °C for 10 min. One hundred microliters of supernatant were diluted with 200 μL of acetonitrile/water (1:1) containing 250 ng/mL KYN-d6 and 250 ng/mL TRP-5. After vortexing for 5 min, samples were centrifuged at 4000 rpm and 4 °C for 5 min. An aliquot of 2 μL was injected into the LC system for separation and analysis. For the analysis of IACS compounds in plasma samples: an aliquot of 25 μL of standards, QC samples, and clinical human plasma samples were manually transferred to a well of a 1 mL 96-DW plate. Two hundred microliters of acetonitrile containing IACS-5318 at 5 ng/mL as the internal standard that was chilled at 4 °C were added to wells using a liquid–liquid handling robot, Biomek FX<sup>P</sup> Automation Workstation. After vortexing for 10 min, samples were centrifuged at 4000 rpm and 4 °C for 10 min. One hundred microliters of supernatant were diluted with 200 μL of water. After vortexing for 5 min, samples were centrifuged at 4000 rpm and 4 °C for 5 min. An aliquot of 2 μL was injected into the LC system for separation and analysis. For analysis of tumor tissue samples, tumor tissue samples were homogenized using OminiBEAD Ruptor24 coupled with Omini BR CRYO to make homogenates at 100 mg(tissue)/mL in MeOH/H<sub>2</sub>O (8:2). The volume (μL) of this solvent added to the vial containing tumor tissue was [(1000 × weight (mg)/100) – weight (mg)] assuming that the density of the tissue was 1.0. After homogenization, homogenates were centrifuged at 15,000 rpm and 4 °C for 15 min. An aliquot of 100 μL of the supernatant was diluted with 100 μL of ACN/H<sub>2</sub>O (1:1) containing 250 ng/mL Trp-<i>d5</i> and 250 ng/mL KYN-<i>d6</i> as IS, vortexed for 15 s, and centrifuged at 15,000 rpm and 4 °C for 5 min before injection for the analysis of KYN and TRP. For the analysis of IACS compounds, 50 μL of the supernatant was diluted with 150 μL of acetonitrile containing an internal standard at 5 ng/mL. The injection volume was 2 μL.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i92"><a href="/doi/suppl/10.1021/acs.jmedchem.1c00679" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47861" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47861" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.1c00679?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00679</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Preparation of compounds 18–20, 23–61, and 63–69; full western blot; procedures for microsomal stability; CYP inhibition; plasma protein binding; hERG assays; X-ray crystallography; sequence alignment of the binding site of IDO1; representative HeLa cellular assay and viability curves for <b>22</b> and <b>62</b>; and LCMS traces for <b>17</b>, <b>17R</b>, <b>21</b>, <b>22</b>, <b>24</b>, <b>31</b>, <b>34</b>, <b>38</b>, <b>56</b>, <b>57</b>, <b>58</b>, <b>59</b>, and <b>62</b> (IACS-9779), <b>63</b>, <b>64</b>, <b>65</b>, and <b>70</b> (IACS-70099), <b>71</b> (IACS-70465), and <b>72</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00679/suppl_file/jm1c00679_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00679/suppl_file/jm1c00679_si_003.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00679/suppl_file/jm1c00679_si_001.pdf">jm1c00679_si_001.pdf (3.58 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00679/suppl_file/jm1c00679_si_003.csv">jm1c00679_si_003.csv (11.57 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.1c00679" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30335" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30335" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matthew M. Hamilton</span> - <span class="hlFld-Affiliation affiliation">IACS
(Institute for Applied Cancer Science), University of Texas, MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-1703-1685" title="Orcid link">https://orcid.org/0000-0002-1703-1685</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#f9949491989490958d9697b9949d98979d9c8b8a9697d7968b9e"><span class="__cf_email__" data-cfemail="365b5b5e575b5f5a425958765b52575852534445595818594451">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Faika Mseeh</span> - <span class="hlFld-Affiliation affiliation">IACS
(Institute for Applied Cancer Science), University of Texas, MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Timothy J. McAfoos</span> - <span class="hlFld-Affiliation affiliation">IACS
(Institute for Applied Cancer Science), University of Texas, MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul G. Leonard</span> - <span class="hlFld-Affiliation affiliation">IACS
(Institute for Applied Cancer Science), University of Texas, MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Naphtali J. Reyna</span> - <span class="hlFld-Affiliation affiliation">IACS
(Institute for Applied Cancer Science), University of Texas, MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Angela L. Harris</span> - <span class="hlFld-Affiliation affiliation">TRACTION
(Translational Research to Advance Therapeutics and Innovation in
Oncology), University of Texas, MD Anderson
Cancer Center, 1881 East
Road, Houston, Texas 77054, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alan Xu</span> - <span class="hlFld-Affiliation affiliation">IACS
(Institute for Applied Cancer Science), University of Texas, MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michelle Han</span> - <span class="hlFld-Affiliation affiliation">IACS
(Institute for Applied Cancer Science), University of Texas, MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael J. Soth</span> - <span class="hlFld-Affiliation affiliation">IACS
(Institute for Applied Cancer Science), University of Texas, MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-2649-5537" title="Orcid link">https://orcid.org/0000-0002-2649-5537</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Barbara Czako</span> - <span class="hlFld-Affiliation affiliation">IACS
(Institute for Applied Cancer Science), University of Texas, MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-3357-7514" title="Orcid link">https://orcid.org/0000-0002-3357-7514</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jay P. Theroff</span> - <span class="hlFld-Affiliation affiliation">IACS
(Institute for Applied Cancer Science), University of Texas, MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pijus K. Mandal</span> - <span class="hlFld-Affiliation affiliation">IACS
(Institute for Applied Cancer Science), University of Texas, MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jason P. Burke</span> - <span class="hlFld-Affiliation affiliation">IACS
(Institute for Applied Cancer Science), University of Texas, MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brett Virgin-Downey</span> - <span class="hlFld-Affiliation affiliation">IACS
(Institute for Applied Cancer Science), University of Texas, MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alessia Petrocchi</span> - <span class="hlFld-Affiliation affiliation">IACS
(Institute for Applied Cancer Science), University of Texas, MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dana Pfaffinger</span> - <span class="hlFld-Affiliation affiliation">IACS
(Institute for Applied Cancer Science), University of Texas, MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Norma E. Rogers</span> - <span class="hlFld-Affiliation affiliation">IACS
(Institute for Applied Cancer Science), University of Texas, MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Connor A. Parker</span> - <span class="hlFld-Affiliation affiliation">IACS
(Institute for Applied Cancer Science), University of Texas, MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Simon S. Yu</span> - <span class="hlFld-Affiliation affiliation">IACS
(Institute for Applied Cancer Science), University of Texas, MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yongying Jiang</span> - <span class="hlFld-Affiliation affiliation">IACS
(Institute for Applied Cancer Science), University of Texas, MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stephan Krapp</span> - <span class="hlFld-Affiliation affiliation">Proteros
Biostructures GmbH, Bunsenstr. 7a, D-82152 Martinsried, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alfred Lammens</span> - <span class="hlFld-Affiliation affiliation">Proteros
Biostructures GmbH, Bunsenstr. 7a, D-82152 Martinsried, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Graham Trevitt</span> - <span class="hlFld-Affiliation affiliation">XenoGesis
Ltd, BioCity Nottingham, Pennyfoot Street, Nottingham, Nottinghamshire NG1 1GF, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Martin R. Tremblay</span> - <span class="hlFld-Affiliation affiliation">Tesaro
Inc., 1000 Winter Street, Waltham, Massachusetts 02451 United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Keith Mikule</span> - <span class="hlFld-Affiliation affiliation">Tesaro
Inc., 1000 Winter Street, Waltham, Massachusetts 02451 United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Keith Wilcoxen</span> - <span class="hlFld-Affiliation affiliation">Tesaro
Inc., 1000 Winter Street, Waltham, Massachusetts 02451 United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jason B. Cross</span> - <span class="hlFld-Affiliation affiliation">IACS
(Institute for Applied Cancer Science), University of Texas, MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Philip Jones</span> - <span class="hlFld-Affiliation affiliation">IACS
(Institute for Applied Cancer Science), University of Texas, MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Joseph R. Marszalek</span> - <span class="hlFld-Affiliation affiliation">TRACTION
(Translational Research to Advance Therapeutics and Innovation in
Oncology), University of Texas, MD Anderson
Cancer Center, 1881 East
Road, Houston, Texas 77054, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Richard T. Lewis</span> - <span class="hlFld-Affiliation affiliation">IACS
(Institute for Applied Cancer Science), University of Texas, MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>This manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br><p class="inlineNote">Authors will release the atomic coordinates and experimental data upon article publication.</p></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i95">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22116" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22116" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by Tesaro Inc. and the University of Texas MD Anderson Cancer Center. The authors would like to thank Fernando Alvarez for proof reading and editing assistance and Dr. Maria Emilia Di Francesco for helpful discussion and suggestions.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">ACN</td><td class="NLM_def"><p class="first last">acetonitrile</p></td></tr><tr><td class="NLM_term">AhR</td><td class="NLM_def"><p class="first last">aryl hydrocarbon receptor</p></td></tr><tr><td class="NLM_term">ATCC</td><td class="NLM_def"><p class="first last">American Type Culture Collection, supplier of authenticated cells lines and microorganisms</p></td></tr><tr><td class="NLM_term">AUC</td><td class="NLM_def"><p class="first last">area under the curve</p></td></tr><tr><td class="NLM_term">BID</td><td class="NLM_def"><p class="first last">twice a day (bis in die)</p></td></tr><tr><td class="NLM_term">BMS</td><td class="NLM_def"><p class="first last">Bristol Myers Squibb</p></td></tr><tr><td class="NLM_term">ClCOMTPA</td><td class="NLM_def"><p class="first last">α-methoxy-α-trifluoromethylphenylacetyl chloride</p></td></tr><tr><td class="NLM_term">Cl<sub>int</sub></td><td class="NLM_def"><p class="first last">intrinsic clearance</p></td></tr><tr><td class="NLM_term">clog <i>P</i></td><td class="NLM_def"><p class="first last">calculated log of partition coefficient</p></td></tr><tr><td class="NLM_term"><i>C</i><sub>max</sub></td><td class="NLM_def"><p class="first last">maximum measured concentration</p></td></tr><tr><td class="NLM_term"><i>C</i><sub>min</sub></td><td class="NLM_def"><p class="first last">minimal effective concentration</p></td></tr><tr><td class="NLM_term">CT26</td><td class="NLM_def"><p class="first last">mouse colorectal carcinoma cell line</p></td></tr><tr><td class="NLM_term"><i>C</i><sub>u</sub></td><td class="NLM_def"><p class="first last">unbound concentration</p></td></tr><tr><td class="NLM_term">CYP</td><td class="NLM_def"><p class="first last">cytochrome P450</p></td></tr><tr><td class="NLM_term">CYP2C9</td><td class="NLM_def"><p class="first last">2C9 isoform of CYP</p></td></tr><tr><td class="NLM_term">CYP3A4</td><td class="NLM_def"><p class="first last">3A4 isoform of CYP</p></td></tr><tr><td class="NLM_term">DAD</td><td class="NLM_def"><p class="first last">diode-array detection</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">DIEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine, Hunig’s base</p></td></tr><tr><td class="NLM_term">Dibal-H</td><td class="NLM_def"><p class="first last">diisobutylaluminum hydride</p></td></tr><tr><td class="NLM_term">DMAP</td><td class="NLM_def"><p class="first last">4-dimethylaminopyridine</p></td></tr><tr><td class="NLM_term">DMEM</td><td class="NLM_def"><p class="first last">Dulbecco’s modified Eagle medium</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last">dimethyl formamide</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">DTNAB</td><td class="NLM_def"><p class="first last">di-<i>tert</i>-butyl azodicarboxylate</p></td></tr><tr><td class="NLM_term">ECG</td><td class="NLM_def"><p class="first last">electrocardiogram</p></td></tr><tr><td class="NLM_term">FBS</td><td class="NLM_def"><p class="first last">fetal bovine serum</p></td></tr><tr><td class="NLM_term">FP</td><td class="NLM_def"><p class="first last">fluorescence polarization hERG assay</p></td></tr><tr><td class="NLM_term">GAS</td><td class="NLM_def"><p class="first last">IFN-γ-activated site</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last">hexafluorophosphate azabenzotriazole tetramethyl uronium</p></td></tr><tr><td class="NLM_term">HEK 293</td><td class="NLM_def"><p class="first last">human embryonic kidney cell line</p></td></tr><tr><td class="NLM_term">HeLa cells, HEPES</td><td class="NLM_def"><p class="first last">4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid buffer</p></td></tr><tr><td class="NLM_term">IC<sub>50</sub></td><td class="NLM_def"><p class="first last">inhibitory concentration at 50%; immortalized cell line derived from Henrietta Lacks</p></td></tr><tr><td class="NLM_term">hERG</td><td class="NLM_def"><p class="first last">human Ether-à-go-go-Related Gene potassium ion channel</p></td></tr><tr><td class="NLM_term">hIDO1</td><td class="NLM_def"><p class="first last">human indoleamine 2,3-dioxygenase 1</p></td></tr><tr><td class="NLM_term">HOBT</td><td class="NLM_def"><p class="first last">1-hydroxybenzotriazole</p></td></tr><tr><td class="NLM_term">hPPB</td><td class="NLM_def"><p class="first last">human plasma protein binding</p></td></tr><tr><td class="NLM_term">IDO1</td><td class="NLM_def"><p class="first last">indoleamine 2,3-dioxygenase 1</p></td></tr><tr><td class="NLM_term">IFNγ</td><td class="NLM_def"><p class="first last">interferon-γ</p></td></tr><tr><td class="NLM_term">ISREs</td><td class="NLM_def"><p class="first last">interferon-stimulated response elements</p></td></tr><tr><td class="NLM_term">IVIVE</td><td class="NLM_def"><p class="first last">in vitro–in vivo extrapolation</p></td></tr><tr><td class="NLM_term">KO<i>t</i>Bu</td><td class="NLM_def"><p class="first last">potassium <i>t</i>-butoxide</p></td></tr><tr><td class="NLM_term">KYN</td><td class="NLM_def"><p class="first last">l-kynurenine</p></td></tr><tr><td class="NLM_term">LAH</td><td class="NLM_def"><p class="first last">lithium aluminum hydride</p></td></tr><tr><td class="NLM_term">LCMS</td><td class="NLM_def"><p class="first last">liquid chromatography mass spectrometry</p></td></tr><tr><td class="NLM_term">LPS</td><td class="NLM_def"><p class="first last">lipopolysaccharides endotoxin molecules</p></td></tr><tr><td class="NLM_term">MES</td><td class="NLM_def"><p class="first last">2-(<i>N</i>-morpholino)-ethanesulfonic acid buffer</p></td></tr><tr><td class="NLM_term">MDCK</td><td class="NLM_def"><p class="first last">Madin Darby canine kidney cell</p></td></tr><tr><td class="NLM_term">MDR1</td><td class="NLM_def"><p class="first last">gene that encodes for efflux protein P-glycoprotein (P-gp)</p></td></tr><tr><td class="NLM_term">mpk</td><td class="NLM_def"><p class="first last">mg per kg</p></td></tr><tr><td class="NLM_term">MP</td><td class="NLM_def"><p class="first last">manual patch clamp hERG assay</p></td></tr><tr><td class="NLM_term">MS</td><td class="NLM_def"><p class="first last">mass spectrometry</p></td></tr><tr><td class="NLM_term">MsCl</td><td class="NLM_def"><p class="first last">mesyl chloride</p></td></tr><tr><td class="NLM_term">NFK</td><td class="NLM_def"><p class="first last"><i>N</i>-formylkynurenine</p></td></tr><tr><td class="NLM_term">NOD</td><td class="NLM_def"><p class="first last">nonobese diabetic strain of mice</p></td></tr><tr><td class="NLM_term">NSG</td><td class="NLM_def"><p class="first last">NOD SCID gamma mice</p></td></tr><tr><td class="NLM_term">PANCO2</td><td class="NLM_def"><p class="first last">mouse pancreatic nonmetastatic cancer cell line</p></td></tr><tr><td class="NLM_term"><i>P</i><sub>app</sub></td><td class="NLM_def"><p class="first last">apparent permeability coefficient</p></td></tr><tr><td class="NLM_term">PBS</td><td class="NLM_def"><p class="first last">phosphate-buffered saline buffer solution</p></td></tr><tr><td class="NLM_term">PCR</td><td class="NLM_def"><p class="first last">polymerase chain reaction</p></td></tr><tr><td class="NLM_term">PD</td><td class="NLM_def"><p class="first last">pharmacodynamics</p></td></tr><tr><td class="NLM_term">PD1</td><td class="NLM_def"><p class="first last">programmed cell death protein 1</p></td></tr><tr><td class="NLM_term">PDL1</td><td class="NLM_def"><p class="first last">programmed death-ligand 1</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetics</p></td></tr><tr><td class="NLM_term">po</td><td class="NLM_def"><p class="first last">per os (oral administration)</p></td></tr><tr><td class="NLM_term">polymer-TPP</td><td class="NLM_def"><p class="first last">triphenylphosphine polymer-bound, Sigma-Aldrich 366455</p></td></tr><tr><td class="NLM_term">QD</td><td class="NLM_def"><p class="first last">once a day (quaque)</p></td></tr><tr><td class="NLM_term">QP</td><td class="NLM_def"><p class="first last">Q-patch hERG assay</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure activity relationship</p></td></tr><tr><td class="NLM_term">SCID</td><td class="NLM_def"><p class="first last">severe combined immunodeficiency</p></td></tr><tr><td class="NLM_term">SFC</td><td class="NLM_def"><p class="first last">supercritical fluid chromatography</p></td></tr><tr><td class="NLM_term">SKOV3</td><td class="NLM_def"><p class="first last">human-derived ovarian cancer cell line</p></td></tr><tr><td class="NLM_term">S<sub>N</sub>Ar</td><td class="NLM_def"><p class="first last">nucleophilic aromatic substitution</p></td></tr><tr><td class="NLM_term">SOC3</td><td class="NLM_def"><p class="first last">suppressor of cytokine signaling 3</p></td></tr><tr><td class="NLM_term">SRC</td><td class="NLM_def"><p class="first last">nonreceptor tyrosine kinases</p></td></tr><tr><td class="NLM_term">T cell</td><td class="NLM_def"><p class="first last">lymphocytes developed in the thymus gland</p></td></tr><tr><td class="NLM_term">TBDPS-Cl</td><td class="NLM_def"><p class="first last"><i>tert</i>-butyl(chloro)diphenylsilane</p></td></tr><tr><td class="NLM_term">TDO</td><td class="NLM_def"><p class="first last">tryptophan 2,3-dioxygenase</p></td></tr><tr><td class="NLM_term">Tdp</td><td class="NLM_def"><p class="first last">torsades de pointes</p></td></tr><tr><td class="NLM_term">TE</td><td class="NLM_def"><p class="first last">target engagement</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">TI</td><td class="NLM_def"><p class="first last">therapeutic index</p></td></tr><tr><td class="NLM_term">TIC</td><td class="NLM_def"><p class="first last">total ion count</p></td></tr><tr><td class="NLM_term">TILs</td><td class="NLM_def"><p class="first last">tumor-infiltrating lymphocytes</p></td></tr><tr><td class="NLM_term">TLC</td><td class="NLM_def"><p class="first last">thin layer chromatography</p></td></tr><tr><td class="NLM_term">Treg cells</td><td class="NLM_def"><p class="first last">regulatory T cells</p></td></tr><tr><td class="NLM_term">Trp</td><td class="NLM_def"><p class="first last">l-tryptophan</p></td></tr><tr><td class="NLM_term"><i>V</i><sub>dss</sub></td><td class="NLM_def"><p class="first last">volume of distribution at the steady state</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i97">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00564" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00564" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 70 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Freewan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rees, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plaza, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glaros, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witting, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terentis, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, S. R.</span></span> <span> </span><span class="NLM_article-title">Human Indoleamine 2,3-Dioxygenase Is A Catalyst Of Physiological Heme Peroxidase Reactions</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>288</i></span>,  <span class="NLM_fpage">1548</span>– <span class="NLM_lpage">1567</span>, <span class="refDoi"> DOI: 10.1074/jbc.M112.410993</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1074%2Fjbc.M112.410993" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=23209301" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFahurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2013&pages=1548-1567&author=M.+Freewanauthor=M.+D.+Reesauthor=T.+S.+Plazaauthor=E.+Glarosauthor=Y.+J.+Limauthor=X.+S.+Wangauthor=A.+W.+Yeungauthor=P.+K.+Wittingauthor=A.+C.+Terentisauthor=S.+R.+Thomas&title=Human+Indoleamine+2%2C3-Dioxygenase+Is+A+Catalyst+Of+Physiological+Heme+Peroxidase+Reactions&doi=10.1074%2Fjbc.M112.410993"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Human indoleamine 2,3-dioxygenase is a catalyst of physiological heme peroxidase reactions</span></div><div class="casAuthors">Freewan, Mohammed; Rees, Martin D.; Sempertegui Plaza, Tito S.; Glaros, Elias; Lim, Yean J.; Wang, Xiao Suo; Yeung, Amanda W. S.; Witting, Paul K.; Terentis, Andrew C.; Thomas, Shane R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">288</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1548-1567</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The heme enzyme, indoleamine 2,3-dioxygenase (IDO), is a key regulator of immune responses through catalyzing L-tryptophan (Trp) oxidn.  Here, the authors show that H2O2 activates the peroxidase function of IDO to induce protein oxidn. and inhibit dioxygenase activity.  Exposure of IDO-expressing cells or recombinant human IDO (rIDO) to H2O2 inhibited dioxygenase activity in a manner abrogated by Trp.  Dioxygenase inhibition correlated with IDO-catalyzed H2O2 consumption, compd. I-mediated formation of protein-centered radicals, altered protein secondary structure, and opening of the distal heme pocket to promote nonproductive substrate binding; these changes were inhibited by Trp, the heme ligand, cyanide, or free radical scavengers.  Protection by Trp coincided with its oxidn. into oxindolylalanine and kynurenine and the formation of a compd. II-type ferryl-oxo heme.  Physiol. peroxidase substrates, ascorbate or tyrosine, enhanced rIDO-mediated H2O2 consumption and attenuated H2O2-induced protein oxidn. and dioxygenase inhibition.  In the presence of H2O2, rIDO catalytically consumed NO and utilized NO2- to promote 3-nitrotyrosine formation on IDO.  The promotion of H2O2 consumption by peroxidase substrates, NO consumption, and IDO nitration was inhibited by Trp.  Thus, this study identifies IDO as a heme peroxidase that, in the absence of substrates, self-inactivates its dioxygenase activity via compd. I-initiated protein oxidn.  Trp protects against dioxygenase inactivation by reacting with compd. I and retarding compd. II redn. to suppress peroxidase turnover.  Peroxidase-mediated dioxygenase inactivation, NO consumption, or protein nitration may modulate the biol. actions of IDO expressed in inflammatory tissues where the levels of H2O2 and NO are elevated and Trp is low.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4W1ahDsUwk7Vg90H21EOLACvtfcHk0lg2TCws7k7omg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFahurg%253D&md5=ffd1e739694ae9bef9fc2fe4ff626381</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M112.410993&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M112.410993%26sid%3Dliteratum%253Aachs%26aulast%3DFreewan%26aufirst%3DM.%26aulast%3DRees%26aufirst%3DM.%2BD.%26aulast%3DPlaza%26aufirst%3DT.%2BS.%26aulast%3DGlaros%26aufirst%3DE.%26aulast%3DLim%26aufirst%3DY.%2BJ.%26aulast%3DWang%26aufirst%3DX.%2BS.%26aulast%3DYeung%26aufirst%3DA.%2BW.%26aulast%3DWitting%26aufirst%3DP.%2BK.%26aulast%3DTerentis%26aufirst%3DA.%2BC.%26aulast%3DThomas%26aufirst%3DS.%2BR.%26atitle%3DHuman%2520Indoleamine%25202%252C3-Dioxygenase%2520Is%2520A%2520Catalyst%2520Of%2520Physiological%2520Heme%2520Peroxidase%2520Reactions%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2013%26volume%3D288%26spage%3D1548%26epage%3D1567%26doi%3D10.1074%2Fjbc.M112.410993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brochez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chevolet, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruse, V.</span></span> <span> </span><span class="NLM_article-title">The Rationale Of Indoleamine 2,3-Dioxygenase Inhibition For Cancer Therapy</span>. <i>Eur. J. Canc.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">167</span>– <span class="NLM_lpage">182</span>, <span class="refDoi"> DOI: 10.1016/j.ejca.2017.01.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1016%2Fj.ejca.2017.01.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=28324751" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjsVGnu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2017&pages=167-182&author=L.+Brochezauthor=I.+Chevoletauthor=V.+Kruse&title=The+Rationale+Of+Indoleamine+2%2C3-Dioxygenase+Inhibition+For+Cancer+Therapy&doi=10.1016%2Fj.ejca.2017.01.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy</span></div><div class="casAuthors">Brochez, Lieve; Chevolet, Ines; Kruse, Vibeke</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">167-182</span>CODEN:
                <span class="NLM_cas:coden">EJCAEL</span>;
        ISSN:<span class="NLM_cas:issn">0959-8049</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Indoleamine 2,3-dioxygenase (IDO, also referred to as IDO1) has been demonstrated to be a normal endogenous mechanism of acquired peripheral immune tolerance in vivo.In the field of oncol., IDO expression and/or activity has been obsd. in several cancer types and has usually been assocd. with neg. prognostic factors and worse outcome measures.This manuscript reviews current available data on the role of IDO in cancer and the current results obtained with IDO inhibition, both in animal models and in phase 1 and 2 clin. trials in humans.  Preliminary results with IDO inhibitors, usually combined with other anti-cancer drugs, seem encouraging.  Further studies are needed to clarify the conditions in which IDO inhibitors can be of value as an anti-cancer strategy.  In addn., further research should address whether the expression of IDO in tissue or blood can be a marker to select patients who can benefit most from IDO inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYAcutfExLmLVg90H21EOLACvtfcHk0li2fGDF356BHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjsVGnu7Y%253D&md5=5f983eb246a008c33a3b186699e1e244</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2017.01.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2017.01.011%26sid%3Dliteratum%253Aachs%26aulast%3DBrochez%26aufirst%3DL.%26aulast%3DChevolet%26aufirst%3DI.%26aulast%3DKruse%26aufirst%3DV.%26atitle%3DThe%2520Rationale%2520Of%2520Indoleamine%25202%252C3-Dioxygenase%2520Inhibition%2520For%2520Cancer%2520Therapy%26jtitle%3DEur.%2520J.%2520Canc.%26date%3D2017%26volume%3D76%26spage%3D167%26epage%3D182%26doi%3D10.1016%2Fj.ejca.2017.01.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giannone, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghisoni, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scotto, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuninetti, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turinetto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valabrega, G.</span></span> <span> </span><span class="NLM_article-title">Immuno-Metabolism And Microenvironment In Cancer: Key Players For Immunotherapy</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">4414</span>, <span class="refDoi"> DOI: 10.3390/ijms21124414</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.3390%2Fijms21124414" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitVSgtLfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2020&pages=4414&author=G.+Giannoneauthor=E.+Ghisoniauthor=S.+Gentaauthor=G.+Scottoauthor=V.+Tuninettiauthor=M.+Turinettoauthor=G.+Valabrega&title=Immuno-Metabolism+And+Microenvironment+In+Cancer%3A+Key+Players+For+Immunotherapy&doi=10.3390%2Fijms21124414"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Immuno-metabolism and microenvironment in cancer: key players for immunotherapy</span></div><div class="casAuthors">Giannone, Gaia; Ghisoni, Eleonora; Genta, Sofia; Scotto, Giulia; Tuninetti, Valentina; Turinetto, Margherita; Valabrega, Giorgio</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4414</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Immune checkpoint inhibitors (ICIs) have changed therapeutic algorithms in several malignancies, although intrinsic and secondary resistance is still an issue.  In this context, the dysregulation of immuno-metab. plays a leading role both in the tumor microenvironment (TME) and at the host level.  In this review, we summarize the most important immune-metabolic factors and how they could be exploited therapeutically.  At the cellular level, an increased concn. of extracellular adenosine as well as the depletion of tryptophan and uncontrolled activation of the PI3K/AKT pathway induces an immune-tolerant TME, reducing the response to ICIs.  Moreover, aberrant angiogenesis induces a hypoxic environment by recruiting VEGF, Treg cells and immune-suppressive tumor assocd. macrophages (TAMs).  On the other hand, factors such as gender and body mass index seem to affect the response to ICIs, while the microbiome compn. (and its alterations) modulates both the response and the development of immune-related adverse events.  Exploiting these complex mechanisms is the next goal in immunotherapy.  The most successful strategy to date has been the combination of antiangiogenic drugs and ICIs, which prolonged the survival of patients with non-small-cell lung cancer (NSCLC) and hepatocellular carcinoma (HCC), while results from tryptophan pathway inhibition studies are inconclusive.  New exciting strategies include targeting the adenosine pathway, TAMs and the microbiota with fecal microbiome transplantation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtWFXaiqD0xrVg90H21EOLACvtfcHk0li2fGDF356BHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitVSgtLfN&md5=5b9fb828cea8feb7c68b957fbb0582c0</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.3390%2Fijms21124414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms21124414%26sid%3Dliteratum%253Aachs%26aulast%3DGiannone%26aufirst%3DG.%26aulast%3DGhisoni%26aufirst%3DE.%26aulast%3DGenta%26aufirst%3DS.%26aulast%3DScotto%26aufirst%3DG.%26aulast%3DTuninetti%26aufirst%3DV.%26aulast%3DTurinetto%26aufirst%3DM.%26aulast%3DValabrega%26aufirst%3DG.%26atitle%3DImmuno-Metabolism%2520And%2520Microenvironment%2520In%2520Cancer%253A%2520Key%2520Players%2520For%2520Immunotherapy%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2020%26volume%3D21%26spage%3D4414%26doi%3D10.3390%2Fijms21124414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Austin, C. J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rendina, L. M.</span></span> <span> </span><span class="NLM_article-title">Targeting Key Dioxygenases In Tryptophan–Kynurenine Metabolism For Immunomodulation And Cancer Chemotherapy</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">609</span>– <span class="NLM_lpage">617</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2014.11.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1016%2Fj.drudis.2014.11.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=25478733" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitV2gu7nJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2015&pages=609-617&author=C.+J.+D.+Austinauthor=L.+M.+Rendina&title=Targeting+Key+Dioxygenases+In+Tryptophan%E2%80%93Kynurenine+Metabolism+For+Immunomodulation+And+Cancer+Chemotherapy&doi=10.1016%2Fj.drudis.2014.11.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting key dioxygenases in tryptophan-kynurenine metabolism for immunomodulation and cancer chemotherapy</span></div><div class="casAuthors">Austin, Christopher J. D.; Rendina, Louis M.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">609-617</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Tryptophan to kynurenine metab. is controlled by three distinct dioxygenase enzymes: tryptophan 2,3-dioxygenase (TDO), indoleamine 2,3-dioxygenase 1 (IDO1), and indoleamine 2,3-dioxygenase 2 (IDO2).  Collectively, the activity of these enzymes contributes to tumor immune tolerance and immune dysregulation in a variety of disease pathologies, including cancer.  Whereas IDO1 inhibitor drug design has been the focus of study for more than two decades (with novel compds. currently in Phase II clin. trials), only recently have the roles of TDO and IDO2 been elucidated in immunosuppression.  Consequently, little comparative work on inhibitor cross-reactivity and selectivity has been performed.  Here, we provide an overview of the current and future drug discovery landscape for targeting TDO, IDO1, and IDO2 (individually and collectively) for pharmacol. intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOoUq5iFaItLVg90H21EOLACvtfcHk0li2fGDF356BHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitV2gu7nJ&md5=3e49304fea87a6564ef051ac67332a06</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2014.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2014.11.007%26sid%3Dliteratum%253Aachs%26aulast%3DAustin%26aufirst%3DC.%2BJ.%2BD.%26aulast%3DRendina%26aufirst%3DL.%2BM.%26atitle%3DTargeting%2520Key%2520Dioxygenases%2520In%2520Tryptophan%25E2%2580%2593Kynurenine%2520Metabolism%2520For%2520Immunomodulation%2520And%2520Cancer%2520Chemotherapy%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2015%26volume%3D20%26spage%3D609%26epage%3D617%26doi%3D10.1016%2Fj.drudis.2014.11.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Théate, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Baren, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilotte, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moulin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larrieu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renauld, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hervé, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutierrez-Roelens, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marbaix, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sempoux, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van den Eynde, B. J.</span></span> <span> </span><span class="NLM_article-title">Extensive Profiling Of The Expression Of The Indoleamine 2,3-Dioxygenase 1 Protein In Normal And Tumoral Human Tissues. Cancer Immunology Research 2014, 3 (2), 161-172</span>. <i>Cancer Immunol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">161</span>– <span class="NLM_lpage">172</span>, <span class="refDoi"> DOI: 10.1158/2326-6066.cir-14-0137</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1158%2F2326-6066.cir-14-0137" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=25271151" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BC2MXis1Knurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2015&pages=161-172&author=I.+Th%C3%A9ateauthor=N.+van+Barenauthor=L.+Pilotteauthor=P.+Moulinauthor=P.+Larrieuauthor=J.-C.+Renauldauthor=C.+Herv%C3%A9author=I.+Gutierrez-Roelensauthor=E.+Marbaixauthor=C.+Sempouxauthor=B.+J.+Van+den+Eynde&title=Extensive+Profiling+Of+The+Expression+Of+The+Indoleamine+2%2C3-Dioxygenase+1+Protein+In+Normal+And+Tumoral+Human+Tissues.+Cancer+Immunology+Research+2014%2C+3+%282%29%2C+161-172&doi=10.1158%2F2326-6066.cir-14-0137"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Extensive Profiling of the Expression of the Indoleamine 2,3-Dioxygenase 1 Protein in Normal and Tumoral Human Tissues</span></div><div class="casAuthors">Theate, Ivan; van Baren, Nicolas; Pilotte, Luc; Moulin, Pierre; Larrieu, Pierre; Renauld, Jean-Christophe; Herve, Caroline; Gutierrez-Roelens, Ilse; Marbaix, Etienne; Sempoux, Christine; Van den Eynde, Benoit J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Immunology Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">161-172</span>CODEN:
                <span class="NLM_cas:coden">CIRACV</span>;
        ISSN:<span class="NLM_cas:issn">2326-6066</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Theate, van Baren, and colleagues used a highly specific antibody to characterize IDO1 expression in a large series of healthy and tumoral human tissues to facilitate the selection of appropriate tumor types for pharmacol. IDO1 inhibition and to anticipate possible side effects of this treatment.  Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 (IDO1) plays a key role in tumoral resistance to immune rejection.  In humans, constitutive expression of IDO1 has been obsd. in several tumor types.  However, a comprehensive anal. of its expression in normal and tumor tissues is still required to anticipate the risks and potential benefits of IDO1 inhibitors.  Using a newly validated monoclonal antibody to human IDO1, we performed an extensive immunohistochem. anal. of IDO1 expression in normal and tumor tissues.  In normal tissues, IDO1 was expressed by endothelial cells in the placenta and lung and by epithelial cells in the female genital tract.  In lymphoid tissues, IDO1 was expressed in mature dendritic cells with a phenotype (CD83+, DC-LAMP+, langerin-, CD123-, CD163-) distinct from plasmacytoid dendritic cells.  Importantly, IDO1-expressing dendritic cells were not enriched in tumor-draining lymph nodes, in contrast with previously reported findings.  IDO1-expressing cells were obsd. in a large fraction (505/866, 58%) of human tumors.  They comprised tumor cells, endothelial cells, and stromal cells in proportions that varied depending on the tumor type.  Tumors showing the highest proportions of IDO1-immunolabeled samples were carcinomas of the endometrium and cervix, followed by kidney, lung, and colon.  This hierarchy of IDO1 expression was confirmed by gene expression data mined from The Cancer Genome Atlas database.  Expression of IDO1 may be used to select tumors likely to benefit from targeted therapy with IDO1 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpG_twsNEJaH7Vg90H21EOLACvtfcHk0liz8porTc3GCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXis1Knurs%253D&md5=c7f8dc1a17c5a4a0fa8bc4bd44d8d0e0</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1158%2F2326-6066.cir-14-0137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2326-6066.cir-14-0137%26sid%3Dliteratum%253Aachs%26aulast%3DTh%25C3%25A9ate%26aufirst%3DI.%26aulast%3Dvan%2BBaren%26aufirst%3DN.%26aulast%3DPilotte%26aufirst%3DL.%26aulast%3DMoulin%26aufirst%3DP.%26aulast%3DLarrieu%26aufirst%3DP.%26aulast%3DRenauld%26aufirst%3DJ.-C.%26aulast%3DHerv%25C3%25A9%26aufirst%3DC.%26aulast%3DGutierrez-Roelens%26aufirst%3DI.%26aulast%3DMarbaix%26aufirst%3DE.%26aulast%3DSempoux%26aufirst%3DC.%26aulast%3DVan%2Bden%2BEynde%26aufirst%3DB.%2BJ.%26atitle%3DExtensive%2520Profiling%2520Of%2520The%2520Expression%2520Of%2520The%2520Indoleamine%25202%252C3-Dioxygenase%25201%2520Protein%2520In%2520Normal%2520And%2520Tumoral%2520Human%2520Tissues.%2520Cancer%2520Immunology%2520Research%25202014%252C%25203%2520%25282%2529%252C%2520161-172%26jtitle%3DCancer%2520Immunol.%2520Res.%26date%3D2015%26volume%3D3%26spage%3D161%26epage%3D172%26doi%3D10.1158%2F2326-6066.cir-14-0137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roszik, J.</span>; <span class="NLM_string-name">Tanese, K.</span>; <span class="NLM_string-name">Ekmekcioglu, S.</span></span> <span> </span><span class="NLM_article-title">Editorial: Targeting Metabolism In Cancer Immunotherapy</span>.  <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume">9</span>.2029 <span class="refDoi"> DOI: 10.3389/fimmu.2018.02029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.3389%2Ffimmu.2018.02029" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&author=J.+Roszik&author=K.+Tanese&author=S.+Ekmekcioglu&title=Editorial%3A+Targeting+Metabolism+In+Cancer+Immunotherapy&doi=10.3389%2Ffimmu.2018.02029"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2018.02029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2018.02029%26sid%3Dliteratum%253Aachs%26aulast%3DRoszik%26aufirst%3DJ.%26atitle%3DEditorial%253A%2520Targeting%2520Metabolism%2520In%2520Cancer%2520Immunotherapy%26jtitle%3DFront.%2520Immunol.%26date%3D2018%26volume%3D9%26doi%3D10.3389%2Ffimmu.2018.02029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span> <span> </span><span class="NLM_article-title">Upregulated Expression Of Indoleamine 2, 3-Dioxygenase In Primary Breast Cancer Correlates With Increase Of Infiltrated Regulatory T Cellsin Situand Lymph Node Metastasis</span>. <i>Clin. Dev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2011</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.1155/2011/469135</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1155%2F2011%2F469135" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2011&publication_year=2011&pages=1-10&author=J.+Yuauthor=J.+Sunauthor=S.+E.+Wangauthor=H.+Liauthor=S.+Caoauthor=Y.+Congauthor=J.+Liuauthor=X.+Ren&title=Upregulated+Expression+Of+Indoleamine+2%2C+3-Dioxygenase+In+Primary+Breast+Cancer+Correlates+With+Increase+Of+Infiltrated+Regulatory+T+Cellsin+Situand+Lymph+Node+Metastasis&doi=10.1155%2F2011%2F469135"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1155%2F2011%2F469135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2011%252F469135%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DS.%2BE.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DCao%26aufirst%3DS.%26aulast%3DCong%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DRen%26aufirst%3DX.%26atitle%3DUpregulated%2520Expression%2520Of%2520Indoleamine%25202%252C%25203-Dioxygenase%2520In%2520Primary%2520Breast%2520Cancer%2520Correlates%2520With%2520Increase%2520Of%2520Infiltrated%2520Regulatory%2520T%2520Cellsin%2520Situand%2520Lymph%2520Node%2520Metastasis%26jtitle%3DClin.%2520Dev.%2520Immunol.%26date%3D2011%26volume%3D2011%26spage%3D1%26epage%3D10%26doi%3D10.1155%2F2011%2F469135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ino, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kajiyama, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terauchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nawa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takikawa, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kikkawa, F.</span></span> <span> </span><span class="NLM_article-title">Inverse Correlation Between Tumoral Indoleamine 2,3-Dioxygenase Expression And Tumor-Infiltrating Lymphocytes In Endometrial Cancer: Its Association With Disease Progression And Survival</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">2310</span>– <span class="NLM_lpage">2317</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.ccr-07-4144</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1158%2F1078-0432.CCR-07-4144" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=18413819" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BD1cXkvFGmtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=2310-2317&author=K.+Inoauthor=E.+Yamamotoauthor=K.+Shibataauthor=H.+Kajiyamaauthor=N.+Yoshidaauthor=M.+Terauchiauthor=A.+Nawaauthor=T.+Nagasakaauthor=O.+Takikawaauthor=F.+Kikkawa&title=Inverse+Correlation+Between+Tumoral+Indoleamine+2%2C3-Dioxygenase+Expression+And+Tumor-Infiltrating+Lymphocytes+In+Endometrial+Cancer%3A+Its+Association+With+Disease+Progression+And+Survival&doi=10.1158%2F1078-0432.ccr-07-4144"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Inverse Correlation between Tumoral Indoleamine 2,3-Dioxygenase Expression and Tumor-Infiltrating Lymphocytes in Endometrial Cancer: Its Association with Disease Progression and Survival</span></div><div class="casAuthors">Ino, Kazuhiko; Yamamoto, Eiko; Shibata, Kiyosumi; Kajiyama, Hiroaki; Yoshida, Norio; Terauchi, Mikio; Nawa, Akihiro; Nagasaka, Tetsuro; Takikawa, Osamu; Kikkawa, Fumitaka</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2310-2317</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Tumor escape from host immune systems is a crucial mechanism for disease progression.  We recently showed that the immunosuppressive enzyme indoleamine 2,3-dioxygenase (IDO) is a prognostic indicator for endometrial cancer.  The purpose of the present study was to investigate the relationship between IDO expression and tumor-infiltrating lymphocytes (TIL) or natural killer (NK) cells and to clarify their prognostic effect in endometrial cancer.  Exptl. Design: Immunohistochem. staining for IDO expression in endometrial cancer tissues (n = 65) was done.  Tumor-infiltrating CD3+ and CD8+ lymphocytes, as well as CD57+ NK cells, were counted in serial tissue sections.  RESULTS: High IDO expression in tumor cells was found in 32 of 65 cases and was pos. correlated with myometrial invasion, nodal metastasis, and lymph-vascular space involvement.  We also found a significant correlation between high IDO expression and reduced nos. of CD3+, CD8+, and CD57+ cells infiltrating into both the tumor epithelium and stroma.  Patients with high IDO expression, a low no. of stromal CD3 (<60), low intraepithelial CD8 (<25), or low stromal CD8 (<40) had significantly impaired progression-free survival.  On multivariate anal., IDO expression and the no. of stromal CD3+ TILs were independent prognostic factors for impaired progression-free survival.  CONCLUSIONS: Tumoral IDO expression correlated with a reduced no. of TILs and NK cells in endometrial cancer, possibly contributing to disease progression and impaired clin. outcome.  These findings suggest that targeting IDO to restore host antitumor immunity may be a therapeutic strategy for endometrial cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZZtHpmlR407Vg90H21EOLACvtfcHk0liz8porTc3GCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXkvFGmtL0%253D&md5=6baa8848c1ba82c24fd749f907c4acef</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-4144&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-4144%26sid%3Dliteratum%253Aachs%26aulast%3DIno%26aufirst%3DK.%26aulast%3DYamamoto%26aufirst%3DE.%26aulast%3DShibata%26aufirst%3DK.%26aulast%3DKajiyama%26aufirst%3DH.%26aulast%3DYoshida%26aufirst%3DN.%26aulast%3DTerauchi%26aufirst%3DM.%26aulast%3DNawa%26aufirst%3DA.%26aulast%3DNagasaka%26aufirst%3DT.%26aulast%3DTakikawa%26aufirst%3DO.%26aulast%3DKikkawa%26aufirst%3DF.%26atitle%3DInverse%2520Correlation%2520Between%2520Tumoral%2520Indoleamine%25202%252C3-Dioxygenase%2520Expression%2520And%2520Tumor-Infiltrating%2520Lymphocytes%2520In%2520Endometrial%2520Cancer%253A%2520Its%2520Association%2520With%2520Disease%2520Progression%2520And%2520Survival%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26spage%3D2310%26epage%3D2317%26doi%3D10.1158%2F1078-0432.ccr-07-4144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galli, F.</span>; <span class="NLM_string-name">Aguilera, J.</span>; <span class="NLM_string-name">Palermo, B.</span>; <span class="NLM_string-name">Markovic, S.</span>; <span class="NLM_string-name">Nisticò, P.</span>; <span class="NLM_string-name">Signore, A.</span></span> <span> </span><span class="NLM_article-title">Relevance Of Immune Cell And Tumor Microenvironment Imaging In The New Era Of Immunotherapy</span>.  <i>J. Exp. Clin. Canc. Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume">39</span>.89 <span class="refDoi"> DOI: 10.1186/s13046-020-01586-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1186%2Fs13046-020-01586-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=32423420" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2020&author=F.+Galli&author=J.+Aguilera&author=B.+Palermo&author=S.+Markovic&author=P.+Nistic%C3%B2&author=A.+Signore&title=Relevance+Of+Immune+Cell+And+Tumor+Microenvironment+Imaging+In+The+New+Era+Of+Immunotherapy&doi=10.1186%2Fs13046-020-01586-y"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1186%2Fs13046-020-01586-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13046-020-01586-y%26sid%3Dliteratum%253Aachs%26aulast%3DGalli%26aufirst%3DF.%26atitle%3DRelevance%2520Of%2520Immune%2520Cell%2520And%2520Tumor%2520Microenvironment%2520Imaging%2520In%2520The%2520New%2520Era%2520Of%2520Immunotherapy%26jtitle%3DJ.%2520Exp.%2520Clin.%2520Canc.%2520Res.%26date%3D2020%26volume%3D39%26doi%3D10.1186%2Fs13046-020-01586-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladomersky, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenzen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauing, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wainwright, D. A.</span></span> <span> </span><span class="NLM_article-title">IDO1 In Cancer: A Gemini Of Immune Checkpoints</span>. <i>Cell. Mol. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">447</span>– <span class="NLM_lpage">457</span>, <span class="refDoi"> DOI: 10.1038/cmi.2017.143</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1038%2Fcmi.2017.143" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=29375124" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVWqsbbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2018&pages=447-457&author=L.+Zhaiauthor=E.+Ladomerskyauthor=A.+Lenzenauthor=B.+Nguyenauthor=R.+Patelauthor=K.+L.+Lauingauthor=M.+Wuauthor=D.+A.+Wainwright&title=IDO1+In+Cancer%3A+A+Gemini+Of+Immune+Checkpoints&doi=10.1038%2Fcmi.2017.143"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">IDO1 in cancer: a Gemini of immune checkpoints</span></div><div class="casAuthors">Zhai, Lijie; Ladomersky, Erik; Lenzen, Alicia; Nguyen, Brenda; Patel, Ricky; Lauing, Kristen L.; Wu, Meijing; Wainwright, Derek A.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular & Molecular Immunology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">447-457</span>CODEN:
                <span class="NLM_cas:coden">CMIEAO</span>;
        ISSN:<span class="NLM_cas:issn">1672-7681</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Indoleamine 2, 3-dioxygenase 1 (IDO1) is a rate-limiting metabolic enzyme that converts the essential amino acid tryptophan (Trp) into downstream catabolites known as kynurenines.  Coincidently, numerous studies have demonstrated that IDO1 is highly expressed in multiple types of human cancer.  Preclin. studies have further introduced an interesting paradox: while single-agent treatment with IDO1 enzyme inhibitor has a negligible effect on decreasing the established cancer burden, approaches combining select therapies with IDO1 blockade tend to yield a synergistic benefit against tumor growth and/or animal subject survival.  Given the high expression of IDO1 among multiple cancer types along with the lack of monotherapeutic efficacy, these data suggest that there is a more complex mechanism of action than previously appreciated.  Similar to the dual faces of the astrol. Gemini, we highlight the multiple roles of IDO1 and review its canonical assocn. with IDO1-dependent tryptophan metab., as well as documented evidence confirming the dispensability of enzyme activity for its immunosuppressive effects.  The gene transcript levels for IDO1 highlight its strong assocn. with T-cell infiltration, but the lack of a universal prognostic significance among all cancer subtypes.  Finally, ongoing clin. trials are discussed with consideration of IDO1-targeting strategies that enhance the efficacy of immunotherapy for cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvVLMCOcWWorVg90H21EOLACvtfcHk0ljn9QljiahVBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVWqsbbP&md5=cf75d557eed8dc2b131f4eefe178b7d1</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fcmi.2017.143&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcmi.2017.143%26sid%3Dliteratum%253Aachs%26aulast%3DZhai%26aufirst%3DL.%26aulast%3DLadomersky%26aufirst%3DE.%26aulast%3DLenzen%26aufirst%3DA.%26aulast%3DNguyen%26aufirst%3DB.%26aulast%3DPatel%26aufirst%3DR.%26aulast%3DLauing%26aufirst%3DK.%2BL.%26aulast%3DWu%26aufirst%3DM.%26aulast%3DWainwright%26aufirst%3DD.%2BA.%26atitle%3DIDO1%2520In%2520Cancer%253A%2520A%2520Gemini%2520Of%2520Immune%2520Checkpoints%26jtitle%3DCell.%2520Mol.%2520Immunol.%26date%3D2018%26volume%3D15%26spage%3D447%26epage%3D457%26doi%3D10.1038%2Fcmi.2017.143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueng, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, C.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, M.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, F.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsiao, W.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsueh, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shia, K.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.-Y.</span></span> <span> </span><span class="NLM_article-title">Important Hydrogen Bond Networks In Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Design Revealed By Crystal Structures Of Imidazoleisoindole Derivatives With IDO1</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">282</span>– <span class="NLM_lpage">293</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01390</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01390" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFKjtLnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=282-293&author=Y.-H.+Pengauthor=S.-H.+Uengauthor=C.-T.+Tsengauthor=M.-S.+Hungauthor=J.-S.+Songauthor=J.-S.+Wuauthor=F.-Y.+Liaoauthor=Y.-S.+Fanauthor=M.-H.+Wuauthor=W.-C.+Hsiaoauthor=C.-C.+Hsuehauthor=S.-Y.+Linauthor=C.-Y.+Chengauthor=C.-H.+Tuauthor=L.-C.+Leeauthor=M.-F.+Chengauthor=K.-S.+Shiaauthor=C.+Shihauthor=S.-Y.+Wu&title=Important+Hydrogen+Bond+Networks+In+Indoleamine+2%2C3-Dioxygenase+1+%28IDO1%29+Inhibitor+Design+Revealed+By+Crystal+Structures+Of+Imidazoleisoindole+Derivatives+With+IDO1&doi=10.1021%2Facs.jmedchem.5b01390"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Important Hydrogen Bond Networks in Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Design Revealed by Crystal Structures of Imidazoleisoindole Derivatives with IDO1</span></div><div class="casAuthors">Peng, Yi-Hui; Ueng, Shau-Hua; Tseng, Chen-Tso; Hung, Ming-Shiu; Song, Jen-Shin; Wu, Jian-Sung; Liao, Fang-Yu; Fan, Yu-Shiou; Wu, Mine-Hsine; Hsiao, Wen-Chi; Hsueh, Ching-Cheng; Lin, Shu-Yu; Cheng, Chia-Yi; Tu, Chih-Hsiang; Lee, Lung-Chun; Cheng, Ming-Fu; Shia, Kak-Shan; Shih, Chuan; Wu, Su-Ying</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">282-293</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1), promoting immune escape of tumors, is a therapeutic target for the cancer immunotherapy.  A no. of IDO1 inhibitors have been identified, but only limited structural biol. studies of IDO1 inhibitors are available to provide insights on the binding mechanism of IDO1.  In this study, we present the structure of IDO1 in complex with 24, a NLG919 analog with potent activity.  The complex structure revealed the imidazole nitrogen atom of 24 to coordinate with the heme iron, and the imidazoleisoindole core situated in pocket A with the 1-cyclohexylethanol moiety extended to pocket B to interact with the surrounding residues.  Most interestingly, 24 formed an extensive hydrogen bond network with IDO1, which is a distinct feature of IDO1/24 complex structure and is not obsd. in the other IDO1 complex structures.  Further structure-activity relationship, UV spectra, and structural biol. studies of several analogs of 24 demonstrated that extensive hydrophobic interactions and the unique hydrogen bonding network contribute to the great potency of imidazoleisoindole derivs.  These results are expected to facilitate the structure-based drug design of new IDO inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodJqtuECqcsrVg90H21EOLACvtfcHk0ljn9QljiahVBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFKjtLnJ&md5=2258be36595a3fa8e6c9064b2f15e1de</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01390&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01390%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DY.-H.%26aulast%3DUeng%26aufirst%3DS.-H.%26aulast%3DTseng%26aufirst%3DC.-T.%26aulast%3DHung%26aufirst%3DM.-S.%26aulast%3DSong%26aufirst%3DJ.-S.%26aulast%3DWu%26aufirst%3DJ.-S.%26aulast%3DLiao%26aufirst%3DF.-Y.%26aulast%3DFan%26aufirst%3DY.-S.%26aulast%3DWu%26aufirst%3DM.-H.%26aulast%3DHsiao%26aufirst%3DW.-C.%26aulast%3DHsueh%26aufirst%3DC.-C.%26aulast%3DLin%26aufirst%3DS.-Y.%26aulast%3DCheng%26aufirst%3DC.-Y.%26aulast%3DTu%26aufirst%3DC.-H.%26aulast%3DLee%26aufirst%3DL.-C.%26aulast%3DCheng%26aufirst%3DM.-F.%26aulast%3DShia%26aufirst%3DK.-S.%26aulast%3DShih%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DS.-Y.%26atitle%3DImportant%2520Hydrogen%2520Bond%2520Networks%2520In%2520Indoleamine%25202%252C3-Dioxygenase%25201%2520%2528IDO1%2529%2520Inhibitor%2520Design%2520Revealed%2520By%2520Crystal%2520Structures%2520Of%2520Imidazoleisoindole%2520Derivatives%2520With%2520IDO1%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D282%26epage%3D293%26doi%3D10.1021%2Facs.jmedchem.5b01390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yue, E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douty, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wayland, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bower, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leffet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansbury, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wynn, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burn, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koblish, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridman, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metcalf, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherle, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Combs, A. P.</span></span> <span> </span><span class="NLM_article-title">Discovery Of Potent Competitive Inhibitors Of Indoleamine 2,3-Dioxygenase With In Vivo Pharmacodynamic Activity and Efficacy In A Mouse Melanoma Model</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">7364</span>– <span class="NLM_lpage">7367</span>, <span class="refDoi"> DOI: 10.1021/jm900518f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900518f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BD1MXntVSksb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=7364-7367&author=E.+W.+Yueauthor=B.+Doutyauthor=B.+Waylandauthor=M.+Bowerauthor=X.+Liuauthor=L.+Leffetauthor=Q.+Wangauthor=K.+J.+Bowmanauthor=M.+J.+Hansburyauthor=C.+Liuauthor=M.+Weiauthor=Y.+Liauthor=R.+Wynnauthor=T.+C.+Burnauthor=H.+K.+Koblishauthor=J.+S.+Fridmanauthor=B.+Metcalfauthor=P.+A.+Scherleauthor=A.+P.+Combs&title=Discovery+Of+Potent+Competitive+Inhibitors+Of+Indoleamine+2%2C3-Dioxygenase+With+In+Vivo+Pharmacodynamic+Activity+and+Efficacy+In+A+Mouse+Melanoma+Model&doi=10.1021%2Fjm900518f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent Competitive Inhibitors of Indoleamine 2,3-Dioxygenase with in Vivo Pharmacodynamic Activity and Efficacy in a Mouse Melanoma Model</span></div><div class="casAuthors">Yue, Eddy W.; Douty, Brent; Wayland, Brian; Bower, Michael; Liu, Xiangdong; Leffet, Lynn; Wang, Qian; Bowman, Kevin J.; Hansbury, Michael J.; Liu, Changnian; Wei, Min; Li, Yanlong; Wynn, Richard; Burn, Timothy C.; Koblish, Holly K.; Fridman, Jordan S.; Metcalf, Brian; Scherle, Peggy A.; Combs, Andrew P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7364-7367</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A hydroxyamidine chemotype has been discovered as a key pharmacophore in novel inhibitors of indoleamine 2,3-dioxygenase (IDO).  Optimization led to the identification of (I), which is a potent (HeLa IC50 = 19 nM) competitive inhibitor of IDO.  Testing of I in mice demonstrated pharmacodynamic inhibition of IDO, as measured by decreased kynurenine levels (>50%) in plasma and dose dependent efficacy in mice bearing GM-CSF-secreting B16 melanoma tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZsq88hx0J77Vg90H21EOLACvtfcHk0liwAqkjz83V_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXntVSksb8%253D&md5=328d92bffb88a86da030c31eff707dc6</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjm900518f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900518f%26sid%3Dliteratum%253Aachs%26aulast%3DYue%26aufirst%3DE.%2BW.%26aulast%3DDouty%26aufirst%3DB.%26aulast%3DWayland%26aufirst%3DB.%26aulast%3DBower%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLeffet%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DBowman%26aufirst%3DK.%2BJ.%26aulast%3DHansbury%26aufirst%3DM.%2BJ.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DWei%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWynn%26aufirst%3DR.%26aulast%3DBurn%26aufirst%3DT.%2BC.%26aulast%3DKoblish%26aufirst%3DH.%2BK.%26aulast%3DFridman%26aufirst%3DJ.%2BS.%26aulast%3DMetcalf%26aufirst%3DB.%26aulast%3DScherle%26aufirst%3DP.%2BA.%26aulast%3DCombs%26aufirst%3DA.%2BP.%26atitle%3DDiscovery%2520Of%2520Potent%2520Competitive%2520Inhibitors%2520Of%2520Indoleamine%25202%252C3-Dioxygenase%2520With%2520In%2520Vivo%2520Pharmacodynamic%2520Activity%2520and%2520Efficacy%2520In%2520A%2520Mouse%2520Melanoma%2520Model%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D7364%26epage%3D7367%26doi%3D10.1021%2Fjm900518f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crosignani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bingham, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottemanne, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cannelle, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cauwenberghs, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cordonnier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalvie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deroose, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomes, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greasley, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaiser, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraus, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Négrerie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maegley, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soloweij, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torti, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Den Eynde, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wythes, M.</span></span> <span> </span><span class="NLM_article-title">Discovery Of A Novel And Selective Indoleamine 2,3-Dioxygenase (IDO-1) Inhibitor 3-(5-Fluoro-1H-Indol-3-Yl)Pyrrolidine-2,5-Dione (EOS200271/PF-06840003) And Its Characterization As A Potential Clinical Candidate</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">9617</span>– <span class="NLM_lpage">9629</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00974</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00974" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslOns7%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=9617-9629&author=S.+Crosignaniauthor=P.+Binghamauthor=P.+Bottemanneauthor=H.+Cannelleauthor=S.+Cauwenberghsauthor=M.+Cordonnierauthor=D.+Dalvieauthor=F.+Derooseauthor=J.+L.+Fengauthor=B.+Gomesauthor=S.+Greasleyauthor=S.+E.+Kaiserauthor=M.+Krausauthor=M.+N%C3%A9grerieauthor=K.+Maegleyauthor=N.+Millerauthor=B.+W.+Murrayauthor=M.+Schneiderauthor=J.+Soloweijauthor=A.+E.+Stewartauthor=J.+Tumangauthor=V.+R.+Tortiauthor=B.+Van+Den+Eyndeauthor=M.+Wythes&title=Discovery+Of+A+Novel+And+Selective+Indoleamine+2%2C3-Dioxygenase+%28IDO-1%29+Inhibitor+3-%285-Fluoro-1H-Indol-3-Yl%29Pyrrolidine-2%2C5-Dione+%28EOS200271%2FPF-06840003%29+And+Its+Characterization+As+A+Potential+Clinical+Candidate&doi=10.1021%2Facs.jmedchem.7b00974"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Novel and Selective Indoleamine 2,3-Dioxygenase (IDO-1) Inhibitor 3-(5-Fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione (EOS200271/PF-06840003) and Its Characterization as a Potential Clinical Candidate</span></div><div class="casAuthors">Crosignani, Stefano; Bingham, Patrick; Bottemanne, Pauline; Cannelle, Helene; Cauwenberghs, Sandra; Cordonnier, Marie; Dalvie, Deepak; Deroose, Frederik; Feng, Jun Li; Gomes, Bruno; Greasley, Samantha; Kaiser, Stephen E.; Kraus, Manfred; Negrerie, Michel; Maegley, Karen; Miller, Nichol; Murray, Brion W.; Schneider, Manfred; Soloweij, James; Stewart, Albert E.; Tumang, Joseph; Torti, Vince R.; Van Den Eynde, Benoit; Wythes, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9617-9629</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tumors use tryptophan-catabolizing enzymes such as indoleamine 2,3-dioxygenase (IDO-1) to induce an immunosuppressive environment.  IDO-1 is induced in response to inflammatory stimuli and promotes immune tolerance through effector T-cell anergy and enhanced Treg function.  As such, IDO-1 is a nexus for the induction of a key immunosuppressive mechanism and represents an important immunotherapeutic target in oncol.  Starting from HTS hit I, IDO-1 inhibitor II has been developed.  The structure-activity relationship around II is described and rationalized using the x-ray crystal structure of II bound to human IDO-1, which shows that II, differently from most of the IDO-1 inhibitors described so far, does not bind to the heme iron atom and has a novel binding mode.  Clin. candidate II shows good potency in an IDO-1 human whole blood assay and also shows a very favorable ADME profile leading to favorable predicted human pharmacokinetic properties, including a predicted half-life of 16-19 h.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogfHmZRAC-dLVg90H21EOLACvtfcHk0liwAqkjz83V_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslOns7%252FK&md5=dc2e45c243aa22c100ccc39db9b5918a</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00974&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00974%26sid%3Dliteratum%253Aachs%26aulast%3DCrosignani%26aufirst%3DS.%26aulast%3DBingham%26aufirst%3DP.%26aulast%3DBottemanne%26aufirst%3DP.%26aulast%3DCannelle%26aufirst%3DH.%26aulast%3DCauwenberghs%26aufirst%3DS.%26aulast%3DCordonnier%26aufirst%3DM.%26aulast%3DDalvie%26aufirst%3DD.%26aulast%3DDeroose%26aufirst%3DF.%26aulast%3DFeng%26aufirst%3DJ.%2BL.%26aulast%3DGomes%26aufirst%3DB.%26aulast%3DGreasley%26aufirst%3DS.%26aulast%3DKaiser%26aufirst%3DS.%2BE.%26aulast%3DKraus%26aufirst%3DM.%26aulast%3DN%25C3%25A9grerie%26aufirst%3DM.%26aulast%3DMaegley%26aufirst%3DK.%26aulast%3DMiller%26aufirst%3DN.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26aulast%3DSchneider%26aufirst%3DM.%26aulast%3DSoloweij%26aufirst%3DJ.%26aulast%3DStewart%26aufirst%3DA.%2BE.%26aulast%3DTumang%26aufirst%3DJ.%26aulast%3DTorti%26aufirst%3DV.%2BR.%26aulast%3DVan%2BDen%2BEynde%26aufirst%3DB.%26aulast%3DWythes%26aufirst%3DM.%26atitle%3DDiscovery%2520Of%2520A%2520Novel%2520And%2520Selective%2520Indoleamine%25202%252C3-Dioxygenase%2520%2528IDO-1%2529%2520Inhibitor%25203-%25285-Fluoro-1H-Indol-3-Yl%2529Pyrrolidine-2%252C5-Dione%2520%2528EOS200271%252FPF-06840003%2529%2520And%2520Its%2520Characterization%2520As%2520A%2520Potential%2520Clinical%2520Candidate%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D9617%26epage%3D9629%26doi%3D10.1021%2Facs.jmedchem.7b00974" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beck, H.</span>; <span class="NLM_string-name">Carlos, J.</span>; <span class="NLM_string-name">Osipov, M.</span>; <span class="NLM_string-name">Powers, J.</span>; <span class="NLM_string-name">Reilly, M.</span>; <span class="NLM_string-name">Shunatona, H.</span>; <span class="NLM_string-name">Walker, J.</span>; <span class="NLM_string-name">Zibinsky, M.</span>; <span class="NLM_string-name">Balog, J.</span>; <span class="NLM_string-name">Williams, D.</span>; <span class="NLM_string-name">Guo, W.</span></span> <span> </span><span class="NLM_article-title">Immunoregulatory agents</span>. <span class="NLM_patent">WO 2016073738 A2</span>, May 12, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=H.+Beck&author=J.+Carlos&author=M.+Osipov&author=J.+Powers&author=M.+Reilly&author=H.+Shunatona&author=J.+Walker&author=M.+Zibinsky&author=J.+Balog&author=D.+Williams&author=W.+Guo&title=Immunoregulatory+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBeck%26aufirst%3DH.%26atitle%3DImmunoregulatory%2520agents%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beck, H.</span>; <span class="NLM_string-name">Carlos, J.</span>; <span class="NLM_string-name">Osiprov, J.</span>; <span class="NLM_string-name">Powers, J.</span>; <span class="NLM_string-name">Reilly, M.</span>; <span class="NLM_string-name">Shunatona, H.</span>; <span class="NLM_string-name">Walker, J.</span>; <span class="NLM_string-name">Zibrinsky, M.</span>; <span class="NLM_string-name">Balog, J.</span>; <span class="NLM_string-name">Williams, D.</span>; <span class="NLM_string-name">Markwalder, J.</span>; <span class="NLM_string-name">Cherney, E.</span>; <span class="NLM_string-name">Shan, W.</span>; <span class="NLM_string-name">Huang, A.</span></span> <span> </span><span class="NLM_article-title">Immunoregulatory agents</span>. <span class="NLM_patent">WO 2016073770 A1</span>, May 12, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=H.+Beck&author=J.+Carlos&author=J.+Osiprov&author=J.+Powers&author=M.+Reilly&author=H.+Shunatona&author=J.+Walker&author=M.+Zibrinsky&author=J.+Balog&author=D.+Williams&author=J.+Markwalder&author=E.+Cherney&author=W.+Shan&author=A.+Huang&title=Immunoregulatory+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBeck%26aufirst%3DH.%26atitle%3DImmunoregulatory%2520agents%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seliger, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Q.</span></span> <span> </span><span class="NLM_article-title">What Is The Prospect Of Indoleamine 2,3-Dioxygenase 1 Inhibition In Cancer? Extrapolation From The Past</span>. <i>J. Exp. Clin. Canc. Res.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">60</span>, <span class="refDoi"> DOI: 10.1186/s13046-021-01847-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1186%2Fs13046-021-01847-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=33557876" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BB3MXktFymtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2021&pages=60&author=Y.+Yaoauthor=H.+Liangauthor=X.+Fangauthor=S.+Zhangauthor=Z.+Xingauthor=L.+Shiauthor=C.+Kuangauthor=B.+Seligerauthor=Q.+Yang&title=What+Is+The+Prospect+Of+Indoleamine+2%2C3-Dioxygenase+1+Inhibition+In+Cancer%3F+Extrapolation+From+The+Past&doi=10.1186%2Fs13046-021-01847-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">What is the prospect of indoleamine 2,3-dioxygenase 1 inhibition in cancer? Extrapolation from the past</span></div><div class="casAuthors">Yao, Yu; Liang, Heng; Fang, Xin; Zhang, Shengnan; Xing, Zikang; Shi, Lei; Kuang, Chunxiang; Seliger, Barbara; Yang, Qing</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental & Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">60</span>CODEN:
                <span class="NLM_cas:coden">JECRDN</span>;
        ISSN:<span class="NLM_cas:issn">1756-9966</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Indoleamine 2,3-dioxygenase 1 (IDO1), a monomeric heme-contg. enzyme, catalyzes the first and rate-limiting step in the kynurenine pathway of tryptophan metab., which plays an important role in immunity and neuronal function.  Its implication in different pathophysiol. processes including cancer and neurodegenerative diseases has inspired the development of IDO1 inhibitors in the past decades.  However, the neg. results of the phase III clin. trial of the would-be first-in-class IDO1 inhibitor (epacadostat) in combination with an anti-PD1 antibody (pembrolizumab) in patients with advanced malignant melanoma call for a better understanding of the role of IDO1 inhibition.  In this review, the current status of the clin. development of IDO1 inhibitors will be introduced and the key pre-clin. and clin. data of epacadostat will be summarized.  Moreover, based on the cautionary notes obtained from the clin. readout of epacadostat, strategies for the identification of reliable predictive biomarkers and pharmacodynamic markers as well as for the selection of the tumor types to be treated with IDO1inhibitors will be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1kT2hGzb3XbVg90H21EOLACvtfcHk0lj_6rQM42K-LA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXktFymtbg%253D&md5=6b3da80ac25d07222ed7a70d9162d3ee</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1186%2Fs13046-021-01847-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13046-021-01847-4%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DY.%26aulast%3DLiang%26aufirst%3DH.%26aulast%3DFang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DXing%26aufirst%3DZ.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DKuang%26aufirst%3DC.%26aulast%3DSeliger%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DQ.%26atitle%3DWhat%2520Is%2520The%2520Prospect%2520Of%2520Indoleamine%25202%252C3-Dioxygenase%25201%2520Inhibition%2520In%2520Cancer%253F%2520Extrapolation%2520From%2520The%2520Past%26jtitle%3DJ.%2520Exp.%2520Clin.%2520Canc.%2520Res.%26date%3D2021%26volume%3D40%26spage%3D60%26doi%3D10.1186%2Fs13046-021-01847-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ping, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bian, J.</span></span> <span> </span><span class="NLM_article-title">Development Of Indoleamine 2,3-Dioxygenase 1 Inhibitors For Cancer Therapy And Beyond: A Recent Perspective</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">15115</span>– <span class="NLM_lpage">15139</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00925</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00925" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitlKrs7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=15115-15139&author=X.+Fengauthor=D.+Liaoauthor=D.+Liuauthor=A.+Pingauthor=Z.+Liauthor=J.+Bian&title=Development+Of+Indoleamine+2%2C3-Dioxygenase+1+Inhibitors+For+Cancer+Therapy+And+Beyond%3A+A+Recent+Perspective&doi=10.1021%2Facs.jmedchem.0c00925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Indoleamine 2,3-Dioxygenase 1 Inhibitors for Cancer Therapy and Beyond: A Recent Perspective</span></div><div class="casAuthors">Feng, Xi; Liao, Dongdong; Liu, Dongyu; Ping, An; Li, Zhiyu; Bian, Jinlei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">15115-15139</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1) has received increasing attention due to its immunosuppressive function in connection with various diseases, including cancer.  A recent increase in the understanding of IDO1 has significantly contributed to the discovery of numerous novel inhibitors, but the latest clin. outcomes raised questions and have indicated a future direction of IDO1 inhibition for therapeutic approaches.  Herein, we present a comprehensive review of IDO1, discussing the latest advances in understanding the IDO1 structure and mechanism, an overview of recent IDO1 inhibitor discoveries and potential therapeutic applications to provide helpful information for medicinal chemists investigating IDO1 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMlqxJwtbFQ7Vg90H21EOLACvtfcHk0lj_6rQM42K-LA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitlKrs7rL&md5=b08b669f697bb0473e94710257890460</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00925%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DX.%26aulast%3DLiao%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DPing%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DBian%26aufirst%3DJ.%26atitle%3DDevelopment%2520Of%2520Indoleamine%25202%252C3-Dioxygenase%25201%2520Inhibitors%2520For%2520Cancer%2520Therapy%2520And%2520Beyond%253A%2520A%2520Recent%2520Perspective%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D15115%26epage%3D15139%26doi%3D10.1021%2Facs.jmedchem.0c00925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beatty, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Dwyer, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherle, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newton, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaub, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maleski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leopold, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gajewski, T. F.</span></span> <span> </span><span class="NLM_article-title">First-In-Human Phase I Study Of The Oral Inhibitor Of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) In Patients With Advanced Solid Malignancies</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">3269</span>– <span class="NLM_lpage">3276</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.ccr-16-2272</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1158%2F1078-0432.CCR-16-2272" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=28053021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFSnurfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=3269-3276&author=G.+L.+Beattyauthor=P.+J.+O%E2%80%99Dwyerauthor=J.+Clarkauthor=J.+G.+Shiauthor=K.+J.+Bowmanauthor=P.+A.+Scherleauthor=R.+C.+Newtonauthor=R.+Schaubauthor=J.+Maleskiauthor=L.+Leopoldauthor=T.+F.+Gajewski&title=First-In-Human+Phase+I+Study+Of+The+Oral+Inhibitor+Of+Indoleamine+2%2C3-Dioxygenase-1+Epacadostat+%28INCB024360%29+In+Patients+With+Advanced+Solid+Malignancies&doi=10.1158%2F1078-0432.ccr-16-2272"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies</span></div><div class="casAuthors">Beatty, Gregory L.; O'Dwyer, Peter J.; Clark, Jason; Shi, Jack G.; Bowman, Kevin J.; Scherle, Peggy A.; Newton, Robert C.; Schaub, Richard; Maleski, Janet; Leopold, Lance; Gajewski, Thomas F.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3269-3276</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase-1 (IDO1) catalyzes the degrdn. of tryptophan to N-formyl-kynurenine.  Overexpressed in many solid malignancies, IDO1 can promote tumor escape from host immunosurveillance.  This first-in-human phase I study investigated the max. tolerated dose, safety, pharmacokinetics, pharmacodynamics, and antitumor activity of epacadostat (INCB024360), a potent and selective inhibitor of IDO1.  Fifty-two patients with advanced solid malignancies were treated with epacadostat [50 mg once daily or 50, 100, 300, 400, 500, 600, or 700 mg twice daily (BID)] in a dose-escalation 3 + 3 design and evaluated in 28-day cycles.  Treatment was continued until disease progression or unacceptable toxicity.  One dose-limiting toxicity (DLT) occurred at the dose of 300 mg BID (grade 3, radiation pneumonitis); another DLT occurred at 400 mg BID (grade 3, fatigue).  The most common adverse events in >20% of patients overall were fatigue, nausea, decreased appetite, vomiting, constipation, abdominal pain, diarrhea, dyspnea, back pain, and cough.  Treatment produced significant dose-dependent redns. in plasma kynurenine levels and in the plasma kynurenine/tryptophan ratio at all doses and in all patients.  Near maximal changes were obsd. at doses of ≥100 mg BID with >80% to 90% inhibition of IDO1 achieved throughout the dosing period.  Although no objective responses were detected, stable disease lasting ≥16 wk was obsd. in 7 of 52 patients.  Epacadostat was generally well tolerated, effectively normalized kynurenine levels, and produced maximal inhibition of IDO1 activity at doses of ≥100 mg BID.  Studies investigating epacadostat in combination with other immunomodulatory drugs are ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLdL__p3Q7B7Vg90H21EOLACvtfcHk0lj_6rQM42K-LA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFSnurfP&md5=dee4464e680b476ebe0dbad7f5ec8d46</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-16-2272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-16-2272%26sid%3Dliteratum%253Aachs%26aulast%3DBeatty%26aufirst%3DG.%2BL.%26aulast%3DO%25E2%2580%2599Dwyer%26aufirst%3DP.%2BJ.%26aulast%3DClark%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DJ.%2BG.%26aulast%3DBowman%26aufirst%3DK.%2BJ.%26aulast%3DScherle%26aufirst%3DP.%2BA.%26aulast%3DNewton%26aufirst%3DR.%2BC.%26aulast%3DSchaub%26aufirst%3DR.%26aulast%3DMaleski%26aufirst%3DJ.%26aulast%3DLeopold%26aufirst%3DL.%26aulast%3DGajewski%26aufirst%3DT.%2BF.%26atitle%3DFirst-In-Human%2520Phase%2520I%2520Study%2520Of%2520The%2520Oral%2520Inhibitor%2520Of%2520Indoleamine%25202%252C3-Dioxygenase-1%2520Epacadostat%2520%2528INCB024360%2529%2520In%2520Patients%2520With%2520Advanced%2520Solid%2520Malignancies%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2017%26volume%3D23%26spage%3D3269%26epage%3D3276%26doi%3D10.1158%2F1078-0432.ccr-16-2272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Long, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dummer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamid, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gajewski, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caglevic, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arance, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlino, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grob, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demidov, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larkin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maleski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diede, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, T. C.</span></span> <span> </span><span class="NLM_article-title">Epacadostat Plus Pembrolizumab Versus Placebo Plus Pembrolizumab In Patients With Unresectable Or Metastatic Melanoma (ECHO-301/KEYNOTE-252): A Phase 3, Randomised, Double-Blind Study</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1083</span>– <span class="NLM_lpage">1097</span>, <span class="refDoi"> DOI: 10.1016/s1470-2045(19)30274-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1016%2FS1470-2045%2819%2930274-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=31221619" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtF2kurbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=1083-1097&author=G.+V.+Longauthor=R.+Dummerauthor=O.+Hamidauthor=T.+F.+Gajewskiauthor=C.+Caglevicauthor=S.+Dalleauthor=A.+Aranceauthor=M.+S.+Carlinoauthor=J.-J.+Grobauthor=T.+M.+Kimauthor=L.+Demidovauthor=C.+Robertauthor=J.+Larkinauthor=J.+R.+Andersonauthor=J.+Maleskiauthor=M.+Jonesauthor=S.+J.+Diedeauthor=T.+C.+Mitchell&title=Epacadostat+Plus+Pembrolizumab+Versus+Placebo+Plus+Pembrolizumab+In+Patients+With+Unresectable+Or+Metastatic+Melanoma+%28ECHO-301%2FKEYNOTE-252%29%3A+A+Phase+3%2C+Randomised%2C+Double-Blind+Study&doi=10.1016%2Fs1470-2045%2819%2930274-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomized, double-blind study</span></div><div class="casAuthors">Long, Georgina V.; Dummer, Reinhard; Hamid, Omid; Gajewski, Thomas F.; Caglevic, Christian; Dalle, Stephane; Arance, Ana; Carlino, Matteo S.; Grob, Jean-Jacques; Kim, Tae Min; Demidov, Lev; Robert, Caroline; Larkin, James; Anderson, James R.; Maleski, Janet; Jones, Mark; Diede, Scott J.; Mitchell, Tara C.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1083-1097</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Immunotherapy combination treatments can improve patient outcomes.  Epacadostat, an IDO1 selective inhibitor, and pembrolizumab, a PD-1 inhibitor, showed promising antitumor activity in the phase 1-2 ECHO-202/KEYNOTE-037 study in advanced melanoma.  In this trial, we aimed to compare progression-free survival and overall survival in patients with unresectable stage III or IV melanoma receiving epacadostat plus pembrolizumab vs. placebo plus pembrolizumab.  In this international, randomized, placebo-controlled, double-blind, parallel-group, phase 3 trial, eligible participants were aged 18 years or older, with unresectable stage III or IV melanoma previously untreated with PD-1 or PD-L1 checkpoint inhibitors, an ECOG performance status of 0 or 1, and had a known BRAFV600 mutant status or consented to BRAFV600 mutation testing during screening.  Patients were stratified by PD-L1 expression and BRAFV600 mutation status and randomly assigned (1:1) through a central interactive voice and integrated web response system to receive epacadostat 100 mg orally twice daily plus pembrolizumab 200 mg i.v. every 3 wk or placebo plus pembrolizumab for up to 2 years.  We used block randomization with a block size of four in each stratum.  Primary endpoints were progression-free survival and overall survival in the intention-to-treat population.  The safety anal. population included randomly assigned patients who received at least one dose of study treatment.  The study was stopped after the second interim anal.; follow-up for safety is ongoing.  This study is registered with ClinicalTrials.gov, no. NCT02752074.  Between June 21, 2016, and Aug 7, 2017, 928 patients were screened and 706 patients were randomly assigned to receive epacadostat plus pembrolizumab (n=354) or placebo plus pembrolizumab (n=352).  Median follow-up was 12·4 mo (IQR 10·3-14·5).  No significant differences were found between the treatment groups for progression-free survival (median 4·7 mo, 95% CI 2·9-6·8, for epacadostat plus pembrolizumab vs 4·9 mo, 2·9-6·8, for placebo plus pembrolizumab; hazard ratio [HR] 1·00, 95% CI 0·83-1·21; one-sided p=0·52) or overall survival (median not reached in either group; epacadostat plus pembrolizumab vs placebo plus pembrolizumab: HR 1·13, 0·86-1·49; one-sided p=0·81).  The most common grade 3 or worse treatment-related adverse event was lipase increase, which occurred in 14 (4%) of 353 patients receiving epacadostat plus pembrolizumab and 11 (3%) of 352 patients receiving placebo plus pembrolizumab.  Treatment-related serious adverse events were reported in 37 (10%) of 353 patients receiving epacadostat plus pembrolizumab and 32 (9%) of 352 patients receiving placebo plus pembrolizumab.  There were no treatment-related deaths in either treatment group.  Epacadostat 100 mg twice daily plus pembrolizumab did not improve progression-free survival or overall survival compared with placebo plus pembrolizumab in patients with unresectable or metastatic melanoma.  The usefulness of IDO1 inhibition as a strategy to enhance anti-PD-1 therapy activity in cancer remains uncertain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8j2WQ35JqjbVg90H21EOLACvtfcHk0lgKpyDc_0_0qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtF2kurbM&md5=f1dce1f431d2650fe4f8b8e46677e03d</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2819%2930274-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252819%252930274-8%26sid%3Dliteratum%253Aachs%26aulast%3DLong%26aufirst%3DG.%2BV.%26aulast%3DDummer%26aufirst%3DR.%26aulast%3DHamid%26aufirst%3DO.%26aulast%3DGajewski%26aufirst%3DT.%2BF.%26aulast%3DCaglevic%26aufirst%3DC.%26aulast%3DDalle%26aufirst%3DS.%26aulast%3DArance%26aufirst%3DA.%26aulast%3DCarlino%26aufirst%3DM.%2BS.%26aulast%3DGrob%26aufirst%3DJ.-J.%26aulast%3DKim%26aufirst%3DT.%2BM.%26aulast%3DDemidov%26aufirst%3DL.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DAnderson%26aufirst%3DJ.%2BR.%26aulast%3DMaleski%26aufirst%3DJ.%26aulast%3DJones%26aufirst%3DM.%26aulast%3DDiede%26aufirst%3DS.%2BJ.%26aulast%3DMitchell%26aufirst%3DT.%2BC.%26atitle%3DEpacadostat%2520Plus%2520Pembrolizumab%2520Versus%2520Placebo%2520Plus%2520Pembrolizumab%2520In%2520Patients%2520With%2520Unresectable%2520Or%2520Metastatic%2520Melanoma%2520%2528ECHO-301%252FKEYNOTE-252%2529%253A%2520A%2520Phase%25203%252C%2520Randomised%252C%2520Double-Blind%2520Study%26jtitle%3DLancet%2520Oncol.%26date%3D2019%26volume%3D20%26spage%3D1083%26epage%3D1097%26doi%3D10.1016%2Fs1470-2045%2819%2930274-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nayak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobbins, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vahanian, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mautino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Link, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Royer-Joo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrissey, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahrus, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCall, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirzkall, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janik, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khleif, S.</span></span> <span> </span><span class="NLM_article-title">346 Phase 1A Study Of The Safety, Pharmacokinetics, And Pharmacodynamics Of GDC-0919 In Patients With Recurrent/Advanced Solid Tumors</span>. <i>Eur. J. Canc.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">S69</span>, <span class="refDoi"> DOI: 10.1016/s0959-8049(16)30209-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1016%2FS0959-8049%2816%2930209-X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2015&pages=S69&author=A.+Nayakauthor=Z.+Haoauthor=R.+Sadekauthor=R.+Dobbinsauthor=L.+Marshallauthor=N.+Vahanianauthor=J.+Ramseyauthor=E.+Kennedyauthor=M.+Mautinoauthor=C.+Linkauthor=R.+Linauthor=S.+Royer-Jooauthor=K.+Morrisseyauthor=S.+Mahrusauthor=B.+McCallauthor=A.+Pirzkallauthor=D.+Munnauthor=J.+Janikauthor=S.+Khleif&title=346+Phase+1A+Study+Of+The+Safety%2C+Pharmacokinetics%2C+And+Pharmacodynamics+Of+GDC-0919+In+Patients+With+Recurrent%2FAdvanced+Solid+Tumors&doi=10.1016%2Fs0959-8049%2816%2930209-x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2FS0959-8049%2816%2930209-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0959-8049%252816%252930209-X%26sid%3Dliteratum%253Aachs%26aulast%3DNayak%26aufirst%3DA.%26aulast%3DHao%26aufirst%3DZ.%26aulast%3DSadek%26aufirst%3DR.%26aulast%3DDobbins%26aufirst%3DR.%26aulast%3DMarshall%26aufirst%3DL.%26aulast%3DVahanian%26aufirst%3DN.%26aulast%3DRamsey%26aufirst%3DJ.%26aulast%3DKennedy%26aufirst%3DE.%26aulast%3DMautino%26aufirst%3DM.%26aulast%3DLink%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DR.%26aulast%3DRoyer-Joo%26aufirst%3DS.%26aulast%3DMorrissey%26aufirst%3DK.%26aulast%3DMahrus%26aufirst%3DS.%26aulast%3DMcCall%26aufirst%3DB.%26aulast%3DPirzkall%26aufirst%3DA.%26aulast%3DMunn%26aufirst%3DD.%26aulast%3DJanik%26aufirst%3DJ.%26aulast%3DKhleif%26aufirst%3DS.%26atitle%3D346%2520Phase%25201A%2520Study%2520Of%2520The%2520Safety%252C%2520Pharmacokinetics%252C%2520And%2520Pharmacodynamics%2520Of%2520GDC-0919%2520In%2520Patients%2520With%2520Recurrent%252FAdvanced%2520Solid%2520Tumors%26jtitle%3DEur.%2520J.%2520Canc.%26date%3D2015%26volume%3D51%26spage%3DS69%26doi%3D10.1016%2Fs0959-8049%2816%2930209-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nelp, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kates, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newitt, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balog, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allentoff, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borzilleri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seitz, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groves, J. T.</span></span> <span> </span><span class="NLM_article-title">Immune-Modulating Enzyme Indoleamine 2,3-Dioxygenase Is Effectively Inhibited By Targeting Its Apo-Form</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">3249</span>– <span class="NLM_lpage">3254</span>, <span class="refDoi"> DOI: 10.1073/pnas.1719190115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1073%2Fpnas.1719190115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=29531094" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1Ckur7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2018&pages=3249-3254&author=M.+T.+Nelpauthor=P.+A.+Katesauthor=J.+T.+Huntauthor=J.+A.+Newittauthor=A.+Balogauthor=D.+Maleyauthor=X.+Zhuauthor=L.+Abellauthor=A.+Allentoffauthor=R.+Borzilleriauthor=H.+A.+Lewisauthor=Z.+Linauthor=S.+P.+Seitzauthor=C.+Yanauthor=J.+T.+Groves&title=Immune-Modulating+Enzyme+Indoleamine+2%2C3-Dioxygenase+Is+Effectively+Inhibited+By+Targeting+Its+Apo-Form&doi=10.1073%2Fpnas.1719190115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Immune-modulating enzyme indoleamine 2,3-dioxygenase is effectively inhibited by targeting its apo-form</span></div><div class="casAuthors">Nelp, Micah T.; Kates, Patrick A.; Hunt, John T.; Newitt, John A.; Balog, Aaron; Maley, Derrick; Zhu, Xiao; Abelle, Lynn; Allentoff, Alban; Borzilleri, Robert; Lewis, Hal A.; Lin, Zeyu; Seitz, Steven P.; Yan, Chunhong; Groves, John T.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3249-3254</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">For cancer cells to survive and proliferate, they must escape normal immune destruction.  One mechanism by which this is accomplished is through immune suppression effected by up-regulation of indole- amine 2,3-dioxygenase (IDO1), a heme enzyme that catalyzes the oxidn. of tryptophan to N-formylkynurenine.  On deformylation, kynurenine and downstream metabolites suppress T cell function.  The importance of this immunosuppressive mechanism has spurred intense interest in the development of clin. IDO1 inhibitors.  Herein, we describe the mechanism by which a class of compds. effectively and specifically inhibits IDO1 by targeting its apo- form.  We show that the in vitro kinetics of inhibition coincide with an unusually high rate of intrinsic enzyme-heme dissocn., esp. in the ferric form.  X-ray crystal structures of the inhibitor-enzyme complexes show that heme is displaced from the enzyme and blocked from rebinding by these compds.  The results reveal that apo-IDO1 serves as a unique target for inhibition and that heme lability plays an important role in posttranslational regulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoqG51BFbfm7Vg90H21EOLACvtfcHk0lgKpyDc_0_0qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1Ckur7I&md5=b44352b022692d150053696bb984665f</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1719190115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1719190115%26sid%3Dliteratum%253Aachs%26aulast%3DNelp%26aufirst%3DM.%2BT.%26aulast%3DKates%26aufirst%3DP.%2BA.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DNewitt%26aufirst%3DJ.%2BA.%26aulast%3DBalog%26aufirst%3DA.%26aulast%3DMaley%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DAbell%26aufirst%3DL.%26aulast%3DAllentoff%26aufirst%3DA.%26aulast%3DBorzilleri%26aufirst%3DR.%26aulast%3DLewis%26aufirst%3DH.%2BA.%26aulast%3DLin%26aufirst%3DZ.%26aulast%3DSeitz%26aufirst%3DS.%2BP.%26aulast%3DYan%26aufirst%3DC.%26aulast%3DGroves%26aufirst%3DJ.%2BT.%26atitle%3DImmune-Modulating%2520Enzyme%2520Indoleamine%25202%252C3-Dioxygenase%2520Is%2520Effectively%2520Inhibited%2520By%2520Targeting%2520Its%2520Apo-Form%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2018%26volume%3D115%26spage%3D3249%26epage%3D3254%26doi%3D10.1073%2Fpnas.1719190115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Balog, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T.-a.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gullo-Brown, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kandoussi, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. T.</span></span> <span> </span><span class="NLM_article-title">Preclinical Characterization Of Linrodostat Mesylate, A Novel, Potent, And Selective Oral Indoleamine 2,3-Dioxygenase 1 Inhibitor</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">467</span>– <span class="NLM_lpage">476</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.mct-20-0251</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1158%2F1535-7163.MCT-20-0251" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=33298590" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2020&pages=467-476&author=A.+Balogauthor=T.-a.+Linauthor=D.+Maleyauthor=J.+Gullo-Brownauthor=E.+H.+Kandoussiauthor=J.+Zengauthor=J.+T.+Hunt&title=Preclinical+Characterization+Of+Linrodostat+Mesylate%2C+A+Novel%2C+Potent%2C+And+Selective+Oral+Indoleamine+2%2C3-Dioxygenase+1+Inhibitor&doi=10.1158%2F1535-7163.mct-20-0251"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-20-0251&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-20-0251%26sid%3Dliteratum%253Aachs%26aulast%3DBalog%26aufirst%3DA.%26aulast%3DLin%26aufirst%3DT.-a.%26aulast%3DMaley%26aufirst%3DD.%26aulast%3DGullo-Brown%26aufirst%3DJ.%26aulast%3DKandoussi%26aufirst%3DE.%2BH.%26aulast%3DZeng%26aufirst%3DJ.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26atitle%3DPreclinical%2520Characterization%2520Of%2520Linrodostat%2520Mesylate%252C%2520A%2520Novel%252C%2520Potent%252C%2520And%2520Selective%2520Oral%2520Indoleamine%25202%252C3-Dioxygenase%25201%2520Inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2020%26volume%3D20%26spage%3D467%26epage%3D476%26doi%3D10.1158%2F1535-7163.mct-20-0251" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, M. M. T.</span>; <span class="NLM_string-name">Dancsok, A. R.</span>; <span class="NLM_string-name">Nielsen, T. O.</span></span> <span> </span><span class="NLM_article-title">Indoleamine Dioxygenase Inhibitors: Clinical Rationale And Current Development</span>.  <i>Curr. Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume">21</span>.2 <span class="refDoi"> DOI: 10.1007/s11912-019-0750-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1007%2Fs11912-019-0750-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=30659394" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2019&author=M.+M.+T.+Zhu&author=A.+R.+Dancsok&author=T.+O.+Nielsen&title=Indoleamine+Dioxygenase+Inhibitors%3A+Clinical+Rationale+And+Current+Development&doi=10.1007%2Fs11912-019-0750-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1007%2Fs11912-019-0750-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11912-019-0750-1%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DM.%2BM.%2BT.%26atitle%3DIndoleamine%2520Dioxygenase%2520Inhibitors%253A%2520Clinical%2520Rationale%2520And%2520Current%2520Development%26jtitle%3DCurr.%2520Oncol.%2520Rep.%26date%3D2019%26volume%3D21%26doi%3D10.1007%2Fs11912-019-0750-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lewis-Ballester, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pham, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batabyal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karkashon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonanno, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulos, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, S. R.</span></span> <span> </span><span class="NLM_article-title">Structural Insights Into Substrate And Inhibitor Binding Sites In Human Indoleamine 2,3-Dioxygenase 1</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1693</span>, <span class="refDoi"> DOI: 10.1038/s41467-017-01725-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1038%2Fs41467-017-01725-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=29167421" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A280%3ADC%252BC1M3ktFOhtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1693&author=A.+Lewis-Ballesterauthor=K.+N.+Phamauthor=D.+Batabyalauthor=S.+Karkashonauthor=J.+B.+Bonannoauthor=T.+L.+Poulosauthor=S.+R.+Yeh&title=Structural+Insights+Into+Substrate+And+Inhibitor+Binding+Sites+In+Human+Indoleamine+2%2C3-Dioxygenase+1&doi=10.1038%2Fs41467-017-01725-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Structural insights into substrate and inhibitor binding sites in human indoleamine 2,3-dioxygenase 1</span></div><div class="casAuthors">Lewis-Ballester Ariel; Pham Khoa N; Karkashon Shay; Yeh Syun-Ru; Batabyal Dipanwita; Poulos Thomas L; Batabyal Dipanwita; Poulos Thomas L; Batabyal Dipanwita; Poulos Thomas L; Bonanno Jeffrey B</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1693</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Human indoleamine 2,3-dioxygenase 1 (hIDO1) is an attractive cancer immunotherapeutic target owing to its role in promoting tumoral immune escape.  However, drug development has been hindered by limited structural information.  Here, we report the crystal structures of hIDO1 in complex with its substrate, Trp, an inhibitor, epacadostat, and/or an effector, indole ethanol (IDE).  The data reveal structural features of the active site (Sa) critical for substrate activation; in addition, they disclose a new inhibitor-binding mode and a distinct small molecule binding site (Si).  Structure-guided mutation of a critical residue, F270, to glycine perturbs the Si site, allowing structural determination of an inhibitory complex, where both the Sa and Si sites are occupied by Trp.  The Si site offers a novel target site for allosteric inhibitors and a molecular explanation for the previously baffling substrate-inhibition behavior of the enzyme.  Taken together, the data open exciting new avenues for structure-based drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQI81SqDTDg0dbHMBt0mMIXfW6udTcc2ebuU_ARShdG7Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M3ktFOhtQ%253D%253D&md5=36b0221b0726c73a6c4345e4cf2ec8be</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fs41467-017-01725-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-017-01725-8%26sid%3Dliteratum%253Aachs%26aulast%3DLewis-Ballester%26aufirst%3DA.%26aulast%3DPham%26aufirst%3DK.%2BN.%26aulast%3DBatabyal%26aufirst%3DD.%26aulast%3DKarkashon%26aufirst%3DS.%26aulast%3DBonanno%26aufirst%3DJ.%2BB.%26aulast%3DPoulos%26aufirst%3DT.%2BL.%26aulast%3DYeh%26aufirst%3DS.%2BR.%26atitle%3DStructural%2520Insights%2520Into%2520Substrate%2520And%2520Inhibitor%2520Binding%2520Sites%2520In%2520Human%2520Indoleamine%25202%252C3-Dioxygenase%25201%26jtitle%3DNat.%2520Commun.%26date%3D2017%26volume%3D8%26spage%3D1693%26doi%3D10.1038%2Fs41467-017-01725-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Röhrig, U. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynaud, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majjigapu, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pojer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoete, V.</span></span> <span> </span><span class="NLM_article-title">Inhibition Mechanisms Of Indoleamine 2,3-Dioxygenase 1 (IDO1)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">8784</span>– <span class="NLM_lpage">8795</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00942</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00942" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslOqu7%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=8784-8795&author=U.+F.+R%C3%B6hrigauthor=A.+Reynaudauthor=S.+R.+Majjigapuauthor=P.+Vogelauthor=F.+Pojerauthor=V.+Zoete&title=Inhibition+Mechanisms+Of+Indoleamine+2%2C3-Dioxygenase+1+%28IDO1%29&doi=10.1021%2Facs.jmedchem.9b00942"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition Mechanisms of Indoleamine 2,3-Dioxygenase 1 (IDO1)</span></div><div class="casAuthors">Rohrig, Ute F.; Reynaud, Aline; Majjigapu, Somi Reddy; Vogel, Pierre; Pojer, Florence; Zoete, Vincent</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8784-8795</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1) catalyzes the rate-limiting step in the kynurenine pathway of tryptophan metab., which is involved in immunity, neuronal function, and aging.  Its implication in pathologies such as cancer and neurodegenerative diseases has stimulated the development of IDO1 inhibitors.  However, neg. phase III clin. trial results of the IDO1 inhibitor epacadostat in cancer immunotherapy call for a better understanding of the role and the mechanisms of IDO1 inhibition.  In this work, we investigate the mol. inhibition mechanisms of four known IDO1 inhibitors and of two quinones in detail, using different exptl. and computational approaches.  We also det. for the first time the X-ray structure of the highly efficient 1,2,3-triazole inhibitor MMG-0358.  Based on our results and a comprehensive literature overview, we propose a classification scheme for IDO1 inhibitors according to their inhibition mechanism, which will be useful for further developments in the field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTZnLePiNWE7Vg90H21EOLACvtfcHk0ljTzSM7o7wziA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslOqu7%252FP&md5=01919796d4821743975fe01a5527008c</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00942&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00942%26sid%3Dliteratum%253Aachs%26aulast%3DR%25C3%25B6hrig%26aufirst%3DU.%2BF.%26aulast%3DReynaud%26aufirst%3DA.%26aulast%3DMajjigapu%26aufirst%3DS.%2BR.%26aulast%3DVogel%26aufirst%3DP.%26aulast%3DPojer%26aufirst%3DF.%26aulast%3DZoete%26aufirst%3DV.%26atitle%3DInhibition%2520Mechanisms%2520Of%2520Indoleamine%25202%252C3-Dioxygenase%25201%2520%2528IDO1%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D8784%26epage%3D8795%26doi%3D10.1021%2Facs.jmedchem.9b00942" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pham, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, S.-R.</span></span> <span> </span><span class="NLM_article-title">Mapping The Binding Trajectory Of A Suicide Inhibitor In Human Indoleamine 2,3-Dioxygenase 1</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>140</i></span>,  <span class="NLM_fpage">14538</span>– <span class="NLM_lpage">14541</span>, <span class="refDoi"> DOI: 10.1021/jacs.8b07994</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.8b07994" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFygsbfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2018&pages=14538-14541&author=K.+N.+Phamauthor=S.-R.+Yeh&title=Mapping+The+Binding+Trajectory+Of+A+Suicide+Inhibitor+In+Human+Indoleamine+2%2C3-Dioxygenase+1&doi=10.1021%2Fjacs.8b07994"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Mapping the Binding Trajectory of a Suicide Inhibitor in Human Indoleamine 2,3-Dioxygenase 1</span></div><div class="casAuthors">Pham, Khoa N.; Yeh, Syun-Ru</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">14538-14541</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Human indoleamine 2,3-dioxygenase 1 (hIDO1) is an important heme-contg. enzyme that is a key drug target for cancer immunotherapy.  Several hIDO1 inhibitors have entered clin. trials, among which BMS-986205 (BMS) stands out as the only suicide inhibitor.  Despite its "best-in-class" activity, the action mechanism of BMS remains elusive.  Here, we report three crystal structures of hIDO1-BMS complexes that define the complete binding trajectory of the inhibitor.  BMS first binds in a solvent exposed surface cleft near the active site in an extended conformation.  The initial binding partially unfolds the active site, which triggers heme release, thereby exposing a new binding pocket.  The inhibitor then undergoes a large scale movement to this new binding pocket, where it binds by adopting a high energy kinked conformation.  Finally, the inhibitor relaxes to a bent conformation, via an addnl. large scale rearrangement, culminating in the energy min. state.  The structural data offer a mol. explanation for the remarkable efficacy and suicide inhibition activity of the inhibitor.  They also suggest a novel strategy that can be applied for drug development targeting hIDO1 and related enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo49tBUq_145rVg90H21EOLACvtfcHk0lharRINpSV44A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFygsbfJ&md5=833164c8276bd3b8d9d93df197cf4780</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjacs.8b07994&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.8b07994%26sid%3Dliteratum%253Aachs%26aulast%3DPham%26aufirst%3DK.%2BN.%26aulast%3DYeh%26aufirst%3DS.-R.%26atitle%3DMapping%2520The%2520Binding%2520Trajectory%2520Of%2520A%2520Suicide%2520Inhibitor%2520In%2520Human%2520Indoleamine%25202%252C3-Dioxygenase%25201%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2018%26volume%3D140%26spage%3D14538%26epage%3D14541%26doi%3D10.1021%2Fjacs.8b07994" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Serafini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torre, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aprile, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosso, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gesù, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griglio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colombo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Travelli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paiella, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adamo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orecchini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coletti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallotta, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ugel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massarotti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirali, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fallarini, S.</span></span> <span> </span><span class="NLM_article-title">Discovery Of Highly Potent Benzimidazole Derivatives As Indoleamine 2,3-Dioxygenase-1 (IDO1) Inhibitors: From Structure-Based Virtual Screening To In Vivo Pharmacodynamic Activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">3047</span>– <span class="NLM_lpage">3065</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01809</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01809" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BB3cXksFaitbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=3047-3065&author=M.+Serafiniauthor=E.+Torreauthor=S.+Aprileauthor=E.+D.+Grossoauthor=A.+Ges%C3%B9author=A.+Griglioauthor=G.+Colomboauthor=C.+Travelliauthor=S.+Paiellaauthor=A.+Adamoauthor=E.+Orecchiniauthor=A.+Colettiauthor=M.+T.+Pallottaauthor=S.+Ugelauthor=A.+Massarottiauthor=T.+Piraliauthor=S.+Fallarini&title=Discovery+Of+Highly+Potent+Benzimidazole+Derivatives+As+Indoleamine+2%2C3-Dioxygenase-1+%28IDO1%29+Inhibitors%3A+From+Structure-Based+Virtual+Screening+To+In+Vivo+Pharmacodynamic+Activity&doi=10.1021%2Facs.jmedchem.9b01809"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Highly Potent Benzimidazole Derivatives as Indoleamine 2,3-Dioxygenase-1 (IDO1) Inhibitors: From Structure-Based Virtual Screening to in Vivo Pharmacodynamic Activity</span></div><div class="casAuthors">Serafini, Marta; Torre, Enza; Aprile, Silvio; Grosso, Erika Del; Gesu, Alessandro; Griglio, Alessia; Colombo, Giorgia; Travelli, Cristina; Paiella, Salvatore; Adamo, Annalisa; Orecchini, Elena; Coletti, Alice; Pallotta, Maria Teresa; Ugel, Stefano; Massarotti, Alberto; Pirali, Tracey; Fallarini, Silvia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">3047-3065</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this study, a successful medicinal chem. campaign that exploited virtual, biophys., and biol. investigations led to the identification of a novel class of IDO1 inhibitors based on a benzimidazole substructure.  This family of compds. is endowed with an extensive bonding network in the protein active site, including the interaction with pocket C, a region not commonly exploited by previously reported IDO1 inhibitors.  The tight packing of selected compds. within the enzyme contributes to the strong binding interaction with IDO1, to the inhibitory potency at the low nanomolar level in several tumoral settings, and to the selectivity toward IDO1 over TDO and CYPs.  Notably, a significant redn. of L-Kyn levels in plasma, together with a potent effect on abrogating immunosuppressive properties of MDSC-like cells isolated from patients affected by pancreatic ductal adenocarcinoma, was obsd., pointing to this class of mols. as a valuable template for boosting the antitumor immune system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSfZttD9qaarVg90H21EOLACvtfcHk0lharRINpSV44A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXksFaitbs%253D&md5=118293cb0e185b77b209568fa4c151a2</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01809&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01809%26sid%3Dliteratum%253Aachs%26aulast%3DSerafini%26aufirst%3DM.%26aulast%3DTorre%26aufirst%3DE.%26aulast%3DAprile%26aufirst%3DS.%26aulast%3DGrosso%26aufirst%3DE.%2BD.%26aulast%3DGes%25C3%25B9%26aufirst%3DA.%26aulast%3DGriglio%26aufirst%3DA.%26aulast%3DColombo%26aufirst%3DG.%26aulast%3DTravelli%26aufirst%3DC.%26aulast%3DPaiella%26aufirst%3DS.%26aulast%3DAdamo%26aufirst%3DA.%26aulast%3DOrecchini%26aufirst%3DE.%26aulast%3DColetti%26aufirst%3DA.%26aulast%3DPallotta%26aufirst%3DM.%2BT.%26aulast%3DUgel%26aufirst%3DS.%26aulast%3DMassarotti%26aufirst%3DA.%26aulast%3DPirali%26aufirst%3DT.%26aulast%3DFallarini%26aufirst%3DS.%26atitle%3DDiscovery%2520Of%2520Highly%2520Potent%2520Benzimidazole%2520Derivatives%2520As%2520Indoleamine%25202%252C3-Dioxygenase-1%2520%2528IDO1%2529%2520Inhibitors%253A%2520From%2520Structure-Based%2520Virtual%2520Screening%2520To%2520In%2520Vivo%2520Pharmacodynamic%2520Activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D3047%26epage%3D3065%26doi%3D10.1021%2Facs.jmedchem.9b01809" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, F.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, C.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuppusamy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, A.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsueh, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shia, K.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, T.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, M.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueng, S.-H.</span></span> <span> </span><span class="NLM_article-title">Unique Sulfur–Aromatic Interactions Contribute To The Binding Of Potent Imidazothiazole Indoleamine 2,3-Dioxygenase Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">1642</span>– <span class="NLM_lpage">1659</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01549</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01549" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsFSmu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=1642-1659&author=Y.-H.+Pengauthor=F.-Y.+Liaoauthor=C.-T.+Tsengauthor=R.+Kuppusamyauthor=A.-S.+Liauthor=C.-H.+Chenauthor=Y.-S.+Fanauthor=S.-Y.+Wangauthor=M.-H.+Wuauthor=C.-C.+Hsuehauthor=J.-Y.+Changauthor=L.-C.+Leeauthor=C.+Shihauthor=K.-S.+Shiaauthor=T.-K.+Yehauthor=M.-S.+Hungauthor=C.-C.+Kuoauthor=J.-S.+Songauthor=S.-Y.+Wuauthor=S.-H.+Ueng&title=Unique+Sulfur%E2%80%93Aromatic+Interactions+Contribute+To+The+Binding+Of+Potent+Imidazothiazole+Indoleamine+2%2C3-Dioxygenase+Inhibitors&doi=10.1021%2Facs.jmedchem.9b01549"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Unique Sulfur-Aromatic Interactions Contribute to the Binding of Potent Imidazothiazole Indoleamine 2,3-Dioxygenase Inhibitors</span></div><div class="casAuthors">Peng, Yi-Hui; Liao, Fang-Yu; Tseng, Chen-Tso; Kuppusamy, Ramajayam; Li, An-Siou; Chen, Chi-Han; Fan, Yu-Shiou; Wang, Sing-Yi; Wu, Mine-Hsine; Hsueh, Ching-Cheng; Chang, Jia-Yu; Lee, Lung-Chun; Shih, Chuan; Shia, Kak-Shan; Yeh, Teng-Kuang; Hung, Ming-Shiu; Kuo, Ching-Chuan; Song, Jen-Shin; Wu, Su-Ying; Ueng, Shau-Hua</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1642-1659</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase (IDO1) inhibitors are speculated to be useful in cancer immunotherapy, but a phase III clin. trial of the most advanced IDO1 inhibitor, epacadostat, did not meet its primary endpoint and was abandoned.  In previous work we identified the novel IDO1 inhibitor N-(4-chlorophenyl)-2-((5-phenylthiazolo[2,3-c][1,2,4]triazol-3-yl)thio)acetamide 1 through high-throughput screening (HTS).  Herein, we report a structure-activity relationship (SAR) study of this compd., which resulted in the potent IDO1 inhibitor 1-(4-cyanophenyl)-3-(3-(cyclopropylethynyl)imidazo[2,1-b]thiazol-5-yl)thiourea 47 (hIDO IC50 = 16.4 nM).  X-ray co-crystal structural anal. revealed that the basis for this high potency is a unique sulfur-arom. interaction network formed by the thiourea moiety of 47 with the F163 and F226.  This finding is expected to inspire new approaches towards the discovery of potent IDO1 inhibitors in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLdRgatLF0JLVg90H21EOLACvtfcHk0lharRINpSV44A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsFSmu7s%253D&md5=fa171b57b2e03f46d1658ba29419a150</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01549&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01549%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DY.-H.%26aulast%3DLiao%26aufirst%3DF.-Y.%26aulast%3DTseng%26aufirst%3DC.-T.%26aulast%3DKuppusamy%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DA.-S.%26aulast%3DChen%26aufirst%3DC.-H.%26aulast%3DFan%26aufirst%3DY.-S.%26aulast%3DWang%26aufirst%3DS.-Y.%26aulast%3DWu%26aufirst%3DM.-H.%26aulast%3DHsueh%26aufirst%3DC.-C.%26aulast%3DChang%26aufirst%3DJ.-Y.%26aulast%3DLee%26aufirst%3DL.-C.%26aulast%3DShih%26aufirst%3DC.%26aulast%3DShia%26aufirst%3DK.-S.%26aulast%3DYeh%26aufirst%3DT.-K.%26aulast%3DHung%26aufirst%3DM.-S.%26aulast%3DKuo%26aufirst%3DC.-C.%26aulast%3DSong%26aufirst%3DJ.-S.%26aulast%3DWu%26aufirst%3DS.-Y.%26aulast%3DUeng%26aufirst%3DS.-H.%26atitle%3DUnique%2520Sulfur%25E2%2580%2593Aromatic%2520Interactions%2520Contribute%2520To%2520The%2520Binding%2520Of%2520Potent%2520Imidazothiazole%2520Indoleamine%25202%252C3-Dioxygenase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D1642%26epage%3D1659%26doi%3D10.1021%2Facs.jmedchem.9b01549" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, L.-h.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis, And Biological Evaluation Of 1,2,5-Oxadiazole-3-Carboximidamide Derivatives As Novel Indoleamine-2,3-Dioxygenase 1 Inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>189</i></span>,  <span class="NLM_fpage">112059</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1016%2Fj.ejmech.2020.112059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=31981851" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslSgtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=189&publication_year=2020&pages=112059&author=X.+Songauthor=P.+Sunauthor=J.+Wangauthor=W.+Guoauthor=Y.+Wangauthor=L.-h.+Mengauthor=H.+Liu&title=Design%2C+Synthesis%2C+And+Biological+Evaluation+Of+1%2C2%2C5-Oxadiazole-3-Carboximidamide+Derivatives+As+Novel+Indoleamine-2%2C3-Dioxygenase+1+Inhibitors&doi=10.1016%2Fj.ejmech.2020.112059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, and biological evaluation of 1,2,5-oxadiazole-3-carboximidamide derivatives as novel indoleamine-2,3-dioxygenase 1 inhibitors</span></div><div class="casAuthors">Song, Xiaohan; Sun, Pu; Wang, Jiang; Guo, Wei; Wang, Yi; Meng, Ling-hua; Liu, Hong</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">189</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112059</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A novel series of 1,2,5-oxadiazole-3-carboximidamide derivs. I [R = (1-sulfamoylpyrrolidin-3-yl)methyl, (1-methanesulfonylpyrrolidin-3-yl)methyl, [1-(cyclopropanesulfonyl)piperidin-3-yl]methyl, etc] bearing cycle in the side chain were designed, synthesized, and biol. evaluated for their anti-tumor activity.  Most of them exhibited potent activity against hIDO1 in enzymic assays and in HEK293T cells over-expressing hIDO1.  Among them, compd. I [R = [(3R)-1-sulfamoylpyrrolidin-3-yl]methyl, [(3R)-1-sulfamoylpiperidin-3-yl]methyl, [(3S)-1-sulfamoylpiperidin-3-yl]methyl] showed significant inhibitory activity against hIDO1 (IC50 = 108.7, 178.1 and 139.1 nM resp.) and in HEK293T cells expressing hIDO1 (cellular IC50 = 19.88, 68.59 and 57.76 nM resp.).  Moreover, compd. I [R = [(3R)-1-sulfamoylpiperidin-3-yl]methyl] displayed improved PK property with longer half-life (t1/2 = 3.81 h in CD-1 mice) and better oral bioavailability (F = 33.6%) compared with epacadostat.  In addn., compd. I [R = [(3R)-1-sulfamoylpiperidin-3-yl]methyl] showed similar potency to inhibit the growth of CT-26 syngeneic xenograft compared to epacadostat, making it justifiable for further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOVCKyiy04nLVg90H21EOLACvtfcHk0licGFy-tMekkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslSgtrc%253D&md5=eaacdbc7d1498bc8644774d4ae1ff3d0</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112059%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DX.%26aulast%3DSun%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DGuo%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DMeng%26aufirst%3DL.-h.%26aulast%3DLiu%26aufirst%3DH.%26atitle%3DDesign%252C%2520Synthesis%252C%2520And%2520Biological%2520Evaluation%2520Of%25201%252C2%252C5-Oxadiazole-3-Carboximidamide%2520Derivatives%2520As%2520Novel%2520Indoleamine-2%252C3-Dioxygenase%25201%2520Inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D189%26spage%3D112059%26doi%3D10.1016%2Fj.ejmech.2020.112059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cowley, P.</span>; <span class="NLM_string-name">McGowan, M.</span>; <span class="NLM_string-name">Brown, T.</span>; <span class="NLM_string-name">Han, Y.</span>; <span class="NLM_string-name">Liu, K.</span>; <span class="NLM_string-name">Pu, Q.</span>; <span class="NLM_string-name">Wise, A.</span>; <span class="NLM_string-name">Zhang, H.</span>; <span class="NLM_string-name">Zhou, H.</span></span> <span> </span><span class="NLM_article-title">Novel substituted imidazopyridine compounds as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan-2,3-dioxygenase</span>. <span class="NLM_patent">WO 2017189386 A1</span>, Nov 2, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=P.+Cowley&author=M.+McGowan&author=T.+Brown&author=Y.+Han&author=K.+Liu&author=Q.+Pu&author=A.+Wise&author=H.+Zhang&author=H.+Zhou&title=Novel+substituted+imidazopyridine+compounds+as+inhibitors+of+indoleamine+2%2C3-dioxygenase+and%2For+tryptophan-2%2C3-dioxygenase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCowley%26aufirst%3DP.%26atitle%3DNovel%2520substituted%2520imidazopyridine%2520compounds%2520as%2520inhibitors%2520of%2520indoleamine%25202%252C3-dioxygenase%2520and%252For%2520tryptophan-2%252C3-dioxygenase%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, R.</span>; <span class="NLM_string-name">Jones, P.</span>; <span class="NLM_string-name">Petrocchi, A.</span>; <span class="NLM_string-name">Reyna, N.</span>; <span class="NLM_string-name">Hamilton, M.</span>; <span class="NLM_string-name">Cross, J.</span>; <span class="NLM_string-name">Tremblay, M.</span>; <span class="NLM_string-name">Leonard, P.</span></span> Compounds. <span class="NLM_patent">WO 2018136887 A1</span>, July 26, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Lewis%2C+R.%3B+Jones%2C+P.%3B+Petrocchi%2C+A.%3B+Reyna%2C+N.%3B+Hamilton%2C+M.%3B+Cross%2C+J.%3B+Tremblay%2C+M.%3B+Leonard%2C+P.+Compounds.+WO+2018136887+A1%2C+July+26%2C+2018."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLewis%26aufirst%3DR.%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cherney, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gullo-Brown, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darienzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Discenza, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranasinghe, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grubb, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziemba, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traeger, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopcho, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fereshteh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefanski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fargnoli, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swanson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delpy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seitz, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borzilleri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vite, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balog, A.</span></span> <span> </span><span class="NLM_article-title">Discovery And Preclinical Evaluation Of BMS-986242, A Potent, Selective Inhibitor Of Indoleamine-2,3-Dioxygenase 1</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">288</span>– <span class="NLM_lpage">294</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.0c00668</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.0c00668" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BB3MXitFyis7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2021&pages=288-294&author=E.+C.+Cherneyauthor=L.+Zhangauthor=S.+Naraauthor=X.+Zhuauthor=J.+Gullo-Brownauthor=D.+Maleyauthor=T.-A.+Linauthor=J.+T.+Huntauthor=C.+Huangauthor=Z.+Yangauthor=C.+Darienzoauthor=L.+Discenzaauthor=A.+Ranasingheauthor=M.+Grubbauthor=T.+Ziembaauthor=S.+C.+Traegerauthor=X.+Liauthor=K.+Johnstonauthor=L.+Kopchoauthor=M.+Fereshtehauthor=K.+Fosterauthor=K.+Stefanskiauthor=J.+Fargnoliauthor=J.+Swansonauthor=J.+Brownauthor=D.+Delpyauthor=S.+P.+Seitzauthor=R.+Borzilleriauthor=G.+Viteauthor=A.+Balog&title=Discovery+And+Preclinical+Evaluation+Of+BMS-986242%2C+A+Potent%2C+Selective+Inhibitor+Of+Indoleamine-2%2C3-Dioxygenase+1&doi=10.1021%2Facsmedchemlett.0c00668"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Preclinical Evaluation of BMS-986242, a Potent, Selective Inhibitor of Indoleamine-2,3-dioxygenase 1</span></div><div class="casAuthors">Cherney, Emily C.; Zhang, Liping; Nara, Susheel; Zhu, Xiao; Gullo-Brown, Johnni; Maley, Derrick; Lin, Tai-An; Hunt, John T.; Huang, Christine; Yang, Zheng; Darienzo, Celia; Discenza, Lorell; Ranasinghe, Asoka; Grubb, Mary; Ziemba, Theresa; Traeger, Sarah C.; Li, Xin; Johnston, Kathy; Kopcho, Lisa; Fereshteh, Mark; Foster, Kimberly; Stefanski, Kevin; Fargnoli, Joseph; Swanson, Jesse; Brown, Jennifer; Delpy, Diane; Seitz, Steven P.; Borzilleri, Robert; Vite, Gregory; Balog, Aaron</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">288-294</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1) is a heme-contg. dioxygenase enzyme implicated in cancer immune response.  This account details the discovery of BMS-986242, a novel IDO1 inhibitor designed for the treatment of a variety of cancers including metastatic melanoma and renal cell carcinoma.  Given the substantial interest around this target for cancer immunotherapy, we sought to identify a structurally differentiated clin. candidate that performs comparably to linrodostat (BMS-986205) in terms of both in vitro potency and in vivo pharmacodynamic effect in a mouse xenograft model.  On the basis of its preclin. profile, BMS-986242 was selected as a candidate for clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMG8_qVFwyi7Vg90H21EOLACvtfcHk0licGFy-tMekkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXitFyis7w%253D&md5=49574830c2c45c4e778f8be9ebd18879</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.0c00668&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.0c00668%26sid%3Dliteratum%253Aachs%26aulast%3DCherney%26aufirst%3DE.%2BC.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DNara%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DGullo-Brown%26aufirst%3DJ.%26aulast%3DMaley%26aufirst%3DD.%26aulast%3DLin%26aufirst%3DT.-A.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DHuang%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DDarienzo%26aufirst%3DC.%26aulast%3DDiscenza%26aufirst%3DL.%26aulast%3DRanasinghe%26aufirst%3DA.%26aulast%3DGrubb%26aufirst%3DM.%26aulast%3DZiemba%26aufirst%3DT.%26aulast%3DTraeger%26aufirst%3DS.%2BC.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DJohnston%26aufirst%3DK.%26aulast%3DKopcho%26aufirst%3DL.%26aulast%3DFereshteh%26aufirst%3DM.%26aulast%3DFoster%26aufirst%3DK.%26aulast%3DStefanski%26aufirst%3DK.%26aulast%3DFargnoli%26aufirst%3DJ.%26aulast%3DSwanson%26aufirst%3DJ.%26aulast%3DBrown%26aufirst%3DJ.%26aulast%3DDelpy%26aufirst%3DD.%26aulast%3DSeitz%26aufirst%3DS.%2BP.%26aulast%3DBorzilleri%26aufirst%3DR.%26aulast%3DVite%26aufirst%3DG.%26aulast%3DBalog%26aufirst%3DA.%26atitle%3DDiscovery%2520And%2520Preclinical%2520Evaluation%2520Of%2520BMS-986242%252C%2520A%2520Potent%252C%2520Selective%2520Inhibitor%2520Of%2520Indoleamine-2%252C3-Dioxygenase%25201%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2021%26volume%3D12%26spage%3D288%26epage%3D294%26doi%3D10.1021%2Facsmedchemlett.0c00668" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherney, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T.-a.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gullo-Brown, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston-Allegretto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopcho, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fereshteh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traeger, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhar, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anandam, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahankali, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padmanabhan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajanna, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murali, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mariappan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borzilleri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vite, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balog, A.</span></span> <span> </span><span class="NLM_article-title">Discovery Of Imidazopyridines As Potent Inhibitors Of Indoleamine 2,3-Dioxygenase 1 For Cancer Immunotherapy</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">494</span>– <span class="NLM_lpage">501</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.1c00014</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.1c00014" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BB3MXltlyhsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2021&pages=494-501&author=L.+Zhangauthor=E.+C.+Cherneyauthor=X.+Zhuauthor=T.-a.+Linauthor=J.+Gullo-Brownauthor=D.+Maleyauthor=K.+Johnston-Allegrettoauthor=L.+Kopchoauthor=M.+Fereshtehauthor=C.+Huangauthor=X.+Liauthor=S.+C.+Traegerauthor=G.+Dharauthor=A.+Anandamauthor=S.+Mahankaliauthor=S.+Padmanabhanauthor=P.+Rajannaauthor=V.+Muraliauthor=T.+Mariappanauthor=R.+Borzilleriauthor=G.+Viteauthor=J.+T.+Huntauthor=A.+Balog&title=Discovery+Of+Imidazopyridines+As+Potent+Inhibitors+Of+Indoleamine+2%2C3-Dioxygenase+1+For+Cancer+Immunotherapy&doi=10.1021%2Facsmedchemlett.1c00014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Imidazopyridines as Potent Inhibitors of Indoleamine 2,3-Dioxygenase 1 for Cancer Immunotherapy</span></div><div class="casAuthors">Zhang, Liping; Cherney, Emily C.; Zhu, Xiao; Lin, Tai-an; Gullo-Brown, Johnni; Maley, Derrick; Johnston-Allegretto, Kathy; Kopcho, Lisa; Fereshteh, Mark; Huang, Christine; Li, Xin; Traeger, Sarah C.; Dhar, Gopal; Anandam, Aravind; Mahankali, Sandeep; Padmanabhan, Shweta; Rajanna, Prabhakar; Murali, Venkata; Mariappan, Thanga; Borzilleri, Robert; Vite, Gregory; Hunt, John T.; Balog, Aaron</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">494-501</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1) has been identified as a target for small-mol. immunotherapy for the treatment of a variety of cancers including renal cell carcinoma and metastatic melanoma.  This work focuses on the identification of IDO1 inhibitors contg. replacements or isosteres for the amide found in BMS-986205, an amide-contg., IDO1-selective inhibitor currently in phase III clin. trials.  Detailed subsequently are efforts to identify a structurally differentiated IDO1 inhibitor via the pursuit of a variety of heterocyclic isosteres, leading to the discovery of highly potent, imidazopyridine-contg. IDO1 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofhLoepiTzULVg90H21EOLACvtfcHk0lg3ZdXKKZoyog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXltlyhsLY%253D&md5=479921e0eb4ee4b4e644eed31bccd331</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.1c00014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.1c00014%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DCherney%26aufirst%3DE.%2BC.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DLin%26aufirst%3DT.-a.%26aulast%3DGullo-Brown%26aufirst%3DJ.%26aulast%3DMaley%26aufirst%3DD.%26aulast%3DJohnston-Allegretto%26aufirst%3DK.%26aulast%3DKopcho%26aufirst%3DL.%26aulast%3DFereshteh%26aufirst%3DM.%26aulast%3DHuang%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DTraeger%26aufirst%3DS.%2BC.%26aulast%3DDhar%26aufirst%3DG.%26aulast%3DAnandam%26aufirst%3DA.%26aulast%3DMahankali%26aufirst%3DS.%26aulast%3DPadmanabhan%26aufirst%3DS.%26aulast%3DRajanna%26aufirst%3DP.%26aulast%3DMurali%26aufirst%3DV.%26aulast%3DMariappan%26aufirst%3DT.%26aulast%3DBorzilleri%26aufirst%3DR.%26aulast%3DVite%26aufirst%3DG.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DBalog%26aufirst%3DA.%26atitle%3DDiscovery%2520Of%2520Imidazopyridines%2520As%2520Potent%2520Inhibitors%2520Of%2520Indoleamine%25202%252C3-Dioxygenase%25201%2520For%2520Cancer%2520Immunotherapy%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2021%26volume%3D12%26spage%3D494%26epage%3D501%26doi%3D10.1021%2Facsmedchemlett.1c00014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doty, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fradera, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesburg, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGowan, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geda, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otte, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sciammetta, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solban, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sloman, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lammens, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neumann, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasternak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery Of Potent And Orally Available Bicyclo[1.1.1]Pentane-Derived Indoleamine-2,3-Dioxygenase 1 (IDO1) Inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1548</span>– <span class="NLM_lpage">1554</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.0c00195</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.0c00195" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtl2jtLbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=1548-1554&author=Q.+Puauthor=H.+Zhangauthor=L.+Guoauthor=M.+Chengauthor=A.+C.+Dotyauthor=H.+Fergusonauthor=X.+Fraderaauthor=C.+A.+Lesburgauthor=M.+A.+McGowanauthor=J.+R.+Millerauthor=P.+Gedaauthor=X.+Songauthor=K.+Otteauthor=N.+Sciammettaauthor=N.+Solbanauthor=W.+Yuauthor=D.+L.+Slomanauthor=H.+Zhouauthor=A.+Lammensauthor=L.+Neumannauthor=D.+J.+Bennettauthor=A.+Pasternakauthor=Y.+Han&title=Discovery+Of+Potent+And+Orally+Available+Bicyclo%5B1.1.1%5DPentane-Derived+Indoleamine-2%2C3-Dioxygenase+1+%28IDO1%29+Inhibitors&doi=10.1021%2Facsmedchemlett.0c00195"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent and Orally Available Bicyclo[1.1.1]pentane-Derived Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitors</span></div><div class="casAuthors">Pu, Qinglin; Zhang, Hongjun; Guo, Liangqin; Cheng, Mangeng; Doty, Amy C.; Ferguson, Heidi; Fradera, Xavier; Lesburg, Charles A.; McGowan, Meredeth A.; Miller, J. Richard; Geda, Prasanthi; Song, Xuelei; Otte, Karin; Sciammetta, Nunzio; Solban, Nicolas; Yu, Wensheng; Sloman, David L.; Zhou, Hua; Lammens, Alfred; Neumann, Lars; Bennett, David Jonathan; Pasternak, Alexander; Han, Yongxin</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1548-1554</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indoleamine-2,3-dioxygenase 1 (IDO1) inhibition and its combination with immune checkpoint inhibitors like pembrolizumab have drawn considerable attention from both academia and the pharmaceutical industry.  Here, we describe the discovery of a novel class of highly potent IDO1 heme-displacing inhibitors featuring a unique bicyclo[1.1.1]pentane motif.  Compd. 1, evolving from an ALIS (automated ligand identification system) hit, exhibited excellent potency but lacked the desired pharmacokinetic profile due to extensive amide hydrolysis of the benzamide moiety.  Replacing the central Ph ring in 1 with a bicyclo[1.1.1]pentane bioisostere effectively circumvented the amide hydrolysis issue, resulting in the discovery of compd. 2(I) with a favorable overall profile such as excellent potency, selectivity, pharmacokinetics, and a low predicted human dose.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCRMnzRWR18LVg90H21EOLACvtfcHk0lg3ZdXKKZoyog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtl2jtLbI&md5=d55b05877e5ee16eeaa7937ef0b83cef</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.0c00195&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.0c00195%26sid%3Dliteratum%253Aachs%26aulast%3DPu%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DGuo%26aufirst%3DL.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DDoty%26aufirst%3DA.%2BC.%26aulast%3DFerguson%26aufirst%3DH.%26aulast%3DFradera%26aufirst%3DX.%26aulast%3DLesburg%26aufirst%3DC.%2BA.%26aulast%3DMcGowan%26aufirst%3DM.%2BA.%26aulast%3DMiller%26aufirst%3DJ.%2BR.%26aulast%3DGeda%26aufirst%3DP.%26aulast%3DSong%26aufirst%3DX.%26aulast%3DOtte%26aufirst%3DK.%26aulast%3DSciammetta%26aufirst%3DN.%26aulast%3DSolban%26aufirst%3DN.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DSloman%26aufirst%3DD.%2BL.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DLammens%26aufirst%3DA.%26aulast%3DNeumann%26aufirst%3DL.%26aulast%3DBennett%26aufirst%3DD.%2BJ.%26aulast%3DPasternak%26aufirst%3DA.%26aulast%3DHan%26aufirst%3DY.%26atitle%3DDiscovery%2520Of%2520Potent%2520And%2520Orally%2520Available%2520Bicyclo%255B1.1.1%255DPentane-Derived%2520Indoleamine-2%252C3-Dioxygenase%25201%2520%2528IDO1%2529%2520Inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26spage%3D1548%26epage%3D1554%26doi%3D10.1021%2Facsmedchemlett.0c00195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">White, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGowan, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sciammetta, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fradera, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nickbarg, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trewick, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Augustin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Köenig, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesburg, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otte, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knemeyer, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spacciapoli, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geda, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smotrov, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curran, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heo, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abeywickrema, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span></span> <span> </span><span class="NLM_article-title">Strategic Incorporation Of Polarity In Heme-Displacing Inhibitors Of Indoleamine-2,3-Dioxygenase-1 (IDO1)</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">550</span>– <span class="NLM_lpage">557</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.0c00010</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.0c00010" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkslWksbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=550-557&author=C.+Whiteauthor=M.+A.+McGowanauthor=H.+Zhouauthor=N.+Sciammettaauthor=X.+Fraderaauthor=J.+Limauthor=E.+M.+Joshiauthor=C.+Andrewsauthor=E.+B.+Nickbargauthor=P.+Cowleyauthor=S.+Trewickauthor=M.+Augustinauthor=K.+von+K%C3%B6enigauthor=C.+A.+Lesburgauthor=K.+Otteauthor=I.+Knemeyerauthor=H.+Wooauthor=W.+Yuauthor=M.+Chengauthor=P.+Spacciapoliauthor=P.+Gedaauthor=X.+Songauthor=N.+Smotrovauthor=P.+Curranauthor=M.+R.+Heoauthor=P.+Abeywickremaauthor=J.+R.+Millerauthor=D.+J.+Bennettauthor=Y.+Han&title=Strategic+Incorporation+Of+Polarity+In+Heme-Displacing+Inhibitors+Of+Indoleamine-2%2C3-Dioxygenase-1+%28IDO1%29&doi=10.1021%2Facsmedchemlett.0c00010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Strategic Incorporation of Polarity in Heme-Displacing Inhibitors of Indoleamine-2,3-dioxygenase-1 (IDO1)</span></div><div class="casAuthors">White, Catherine; McGowan, Meredeth A.; Zhou, Hua; Sciammetta, Nunzio; Fradera, Xavier; Lim, Jongwon; Joshi, Elizabeth M.; Andrews, Christine; Nickbarg, Elliott B.; Cowley, Phillip; Trewick, Sarah; Augustin, Martin; von Koenig, Konstanze; Lesburg, Charles A.; Otte, Karin; Knemeyer, Ian; Woo, Hyun; Yu, Wensheng; Cheng, Mangeng; Spacciapoli, Peter; Geda, Prasanthi; Song, Xuelei; Smotrov, Nadya; Curran, Patrick; Heo, Mee Ra; Abeywickrema, Pravien; Miller, J. Richard; Bennett, David Jonathan; Han, Yongxin</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">550-557</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indoleamine-2,3-dioxygenase-1 (IDO1) has emerged as a target of significant interest to the field of cancer immunotherapy, as the upregulation of IDO1 in certain cancers has been linked to host immune evasion and poor prognosis for patients.  In particular, IDO1 inhibition is of interest as a combination therapy with immune checkpoint inhibition.  Through an Automated Ligand Identification System (ALIS) screen, a diamide class of compds. was identified as a promising lead for the inhibition of IDO1.  While hit 1() possessed attractive cell-based potency, it suffered from a significant right-shift in a whole blood assay, poor soly., and poor pharmacokinetic properties.  Through a physicochem. property-based approach, including a focus on lowering AlogP98 via the strategic introduction of polar substitution, compd. 13 was identified bearing a pyridyl oxetane core.  Compd. 13() demonstrated improved whole blood potency and soly., and an improved pharmacokinetic profile resulting in a low predicted human dose.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnzfQfxAahcbVg90H21EOLACvtfcHk0lgSGJmsIlxKJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkslWksbc%253D&md5=cad9d7aa1db10d920c558cd4ba4af9cd</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.0c00010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.0c00010%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DC.%26aulast%3DMcGowan%26aufirst%3DM.%2BA.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DSciammetta%26aufirst%3DN.%26aulast%3DFradera%26aufirst%3DX.%26aulast%3DLim%26aufirst%3DJ.%26aulast%3DJoshi%26aufirst%3DE.%2BM.%26aulast%3DAndrews%26aufirst%3DC.%26aulast%3DNickbarg%26aufirst%3DE.%2BB.%26aulast%3DCowley%26aufirst%3DP.%26aulast%3DTrewick%26aufirst%3DS.%26aulast%3DAugustin%26aufirst%3DM.%26aulast%3Dvon%2BK%25C3%25B6enig%26aufirst%3DK.%26aulast%3DLesburg%26aufirst%3DC.%2BA.%26aulast%3DOtte%26aufirst%3DK.%26aulast%3DKnemeyer%26aufirst%3DI.%26aulast%3DWoo%26aufirst%3DH.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DSpacciapoli%26aufirst%3DP.%26aulast%3DGeda%26aufirst%3DP.%26aulast%3DSong%26aufirst%3DX.%26aulast%3DSmotrov%26aufirst%3DN.%26aulast%3DCurran%26aufirst%3DP.%26aulast%3DHeo%26aufirst%3DM.%2BR.%26aulast%3DAbeywickrema%26aufirst%3DP.%26aulast%3DMiller%26aufirst%3DJ.%2BR.%26aulast%3DBennett%26aufirst%3DD.%2BJ.%26aulast%3DHan%26aufirst%3DY.%26atitle%3DStrategic%2520Incorporation%2520Of%2520Polarity%2520In%2520Heme-Displacing%2520Inhibitors%2520Of%2520Indoleamine-2%252C3-Dioxygenase-1%2520%2528IDO1%2529%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26spage%3D550%26epage%3D557%26doi%3D10.1021%2Facsmedchemlett.0c00010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dorsey, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benhadji, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sams, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schindler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huss, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolayev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpenito, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clawson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faber, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haney, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMillen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sall, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geeganage, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, J.</span></span> <span> </span><span class="NLM_article-title">Identification And Characterization Of The IDO1 Inhibitor LY3381916. Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA) AACR</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">5245</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=5245&author=F.+C.+Dorseyauthor=K.+Benhadjiauthor=L.+Samsauthor=D.+Youngauthor=J.+Schindlerauthor=K.+Hussauthor=A.+Nikolayevauthor=C.+Carpenitoauthor=D.+Clawsonauthor=B.+Jonesauthor=A.+Faberauthor=J.+Thomasauthor=S.+Haneyauthor=G.+Zhaoauthor=W.+McMillenauthor=T.+Smealauthor=D.+Sallauthor=M.+Kalosauthor=S.+Geeganageauthor=J.+Henry&title=Identification+And+Characterization+Of+The+IDO1+Inhibitor+LY3381916.+Proceedings+of+the+American+Association+for+Cancer+Research+Annual+Meeting+2018%3B+2018+Apr+14-18%3B+Chicago%2C+IL.+Philadelphia+%28PA%29+AACR"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDorsey%26aufirst%3DF.%2BC.%26aulast%3DBenhadji%26aufirst%3DK.%26aulast%3DSams%26aufirst%3DL.%26aulast%3DYoung%26aufirst%3DD.%26aulast%3DSchindler%26aufirst%3DJ.%26aulast%3DHuss%26aufirst%3DK.%26aulast%3DNikolayev%26aufirst%3DA.%26aulast%3DCarpenito%26aufirst%3DC.%26aulast%3DClawson%26aufirst%3DD.%26aulast%3DJones%26aufirst%3DB.%26aulast%3DFaber%26aufirst%3DA.%26aulast%3DThomas%26aufirst%3DJ.%26aulast%3DHaney%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DG.%26aulast%3DMcMillen%26aufirst%3DW.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DSall%26aufirst%3DD.%26aulast%3DKalos%26aufirst%3DM.%26aulast%3DGeeganage%26aufirst%3DS.%26aulast%3DHenry%26aufirst%3DJ.%26atitle%3DIdentification%2520And%2520Characterization%2520Of%2520The%2520IDO1%2520Inhibitor%2520LY3381916.%2520Proceedings%2520of%2520the%2520American%2520Association%2520for%2520Cancer%2520Research%2520Annual%2520Meeting%25202018%253B%25202018%2520Apr%252014-18%253B%2520Chicago%252C%2520IL.%2520Philadelphia%2520%2528PA%2529%2520AACR%26jtitle%3DCancer%2520Res.%26date%3D2018%26volume%3D78%26spage%3D5245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Achab, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bharathan, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanyal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fradera, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesburg, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lammens, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinot, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doty, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nickbarg, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spacciapoli, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geda, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smotrov, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abeywickrema, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mabrouk, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curran, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richards, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saradjian, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knemeyer, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otte, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sciammetta, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasternak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span></span> <span> </span><span class="NLM_article-title">Carbamate And N-Pyrimidine Mitigate Amide Hydrolysis: Structure-Based Drug Design Of Tetrahydroquinoline IDO1 Inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">389</span>– <span class="NLM_lpage">396</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.0c00525</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.0c00525" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BB3MXltFSks7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2021&pages=389-396&author=D.+Liauthor=Y.+Dengauthor=A.+Achabauthor=I.+Bharathanauthor=B.+A.+Hopkinsauthor=W.+Yuauthor=H.+Zhangauthor=S.+Sanyalauthor=Q.+Puauthor=H.+Zhouauthor=K.+Liuauthor=J.+Limauthor=X.+Fraderaauthor=C.+A.+Lesburgauthor=A.+Lammensauthor=T.+A.+Martinotauthor=R.+D.+Cohenauthor=A.+C.+Dotyauthor=H.+Fergusonauthor=E.+B.+Nickbargauthor=M.+Chengauthor=P.+Spacciapoliauthor=P.+Gedaauthor=X.+Songauthor=N.+Smotrovauthor=P.+Abeywickremaauthor=C.+Andrewsauthor=C.+Chamberlinauthor=O.+Mabroukauthor=P.+Curranauthor=M.+Richardsauthor=P.+Saradjianauthor=J.+R.+Millerauthor=I.+Knemeyerauthor=K.+M.+Otteauthor=S.+Vincentauthor=N.+Sciammettaauthor=A.+Pasternakauthor=D.+J.+Bennettauthor=Y.+Han&title=Carbamate+And+N-Pyrimidine+Mitigate+Amide+Hydrolysis%3A+Structure-Based+Drug+Design+Of+Tetrahydroquinoline+IDO1+Inhibitors&doi=10.1021%2Facsmedchemlett.0c00525"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Carbamate and N-Pyrimidine Mitigate Amide Hydrolysis: Structure-Based Drug Design of Tetrahydroquinoline IDO1 Inhibitors</span></div><div class="casAuthors">Li, Derun; Deng, Yongqi; Achab, Abdelghani; Bharathan, Indu; Hopkins, Brett Andrew; Yu, Wensheng; Zhang, Hongjun; Sanyal, Sulagna; Pu, Qinglin; Zhou, Hua; Liu, Kun; Lim, Jongwon; Fradera, Xavier; Lesburg, Charles A.; Lammens, Alfred; Martinot, Theodore A.; Cohen, Ryan D.; Doty, Amy C.; Ferguson, Heidi; Nickbarg, Elliott B.; Cheng, Mangeng; Spacciapoli, Peter; Geda, Prasanthi; Song, Xuelei; Smotrov, Nadya; Abeywickrema, Pravien; Andrews, Christine; Chamberlin, Chad; Mabrouk, Omar; Curran, Patrick; Richards, Matthew; Saradjian, Peter; Miller, J. Richard; Knemeyer, Ian; Otte, Karin M.; Vincent, Stella; Sciammetta, Nunzio; Pasternak, Alexander; Bennett, David Jonathan; Han, Yongxin</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">389-396</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indoleamine-2,3-dioxygenase-1 (IDO1) has emerged as an attractive target for cancer immunotherapy.  An automated ligand identification system screen afforded the tetrahydroquinoline class of novel IDO1 inhibitors.  Potency and pharmacokinetic (PK) were key issues with this class of compds.  Structure-based drug design and strategic incorporation of polarity enabled the rapid improvement on potency, soly., and oxidative metabolic stability.  Metabolite identification studies revealed that amide hydrolysis in the D-pocket was the key clearance mechanism for this class.  Strategic survey of amide isosteres revealed that carbamates and N-pyrimidines, which maintained exquisite potencies, mitigated the amide hydrolysis issue and led to an improved rat PK profile.  The lead compd. 28 is a potent IDO1 inhibitor, with clean off-target profiles and the potential for quaque die dosing in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJaibKNJjuVrVg90H21EOLACvtfcHk0ljb_6vBd79vkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXltFSks7Y%253D&md5=a2bbc31ff1de8f8aa6668a7079dcf905</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.0c00525&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.0c00525%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DD.%26aulast%3DDeng%26aufirst%3DY.%26aulast%3DAchab%26aufirst%3DA.%26aulast%3DBharathan%26aufirst%3DI.%26aulast%3DHopkins%26aufirst%3DB.%2BA.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DSanyal%26aufirst%3DS.%26aulast%3DPu%26aufirst%3DQ.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DK.%26aulast%3DLim%26aufirst%3DJ.%26aulast%3DFradera%26aufirst%3DX.%26aulast%3DLesburg%26aufirst%3DC.%2BA.%26aulast%3DLammens%26aufirst%3DA.%26aulast%3DMartinot%26aufirst%3DT.%2BA.%26aulast%3DCohen%26aufirst%3DR.%2BD.%26aulast%3DDoty%26aufirst%3DA.%2BC.%26aulast%3DFerguson%26aufirst%3DH.%26aulast%3DNickbarg%26aufirst%3DE.%2BB.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DSpacciapoli%26aufirst%3DP.%26aulast%3DGeda%26aufirst%3DP.%26aulast%3DSong%26aufirst%3DX.%26aulast%3DSmotrov%26aufirst%3DN.%26aulast%3DAbeywickrema%26aufirst%3DP.%26aulast%3DAndrews%26aufirst%3DC.%26aulast%3DChamberlin%26aufirst%3DC.%26aulast%3DMabrouk%26aufirst%3DO.%26aulast%3DCurran%26aufirst%3DP.%26aulast%3DRichards%26aufirst%3DM.%26aulast%3DSaradjian%26aufirst%3DP.%26aulast%3DMiller%26aufirst%3DJ.%2BR.%26aulast%3DKnemeyer%26aufirst%3DI.%26aulast%3DOtte%26aufirst%3DK.%2BM.%26aulast%3DVincent%26aufirst%3DS.%26aulast%3DSciammetta%26aufirst%3DN.%26aulast%3DPasternak%26aufirst%3DA.%26aulast%3DBennett%26aufirst%3DD.%2BJ.%26aulast%3DHan%26aufirst%3DY.%26atitle%3DCarbamate%2520And%2520N-Pyrimidine%2520Mitigate%2520Amide%2520Hydrolysis%253A%2520Structure-Based%2520Drug%2520Design%2520Of%2520Tetrahydroquinoline%2520IDO1%2520Inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2021%26volume%3D12%26spage%3D389%26epage%3D396%26doi%3D10.1021%2Facsmedchemlett.0c00525" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kinzel, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steeneck, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderhub, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hornberger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morschhaeuser, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonnek, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallinger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czekańska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, T.</span></span> <span> </span><span class="NLM_article-title">Discovery Of Highly Potent Heme-Displacing IDO1 Inhibitors Based On A Spirofused Bicyclic Scaffold</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">127738</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2020.127738</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1016%2Fj.bmcl.2020.127738" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=33316404" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BB3MXks1Oguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2021&pages=127738&author=O.+Kinzelauthor=C.+Steeneckauthor=S.+Anderhubauthor=M.+Hornbergerauthor=S.+Pintoauthor=B.+Morschhaeuserauthor=M.+Albersauthor=C.+Sonnekauthor=Y.+Wangauthor=A.+Mallingerauthor=M.+Czeka%C5%84skaauthor=T.+Hoffmann&title=Discovery+Of+Highly+Potent+Heme-Displacing+IDO1+Inhibitors+Based+On+A+Spirofused+Bicyclic+Scaffold&doi=10.1016%2Fj.bmcl.2020.127738"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of highly potent heme-displacing IDO1 inhibitors based on a spirofused bicyclic scaffold</span></div><div class="casAuthors">Kinzel, Olaf; Steeneck, Christoph; Anderhub, Simon; Hornberger, Martin; Pinto, Sheena; Morschhaeuser, Barbara; Albers, Michael; Sonnek, Christina; Wang, Yansong; Mallinger, Aurelie; Czekanska, Marta; Hoffmann, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">127738</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Through structural modification of an oxalamide derived chemotype, a novel class of highly potent, orally bioavailable IDO1-specific inhibitors was identified.  Representative compd. 18 inhibited human IDO1 with IC50 values of 3.9 nM and 52 nM in a cellular and human whole blood assay, resp.  In vitro assessment of the ADME properties of 18 demonstrated very high metabolic stability.  Pharmacokinetic profiling in mice showed a significantly reduced clearance compared to the oxalamides.  In a mouse pharmacodynamic model 18 nearly completely suppressed lipopolysaccharide-induced kynurenine prodn.  Hepatocyte data of 18 suggest the human clearance to be in a similar range to linrodostat (1).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonffyAQcOpG7Vg90H21EOLACvtfcHk0ljb_6vBd79vkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXks1Oguw%253D%253D&md5=913fcc9195925ccaecc22108a06731f8</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2020.127738&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2020.127738%26sid%3Dliteratum%253Aachs%26aulast%3DKinzel%26aufirst%3DO.%26aulast%3DSteeneck%26aufirst%3DC.%26aulast%3DAnderhub%26aufirst%3DS.%26aulast%3DHornberger%26aufirst%3DM.%26aulast%3DPinto%26aufirst%3DS.%26aulast%3DMorschhaeuser%26aufirst%3DB.%26aulast%3DAlbers%26aufirst%3DM.%26aulast%3DSonnek%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DMallinger%26aufirst%3DA.%26aulast%3DCzeka%25C5%2584ska%26aufirst%3DM.%26aulast%3DHoffmann%26aufirst%3DT.%26atitle%3DDiscovery%2520Of%2520Highly%2520Potent%2520Heme-Displacing%2520IDO1%2520Inhibitors%2520Based%2520On%2520A%2520Spirofused%2520Bicyclic%2520Scaffold%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2021%26volume%3D33%26spage%3D127738%26doi%3D10.1016%2Fj.bmcl.2020.127738" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><a href="http://ClinicalTrials.gov/ct2/show/NCT03351231" class="extLink">ClinicalTrials.gov/ct2/show/NCT03351231</a> (accessed March 21,
2021).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=ClinicalTrials.gov%2Fct2%2Fshow%2FNCT03351231+%28accessed+March+21%2C%0A2021%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hutchinson, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leveridge, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heathcote, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gee, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munoz-Muriedas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leavens, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shillings, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Homes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baddeley, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, C.-w.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bridges, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Argyrou, A.</span></span> <span> </span><span class="NLM_article-title">Enabling Lead Discovery For Histone Lysine Demethylases By High-Throughput Rapidfire Mass Spectrometry</span>. <i>J. Biomol. Screen</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">39</span>– <span class="NLM_lpage">48</span>, <span class="refDoi"> DOI: 10.1177/1087057111416660</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1177%2F1087057111416660" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=21859681" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=39-48&author=S.+E.+Hutchinsonauthor=M.+V.+Leveridgeauthor=M.+L.+Heathcoteauthor=P.+Francisauthor=L.+Williamsauthor=M.+Geeauthor=J.+Munoz-Muriedasauthor=B.+Leavensauthor=A.+Shillingsauthor=E.+Jonesauthor=P.+Homesauthor=S.+Baddeleyauthor=C.-w.+Chungauthor=A.+Bridgesauthor=A.+Argyrou&title=Enabling+Lead+Discovery+For+Histone+Lysine+Demethylases+By+High-Throughput+Rapidfire+Mass+Spectrometry&doi=10.1177%2F1087057111416660"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1177%2F1087057111416660&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1087057111416660%26sid%3Dliteratum%253Aachs%26aulast%3DHutchinson%26aufirst%3DS.%2BE.%26aulast%3DLeveridge%26aufirst%3DM.%2BV.%26aulast%3DHeathcote%26aufirst%3DM.%2BL.%26aulast%3DFrancis%26aufirst%3DP.%26aulast%3DWilliams%26aufirst%3DL.%26aulast%3DGee%26aufirst%3DM.%26aulast%3DMunoz-Muriedas%26aufirst%3DJ.%26aulast%3DLeavens%26aufirst%3DB.%26aulast%3DShillings%26aufirst%3DA.%26aulast%3DJones%26aufirst%3DE.%26aulast%3DHomes%26aufirst%3DP.%26aulast%3DBaddeley%26aufirst%3DS.%26aulast%3DChung%26aufirst%3DC.-w.%26aulast%3DBridges%26aufirst%3DA.%26aulast%3DArgyrou%26aufirst%3DA.%26atitle%3DEnabling%2520Lead%2520Discovery%2520For%2520Histone%2520Lysine%2520Demethylases%2520By%2520High-Throughput%2520Rapidfire%2520Mass%2520Spectrometry%26jtitle%3DJ.%2520Biomol.%2520Screen%26date%3D2011%26volume%3D17%26spage%3D39%26epage%3D48%26doi%3D10.1177%2F1087057111416660" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marquez, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comin, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russ, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huleihel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ben-Kasus, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agbaria, R.</span></span> <span> </span><span class="NLM_article-title">Understanding How The Herpes Thymidine Kinase Orchestrates Optimal Sugar And Nucleobase Conformations To Accommodate Its Substrate At The Active Site: A Chemical Approach</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">15145</span>– <span class="NLM_lpage">15150</span>, <span class="refDoi"> DOI: 10.1021/ja053789s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja053789s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVKmtLjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2005&pages=15145-15150&author=V.+E.+Marquezauthor=Y.+Choiauthor=M.+J.+Cominauthor=P.+Russauthor=C.+Georgeauthor=M.+Huleihelauthor=T.+Ben-Kasusauthor=R.+Agbaria&title=Understanding+How+The+Herpes+Thymidine+Kinase+Orchestrates+Optimal+Sugar+And+Nucleobase+Conformations+To+Accommodate+Its+Substrate+At+The+Active+Site%3A+A+Chemical+Approach&doi=10.1021%2Fja053789s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Understanding How the Herpes Thymidine Kinase Orchestrates Optimal Sugar and Nucleobase Conformations To Accommodate Its Substrate at the Active Site: A Chemical Approach</span></div><div class="casAuthors">Marquez, Victor E.; Choi, Yongseok; Comin, Maria Julieta; Russ, Pamela; George, Clifford; Huleihel, Mahmoud; Ben-Kasus, Tsipi; Agbaria, Riad</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">15145-15150</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The herpes virus thymidine kinase (HSV-tk) is a crit. enzyme for the activation of anti-HSV nucleosides.  However, a successful therapeutic outcome depends not only on the activity of this enzyme but also on the ability of the compd.(s) to interact effectively with cellular kinases and with the target viral or cellular DNA polymerases.  Herein, we describe the synthesis and study of two nucleoside analogs built on a conformationally locked bicyclo[3.1.0]hexane template designed to investigate the conformational preferences of HSV-tk for the 2'-deoxyribose ring.  Intimately assocd. with the conformation of the 2'-deoxyribose ring is the value of the C-N torsion angle χ, which positions the nucleobase into two different domains (syn or anti).  The often-conflicting sugar and nucleobase conformational parameters were studied using North and South methanocarbadeoxythymidine analogs (6 and 7), which forced HSV-tk to make a clear choice in the conformation of the substrate.  The results provide new insights into the mechanism of action of this enzyme, which cannot be gleaned from a static X-ray crystal structure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTI23V1P863bVg90H21EOLACvtfcHk0liUqFQpLEVa9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVKmtLjO&md5=f4d4192e81bf6fb821d41c34827b7cc2</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Fja053789s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja053789s%26sid%3Dliteratum%253Aachs%26aulast%3DMarquez%26aufirst%3DV.%2BE.%26aulast%3DChoi%26aufirst%3DY.%26aulast%3DComin%26aufirst%3DM.%2BJ.%26aulast%3DRuss%26aufirst%3DP.%26aulast%3DGeorge%26aufirst%3DC.%26aulast%3DHuleihel%26aufirst%3DM.%26aulast%3DBen-Kasus%26aufirst%3DT.%26aulast%3DAgbaria%26aufirst%3DR.%26atitle%3DUnderstanding%2520How%2520The%2520Herpes%2520Thymidine%2520Kinase%2520Orchestrates%2520Optimal%2520Sugar%2520And%2520Nucleobase%2520Conformations%2520To%2520Accommodate%2520Its%2520Substrate%2520At%2520The%2520Active%2520Site%253A%2520A%2520Chemical%2520Approach%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2005%26volume%3D127%26spage%3D15145%26epage%3D15150%26doi%3D10.1021%2Fja053789s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowary, T. L.</span></span> <span> </span><span class="NLM_article-title">Synthesis Of Bicyclo[3.1.0]Hexane Derivatives As Conformationally Restricted Analogues Of Β-Arabinofuranosyl And Α-Galactofuranosyl Rings</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">881</span>– <span class="NLM_lpage">884</span>, <span class="refDoi"> DOI: 10.1021/ol703041y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol703041y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFCitLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2008&pages=881-884&author=J.+Liauthor=T.+L.+Lowary&title=Synthesis+Of+Bicyclo%5B3.1.0%5DHexane+Derivatives+As+Conformationally+Restricted+Analogues+Of+%CE%92-Arabinofuranosyl+And+%CE%91-Galactofuranosyl+Rings&doi=10.1021%2Fol703041y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of Bicyclo[3.1.0]hexane Derivatives as Conformationally Restricted Analogues of β-Arabinofuranosyl and α-Galactofuranosyl Rings</span></div><div class="casAuthors">Li, Jing; Lowary, Todd L.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">881-884</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A route for the synthesis of bicyclo[3.1.0]hexane-derived conformationally restricted analogs I and II of β-arabinofuranosyl and α-galactofuranosyl rings is described.  Advantage is taken of the pseudo-enantiomeric relationship between the two ring systems to develop a route that provides both targets from a single precursor.  Key steps include a base-promoted ring contraction of an epoxy ketone obtained from cyclohexane-1,4-dione to give the bicyclo[3.1.0]hexane ring system and a late stage resoln. involving esterification with O-acetyl-(S)-mandelic acid.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYv7Hc-GPmt7Vg90H21EOLACvtfcHk0ljAPEvR32iDRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFCitLk%253D&md5=b226ad723ec550dfbe8a9fd3d155d3ed</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fol703041y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol703041y%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLowary%26aufirst%3DT.%2BL.%26atitle%3DSynthesis%2520Of%2520Bicyclo%255B3.1.0%255DHexane%2520Derivatives%2520As%2520Conformationally%2520Restricted%2520Analogues%2520Of%2520%25CE%2592-Arabinofuranosyl%2520And%2520%25CE%2591-Galactofuranosyl%2520Rings%26jtitle%3DOrg.%2520Lett.%26date%3D2008%26volume%3D10%26spage%3D881%26epage%3D884%26doi%3D10.1021%2Fol703041y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Colombo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernardi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennet, A. J.</span></span> <span> </span><span class="NLM_article-title">Synthesis And Evaluation Of Influenza A Viral Neuraminidase Candidate Inhibitors Based On A Bicyclo[3.1.0]Hexane Scaffold</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">6539</span>– <span class="NLM_lpage">6553</span>, <span class="refDoi"> DOI: 10.1039/c6ob00999a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1039%2FC6OB00999A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=27305457" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BC28Xptl2qtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2016&pages=6539-6553&author=C.+Colomboauthor=B.+M.+Pintoauthor=A.+Bernardiauthor=A.+J.+Bennet&title=Synthesis+And+Evaluation+Of+Influenza+A+Viral+Neuraminidase+Candidate+Inhibitors+Based+On+A+Bicyclo%5B3.1.0%5DHexane+Scaffold&doi=10.1039%2Fc6ob00999a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of influenza A viral neuraminidase candidate inhibitors based on a bicyclo[3.1.0]hexane scaffold</span></div><div class="casAuthors">Colombo, Cinzia; Pinto, B. Mario; Bernardi, Anna; Bennet, Andrew J.</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">6539-6553</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">This manuscript describes a novel class of derivs. based on a bicyclo[3.1.0]hexane scaffold, proposed as mimics of sialic acid in a distorted boat conformation that is on the catalytic pathway of neuraminidases (sialidases).  A general synthetic route for these constrained-ring mols. was developed using a photochem. reaction followed by a Johnson-Corey-Chaykovsky cyclopropanation.  Functionalization with the goal of occupying the 150-cavity was also exploited.  Inhibition assays demonstrated low micromolar inhibition against both group-1 (H5N1) and group-2 (H9N2) influenza neuraminidase subtypes, indicating good affinity for the alpha and beta sialic acid mimics and 150-cavity-targeted derivs.  These results provide a validation of a bicyclo[3.1.0]hexane scaffold as a mimic of a distorted sialic acid bound in the neuraminidase active site during catalysis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgDJ0TA7VUqbVg90H21EOLACvtfcHk0ljAPEvR32iDRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xptl2qtbg%253D&md5=30a40819786fd77b8d1b5c698ac62c82</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1039%2FC6OB00999A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6OB00999A%26sid%3Dliteratum%253Aachs%26aulast%3DColombo%26aufirst%3DC.%26aulast%3DPinto%26aufirst%3DB.%2BM.%26aulast%3DBernardi%26aufirst%3DA.%26aulast%3DBennet%26aufirst%3DA.%2BJ.%26atitle%3DSynthesis%2520And%2520Evaluation%2520Of%2520Influenza%2520A%2520Viral%2520Neuraminidase%2520Candidate%2520Inhibitors%2520Based%2520On%2520A%2520Bicyclo%255B3.1.0%255DHexane%2520Scaffold%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2016%26volume%3D14%26spage%3D6539%26epage%3D6553%26doi%3D10.1039%2Fc6ob00999a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bentzien, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickey, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemper, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brewer, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyekjær, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">East, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittaker, M.</span></span> <span> </span><span class="NLM_article-title">An In Silico Method For Predicting Ames Activities Of Primary Aromatic Amines By Calculating The Stabilities Of Nitrenium Ions</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">274</span>– <span class="NLM_lpage">297</span>, <span class="refDoi"> DOI: 10.1021/ci900378x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci900378x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlvFWgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2010&pages=274-297&author=J.+Bentzienauthor=E.+R.+Hickeyauthor=R.+A.+Kemperauthor=M.+L.+Brewerauthor=J.+D.+Dyekj%C3%A6rauthor=S.+P.+Eastauthor=M.+Whittaker&title=An+In+Silico+Method+For+Predicting+Ames+Activities+Of+Primary+Aromatic+Amines+By+Calculating+The+Stabilities+Of+Nitrenium+Ions&doi=10.1021%2Fci900378x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">An in Silico Method for Predicting Ames Activities of Primary Aromatic Amines by Calculating the Stabilities of Nitrenium Ions</span></div><div class="casAuthors">Bentzien, Joerg; Hickey, Eugene R.; Kemper, Raymond A.; Brewer, Mark L.; Dyekjaer, Jane D.; East, Stephen P.; Whittaker, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">274-297</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this paper, the authors describe an in silico first principal approach to predict the mutagenic potential of primary arom. amines.  This approach is based on the so-called "nitrenium hypothesis", which was developed by Ford et al. in the early 1990s.  This hypothesis asserts that the mutagenic effect for this class of mols. is mediated through the transient formation of a nitrenium ion and that the stability of this cation is correlated with the mutagenic potential.  Here the authors use quantum mech. calcns. at different levels of theory (semiempirical AM1, ab initio HF/3-21G, HF/6-311G(d,p), and DFT/B3LYP/6-311G(d,p)) to compute the stability of nitrenium ions.  When applied to a test set of 257 primary arom. amines, the authors show that this method can correctly differentiate between Ames active and inactive compds., and furthermore that it is able to rationalize and predict SAR trends within structurally related chem. series.  For this test set, the AM1 nitrenium stability calcns. are found to provide a good balance between speed and accuracy, resulting in an overall accuracy of 85%, and sensitivity and specificity of 91% and 72%, resp.  The nitrenium-based predictions are also compared to the com. software packages DEREK, MULTICASE, and the MOE-Toxicophore descriptor.  One advantage of the approach presented here is that the calcn. of relative stabilities results in a continuous spectrum of activities and not a simple yes/no answer.  This allows the authors to observe and rationalize subtle trends due to the different electrostatic properties of the org. mols.  The authors' results strongly indicate that nitrenium ion stability calcns. should be used as a complementary approach to assist the medicinal chemist in prioritizing and selecting nonmutagenic primary arom. amines during preclin. drug discovery programs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkMtrGYCOK9rVg90H21EOLACvtfcHk0ljAPEvR32iDRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlvFWgug%253D%253D&md5=ded91291e2d099e1f333f66170f6be3b</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Fci900378x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci900378x%26sid%3Dliteratum%253Aachs%26aulast%3DBentzien%26aufirst%3DJ.%26aulast%3DHickey%26aufirst%3DE.%2BR.%26aulast%3DKemper%26aufirst%3DR.%2BA.%26aulast%3DBrewer%26aufirst%3DM.%2BL.%26aulast%3DDyekj%25C3%25A6r%26aufirst%3DJ.%2BD.%26aulast%3DEast%26aufirst%3DS.%2BP.%26aulast%3DWhittaker%26aufirst%3DM.%26atitle%3DAn%2520In%2520Silico%2520Method%2520For%2520Predicting%2520Ames%2520Activities%2520Of%2520Primary%2520Aromatic%2520Amines%2520By%2520Calculating%2520The%2520Stabilities%2520Of%2520Nitrenium%2520Ions%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2010%26volume%3D50%26spage%3D274%26epage%3D297%26doi%3D10.1021%2Fci900378x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shamovsky, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ripa, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Börjesson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nordén, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasselgren, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donovan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sjö, P.</span></span> <span> </span><span class="NLM_article-title">Explanation For Main Features Of Structure–Genotoxicity Relationships Of Aromatic Amines By Theoretical Studies Of Their Activation Pathways In CYP1A2</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>133</i></span>,  <span class="NLM_fpage">16168</span>– <span class="NLM_lpage">16185</span>, <span class="refDoi"> DOI: 10.1021/ja206427u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja206427u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1SrsrvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2011&pages=16168-16185&author=I.+Shamovskyauthor=L.+Ripaauthor=L.+B%C3%B6rjessonauthor=C.+Meeauthor=B.+Nord%C3%A9nauthor=P.+Hansenauthor=C.+Hasselgrenauthor=M.+O%E2%80%99Donovanauthor=P.+Sj%C3%B6&title=Explanation+For+Main+Features+Of+Structure%E2%80%93Genotoxicity+Relationships+Of+Aromatic+Amines+By+Theoretical+Studies+Of+Their+Activation+Pathways+In+CYP1A2&doi=10.1021%2Fja206427u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Explanation for Main Features of Structure-Genotoxicity Relationships of Aromatic Amines by Theoretical Studies of Their Activation Pathways in CYP1A2</span></div><div class="casAuthors">Shamovsky, Igor; Ripa, Lena; Borjesson, Lena; Mee, Christine; Norden, Bo; Hansen, Peter; Hasselgren, Catrin; O'Donovan, Mike; Sjo, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">16168-16185</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Arom. and heteroarom. amines (ArNH2) represent a class of potential mutagens that after being metabolically activated covalently modify DNA.  Activation of ArNH2 in many cases starts with N-hydroxylation by P 450 enzymes, primarily CYP1A2.  Poor understanding of structure-mutagenicity relationships of ArNH2 limits their use in drug discovery programs.  Key factors that facilitate activation of ArNH2 are revealed by exploring their reaction intermediates in CYP1A2 using DFT calcns.  On the basis of these calcns. and extensive anal. of structure-mutagenicity data, we suggest that mutagenic metabolites are generated by ferric peroxo intermediate, (CYP1A2)FeIII-OO-, in a three-step heterolytic mechanism.  First, the distal oxygen of the oxidant abstrs. proton from H-bonded ArNH2.  The subsequent proximal protonation of the resulting (CYP1A2)FeIII-OOH weakens both the O-O and the O-H bonds of the oxidant.  Heterolytic cleavage of the O-O bond leads to N-hydroxylation of ArNH- via SN2 mechanism, whereas cleavage of the O-H bond results in release of hydroperoxy radical.  Thus, our proposed reaction offers a mechanistic explanation for previous observations that metab. of arom. amines could cause oxidative stress.  The primary drivers for mutagenic potency of ArNH2 are (i) binding affinity of ArNH2 in the productive binding mode within the CYP1A2 substrate cavity, (ii) resonance stabilization of the anionic forms of ArNH2, and (iii) exothermicity of proton-assisted heterolytic cleavage of N-O bonds of hydroxylamines and their bioconjugates.  This leads to a strategy for designing mutagenicity free ArNH2: Structural alterations in ArNH2, which disrupt geometric compatibility with CYP1A2, hinder proton abstraction, or strongly destabilize the nitrenium ion, in this order of priority, prevent genotoxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrctr81IIN2trVg90H21EOLACvtfcHk0lia4wLho2KzQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1SrsrvI&md5=9447ee2144a899b65e9350b712ca2a46</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fja206427u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja206427u%26sid%3Dliteratum%253Aachs%26aulast%3DShamovsky%26aufirst%3DI.%26aulast%3DRipa%26aufirst%3DL.%26aulast%3DB%25C3%25B6rjesson%26aufirst%3DL.%26aulast%3DMee%26aufirst%3DC.%26aulast%3DNord%25C3%25A9n%26aufirst%3DB.%26aulast%3DHansen%26aufirst%3DP.%26aulast%3DHasselgren%26aufirst%3DC.%26aulast%3DO%25E2%2580%2599Donovan%26aufirst%3DM.%26aulast%3DSj%25C3%25B6%26aufirst%3DP.%26atitle%3DExplanation%2520For%2520Main%2520Features%2520Of%2520Structure%25E2%2580%2593Genotoxicity%2520Relationships%2520Of%2520Aromatic%2520Amines%2520By%2520Theoretical%2520Studies%2520Of%2520Their%2520Activation%2520Pathways%2520In%2520CYP1A2%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2011%26volume%3D133%26spage%3D16168%26epage%3D16185%26doi%3D10.1021%2Fja206427u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Teasdale, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elder, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, S.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez Flores, I. H.</span></span> <span> </span><span class="NLM_article-title">Risk Assessment Of Genotoxic Impurities In New Chemical Entities: Strategies To Demonstrate Control</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">221</span>– <span class="NLM_lpage">230</span>, <span class="refDoi"> DOI: 10.1021/op300268u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/op300268u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntVWiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2013&pages=221-230&author=A.+Teasdaleauthor=D.+Elderauthor=S.-J.+Changauthor=S.+Wangauthor=R.+Thompsonauthor=N.+Benzauthor=I.+H.+Sanchez+Flores&title=Risk+Assessment+Of+Genotoxic+Impurities+In+New+Chemical+Entities%3A+Strategies+To+Demonstrate+Control&doi=10.1021%2Fop300268u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Risk Assessment of Genotoxic Impurities in New Chemical Entities: Strategies To Demonstrate Control</span></div><div class="casAuthors">Teasdale, Andrew; Elder, David; Chang, Sou-Jen; Wang, Sophie; Thompson, Richard; Benz, Nancy; Sanchez Flores, Ignacio H.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">221-230</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The control of genotoxic impurities (GTIs) is a crucial activity that is performed for any new chem. entity intended for clin. use.  A key element of this is the quality risk assessment.  This article seeks to examine the primary components of such a strategy, focusing specifically on the effective use of in silico assessment tools to augment this process, in particular the calcn. of theor. purge factors based on the physicochem. properties of a specific GTI and its interrelationship to the process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphCkprmUbIMLVg90H21EOLACvtfcHk0lia4wLho2KzQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntVWiuw%253D%253D&md5=0c78ffdb8527c57ce278e7625ab559c0</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fop300268u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop300268u%26sid%3Dliteratum%253Aachs%26aulast%3DTeasdale%26aufirst%3DA.%26aulast%3DElder%26aufirst%3DD.%26aulast%3DChang%26aufirst%3DS.-J.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DThompson%26aufirst%3DR.%26aulast%3DBenz%26aufirst%3DN.%26aulast%3DSanchez%2BFlores%26aufirst%3DI.%2BH.%26atitle%3DRisk%2520Assessment%2520Of%2520Genotoxic%2520Impurities%2520In%2520New%2520Chemical%2520Entities%253A%2520Strategies%2520To%2520Demonstrate%2520Control%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2013%26volume%3D17%26spage%3D221%26epage%3D230%26doi%3D10.1021%2Fop300268u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Teffera, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brake, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saffran, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span> <span> </span><span class="NLM_article-title">Impact Of Hydrolysis-Mediated Clearance On The Pharmacokinetics Of Novel Anaplastic Lymphoma Kinase Inhibitors</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">238</span>– <span class="NLM_lpage">247</span>, <span class="refDoi"> DOI: 10.1124/dmd.112.047993</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1124%2Fdmd.112.047993" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=23118327" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlt1OntA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2013&pages=238-247&author=Y.+Tefferaauthor=L.+M.+Berryauthor=R.+L.+Brakeauthor=R.+T.+Lewisauthor=D.+C.+Saffranauthor=E.+Mooreauthor=J.+Liuauthor=Z.+Zhao&title=Impact+Of+Hydrolysis-Mediated+Clearance+On+The+Pharmacokinetics+Of+Novel+Anaplastic+Lymphoma+Kinase+Inhibitors&doi=10.1124%2Fdmd.112.047993"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of hydrolysis-mediated clearance on the pharmacokinetics of novel anaplastic lymphoma kinase inhibitors</span></div><div class="casAuthors">Teffera, Yohannes; Berry, Loren M.; Brake, Rachael L.; Lewis, Richard T.; Saffran, Douglas C.; Moore, Earl; Liu, Jingzhou; Zhao, Zhiyang</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">238-247</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Compd. 1 [(E)-4-fluoro-N-(6-((4-(2-hydroxypropan-2-yl)piperidin-1-yl)methyl)-1-((1S,4S)-4-(isopropylcarbamoyl)cyclohexyl)-1H-benzo[d]imidazol-2(3H)-ylidene)benzamide], a new, potent, selective anaplastic lymphoma kinase (ALK) inhibitor with potential application for the treatment of cancer, was selected as candidate to advance into efficacy studies in mice.  However, the compd. underwent mouse-specific enzymic hydrolysis in plasma to a primary amine product (M1).  Subsequent i.v. pharmacokinetics studies in mice showed that compd. 1 had high clearance (CL) and a short half-life.  Oral dose escalation studies in mice indicated that elimination of compd. 1 was saturable, with higher doses achieving sufficient exposures above in vitro IC50.  Chem. efforts to minimize hydrolysis resulted in the discovery of several analogs that were stable in mouse plasma.  Three were taken in vivo into mice and showed decreased CL corresponding to increased in vitro stability in plasma.  However, the more stable compds. also showed reduced potency against ALK.  Kinetic studies in NADPH-fortified and unfortified microsomes and plasma produced submicromolar Km values and could help explain the satn. of elimination obsd. in vivo.  Predictions of CL based on kinetics from hydrolysis and NADPH-dependent pathways produced predicted hepatic CL values of 3.8, 3.0, 1.6, and 1.2 l/h·kg for compd. 1, compd. 2 [(E)-3,5-difluoro-N-(6-((4-(2-hydroxypropan-2-yl)piperidin-1-yl)methyl)-1-((1s,4s)-4-(isopropylcarbamoyl)cyclohexyl)-1H-benzo[d]imidazo-2(3H)-ylidene)benzamide], compd. 3 [(E)-3-chloro-5-fluoro-N-(6-((4-(2-hydroxypropan-2-yl)piperidin-1-yl)methyl)-1-((1s,4s)-4-(isopropylcarbamoyl)cyclohexyl)-1H-benzo[d]imidazol-2(3H)-ylidene)benzamide], and compd. 4 [(E)-N-(6-((4-(2-hydroxypropan-2-yl)piperidin-1-yl)methyl)-1-((1s,4s)-4-(isopropylcarbamoyl)cyclohexyl)-1H-benzo[d]imidazol-2(3H)-ylidene)-3-(trifluoromethyl)benzamide], resp.  The in vivo obsd. CLs for compds. 1, 2, 3, and 4 were 5.52, 3.51, 2.14, and 2.66 l/h kg, resp.  These results indicate that in vitro metab. kinetic data, incorporating contributions from both hydrolysis and NADPH-dependent metab., could be used to predict the systemic CL of compds. cleared via hydrolytic pathways provided that the in vitro assays thoroughly investigate the processes, including the contribution of other metabolic pathways and the possibility of satn. kinetics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokHx1C0KZVi7Vg90H21EOLACvtfcHk0lia4wLho2KzQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlt1OntA%253D%253D&md5=a46b21704e0ecab631a6048ca947fe01</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1124%2Fdmd.112.047993&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.112.047993%26sid%3Dliteratum%253Aachs%26aulast%3DTeffera%26aufirst%3DY.%26aulast%3DBerry%26aufirst%3DL.%2BM.%26aulast%3DBrake%26aufirst%3DR.%2BL.%26aulast%3DLewis%26aufirst%3DR.%2BT.%26aulast%3DSaffran%26aufirst%3DD.%2BC.%26aulast%3DMoore%26aufirst%3DE.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DZ.%26atitle%3DImpact%2520Of%2520Hydrolysis-Mediated%2520Clearance%2520On%2520The%2520Pharmacokinetics%2520Of%2520Novel%2520Anaplastic%2520Lymphoma%2520Kinase%2520Inhibitors%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2013%26volume%3D41%26spage%3D238%26epage%3D247%26doi%3D10.1124%2Fdmd.112.047993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="note"><p class="first last">Compound <b>21</b>: permeability MDCK-MDR1 cell line assay (<i>P</i><sub>app</sub> × 10<sup>–6</sup> cm/s, wt A–B/B–A, ratio; MDR1 A–B/B–A, ratio) 5.53/5.61, 1.02; 3.70/2.07, 0.56. Compound <b>22</b>: mouse plasma stability, 12.8 h. permeability (<i>P</i><sub>app</sub> × 10<sup>-6</sup> cm/s, wt A–B/B–A, ratio; MDR1 A–B/B–A, ratio) 3.63/1.73, 0.48; 1.86/1.40, 0.75.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, A. W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terentis, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, N. J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, S. R.</span></span> <span> </span><span class="NLM_article-title">Role Of Indoleamine 2,3-Dioxygenase In Health And Disease</span>. <i>Clin. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">601</span>– <span class="NLM_lpage">672</span>, <span class="refDoi"> DOI: 10.1042/cs20140392</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1042%2FCS20140392" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslKqtLnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2015&pages=601-672&author=A.+W.+S.+Yeungauthor=A.+C.+Terentisauthor=N.+J.+C.+Kingauthor=S.+R.+Thomas&title=Role+Of+Indoleamine+2%2C3-Dioxygenase+In+Health+And+Disease&doi=10.1042%2Fcs20140392"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Role of indoleamine 2,3-dioxygenase in health and disease</span></div><div class="casAuthors">Yeung, Amanda W. S.; Terentis, Andrew C.; King, Nicholas J. C.; Thomas, Shane R.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Science</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">601-672</span>CODEN:
                <span class="NLM_cas:coden">CSCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1470-8736</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">IDO1 (indoleamine 2,3-dioxygenase 1) is a member of a unique class of mammalian heme dioxygenases that catalyze the oxidative catabolism of the least-abundant essential amino acid, L-Trp (L-tryptophan), along the kynurenine pathway.  Significant increases in knowledge have been recently gained with respect to understanding the fundamental biochem. of IDO1 including its catalytic reaction mechanism, the scope of enzyme reactions it catalyzes, the biochem. mechanisms controlling IDO1 expression and enzyme activity, and the discovery of enzyme inhibitors.  Major advances in understanding the roles of IDO1 in physiol. and disease have also been realized.  IDO1 is recognized as a prominent immune regulatory enzyme capable of modulating immune cell activation status and phenotype via several mol. mechanisms including enzyme-dependent deprivation of L-Trp and its conversion into the aryl hydrocarbon receptor ligand kynurenine and other bioactive kynurenine pathway metabolites, or non-enzymic cell signalling actions involving tyrosine phosphorylation of IDO1.  Through these different modes of biochem. signalling, IDO1 regulates certain physiol. functions (e.g. pregnancy) and modulates the pathogenesis and severity of diverse conditions including chronic inflammation, infectious disease, allergic and autoimmune disorders, transplantation, neuropathol. and cancer.  In the present review, we detail the current understanding of IDO1's catalytic actions and the biochem. mechanisms regulating IDO1 expression and activity.  We also discuss the biol. functions of IDO1 with a focus on the enzyme's immune-modulatory function, its medical implications in diverse pathol. settings and its utility as a therapeutic target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpK04GKaRGhtrVg90H21EOLACvtfcHk0lgiPvtGR6E0Gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslKqtLnN&md5=86a912483bbe5504a07011513059aa95</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1042%2FCS20140392&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FCS20140392%26sid%3Dliteratum%253Aachs%26aulast%3DYeung%26aufirst%3DA.%2BW.%2BS.%26aulast%3DTerentis%26aufirst%3DA.%2BC.%26aulast%3DKing%26aufirst%3DN.%2BJ.%2BC.%26aulast%3DThomas%26aufirst%3DS.%2BR.%26atitle%3DRole%2520Of%2520Indoleamine%25202%252C3-Dioxygenase%2520In%2520Health%2520And%2520Disease%26jtitle%3DClin.%2520Sci.%26date%3D2015%26volume%3D129%26spage%3D601%26epage%3D672%26doi%3D10.1042%2Fcs20140392" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Badawy, A. A.-B.</span></span> <span> </span><span class="NLM_article-title">Kynurenine Pathway Of Tryptophan Metabolism: Regulatory And Functional Aspects</span>. <i>Int. J. Tryptophan Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">117864691769193</span>, <span class="refDoi"> DOI: 10.1177/1178646917691938</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1177%2F1178646917691938" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2017&pages=117864691769193&author=A.+A.-B.+Badawy&title=Kynurenine+Pathway+Of+Tryptophan+Metabolism%3A+Regulatory+And+Functional+Aspects&doi=10.1177%2F1178646917691938"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1177%2F1178646917691938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1178646917691938%26sid%3Dliteratum%253Aachs%26aulast%3DBadawy%26aufirst%3DA.%2BA.-B.%26atitle%3DKynurenine%2520Pathway%2520Of%2520Tryptophan%2520Metabolism%253A%2520Regulatory%2520And%2520Functional%2520Aspects%26jtitle%3DInt.%2520J.%2520Tryptophan%2520Res.%26date%3D2017%26volume%3D10%26spage%3D117864691769193%26doi%3D10.1177%2F1178646917691938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirey, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlin, J. M.</span></span> <span> </span><span class="NLM_article-title">Synergistic Transcriptional Activation Of Indoleamine Dioxygenase By IFN-Γ And Tumor Necrosis Factor-Α</span>. <i>J. Interferon Cytokine Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">413</span>– <span class="NLM_lpage">421</span>, <span class="refDoi"> DOI: 10.1089/107999003322277829</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1089%2F107999003322277829" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=13678429" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmvVOmsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2003&pages=413-421&author=C.+M.+Robinsonauthor=K.+A.+Shireyauthor=J.+M.+Carlin&title=Synergistic+Transcriptional+Activation+Of+Indoleamine+Dioxygenase+By+IFN-%CE%93+And+Tumor+Necrosis+Factor-%CE%91&doi=10.1089%2F107999003322277829"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic Transcriptional Activation of Indoleamine Dioxygenase by IFNγ and Tumor Necrosis Factor-α</span></div><div class="casAuthors">Robinson, Cory M.; Shirey, Kari Ann; Carlin, Joseph M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Interferon and Cytokine Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">413-421</span>CODEN:
                <span class="NLM_cas:coden">JICRFJ</span>;
        ISSN:<span class="NLM_cas:issn">1079-9907</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">Interferon-γ (IFN-γ)-induced indoleamine 2,3-dioxygenase (IDO) activity inhibits the growth of susceptible intracellular pathogens by catalyzing the oxidative cleavage of the indole ring of L-tryptophan and depleting pools of the essential amino acid.  Tumor necrosis factor-α (TNF-α) synergistically enhances the IDO activity induced by IFN-γ at the level of transcription in human epithelial cells.  The purpose here was to characterize the mol. mechanisms responsible for synergistic gene expression in response to IFN-γ and TNF α.  It was found that IFN-γ-induced mechanisms, such as the binding of Stat1 to gamma activation sequences (GAS) and IFN regulatory factor-1 (IRF-1) to IFN-stimulated response elements (ISREs), are more highly activated following treatment with IFN and TNF-α.  This enhanced signal transduction may be due to the increase in IFN-γ receptor (IFNGR) expression following combined cytokine stimulation and is a likely contributor to the synergy.  Addnl., the contribution of a third previously uncharacterized GAS element that forms a complex with Stat1 was investigated using a plasmid reporter system that controls for copy no.  When the GAS-3 sequence was included in the regulatory region, gene expression was increased relative to a region contg. the mutated GAS-3.  This suggests that GAS-3 is transcriptionally active and contributes to IFN-γ-induced regulation of the IDO gene.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJev_oK-00RLVg90H21EOLACvtfcHk0lgiPvtGR6E0Gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmvVOmsrg%253D&md5=cd0fc93db235c0938650bb96bdb1a00d</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1089%2F107999003322277829&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252F107999003322277829%26sid%3Dliteratum%253Aachs%26aulast%3DRobinson%26aufirst%3DC.%2BM.%26aulast%3DShirey%26aufirst%3DK.%2BA.%26aulast%3DCarlin%26aufirst%3DJ.%2BM.%26atitle%3DSynergistic%2520Transcriptional%2520Activation%2520Of%2520Indoleamine%2520Dioxygenase%2520By%2520IFN-%25CE%2593%2520And%2520Tumor%2520Necrosis%2520Factor-%25CE%2591%26jtitle%3DJ.%2520Interferon%2520Cytokine%2520Res.%26date%3D2003%26volume%3D23%26spage%3D413%26epage%3D421%26doi%3D10.1089%2F107999003322277829" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salahifar, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mashima, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stocker, R.</span></span> <span> </span><span class="NLM_article-title">Antioxidants Inhibit Indoleamine 2,3-Dioxygenase In IFN-Γ-Activated Human Macrophages: Posttranslational Regulation By Pyrrolidine Dithiocarbamate</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>166</i></span>,  <span class="NLM_fpage">6332</span>– <span class="NLM_lpage">6340</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.166.10.6332</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.4049%2Fjimmunol.166.10.6332" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=11342657" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjsFCqtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=166&publication_year=2001&pages=6332-6340&author=S.+R.+Thomasauthor=H.+Salahifarauthor=R.+Mashimaauthor=N.+H.+Huntauthor=D.+R.+Richardsonauthor=R.+Stocker&title=Antioxidants+Inhibit+Indoleamine+2%2C3-Dioxygenase+In+IFN-%CE%93-Activated+Human+Macrophages%3A+Posttranslational+Regulation+By+Pyrrolidine+Dithiocarbamate&doi=10.4049%2Fjimmunol.166.10.6332"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Antioxidants inhibit indoleamine 2,3-dioxygenase in IFN-γ-activated human macrophages: posttranslational regulation by pyrrolidine dithiocarbamate</span></div><div class="casAuthors">Thomas, Shane R.; Salahifar, Houta; Mashima, Ryuichi; Hunt, Nicholas H.; Richardson, Des R.; Stocker, Roland</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">166</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">6332-6340</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Induction of the heme-contg. indoleamine 2,3-dioxygenase (IDO) by IFN-γ is implicated in anti-microbial and pro-inflammatory activities of human macrophages.  Antioxidants can modulate the expression of immune and inflammatory genes, and pyrrolidine dithiocarbamate (PDTC) is a frequently used antioxidant to inhibit the transcription factor NF-κB.  Here the authors show that IFN-γ treatment of human monocyte-derived macrophages (hMDMs) increased the proportion of oxidized glutathione.  PDTC attenuated this increase and inhibited IDO activity, although it increased IDO protein expression and did not affect IDO mRNA expression and enzyme activity directly.  Other antioxidants, 2-ME, ebselen, and t-Bu hydroquinone, inhibited IDO protein expression.  Similar to PDTC, the heme biosynthesis inhibitor succinylacetone (SA) and the iron-chelator pyridoxal isonicotinoyl hydrazone inhibited cellular IDO activity without affecting protein expression, whereas addn. of hemin or the heme precursor δ-aminolevulinic acid increased IDO activity.  Also, incubation of IFN-γ-activated hMDM with δ-[14C]-aminolevulinic acid resulted in the incorporation of label into immunopptd. IDO, a process inhibited by PDTC and SA.  Furthermore, supplementation of lysates from PDTC- or SA-treated hMDM with hemin fully restored IDO activity to control levels, and hemin also reversed the inhibitory action of SA but not PDTC in intact cells.  Together these results establish a requirement for de novo heme synthesis for IDO activity in IFN-γ-activated hMDM.  They show that, similar to other pro-inflammatory proteins, the activity of IDO is modulated by antioxidants though in the case of PDTC this takes place posttranslationally, in part by limiting the availability of heme for the formation of holo-IDO.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorX-KrrnzpGbVg90H21EOLACvtfcHk0lgiPvtGR6E0Gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjsFCqtL4%253D&md5=5f56a998c930c1d0858d37a2635e7c5a</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.166.10.6332&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.166.10.6332%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DS.%2BR.%26aulast%3DSalahifar%26aufirst%3DH.%26aulast%3DMashima%26aufirst%3DR.%26aulast%3DHunt%26aufirst%3DN.%2BH.%26aulast%3DRichardson%26aufirst%3DD.%2BR.%26aulast%3DStocker%26aufirst%3DR.%26atitle%3DAntioxidants%2520Inhibit%2520Indoleamine%25202%252C3-Dioxygenase%2520In%2520IFN-%25CE%2593-Activated%2520Human%2520Macrophages%253A%2520Posttranslational%2520Regulation%2520By%2520Pyrrolidine%2520Dithiocarbamate%26jtitle%3DJ.%2520Immunol.%26date%3D2001%26volume%3D166%26spage%3D6332%26epage%3D6340%26doi%3D10.4049%2Fjimmunol.166.10.6332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Orabona, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallotta, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volpi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fallarino, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacca, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bianchi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belladonna, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fioretti, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grohmann, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puccetti, P.</span></span> <span> </span><span class="NLM_article-title">SOCS3 Drives Proteasomal Degradation Of Indoleamine 2,3-Dioxygenase (IDO) And Antagonizes IDO-Dependent Tolerogenesis</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">20828</span>– <span class="NLM_lpage">20833</span>, <span class="refDoi"> DOI: 10.1073/pnas.0810278105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1073%2Fpnas.0810278105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=19088199" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BD1MXksFSnsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=20828-20833&author=C.+Orabonaauthor=M.+T.+Pallottaauthor=C.+Volpiauthor=F.+Fallarinoauthor=C.+Vaccaauthor=R.+Bianchiauthor=M.+L.+Belladonnaauthor=M.+C.+Fiorettiauthor=U.+Grohmannauthor=P.+Puccetti&title=SOCS3+Drives+Proteasomal+Degradation+Of+Indoleamine+2%2C3-Dioxygenase+%28IDO%29+And+Antagonizes+IDO-Dependent+Tolerogenesis&doi=10.1073%2Fpnas.0810278105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">SOCS3 drives proteasomal degradation of indoleamine 2,3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis</span></div><div class="casAuthors">Orabona, Ciriana; Pallotta, Maria T.; Volpi, Claudia; Fallarino, Francesca; Vacca, Carmine; Bianchi, Roberta; Belladonna, Maria L.; Fioretti, Maria C.; Grohmann, Ursula; Puccetti, Paolo</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">52</span>),
    <span class="NLM_cas:pages">20828-20833</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Despite their common ability to activate intracellular signaling through CD80/CD86 mols., cytotoxic T lymphocyte antigen 4 (CTLA-4)-Ig and CD28-Ig bias the downstream response in opposite directions, the latter promoting immunity, and CTLA-4-Ig tolerance, in dendritic cells (DCs) with opposite but flexible programs of antigen presentation.  Nevertheless, in the absence of suppressor of cytokine signaling 3 (SOCS3), CD28-Ig - and the assocd., dominant IL-6 response-become immunosuppressive and mimic the effect of CTLA-4-Ig, including a high functional expression of the tolerogenic enzyme indoleamine 2,3-dioxygenase (IDO).  Here we show that forced SOCS3 expression antagonized CTLA-4-Ig activity in a proteasome-dependent fashion.  Unrecognized by previous studies, IDO appeared to possess two tyrosine residues within two distinct putative immunoreceptor tyrosine-based inhibitory motifs, VPY115CEL and LLY253EGV.  We found that SOCS3 - known to interact with phosphotyrosine-contg. peptides and be selectively induced by CD28-Ig/IL-6 - would bind IDO and target the IDO/SOCS3 complex for ubiquitination and subsequent proteasomal degrdn.  This event accounted for the ability of CD28-Ig and IL-6 to convert otherwise tolerogenic, IDO-competent DCs into immunogenic cells.  Thus onset of immunity in response to antigen within an early inflammatory context requires that IDO be degraded in tolerogenic DCs.  In addn. to identifying SOCS3 as a candidate signature for mouse DC subsets programmed to direct immunity, this study demonstrates that IDO undergoes regulatory proteolysis in response to immunogenic stimuli.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX7Y39qFDWH7Vg90H21EOLACvtfcHk0ljlOb3mGiG1cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXksFSnsw%253D%253D&md5=31aa780e675a4e11490f79a329ca2e01</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0810278105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0810278105%26sid%3Dliteratum%253Aachs%26aulast%3DOrabona%26aufirst%3DC.%26aulast%3DPallotta%26aufirst%3DM.%2BT.%26aulast%3DVolpi%26aufirst%3DC.%26aulast%3DFallarino%26aufirst%3DF.%26aulast%3DVacca%26aufirst%3DC.%26aulast%3DBianchi%26aufirst%3DR.%26aulast%3DBelladonna%26aufirst%3DM.%2BL.%26aulast%3DFioretti%26aufirst%3DM.%2BC.%26aulast%3DGrohmann%26aufirst%3DU.%26aulast%3DPuccetti%26aufirst%3DP.%26atitle%3DSOCS3%2520Drives%2520Proteasomal%2520Degradation%2520Of%2520Indoleamine%25202%252C3-Dioxygenase%2520%2528IDO%2529%2520And%2520Antagonizes%2520IDO-Dependent%2520Tolerogenesis%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2008%26volume%3D105%26spage%3D20828%26epage%3D20833%26doi%3D10.1073%2Fpnas.0810278105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poncelet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ait-Belkacem, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marillier, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomes, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stauber, J.</span></span> <span> </span><span class="NLM_article-title">Target Exposure and Pharmacodynamics Study Of The Indoleamine 2,3-Dioxygenase-1 (IDO-1) Inhibitor Epacadostat In The CT26 Mouse Tumor Model</span>. <i>J. Pharm. Biomed. Anal.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>170</i></span>,  <span class="NLM_fpage">220</span>– <span class="NLM_lpage">227</span>, <span class="refDoi"> DOI: 10.1016/j.jpba.2019.02.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1016%2Fj.jpba.2019.02.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=30933897" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmtlyhsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=170&publication_year=2019&pages=220-227&author=L.+Ponceletauthor=R.+Ait-Belkacemauthor=R.+Marillierauthor=B.+Gomesauthor=J.+Stauber&title=Target+Exposure+and+Pharmacodynamics+Study+Of+The+Indoleamine+2%2C3-Dioxygenase-1+%28IDO-1%29+Inhibitor+Epacadostat+In+The+CT26+Mouse+Tumor+Model&doi=10.1016%2Fj.jpba.2019.02.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Target exposure and pharmacodynamics study of the indoleamine 2,3-dioxygenase-1 (IDO-1) inhibitor epacadostat in the CT26 mouse tumor model</span></div><div class="casAuthors">Poncelet, Lauranne; Ait-Belkacem, Rima; Marillier, Reece; Gomes, Bruno; Stauber, Jonathan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical and Biomedical Analysis</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">170</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">220-227</span>CODEN:
                <span class="NLM_cas:coden">JPBADA</span>;
        ISSN:<span class="NLM_cas:issn">0731-7085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Indoleamine-2,3-dioxygenase (IDO1) is an enzyme which converts tryptophan (Trp) into kynurenine (Kyn).  Having a crit. role in tumor immune escape by decreasing Trp and increasing Kyn levels in the microenvironment, IDO1 was one of the first targets for small mols. drug discovery in the field of immuno-oncol.  A potent and selective IDO1 inhibitor such as Epacadostat (EPA) was shown to enhance the antitumor activity by restoring the immune system fitness.  As exposure at the site of action and to its specific target are identified as the most important factors for success in drug discovery, the objective of this study was to explore the target exposure and intra-tumor pharmacodynamics effects of EPA drug on the tumor metab.  To do so, we used both Quant. Mass Spectrometry Imaging (QMSI) and liq. chromatog. coupled with tandem mass spectrometry (LC-MS/MS) technologies in order to monitor drug and metabolites distribution and their endogenous quantity in the CT26 mouse tumor model.  Target exposure anal. showed that almost 61% of EPA signal (26 μg/g) was concd. within 38% of the entire tumor surface.  Semi quant. anal. of this region confirmed a pos. correlation between IDO1 expression and EPA concn.  In parallel, pharmacodynamics anal. highlighted a response efficacy through Kyn/Trp ratio calcn. that was shown decreasing after EPA treatment as noticed in treated CT26 tumors (-82%), plasma (-63%) and blood (-62%) compared to control samples.  Finally, 15% and 85% of Kyn signal was found in regions with high and low EPA, resp.  In this study, using QMSI, we went further than only quantifying the metabolites and the drug, by estg. the pharmacol. effect efficacy of the drug through a target exposure study handled in different regions of the tumor either expressing IDO1 or Kyn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYWZJdqzRfj7Vg90H21EOLACvtfcHk0ljlOb3mGiG1cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmtlyhsbk%253D&md5=3187f470111997d1761f259628694c00</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2Fj.jpba.2019.02.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jpba.2019.02.038%26sid%3Dliteratum%253Aachs%26aulast%3DPoncelet%26aufirst%3DL.%26aulast%3DAit-Belkacem%26aufirst%3DR.%26aulast%3DMarillier%26aufirst%3DR.%26aulast%3DGomes%26aufirst%3DB.%26aulast%3DStauber%26aufirst%3DJ.%26atitle%3DTarget%2520Exposure%2520and%2520Pharmacodynamics%2520Study%2520Of%2520The%2520Indoleamine%25202%252C3-Dioxygenase-1%2520%2528IDO-1%2529%2520Inhibitor%2520Epacadostat%2520In%2520The%2520CT26%2520Mouse%2520Tumor%2520Model%26jtitle%3DJ.%2520Pharm.%2520Biomed.%2520Anal.%26date%3D2019%26volume%3D170%26spage%3D220%26epage%3D227%26doi%3D10.1016%2Fj.jpba.2019.02.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, E.</span></span> <span> </span><span class="NLM_article-title">Subcutaneous Inoculation Position Affects The Immune Environment In CT26 Carcinomas</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>512</i></span>,  <span class="NLM_fpage">244</span>– <span class="NLM_lpage">249</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2019.03.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1016%2Fj.bbrc.2019.03.042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=30879760" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BC1MXltVSgt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=512&publication_year=2019&pages=244-249&author=X.+Fuauthor=Y.+Yangauthor=J.+Xieauthor=X.+Panauthor=X.+Yangauthor=Z.+Duauthor=E.+Hao&title=Subcutaneous+Inoculation+Position+Affects+The+Immune+Environment+In+CT26+Carcinomas&doi=10.1016%2Fj.bbrc.2019.03.042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Subcutaneous inoculation position affects the immune environment in CT26 carcinomas</span></div><div class="casAuthors">Fu, Xiaocong; Yang, Yeguo; Xie, Jinling; Pan, Xianglong; Yang, Xue; Du, Zhengcai; Hao, Erwei</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">512</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">244-249</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Comprehensive knowledge on the murine CT26 colon carcinoma line is a classic model used in the pharmacodynamic expts. involving IDO-1 inhibitors, immune-related checkpoint antibodies and immune related mechanisms.  In this study, we detd. the impact of different s.c. inoculation locations on tumor growth and immune factor expression.  CT26 cells were treated with the IDO-1 inhibitor, INCB024360, following INF-γ stimulation and analyzed for kynurenine concn.  Female Balb/c mice were inoculated with CT26 cells in either or both the right upper flank or the right lower flank.  Isolated tumors were evaluated for changes in tumor vol. following treatment with anti-PD-1, anti-CTLA-4, or no treatment.  Isolated tumors were also evaluated for changes in immune cell subpopulations and expression of key immune factors using FACS.  Treatment of two CT26 cell lines with INCB024360 produced similar results.  IC50 values were 222.5 and 276.0, and the peak inhibitory rates were 97.99% and 91.85% resp.  Anal. of tumor growth revealed that tumor vols. were larger (1925 mm3 vs. 767 mm3), and the anti-tumor effects of both anti-PD-1 and anti-CTLA-4 were different in mice inoculated in the right lower flank than in those inoculated in the upper flank.  FACS anal. revealed that the CD8+T subpopulation in the right upper flank was higher than that in the lower flank (*P < 0.05).  By contrast, the myeloid cell populations was lower in the right upper flank than it was in the right lower flank (*P < 0.05).  The INF-γ populations in CD8+T (*P < 0.05) and regulatory T (Treg) cell subpopulation (*P < 0.05) were also more abundant in the right upper flank than in the right lower flank.  In contrast to the uniform of the results from the in vitro expt., the anti-CTLA-4 and anti-PD-1 antibodies had different efficacies depending on the location of the s.c. inoculation of CT26 in mice.  The differences in the percentages of CD8+T, myeloid cells, INF-γ in CD8+T, and Treg subpopulations indicated that the tumor microenvironment was affected by inoculation position.  Taken together, these results suggest that tumors isolated from same cell line with different inoculation positions are different enough to be considered different models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq44q9XBHhcprVg90H21EOLACvtfcHk0ljlOb3mGiG1cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXltVSgt74%253D&md5=ce5877da2f6ef22b54e6139c771b358d</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2019.03.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2019.03.042%26sid%3Dliteratum%253Aachs%26aulast%3DFu%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DPan%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DDu%26aufirst%3DZ.%26aulast%3DHao%26aufirst%3DE.%26atitle%3DSubcutaneous%2520Inoculation%2520Position%2520Affects%2520The%2520Immune%2520Environment%2520In%2520CT26%2520Carcinomas%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2019%26volume%3D512%26spage%3D244%26epage%3D249%26doi%3D10.1016%2Fj.bbrc.2019.03.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tuntland, T.</span>; <span class="NLM_string-name">Ethell, B.</span>; <span class="NLM_string-name">Kosaka, T.</span>; <span class="NLM_string-name">Blasco, F.</span>; <span class="NLM_string-name">Zang, R. X.</span>; <span class="NLM_string-name">Jain, M.</span>; <span class="NLM_string-name">Gould, T.</span>; <span class="NLM_string-name">Hoffmaster, K.</span></span> <span> </span><span class="NLM_article-title">Implementation Of Pharmacokinetic And Pharmacodynamic Strategies In Early Research Phases Of Drug Discovery And Development At Novartis Institute Of Biomedical Research</span>.  <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume">5</span>.174 <span class="refDoi"> DOI: 10.3389/fphar.2014.00174</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.3389%2Ffphar.2014.00174" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=25120485" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&author=T.+Tuntland&author=B.+Ethell&author=T.+Kosaka&author=F.+Blasco&author=R.+X.+Zang&author=M.+Jain&author=T.+Gould&author=K.+Hoffmaster&title=Implementation+Of+Pharmacokinetic+And+Pharmacodynamic+Strategies+In+Early+Research+Phases+Of+Drug+Discovery+And+Development+At+Novartis+Institute+Of+Biomedical+Research&doi=10.3389%2Ffphar.2014.00174"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2014.00174&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2014.00174%26sid%3Dliteratum%253Aachs%26aulast%3DTuntland%26aufirst%3DT.%26atitle%3DImplementation%2520Of%2520Pharmacokinetic%2520And%2520Pharmacodynamic%2520Strategies%2520In%2520Early%2520Research%2520Phases%2520Of%2520Drug%2520Discovery%2520And%2520Development%2520At%2520Novartis%2520Institute%2520Of%2520Biomedical%2520Research%26jtitle%3DFront.%2520Pharmacol.%26date%3D2014%26volume%3D5%26doi%3D10.3389%2Ffphar.2014.00174" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jamieson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moir, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wishart, G.</span></span> <span> </span><span class="NLM_article-title">Medicinal Chemistry Of Herg Optimizations: Highlights And Hang-Ups</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">5029</span>– <span class="NLM_lpage">5046</span>, <span class="refDoi"> DOI: 10.1021/jm060379l</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060379l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BD28Xns1WqsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=5029-5046&author=C.+Jamiesonauthor=E.+M.+Moirauthor=Z.+Rankovicauthor=G.+Wishart&title=Medicinal+Chemistry+Of+Herg+Optimizations%3A+Highlights+And+Hang-Ups&doi=10.1021%2Fjm060379l"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Medicinal chemistry of hERG optimizations: Highlights and hang-ups</span></div><div class="casAuthors">Jamieson, Craig; Moir, Elizabeth M.; Rankovic, Zoran; Wishart, Grant</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5029-5046</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  A brief summary of the in silico, in vitro, and in vivo approaches employed to measure blockade of hERG and QT prolongation is detailed.  The discussion aims to summarize the approaches engaged to circumvent activity at hERG, identified through an extensive literature survey.  The optimizations are recorded as pairs of compds., which have been categorized in terms of the tactics employed to diminish hERG activity. Examn. of the properties of the compds. within each category has enabled formulation os some empirical guidelines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqv6eM5w53KebVg90H21EOLACvtfcHk0ljji-ylbT6VxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xns1WqsL8%253D&md5=117c84a010f877c835b7dbc945996b92</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1021%2Fjm060379l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060379l%26sid%3Dliteratum%253Aachs%26aulast%3DJamieson%26aufirst%3DC.%26aulast%3DMoir%26aufirst%3DE.%2BM.%26aulast%3DRankovic%26aufirst%3DZ.%26aulast%3DWishart%26aufirst%3DG.%26atitle%3DMedicinal%2520Chemistry%2520Of%2520Herg%2520Optimizations%253A%2520Highlights%2520And%2520Hang-Ups%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D5029%26epage%3D5046%26doi%3D10.1021%2Fjm060379l" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Redfern, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlsson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackenzie, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palethorpe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegl, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strang, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallis, R.</span></span> <span> </span><span class="NLM_article-title">Relationships Between Preclinical Cardiac Electrophysiology, Clinical QT Interval Prolongation And Torsade De Pointes For A Broad Range Of Drugs: Evidence For A Provisional Safety Margin In Drug Development</span>. <i>Cardiovasc. Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">45</span>, <span class="refDoi"> DOI: 10.1016/s0008-6363(02)00846-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1016%2FS0008-6363%2802%2900846-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=12667944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BD3sXit12gsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2003&pages=32-45&author=W.+Redfernauthor=L.+Carlssonauthor=A.+Davisauthor=W.+Lynchauthor=I.+Mackenzieauthor=S.+Palethorpeauthor=P.+Sieglauthor=I.+Strangauthor=A.+Sullivanauthor=R.+Wallis&title=Relationships+Between+Preclinical+Cardiac+Electrophysiology%2C+Clinical+QT+Interval+Prolongation+And+Torsade+De+Pointes+For+A+Broad+Range+Of+Drugs%3A+Evidence+For+A+Provisional+Safety+Margin+In+Drug+Development&doi=10.1016%2Fs0008-6363%2802%2900846-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development</span></div><div class="casAuthors">Redfern, W. S.; Carlsson, L.; Davis, A. S.; Lynch, W. G.; MacKenzie, I.; Palethorpe, S.; Siegl, P. K. S.; Strang, I.; Sullivan, A. T.; Wallis, R.; Camm, A. J.; Hammond, T. G.</div><div class="citationInfo"><span class="NLM_cas:title">Cardiovascular Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32-45</span>CODEN:
                <span class="NLM_cas:coden">CVREAU</span>;
        ISSN:<span class="NLM_cas:issn">0008-6363</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review discussing attempts to det. the relative value of preclin. cardiac electrophysiol. data (in vitro and in vivo) for predicting risk of torsades de pointes (TdP) in clin. use.  Published data on human ether-a-go-go-related gene-encoded voltage-dependent potassium channel (hERG) (or IKr) activity, cardiac action potential duration (at 90% repolarization; APD90), and QT prolongation in dogs were compared against QT effects and reports of TdP in humans for 100 drugs.  These data were set against the free plasma concns. attained during clin. use (effective therapeutic plasma concns.; ETPCunbound).  The drugs were divided into five categories: (1) Class Ia and III antiarrhythmics; (2) withdrawn from market due to TdP; (3) measurable incidence/numerous reports of TdP in humans; (4) isolated reports of TdP in humans; (5) no reports of TdP in humans.  Data from hERG (or IKr) assays in addn. to ETPCunbound data were available for 52 drugs.  For Category 1 drugs, data for hERG/IKr IC50, APD90, QTc in animals and QTc in humans were generally close to or superimposed on the ETPCunbound values.  This relationship was uncoupled in the other categories, with more complex relationships between the data.  In Category 1 (except amiodarone), the ratios between hERG/IKr IC50 and ETPCunbound (max) ranged 0.1-31-fold.  Similar ranges were obtained for drugs in Category 2 (0.31-13-fold) and Category 3 (0.03-35-fold).  A large spread was found for Category 4 drugs (0.13-35,700-fold); this category embraced an assortment of mechanisms ranging from drugs which may well be affecting IKr currents in clin. use (e.g., sparfloxacin) to others such as nifedipine (35,700-fold) where channel block is not involved.  Finally, for the majority of Category 5 drugs there was a >30-fold sepn. between hERG/IKr activity and ETPCunbound values, with the notable exception of verapamil (1.7-fold), which is free from QT prolongation in man; this is probably explained by its multiple interactions with cardiac ion channels.  The dataset confirms the widely held belief that most drugs assocd. with TdP in humans are also assocd. with hERG K+ channel block at concns. close to or superimposed upon the free plasma concns. found in clin. use.  A 30-fold margin between Cmax and hERG IC50 may suffice for drugs currently undergoing clin. evaluation, but for future drug discovery programs, pharmaceutical companies should consider increasing this margin, particularly for drugs aimed at nondebilitating diseases.  However, interactions with multiple cardiac ion channels can either mitigate or exacerbate the prolongation of APD and QT that would ensue from block of IKr currents alone, and delay of repolarization per se is not necessarily torsadogenic.  Clearly, an integrated assessment of in vitro and in vivo data is required in order to predict the torsadogenic risk of a new candidate drug in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkpRDUH0rhyrVg90H21EOLACvtfcHk0ljji-ylbT6VxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXit12gsb8%253D&md5=a236c07febd2e05fe70e61604619bf2e</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2FS0008-6363%2802%2900846-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0008-6363%252802%252900846-5%26sid%3Dliteratum%253Aachs%26aulast%3DRedfern%26aufirst%3DW.%26aulast%3DCarlsson%26aufirst%3DL.%26aulast%3DDavis%26aufirst%3DA.%26aulast%3DLynch%26aufirst%3DW.%26aulast%3DMackenzie%26aufirst%3DI.%26aulast%3DPalethorpe%26aufirst%3DS.%26aulast%3DSiegl%26aufirst%3DP.%26aulast%3DStrang%26aufirst%3DI.%26aulast%3DSullivan%26aufirst%3DA.%26aulast%3DWallis%26aufirst%3DR.%26atitle%3DRelationships%2520Between%2520Preclinical%2520Cardiac%2520Electrophysiology%252C%2520Clinical%2520QT%2520Interval%2520Prolongation%2520And%2520Torsade%2520De%2520Pointes%2520For%2520A%2520Broad%2520Range%2520Of%2520Drugs%253A%2520Evidence%2520For%2520A%2520Provisional%2520Safety%2520Margin%2520In%2520Drug%2520Development%26jtitle%3DCardiovasc.%2520Res.%26date%3D2003%26volume%3D58%26spage%3D32%26epage%3D45%26doi%3D10.1016%2Fs0008-6363%2802%2900846-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selvaggio, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearlstein, R. A.</span></span> <span> </span><span class="NLM_article-title">Toward In Vivo-Relevant Herg Safety Assessment And Mitigation Strategies Based On Relationships Between Non-Equilibrium Blocker Binding, Three-Dimensional Channel-Blocker Interactions, Dynamic Occupancy, Dynamic Exposure, And Cellular Arrhythmia</span>. <i>PloS One</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>15</i></span>, <span class="NLM_elocation-id">e0234946</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0234946</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1371%2Fjournal.pone.0234946" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=33147278" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitlWisb3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2020&author=H.+Wanauthor=G.+Selvaggioauthor=R.+A.+Pearlstein&title=Toward+In+Vivo-Relevant+Herg+Safety+Assessment+And+Mitigation+Strategies+Based+On+Relationships+Between+Non-Equilibrium+Blocker+Binding%2C+Three-Dimensional+Channel-Blocker+Interactions%2C+Dynamic+Occupancy%2C+Dynamic+Exposure%2C+And+Cellular+Arrhythmia&doi=10.1371%2Fjournal.pone.0234946"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Toward in vivo-relevant hERG safety assessment and mitigation strategies based on relationships between non-equilibrium blocker binding, three-dimensional channel-blocker interactions, dynamic occupancy, dynamic exposure, and cellular arrhythmia</span></div><div class="casAuthors">Wan, Hongbin; Selvaggio, Gianluca; Pearlstein, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">e0234946</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">We propose a two-step blocker binding process consisting of: The initial capture step: diffusion of a single fully solvated blocker copy into a large cavity lined by the intra-cellular cyclic nucleotide binding homol. domain (CNBHD).  Occupation of this cavity is necessary but insufficient condition for ion current disruption.  The IKr disruption step: translocation of the captured blocker along channel axis, such that: head group, consisting of quasi-rod-shaped moiety, projects into open pore, accompanied by partial de-solvation of binding interface.  One tail moiety packs along kink between S6 helix and proximal C-linker helix adjacent to intra-cellular entrance of pore, likewise accompanied by mutual de-solvation of binding interface.  Blockers contg. highly planar moiety that projects into a putative constriction zone within the closed channel become trapped upon closing, as do blockers terminating prior to this region.  A single captured blocker copy may conceivably assoc. and dissoc. to/from the pore many times before exiting the CNBHD cavity.  The predicted arrhythmogenic fractional hERG occupancy (based on action potential (AP) simulations of the undiseased human ventricular cardiomyocyte).  Risk of exposure escalation toward the predicted arrhythmic limit due to patient-to-patient pharmacokinetic (PK) variability, drug-drug interactions, overdose, and use for off-label indications in which the hERG safety parameters may differ from their on-label counterparts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp08X5mSqeNQrVg90H21EOLACvtfcHk0ljbvVfEmNt9QQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitlWisb3J&md5=0e15f6b5cf1751443b27773a679b5e47</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0234946&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0234946%26sid%3Dliteratum%253Aachs%26aulast%3DWan%26aufirst%3DH.%26aulast%3DSelvaggio%26aufirst%3DG.%26aulast%3DPearlstein%26aufirst%3DR.%2BA.%26atitle%3DToward%2520In%2520Vivo-Relevant%2520Herg%2520Safety%2520Assessment%2520And%2520Mitigation%2520Strategies%2520Based%2520On%2520Relationships%2520Between%2520Non-Equilibrium%2520Blocker%2520Binding%252C%2520Three-Dimensional%2520Channel-Blocker%2520Interactions%252C%2520Dynamic%2520Occupancy%252C%2520Dynamic%2520Exposure%252C%2520And%2520Cellular%2520Arrhythmia%26jtitle%3DPloS%2520One%26date%3D2020%26volume%3D15%26doi%3D10.1371%2Fjournal.pone.0234946" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kongsamut, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roehr, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rampe, D.</span></span> <span> </span><span class="NLM_article-title">A Comparison Of The Receptor Binding And HERG Channel Affinities For A Series Of Antipsychotic Drugs</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>450</i></span>,  <span class="NLM_fpage">37</span>– <span class="NLM_lpage">41</span>, <span class="refDoi"> DOI: 10.1016/s0014-2999(02)02074-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1016%2FS0014-2999%2802%2902074-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=12176106" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BD38XmtlKjsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=450&publication_year=2002&pages=37-41&author=S.+Kongsamutauthor=J.+Kangauthor=X.-L.+Chenauthor=J.+Roehrauthor=D.+Rampe&title=A+Comparison+Of+The+Receptor+Binding+And+HERG+Channel+Affinities+For+A+Series+Of+Antipsychotic+Drugs&doi=10.1016%2Fs0014-2999%2802%2902074-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs</span></div><div class="casAuthors">Kongsamut, Sathapana; Kang, Jiesheng; Chen, Xiao-Liang; Roehr, Joachim; Rampe, David</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">450</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">37-41</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">Many antipsychotic drugs produce QT interval prolongation on the ECG.  Blockade of the human cardiac K+ channel known as human ether-a-go-go-related gene (HERG) often underlies such clin. findings.  In fact, HERG channel inhibition is now commonly used as a screen to predict the ability of a drug to prolong QT interval.  However, the exact relation between HERG channel blockade, target receptor binding affinity and clin. QT prolongation is not known.  Using patch-clamp electrophysiol., the authors examd. a series of seven antipsychotic drugs for their ability to block HERG, and detd. their IC50 values.  The authors then compared these results to their binding affinities (Ki values) for the dopamine D2 receptor, the 5-HT2A receptor and, where available, to clin. QT prolongation data.  The authors found that sertindole, pimozide and thioridazine displayed little (<10-fold) or no selectivity for dopamine D2 or 5-HT2A receptors relative to their HERG channel affinities.  This lack of selectivity likely underlies the significant QT interval prolongation obsd. with administration of these drugs.  Of the other drugs tested (ziprasidone, quetiapine, risperidone and olanzapine), olanzapine displayed the greatest selectivity for dopamine D2 and 5-HT2A receptor binding (100-1000-fold) compared to its HERG channel IC50.  The authors also compared these HERG channel IC50 values to QT interval prolongation and plasma drug levels obtained in a recent clin. study.  The authors found that the ratio of total plasma drug concn. to HERG IC50 value was indicative of the degree of QT prolongation obsd.  Target receptor affinity and expected clin. plasma levels are important parameters to consider for the interpretation of HERG channel data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1PPyFCa8xyrVg90H21EOLACvtfcHk0ljbvVfEmNt9QQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmtlKjsbo%253D&md5=8b5879e5d59e01dcd490e71d57844fdf</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2FS0014-2999%2802%2902074-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-2999%252802%252902074-5%26sid%3Dliteratum%253Aachs%26aulast%3DKongsamut%26aufirst%3DS.%26aulast%3DKang%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DX.-L.%26aulast%3DRoehr%26aufirst%3DJ.%26aulast%3DRampe%26aufirst%3DD.%26atitle%3DA%2520Comparison%2520Of%2520The%2520Receptor%2520Binding%2520And%2520HERG%2520Channel%2520Affinities%2520For%2520A%2520Series%2520Of%2520Antipsychotic%2520Drugs%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2002%26volume%3D450%26spage%3D37%26epage%3D41%26doi%3D10.1016%2Fs0014-2999%2802%2902074-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shahripour, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jesus, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teumelsan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Priest, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swensen, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alonso-Galicia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felix, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brochu, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas-Fowlkes, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pai, L.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hampton, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehrhart, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaczorowski, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasternak, A.</span></span> <span> </span><span class="NLM_article-title">Differentiation Of ROMK Potency From Herg Potency In The Phenacetyl Piperazine Series Through Heterocycle Incorporation</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">2339</span>– <span class="NLM_lpage">2343</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.03.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1016%2Fj.bmcl.2016.03.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=27017115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BC28XkvVCms7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=2339-2343&author=S.+P.+Walshauthor=A.+Shahripourauthor=H.+Tangauthor=R.+K.+de+Jesusauthor=N.+Teumelsanauthor=Y.+Zhuauthor=J.+Frieauthor=B.+T.+Priestauthor=A.+M.+Swensenauthor=M.+Alonso-Galiciaauthor=J.+P.+Felixauthor=R.+M.+Brochuauthor=T.+Baileyauthor=B.+Thomas-Fowlkesauthor=X.+Zhouauthor=L.-Y.+Paiauthor=C.+Hamptonauthor=M.+Hernandezauthor=K.+Owensauthor=J.+Ehrhartauthor=S.+Royauthor=G.+J.+Kaczorowskiauthor=L.+Yangauthor=M.+L.+Garciaauthor=A.+Pasternak&title=Differentiation+Of+ROMK+Potency+From+Herg+Potency+In+The+Phenacetyl+Piperazine+Series+Through+Heterocycle+Incorporation&doi=10.1016%2Fj.bmcl.2016.03.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Differentiation of ROMK potency from hERG potency in the phenacetyl piperazine series through heterocycle incorporation</span></div><div class="casAuthors">Walsh, Shawn P.; Shahripour, Aurash; Tang, Haifeng; de Jesus, Reynalda K.; Teumelsan, Nardos; Zhu, Yuping; Frie, Jessica; Priest, Birgit T.; Swensen, Andrew M.; Alonso-Galicia, Magdalena; Felix, John P.; Brochu, Richard M.; Bailey, Timothy; Thomas-Fowlkes, Brande; Zhou, Xiaoyan; Pai, Lee-Yuh; Hampton, Caryn; Hernandez, Melba; Owens, Karen; Ehrhart, Juliann; Roy, Sophie; Kaczorowski, Gregory J.; Yang, Lihu; Garcia, Maria L.; Pasternak, Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2339-2343</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Following the discovery of small mol. acyl piperazine ROMK inhibitors and their initial preclin. validation as a novel diuretic agent, the authors' group set out to discover new ROMK inhibitors with reduced risk for QT effects, suitable for further pharmacol. expts. in addnl. species.  Several strategies for decreasing hERG affinity while maintaining ROMK inhibition were investigated and are described herein.  The most promising candidate, derived from the newly discovered 4-N-heteroaryl acetyl series, improved functional hERG/ROMK ratio by >10× over the previous lead.  In vivo evaluation demonstrated comparable diuretic effects in rat with no detectable QT effects at the doses evaluated in an in vivo dog model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLmiCSrRXlP7Vg90H21EOLACvtfcHk0ljbvVfEmNt9QQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XkvVCms7c%253D&md5=e38c26bd27012f90c551c56469ef86db</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.03.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.03.035%26sid%3Dliteratum%253Aachs%26aulast%3DWalsh%26aufirst%3DS.%2BP.%26aulast%3DShahripour%26aufirst%3DA.%26aulast%3DTang%26aufirst%3DH.%26aulast%3Dde%2BJesus%26aufirst%3DR.%2BK.%26aulast%3DTeumelsan%26aufirst%3DN.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DFrie%26aufirst%3DJ.%26aulast%3DPriest%26aufirst%3DB.%2BT.%26aulast%3DSwensen%26aufirst%3DA.%2BM.%26aulast%3DAlonso-Galicia%26aufirst%3DM.%26aulast%3DFelix%26aufirst%3DJ.%2BP.%26aulast%3DBrochu%26aufirst%3DR.%2BM.%26aulast%3DBailey%26aufirst%3DT.%26aulast%3DThomas-Fowlkes%26aufirst%3DB.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DPai%26aufirst%3DL.-Y.%26aulast%3DHampton%26aufirst%3DC.%26aulast%3DHernandez%26aufirst%3DM.%26aulast%3DOwens%26aufirst%3DK.%26aulast%3DEhrhart%26aufirst%3DJ.%26aulast%3DRoy%26aufirst%3DS.%26aulast%3DKaczorowski%26aufirst%3DG.%2BJ.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DGarcia%26aufirst%3DM.%2BL.%26aulast%3DPasternak%26aufirst%3DA.%26atitle%3DDifferentiation%2520Of%2520ROMK%2520Potency%2520From%2520Herg%2520Potency%2520In%2520The%2520Phenacetyl%2520Piperazine%2520Series%2520Through%2520Heterocycle%2520Incorporation%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D2339%26epage%3D2343%26doi%3D10.1016%2Fj.bmcl.2016.03.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, J.</span></span> <span> </span><span class="NLM_article-title">Pre-Clinical Murine Models: Syngeneic Models For Immuno-Oncology</span>.  <i>MOJ Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume">2</span>()00052 .<span class="refDoi"> DOI: 10.15406/moji.2015.02.00052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.15406%2Fmoji.2015.02.00052" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2015&author=J.+Murphy&title=Pre-Clinical+Murine+Models%3A+Syngeneic+Models+For+Immuno-Oncology&doi=10.15406%2Fmoji.2015.02.00052"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.15406%2Fmoji.2015.02.00052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.15406%252Fmoji.2015.02.00052%26sid%3Dliteratum%253Aachs%26aulast%3DMurphy%26aufirst%3DJ.%26atitle%3DPre-Clinical%2520Murine%2520Models%253A%2520Syngeneic%2520Models%2520For%2520Immuno-Oncology%26jtitle%3DMOJ%2520Immunol.%26date%3D2015%26volume%3D2%26doi%3D10.15406%2Fmoji.2015.02.00052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saito, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashima, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, O.</span></span> <span> </span><span class="NLM_article-title">Faithful Preclinical Mouse Models For Better Translation To Bedside In The Field Of Immuno-Oncology</span>. <i>Int. J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">831</span>– <span class="NLM_lpage">841</span>, <span class="refDoi"> DOI: 10.1007/s10147-019-01520-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1007%2Fs10147-019-01520-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=31407168" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2019&pages=831-841&author=R.+Saitoauthor=T.+Kobayashiauthor=S.+Kashimaauthor=K.+Matsumotoauthor=O.+Ogawa&title=Faithful+Preclinical+Mouse+Models+For+Better+Translation+To+Bedside+In+The+Field+Of+Immuno-Oncology&doi=10.1007%2Fs10147-019-01520-z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1007%2Fs10147-019-01520-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10147-019-01520-z%26sid%3Dliteratum%253Aachs%26aulast%3DSaito%26aufirst%3DR.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DKashima%26aufirst%3DS.%26aulast%3DMatsumoto%26aufirst%3DK.%26aulast%3DOgawa%26aufirst%3DO.%26atitle%3DFaithful%2520Preclinical%2520Mouse%2520Models%2520For%2520Better%2520Translation%2520To%2520Bedside%2520In%2520The%2520Field%2520Of%2520Immuno-Oncology%26jtitle%3DInt.%2520J.%2520Clin.%2520Oncol.%26date%3D2019%26volume%3D25%26spage%3D831%26epage%3D841%26doi%3D10.1007%2Fs10147-019-01520-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, R.</span>; <span class="NLM_string-name">Hamilton, M.</span>; <span class="NLM_string-name">Jones, P.</span>; <span class="NLM_string-name">Petrocchi, A.</span>; <span class="NLM_string-name">Reyna, N.</span>; <span class="NLM_string-name">McAfoos, T.</span>; <span class="NLM_string-name">Cross, J.</span>; <span class="NLM_string-name">Soth, M.</span></span> <span> </span><span class="NLM_article-title">Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase</span>. <span class="NLM_patent">WO 2020018670 A1</span>, Janurary 23, <span class="NLM_year">2020</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=R.+Lewis&author=M.+Hamilton&author=P.+Jones&author=A.+Petrocchi&author=N.+Reyna&author=T.+McAfoos&author=J.+Cross&author=M.+Soth&title=Compounds+useful+as+inhibitors+of+indoleamine+2%2C3-dioxygenase+and%2For+tryptophan+dioxygenase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLewis%26aufirst%3DR.%26atitle%3DCompounds%2520useful%2520as%2520inhibitors%2520of%2520indoleamine%25202%252C3-dioxygenase%2520and%252For%2520tryptophan%2520dioxygenase%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sonpavde, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Necchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinberg, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gschwend, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Der Heijden, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garzon, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raybold, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liaw, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutstein, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galsky, M. D.</span></span> <span> </span><span class="NLM_article-title">ENERGIZE: A Phase III Study Of Neoadjuvant Chemotherapy Alone Or With Nivolumab With/Without Linrodostat Mesylate For Muscle-Invasive Bladder Cancer</span>. <i>Future Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">4359</span>– <span class="NLM_lpage">4368</span>, <span class="refDoi"> DOI: 10.2217/fon-2019-0611</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.2217%2Ffon-2019-0611" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=31823654" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVSntr3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2020&pages=4359-4368&author=G.+Sonpavdeauthor=A.+Necchiauthor=S.+Guptaauthor=G.+D.+Steinbergauthor=J.+E.+Gschwendauthor=M.+S.+Van+Der+Heijdenauthor=N.+Garzonauthor=M.+Ibrahimauthor=B.+Rayboldauthor=D.+Liawauthor=M.+Rutsteinauthor=M.+D.+Galsky&title=ENERGIZE%3A+A+Phase+III+Study+Of+Neoadjuvant+Chemotherapy+Alone+Or+With+Nivolumab+With%2FWithout+Linrodostat+Mesylate+For+Muscle-Invasive+Bladder+Cancer&doi=10.2217%2Ffon-2019-0611"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">ENERGIZE: a Phase III study of neoadjuvant chemotherapy alone or with nivolumab with/without linrodostat mesylate for muscle-invasive bladder cancer</span></div><div class="casAuthors">Sonpavde, Guru; Necchi, Andrea; Gupta, Shilpa; Steinberg, Gary D.; Gschwend, Juergen E.; Van Der Heijden, Michiel Simon; Garzon, Nathalie; Ibrahim, Mohammed; Raybold, Bradley; Liaw, Danny; Rutstein, Mark; Galsky, Matt D.</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">4359-4368</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1744-8301</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">Immune checkpoint inhibitors have revolutionized the treatment of patients with metastatic urothelial carcinoma.  In cisplatin-eligible muscle-invasive bladder cancer (MIBC), cisplatin-based neoadjuvant chemotherapy (NAC) before radical cystectomy improves overall survival.  Tumor PD-L1 expression increases in MIBC after NAC, suggesting potential synergy in combining PD1/PD-L1 inhibitors with NAC.  IDO1 is overexpressed in bladder cancer and is assocd. with poor outcomes.  Linrodostat mesylate (BMS-986205) a selective, potent, oral IDO1 inhibitor combined with nivolumab has demonstrated safety and preliminary evidence of clin. activity in metastatic urothelial carcinoma.  Here, we discuss the rationale and trial design of the ENERGIZE, a Phase III trial investigating the efficacy of NAC in combination with nivolumab with or without linrodostat followed by postsurgery nivolumab or nivolumab with linrodostat in cisplatin-eligible patients with MIBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3VxHx2k7HEbVg90H21EOLACvtfcHk0li6DtR6g72k8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVSntr3N&md5=68ce0cc3472d7958423c4b0f57b75c78</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.2217%2Ffon-2019-0611&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffon-2019-0611%26sid%3Dliteratum%253Aachs%26aulast%3DSonpavde%26aufirst%3DG.%26aulast%3DNecchi%26aufirst%3DA.%26aulast%3DGupta%26aufirst%3DS.%26aulast%3DSteinberg%26aufirst%3DG.%2BD.%26aulast%3DGschwend%26aufirst%3DJ.%2BE.%26aulast%3DVan%2BDer%2BHeijden%26aufirst%3DM.%2BS.%26aulast%3DGarzon%26aufirst%3DN.%26aulast%3DIbrahim%26aufirst%3DM.%26aulast%3DRaybold%26aufirst%3DB.%26aulast%3DLiaw%26aufirst%3DD.%26aulast%3DRutstein%26aufirst%3DM.%26aulast%3DGalsky%26aufirst%3DM.%2BD.%26atitle%3DENERGIZE%253A%2520A%2520Phase%2520III%2520Study%2520Of%2520Neoadjuvant%2520Chemotherapy%2520Alone%2520Or%2520With%2520Nivolumab%2520With%252FWithout%2520Linrodostat%2520Mesylate%2520For%2520Muscle-Invasive%2520Bladder%2520Cancer%26jtitle%3DFuture%2520Oncol.%26date%3D2020%26volume%3D16%26spage%3D4359%26epage%3D4368%26doi%3D10.2217%2Ffon-2019-0611" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lyssikatos, J. P.</span>; <span class="NLM_string-name">Liu, W.</span>; <span class="NLM_string-name">Siu, M.</span>; <span class="NLM_string-name">Estrada, A.</span>; <span class="NLM_string-name">Patel, S.</span>; <span class="NLM_string-name">Liang, G.</span>; <span class="NLM_string-name">Huestis, M.</span>; <span class="NLM_string-name">Chen, K.</span></span> <span> </span><span class="NLM_article-title">Pyrazole derivatives and uses thereof as inhibitors of dlk</span>. <span class="NLM_patent">WO 2015091889 A1</span>, June 25, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=J.+P.+Lyssikatos&author=W.+Liu&author=M.+Siu&author=A.+Estrada&author=S.+Patel&author=G.+Liang&author=M.+Huestis&author=K.+Chen&title=Pyrazole+derivatives+and+uses+thereof+as+inhibitors+of+dlk"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLyssikatos%26aufirst%3DJ.%2BP.%26atitle%3DPyrazole%2520derivatives%2520and%2520uses%2520thereof%2520as%2520inhibitors%2520of%2520dlk%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrada, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shore, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyssikatos, J.</span></span> <span> </span><span class="NLM_article-title">Mild And General One-Pot Reduction And Cyclization Of Aromatic And Heteroaromatic 2-Nitroamines To Bicyclic 2H-Imidazoles</span>. <i>Synlett</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>2010</i></span>,  <span class="NLM_fpage">2759</span>– <span class="NLM_lpage">2764</span>, <span class="refDoi"> DOI: 10.1055/s-0030-1259007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1055%2Fs-0030-1259007" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2010&publication_year=2010&pages=2759-2764&author=E.+Hananauthor=B.+Chanauthor=A.+Estradaauthor=D.+Shoreauthor=J.+Lyssikatos&title=Mild+And+General+One-Pot+Reduction+And+Cyclization+Of+Aromatic+And+Heteroaromatic+2-Nitroamines+To+Bicyclic+2H-Imidazoles&doi=10.1055%2Fs-0030-1259007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1055%2Fs-0030-1259007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0030-1259007%26sid%3Dliteratum%253Aachs%26aulast%3DHanan%26aufirst%3DE.%26aulast%3DChan%26aufirst%3DB.%26aulast%3DEstrada%26aufirst%3DA.%26aulast%3DShore%26aufirst%3DD.%26aulast%3DLyssikatos%26aufirst%3DJ.%26atitle%3DMild%2520And%2520General%2520One-Pot%2520Reduction%2520And%2520Cyclization%2520Of%2520Aromatic%2520And%2520Heteroaromatic%25202-Nitroamines%2520To%2520Bicyclic%25202H-Imidazoles%26jtitle%3DSynlett%26date%3D2010%26volume%3D2010%26spage%3D2759%26epage%3D2764%26doi%3D10.1055%2Fs-0030-1259007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ellman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, T. P.</span></span> <span> </span><span class="NLM_article-title">N-Tert-Butanesulfinyl Imines: Versatile Intermediates For The Asymmetric Synthesis Of Amines</span>. <i>Acc. Chem. Res.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">984</span>– <span class="NLM_lpage">995</span>, <span class="refDoi"> DOI: 10.1021/ar020066u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ar020066u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BD38XmtVShsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2002&pages=984-995&author=J.+A.+Ellmanauthor=T.+D.+Owensauthor=T.+P.+Tang&title=N-Tert-Butanesulfinyl+Imines%3A+Versatile+Intermediates+For+The+Asymmetric+Synthesis+Of+Amines&doi=10.1021%2Far020066u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">N-tert-Butanesulfinyl Imines: Versatile Intermediates for the Asymmetric Synthesis of Amines</span></div><div class="casAuthors">Ellman, Jonathan A.; Owens, Timothy D.; Tang, Tony P.</div><div class="citationInfo"><span class="NLM_cas:title">Accounts of Chemical Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">984-995</span>CODEN:
                <span class="NLM_cas:coden">ACHRE4</span>;
        ISSN:<span class="NLM_cas:issn">0001-4842</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  N-tert-Butanesulfinyl aldimines and ketimines are exceedingly versatile intermediates for the asym. synthesis of amines.  The N-tert-butanesulfinyl imines are prepd. in high yields by condensing enantiomerically pure tert-butanesulfinamide, which is readily available in either configuration, with a wide range of aldehydes and ketones.  The tert-butanesulfinyl group activates the imines for the addn. of many different classes of nucleophiles, serves as a powerful chiral directing group, and after nucleophilic addn. is readily cleaved by treatment of the product with acid.  A wide range of highly enantioenriched amines, including α-branched and α,α-dibranched amines, α- and β-amino acids, 1,2- and 1,3-amino alcs., and α-trifluoromethyl amines, are efficiently synthesized using this methodol.  In addn., N-tert-butanesulfinyl imine derivs. provide a new family of ligands for asym. catalysis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIvB8xHaLharVg90H21EOLACvtfcHk0ljjf2TgnkLlBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmtVShsb8%253D&md5=7eb60c0d6e186f6ac10c874f9b34989f</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1021%2Far020066u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Far020066u%26sid%3Dliteratum%253Aachs%26aulast%3DEllman%26aufirst%3DJ.%2BA.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26aulast%3DTang%26aufirst%3DT.%2BP.%26atitle%3DN-Tert-Butanesulfinyl%2520Imines%253A%2520Versatile%2520Intermediates%2520For%2520The%2520Asymmetric%2520Synthesis%2520Of%2520Amines%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D2002%26volume%3D35%26spage%3D984%26epage%3D995%26doi%3D10.1021%2Far020066u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoye, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffrey, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, F.</span></span> <span> </span><span class="NLM_article-title">Mosher Ester Analysis For The Determination Of Absolute Configuration Of Stereogenic (Chiral) Carbinol Carbons</span>. <i>Nat. Protoc.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">2451</span>– <span class="NLM_lpage">2458</span>, <span class="refDoi"> DOI: 10.1038/nprot.2007.354</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1038%2Fnprot.2007.354" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=17947986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFOksL3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=2451-2458&author=T.+R.+Hoyeauthor=C.+S.+Jeffreyauthor=F.+Shao&title=Mosher+Ester+Analysis+For+The+Determination+Of+Absolute+Configuration+Of+Stereogenic+%28Chiral%29+Carbinol+Carbons&doi=10.1038%2Fnprot.2007.354"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Mosher ester analysis for the determination of absolute configuration of stereogenic (chiral) carbinol carbons</span></div><div class="casAuthors">Hoye, Thomas R.; Jeffrey, Christopher S.; Shao, Feng</div><div class="citationInfo"><span class="NLM_cas:title">Nature Protocols</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2451-2458</span>CODEN:
                <span class="NLM_cas:coden">NPARDW</span>;
        ISSN:<span class="NLM_cas:issn">1750-2799</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">This protocol details the most commonly used NMR-based method for deducing the configuration of otherwise unknown stereogenic, secondary carbinol (alc.) centers (R1R2CHOH (or the analogous amines where OH is replaced by NH2)).  This 'Mosher ester anal.' relies on the fact that the protons in diastereomeric α-methoxy-α-trifluoromethylphenylacetic acid (MTPA) esters (i.e., those derived from conjugation of the carbinol under interrogation with MTPA) display different arrays of chem. shifts (δs) in their 1H NMR spectra.  The protocol consists of the following: (i) prepn. of each of the diastereomeric S- and R-MTPA esters and (ii) comparative (ΔδSR) anal. of the 1H NMR spectral data of these two esters.  By analyzing the sign of the difference in chem. shifts for a no. of analogous pairs of protons (the set of ΔδSR values) in the diastereomeric esters (or amides), the abs. configuration of the original carbinol (or amino) stereocenter can be reliably deduced.  A typical Mosher ester anal. requires approx. 4-6 h of active effort over a 1- to 2-d period.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsdQys4JRj4LVg90H21EOLACvtfcHk0ljjf2TgnkLlBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFOksL3E&md5=741bb9fd8eb7c18c310196f298e5ea3f</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1038%2Fnprot.2007.354&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnprot.2007.354%26sid%3Dliteratum%253Aachs%26aulast%3DHoye%26aufirst%3DT.%2BR.%26aulast%3DJeffrey%26aufirst%3DC.%2BS.%26aulast%3DShao%26aufirst%3DF.%26atitle%3DMosher%2520Ester%2520Analysis%2520For%2520The%2520Determination%2520Of%2520Absolute%2520Configuration%2520Of%2520Stereogenic%2520%2528Chiral%2529%2520Carbinol%2520Carbons%26jtitle%3DNat.%2520Protoc.%26date%3D2007%26volume%3D2%26spage%3D2451%26epage%3D2458%26doi%3D10.1038%2Fnprot.2007.354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomiyama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirata, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayaishi, O.</span></span> <span> </span><span class="NLM_article-title">Indoleamine 2,3-Dioxygenase. Purification And Some Properties</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1978</span>,  <span class="NLM_volume"><i>253</i></span>,  <span class="NLM_fpage">4700</span>– <span class="NLM_lpage">4706</span>, <span class="refDoi"> DOI: 10.1016/s0021-9258(17)30447-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1016%2FS0021-9258%2817%2930447-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=26687" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADyaE1cXkvVKgtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=253&publication_year=1978&pages=4700-4706&author=T.+Shimizuauthor=S.+Nomiyamaauthor=F.+Hirataauthor=O.+Hayaishi&title=Indoleamine+2%2C3-Dioxygenase.+Purification+And+Some+Properties&doi=10.1016%2Fs0021-9258%2817%2930447-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Indoleamine 2,3-dioxygenase.  Purification and some properties</span></div><div class="casAuthors">Shimizu, Takao; Nomiyama, Sumitsugu; Hirata, Fusao; Hayaishi, Osamu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1978</span>),
    <span class="NLM_cas:volume">253</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4700-6</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">Indoleamine 2,3-dioxygenase (I) was purified from rabbit small intestine to apparent homogeneity as judged by polyacrylamide gel electrophoresis and anal. ultracentrifugation.  Native I was a monomeric protein of mol. wt. 41,000 with sedimentation coeff. of 3.45 S.  It had a relative abundance of hydrophobic amino acids and contained ∼5% carbohydrate by wt.  One mol I had 0.8 mol protoheme IX as a prosthetic group.  However, Cu was not detected in significant amt. and the ratio of Cu to heme was <0.03.  EPR spectra of the NO complex of Fe2+-I indicated that a N atom, possibly in an imidazole group, might be coordinated as the 5th ligand of the heme coenzyme.  A single enzyme protein catalyzed the oxygenative ring cleavage of D- and L-tryptophan, D- and L-5-hydroxytryptophan, tryptamine, and serotonin.  In addn. purified I had peroxidase activity with guaiacol and KI as H-donors, but not catalase activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB_vYru3V9SLVg90H21EOLACvtfcHk0ljjf2TgnkLlBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1cXkvVKgtrc%253D&md5=5e0a989a09b1c8243ff2e79db390851f</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1016%2FS0021-9258%2817%2930447-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0021-9258%252817%252930447-7%26sid%3Dliteratum%253Aachs%26aulast%3DShimizu%26aufirst%3DT.%26aulast%3DNomiyama%26aufirst%3DS.%26aulast%3DHirata%26aufirst%3DF.%26aulast%3DHayaishi%26aufirst%3DO.%26atitle%3DIndoleamine%25202%252C3-Dioxygenase.%2520Purification%2520And%2520Some%2520Properties%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1978%26volume%3D253%26spage%3D4700%26epage%3D4706%26doi%3D10.1016%2Fs0021-9258%2817%2930447-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':[],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/medium/jm1c00679_0029.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00679&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/medium/jm1c00679_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Known inhibitors of hIDO1.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00679&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/medium/jm1c00679_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Apo-IDO1 inihibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00679&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/medium/jm1c00679_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Holo-IDO1 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00679&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/medium/jm1c00679_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Crystal structure of <b>17</b> bound to human IDO1 showing key interactions in the binding pocket (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7M7D">7M7D</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00679&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/medium/jm1c00679_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Proposed concept compounds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00679&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/medium/jm1c00679_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Effect of compound treatment on cellular IDO1 activity and protein level. HeLa cells stimulated with 10 ng/mL of IFN-γ in the absence or the presence of IDO1 inhibitors (1 μM) for 24 h. IDO1 Activity (NFK_AUC) is the cellular production of NFK measured from aliquots of harvested cell conditioned media analyzed via RFMS [NFK_AUC is the area under the curve and is the integration of the total ion count peak intensities from the relative abundance of NFK in the mass spectrometry (MS) signal]. All compounds significantly (<i>p</i> < 0.01) inhibited cellular NFK production as compared to their absence. Western-blot analysis of cell lysates for expression levels of IDO1 protein (HSP90 as control). These are representative results from at least two independent test occasions performed in triplicate.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00679&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/medium/jm1c00679_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Compound <b>22</b> competes against heme incorporation into newly synthesized IDO1 protein. HEK293 cells were stimulated with doxycycline (1 ng/mL) in the absence (<b>7A</b>) or presence (<b>7B</b>) of <b>22</b> (1 μM). IDO1 activity in the cell lysates was assessed in (1) the absence of hemin (black), (2) the presence of hemin (3 μM, red), or (3) the presence of hemin (3 μM) plus <b>22</b> (1 μM) (blue). (<b>7C</b>) Western-blot analysis for IDO1 protein expression in the absence (1) or presence (2) of <b>22</b> (HSP90 as control). (<b>7D</b>) Activity of purified low heme-IDO1 in the presence of increasing concentrations of hemin and <b>22</b>. These are representative results from at least two independent test occasions performed in triplicates.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00679&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/medium/jm1c00679_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0009.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Compound <b>22</b> binds and promotes thermal stability of purified low-heme content IDO1 enzyme. (A) DSF profile of purified low heme-IDO1 protein in the presence of DMSO (control, red) or 50 μM of epacadostat (blue), displaying an unchanged <i>T</i><sub>m</sub> value of 55.5 °C under both treatment. (B) DSF profile of purified low heme-IDO1 protein in the presence of DMSO (control, red) or 50 μM of <b>22</b> (blue). IDO1 melting temperature (<i>T</i><sub>m</sub>) values showed a significant (<i>p</i> < 0.01) shift from 55.5 to 58 °C. <i>T</i><sub>m</sub> values were calculated by averaging the results from at least four independent test occasions.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00679&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/medium/jm1c00679_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0010.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. (A) Crystal structure of <b>22</b> bound to human IDO1 showing key interactions in the binding pocket (purple, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7B1O">7B1O</a>). (B) Crystal structure of <b>22</b> (light purple) superposed with the crystal structure of the IDO1 holoenzyme with <b>17</b> (yellow, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7M7D">7M7D</a>) with the heme (teal) depicted using a surface representation, to show the volume occupied by heme in the IDO1 holoenzyme.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00679&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/medium/jm1c00679_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0011.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. In vivo modulation of tumor KYN production after compound administration (po) using SKOV3 xenograft mouse model. Compounds were dosed as follows: (a) 125 mg/kg, po, QD, 5 days, tumor collected 4 h after last dose; (b) 125 mg/kg, po, QD, 5 days, tumor collected 24 h after last dose; (c) 3 mg/kg, po, tumor collected 24 h after single dose; (d) 50 mg/kg, po, tumor collected 24 h after single dose; (e) 125 mg/kg, po, BID, 5 days, tumor collected 24 h after last dose. Each symbol represents an individual animal, and at least five vehicle-treated animals per study was used as control. Tumor samples were harvested at 4 or 24 h after last dose for KYN quantification. For each study, the average of tumor KYN concentration in the vehicle control was used to calculate the percent inhibition of IDO1 in treated animals. Means ± standard error of the mean (SEM) are represented. po (oral administration); QD (once daily dose). Statistical <i>t</i>-test was performed and there was no statistical difference between <b>6(b)</b> and <b>62(a)</b>, <b>62(b)</b> and <b>71(c)</b> but there was between <b>6(b)</b> and <b>71(d)</b>, <i>p</i> = 0.012.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00679&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/medium/jm1c00679_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0012.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Crystal structure of <b>70</b> (light purple, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7M63">7M63</a>) superposed with the crystal structure of <b>22</b> (green).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00679&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/medium/jm1c00679_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0013.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Human whole blood assay. Fresh human peripheral blood was collected from volunteers, treated with DMSO control or increasing concentration of compounds, and stimulated with LPS/IFNγ for 24 h. Plasma samples were then collected for KYN quantification. The percent inhibition of KYN production was determined relative to the DMSO control, and compound potency was calculated: IC<sub>50</sub>: and IC<sub>90</sub>: values reported in <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>. The results are representative of three independent test occasions performed in duplicate.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00679&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/medium/jm1c00679_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0014.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Compound PK/PD relationship. The concentrations of KYN in tumor and compound in plasma samples were derived from in vivo studies using a human SKOV3 xenograft model after administration of compounds at doses ranging from 10 to 125 mg/kg: IACS-9779 (po, QD, 5 days) and linrodostat (po, BID, 5 days), IACS-70099 (po, QD, 5 days), and IACS-70465 (po, single dose). Plasma and tumor samples were collected at 12 h after the last dose for linrodostat, or 24 h after the last dose for IACS-9779, IACS-70099, and IACS-70465. Compound-mediated inhibition of tumor KYN was calculated relative to vehicle-treated animals (vehicle tumor [KYN] = 96 ± 36 μM). Each symbol represents a treated mouse. Estimated tumor PD: IC<sub>50</sub>: and IC<sub>90</sub>: values reported in <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00679&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/medium/jm1c00679_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0015.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. IACS-9779 human prediction of dose escalation over 10 half lives.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00679&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/medium/jm1c00679_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0016.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Hydroxy Bicyclo[3.1.0]hexane Diastereomers<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00679&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Regents and conditions: (a) MeNHOMe·HCl, DMAP, DIEA, EDCI, DCM; (b) DIBAL-H, PhMe; (c) 2-methylpropane-2-sulfinamide, CuSO<sub>4</sub>, DCM; (d) R<sub>1</sub>MgBr, THF; (e) LAH, THF; (f) HCl/Dioxane, MeOH; (g) R<sub>2</sub>COOH, DIEA, HATU, DMF or EDCI, HOBT, DIEA, DCM.</p></p></figure><figure data-id="sch2" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/medium/jm1c00679_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0017.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Quinolines and Symmetric Benzimidazoles<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00679&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (h<sub>a</sub>) 4-bromoquinoline, NaH, DMSO or KOtBu, THF; (h<sub>b</sub>) polymer-TPP, quinolin-4-ol, DTAB, THF; (i) MsCl, TEA DCM; (j) Benzimidazole, K<sub>2</sub>CO<sub>3</sub>, DMF.</p></p></figure><figure data-id="sch3" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/medium/jm1c00679_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0018.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Unsymmetrical Benzimidazoles<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00679&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (k) NaN<sub>3</sub>, DMF; (l) polymer-TPP, THF, H<sub>2</sub>O; (m) 2-fluoronitrobenzene, K<sub>2</sub>CO<sub>3</sub>, THF, (n) Fe, HCOOH, IPA.</p></p></figure><figure data-id="sch4" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/medium/jm1c00679_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0019.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Diastereomeric Chiral Bicyclo[3.1.0]hexane Amine<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00679&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (<i>S</i>)-2-methylpropane-2-sulfinamide, CuSO<sub>4</sub>, DCM; (b) R<sub>1</sub>MgBr, THF; (o) HCl/Dioxane, MeOH.</p></p></figure><figure data-id="sch5" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/medium/jm1c00679_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0020.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Mosher Amide Analysis<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00679&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Regents and conditions: (a) DIEA, ClCOMTPA, DCM.</p></p></figure><figure data-id="sch6" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/medium/jm1c00679_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0021.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Common Intermediate, Reversed Amides<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00679&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (p) 0 °C, THF, MeMgBr; (q) 0 °C, DCM(wet) DMP; (r) −13 °C Ph<sub>3</sub>PCH<sub>2</sub>OMe·Cl, THF, LHMDS; (s) PPTS, dioxane, H<sub>2</sub>O, 70 °C; (t) 0 °C, tBuOH, CH<sub>3</sub>(CH<sub>3</sub>)C═CHCH<sub>3</sub>, NaClO<sub>2</sub>, KH<sub>2</sub>PO<sub>4</sub>, H<sub>2</sub>O; (u) Pyridine, EtOAc, T3P; (v) THF, TBAF, 50 °C. (w) 0 °C, NaH, DMF.</p></p></figure><figure data-id="sch7" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/medium/jm1c00679_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0022.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Benzimidazole Synthesis<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00679/20210722/images/large/jm1c00679_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00679&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (x) pyridine, EtOAc, T3P, 65 °C; (y) PhMe, pTsOH, 110 °C.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i97">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28708" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28708" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 70 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Freewan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rees, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plaza, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glaros, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witting, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terentis, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, S. R.</span></span> <span> </span><span class="NLM_article-title">Human Indoleamine 2,3-Dioxygenase Is A Catalyst Of Physiological Heme Peroxidase Reactions</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>288</i></span>,  <span class="NLM_fpage">1548</span>– <span class="NLM_lpage">1567</span>, <span class="refDoi"> DOI: 10.1074/jbc.M112.410993</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1074%2Fjbc.M112.410993" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=23209301" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFahurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2013&pages=1548-1567&author=M.+Freewanauthor=M.+D.+Reesauthor=T.+S.+Plazaauthor=E.+Glarosauthor=Y.+J.+Limauthor=X.+S.+Wangauthor=A.+W.+Yeungauthor=P.+K.+Wittingauthor=A.+C.+Terentisauthor=S.+R.+Thomas&title=Human+Indoleamine+2%2C3-Dioxygenase+Is+A+Catalyst+Of+Physiological+Heme+Peroxidase+Reactions&doi=10.1074%2Fjbc.M112.410993"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Human indoleamine 2,3-dioxygenase is a catalyst of physiological heme peroxidase reactions</span></div><div class="casAuthors">Freewan, Mohammed; Rees, Martin D.; Sempertegui Plaza, Tito S.; Glaros, Elias; Lim, Yean J.; Wang, Xiao Suo; Yeung, Amanda W. S.; Witting, Paul K.; Terentis, Andrew C.; Thomas, Shane R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">288</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1548-1567</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The heme enzyme, indoleamine 2,3-dioxygenase (IDO), is a key regulator of immune responses through catalyzing L-tryptophan (Trp) oxidn.  Here, the authors show that H2O2 activates the peroxidase function of IDO to induce protein oxidn. and inhibit dioxygenase activity.  Exposure of IDO-expressing cells or recombinant human IDO (rIDO) to H2O2 inhibited dioxygenase activity in a manner abrogated by Trp.  Dioxygenase inhibition correlated with IDO-catalyzed H2O2 consumption, compd. I-mediated formation of protein-centered radicals, altered protein secondary structure, and opening of the distal heme pocket to promote nonproductive substrate binding; these changes were inhibited by Trp, the heme ligand, cyanide, or free radical scavengers.  Protection by Trp coincided with its oxidn. into oxindolylalanine and kynurenine and the formation of a compd. II-type ferryl-oxo heme.  Physiol. peroxidase substrates, ascorbate or tyrosine, enhanced rIDO-mediated H2O2 consumption and attenuated H2O2-induced protein oxidn. and dioxygenase inhibition.  In the presence of H2O2, rIDO catalytically consumed NO and utilized NO2- to promote 3-nitrotyrosine formation on IDO.  The promotion of H2O2 consumption by peroxidase substrates, NO consumption, and IDO nitration was inhibited by Trp.  Thus, this study identifies IDO as a heme peroxidase that, in the absence of substrates, self-inactivates its dioxygenase activity via compd. I-initiated protein oxidn.  Trp protects against dioxygenase inactivation by reacting with compd. I and retarding compd. II redn. to suppress peroxidase turnover.  Peroxidase-mediated dioxygenase inactivation, NO consumption, or protein nitration may modulate the biol. actions of IDO expressed in inflammatory tissues where the levels of H2O2 and NO are elevated and Trp is low.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4W1ahDsUwk7Vg90H21EOLACvtfcHk0li2v4E11srAtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFahurg%253D&md5=ffd1e739694ae9bef9fc2fe4ff626381</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M112.410993&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M112.410993%26sid%3Dliteratum%253Aachs%26aulast%3DFreewan%26aufirst%3DM.%26aulast%3DRees%26aufirst%3DM.%2BD.%26aulast%3DPlaza%26aufirst%3DT.%2BS.%26aulast%3DGlaros%26aufirst%3DE.%26aulast%3DLim%26aufirst%3DY.%2BJ.%26aulast%3DWang%26aufirst%3DX.%2BS.%26aulast%3DYeung%26aufirst%3DA.%2BW.%26aulast%3DWitting%26aufirst%3DP.%2BK.%26aulast%3DTerentis%26aufirst%3DA.%2BC.%26aulast%3DThomas%26aufirst%3DS.%2BR.%26atitle%3DHuman%2520Indoleamine%25202%252C3-Dioxygenase%2520Is%2520A%2520Catalyst%2520Of%2520Physiological%2520Heme%2520Peroxidase%2520Reactions%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2013%26volume%3D288%26spage%3D1548%26epage%3D1567%26doi%3D10.1074%2Fjbc.M112.410993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brochez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chevolet, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruse, V.</span></span> <span> </span><span class="NLM_article-title">The Rationale Of Indoleamine 2,3-Dioxygenase Inhibition For Cancer Therapy</span>. <i>Eur. J. Canc.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">167</span>– <span class="NLM_lpage">182</span>, <span class="refDoi"> DOI: 10.1016/j.ejca.2017.01.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1016%2Fj.ejca.2017.01.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=28324751" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjsVGnu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2017&pages=167-182&author=L.+Brochezauthor=I.+Chevoletauthor=V.+Kruse&title=The+Rationale+Of+Indoleamine+2%2C3-Dioxygenase+Inhibition+For+Cancer+Therapy&doi=10.1016%2Fj.ejca.2017.01.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy</span></div><div class="casAuthors">Brochez, Lieve; Chevolet, Ines; Kruse, Vibeke</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">167-182</span>CODEN:
                <span class="NLM_cas:coden">EJCAEL</span>;
        ISSN:<span class="NLM_cas:issn">0959-8049</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Indoleamine 2,3-dioxygenase (IDO, also referred to as IDO1) has been demonstrated to be a normal endogenous mechanism of acquired peripheral immune tolerance in vivo.In the field of oncol., IDO expression and/or activity has been obsd. in several cancer types and has usually been assocd. with neg. prognostic factors and worse outcome measures.This manuscript reviews current available data on the role of IDO in cancer and the current results obtained with IDO inhibition, both in animal models and in phase 1 and 2 clin. trials in humans.  Preliminary results with IDO inhibitors, usually combined with other anti-cancer drugs, seem encouraging.  Further studies are needed to clarify the conditions in which IDO inhibitors can be of value as an anti-cancer strategy.  In addn., further research should address whether the expression of IDO in tissue or blood can be a marker to select patients who can benefit most from IDO inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYAcutfExLmLVg90H21EOLACvtfcHk0li2v4E11srAtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjsVGnu7Y%253D&md5=5f983eb246a008c33a3b186699e1e244</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2017.01.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2017.01.011%26sid%3Dliteratum%253Aachs%26aulast%3DBrochez%26aufirst%3DL.%26aulast%3DChevolet%26aufirst%3DI.%26aulast%3DKruse%26aufirst%3DV.%26atitle%3DThe%2520Rationale%2520Of%2520Indoleamine%25202%252C3-Dioxygenase%2520Inhibition%2520For%2520Cancer%2520Therapy%26jtitle%3DEur.%2520J.%2520Canc.%26date%3D2017%26volume%3D76%26spage%3D167%26epage%3D182%26doi%3D10.1016%2Fj.ejca.2017.01.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giannone, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghisoni, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scotto, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuninetti, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turinetto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valabrega, G.</span></span> <span> </span><span class="NLM_article-title">Immuno-Metabolism And Microenvironment In Cancer: Key Players For Immunotherapy</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">4414</span>, <span class="refDoi"> DOI: 10.3390/ijms21124414</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.3390%2Fijms21124414" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitVSgtLfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2020&pages=4414&author=G.+Giannoneauthor=E.+Ghisoniauthor=S.+Gentaauthor=G.+Scottoauthor=V.+Tuninettiauthor=M.+Turinettoauthor=G.+Valabrega&title=Immuno-Metabolism+And+Microenvironment+In+Cancer%3A+Key+Players+For+Immunotherapy&doi=10.3390%2Fijms21124414"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Immuno-metabolism and microenvironment in cancer: key players for immunotherapy</span></div><div class="casAuthors">Giannone, Gaia; Ghisoni, Eleonora; Genta, Sofia; Scotto, Giulia; Tuninetti, Valentina; Turinetto, Margherita; Valabrega, Giorgio</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4414</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Immune checkpoint inhibitors (ICIs) have changed therapeutic algorithms in several malignancies, although intrinsic and secondary resistance is still an issue.  In this context, the dysregulation of immuno-metab. plays a leading role both in the tumor microenvironment (TME) and at the host level.  In this review, we summarize the most important immune-metabolic factors and how they could be exploited therapeutically.  At the cellular level, an increased concn. of extracellular adenosine as well as the depletion of tryptophan and uncontrolled activation of the PI3K/AKT pathway induces an immune-tolerant TME, reducing the response to ICIs.  Moreover, aberrant angiogenesis induces a hypoxic environment by recruiting VEGF, Treg cells and immune-suppressive tumor assocd. macrophages (TAMs).  On the other hand, factors such as gender and body mass index seem to affect the response to ICIs, while the microbiome compn. (and its alterations) modulates both the response and the development of immune-related adverse events.  Exploiting these complex mechanisms is the next goal in immunotherapy.  The most successful strategy to date has been the combination of antiangiogenic drugs and ICIs, which prolonged the survival of patients with non-small-cell lung cancer (NSCLC) and hepatocellular carcinoma (HCC), while results from tryptophan pathway inhibition studies are inconclusive.  New exciting strategies include targeting the adenosine pathway, TAMs and the microbiota with fecal microbiome transplantation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtWFXaiqD0xrVg90H21EOLACvtfcHk0li2v4E11srAtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitVSgtLfN&md5=5b9fb828cea8feb7c68b957fbb0582c0</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.3390%2Fijms21124414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms21124414%26sid%3Dliteratum%253Aachs%26aulast%3DGiannone%26aufirst%3DG.%26aulast%3DGhisoni%26aufirst%3DE.%26aulast%3DGenta%26aufirst%3DS.%26aulast%3DScotto%26aufirst%3DG.%26aulast%3DTuninetti%26aufirst%3DV.%26aulast%3DTurinetto%26aufirst%3DM.%26aulast%3DValabrega%26aufirst%3DG.%26atitle%3DImmuno-Metabolism%2520And%2520Microenvironment%2520In%2520Cancer%253A%2520Key%2520Players%2520For%2520Immunotherapy%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2020%26volume%3D21%26spage%3D4414%26doi%3D10.3390%2Fijms21124414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Austin, C. J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rendina, L. M.</span></span> <span> </span><span class="NLM_article-title">Targeting Key Dioxygenases In Tryptophan–Kynurenine Metabolism For Immunomodulation And Cancer Chemotherapy</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">609</span>– <span class="NLM_lpage">617</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2014.11.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1016%2Fj.drudis.2014.11.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=25478733" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitV2gu7nJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2015&pages=609-617&author=C.+J.+D.+Austinauthor=L.+M.+Rendina&title=Targeting+Key+Dioxygenases+In+Tryptophan%E2%80%93Kynurenine+Metabolism+For+Immunomodulation+And+Cancer+Chemotherapy&doi=10.1016%2Fj.drudis.2014.11.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting key dioxygenases in tryptophan-kynurenine metabolism for immunomodulation and cancer chemotherapy</span></div><div class="casAuthors">Austin, Christopher J. D.; Rendina, Louis M.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">609-617</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Tryptophan to kynurenine metab. is controlled by three distinct dioxygenase enzymes: tryptophan 2,3-dioxygenase (TDO), indoleamine 2,3-dioxygenase 1 (IDO1), and indoleamine 2,3-dioxygenase 2 (IDO2).  Collectively, the activity of these enzymes contributes to tumor immune tolerance and immune dysregulation in a variety of disease pathologies, including cancer.  Whereas IDO1 inhibitor drug design has been the focus of study for more than two decades (with novel compds. currently in Phase II clin. trials), only recently have the roles of TDO and IDO2 been elucidated in immunosuppression.  Consequently, little comparative work on inhibitor cross-reactivity and selectivity has been performed.  Here, we provide an overview of the current and future drug discovery landscape for targeting TDO, IDO1, and IDO2 (individually and collectively) for pharmacol. intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOoUq5iFaItLVg90H21EOLACvtfcHk0lh047ZZWOsSGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitV2gu7nJ&md5=3e49304fea87a6564ef051ac67332a06</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2014.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2014.11.007%26sid%3Dliteratum%253Aachs%26aulast%3DAustin%26aufirst%3DC.%2BJ.%2BD.%26aulast%3DRendina%26aufirst%3DL.%2BM.%26atitle%3DTargeting%2520Key%2520Dioxygenases%2520In%2520Tryptophan%25E2%2580%2593Kynurenine%2520Metabolism%2520For%2520Immunomodulation%2520And%2520Cancer%2520Chemotherapy%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2015%26volume%3D20%26spage%3D609%26epage%3D617%26doi%3D10.1016%2Fj.drudis.2014.11.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Théate, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Baren, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilotte, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moulin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larrieu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renauld, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hervé, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutierrez-Roelens, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marbaix, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sempoux, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van den Eynde, B. J.</span></span> <span> </span><span class="NLM_article-title">Extensive Profiling Of The Expression Of The Indoleamine 2,3-Dioxygenase 1 Protein In Normal And Tumoral Human Tissues. Cancer Immunology Research 2014, 3 (2), 161-172</span>. <i>Cancer Immunol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">161</span>– <span class="NLM_lpage">172</span>, <span class="refDoi"> DOI: 10.1158/2326-6066.cir-14-0137</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1158%2F2326-6066.cir-14-0137" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=25271151" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BC2MXis1Knurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2015&pages=161-172&author=I.+Th%C3%A9ateauthor=N.+van+Barenauthor=L.+Pilotteauthor=P.+Moulinauthor=P.+Larrieuauthor=J.-C.+Renauldauthor=C.+Herv%C3%A9author=I.+Gutierrez-Roelensauthor=E.+Marbaixauthor=C.+Sempouxauthor=B.+J.+Van+den+Eynde&title=Extensive+Profiling+Of+The+Expression+Of+The+Indoleamine+2%2C3-Dioxygenase+1+Protein+In+Normal+And+Tumoral+Human+Tissues.+Cancer+Immunology+Research+2014%2C+3+%282%29%2C+161-172&doi=10.1158%2F2326-6066.cir-14-0137"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Extensive Profiling of the Expression of the Indoleamine 2,3-Dioxygenase 1 Protein in Normal and Tumoral Human Tissues</span></div><div class="casAuthors">Theate, Ivan; van Baren, Nicolas; Pilotte, Luc; Moulin, Pierre; Larrieu, Pierre; Renauld, Jean-Christophe; Herve, Caroline; Gutierrez-Roelens, Ilse; Marbaix, Etienne; Sempoux, Christine; Van den Eynde, Benoit J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Immunology Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">161-172</span>CODEN:
                <span class="NLM_cas:coden">CIRACV</span>;
        ISSN:<span class="NLM_cas:issn">2326-6066</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Theate, van Baren, and colleagues used a highly specific antibody to characterize IDO1 expression in a large series of healthy and tumoral human tissues to facilitate the selection of appropriate tumor types for pharmacol. IDO1 inhibition and to anticipate possible side effects of this treatment.  Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 (IDO1) plays a key role in tumoral resistance to immune rejection.  In humans, constitutive expression of IDO1 has been obsd. in several tumor types.  However, a comprehensive anal. of its expression in normal and tumor tissues is still required to anticipate the risks and potential benefits of IDO1 inhibitors.  Using a newly validated monoclonal antibody to human IDO1, we performed an extensive immunohistochem. anal. of IDO1 expression in normal and tumor tissues.  In normal tissues, IDO1 was expressed by endothelial cells in the placenta and lung and by epithelial cells in the female genital tract.  In lymphoid tissues, IDO1 was expressed in mature dendritic cells with a phenotype (CD83+, DC-LAMP+, langerin-, CD123-, CD163-) distinct from plasmacytoid dendritic cells.  Importantly, IDO1-expressing dendritic cells were not enriched in tumor-draining lymph nodes, in contrast with previously reported findings.  IDO1-expressing cells were obsd. in a large fraction (505/866, 58%) of human tumors.  They comprised tumor cells, endothelial cells, and stromal cells in proportions that varied depending on the tumor type.  Tumors showing the highest proportions of IDO1-immunolabeled samples were carcinomas of the endometrium and cervix, followed by kidney, lung, and colon.  This hierarchy of IDO1 expression was confirmed by gene expression data mined from The Cancer Genome Atlas database.  Expression of IDO1 may be used to select tumors likely to benefit from targeted therapy with IDO1 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpG_twsNEJaH7Vg90H21EOLACvtfcHk0lh047ZZWOsSGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXis1Knurs%253D&md5=c7f8dc1a17c5a4a0fa8bc4bd44d8d0e0</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1158%2F2326-6066.cir-14-0137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2326-6066.cir-14-0137%26sid%3Dliteratum%253Aachs%26aulast%3DTh%25C3%25A9ate%26aufirst%3DI.%26aulast%3Dvan%2BBaren%26aufirst%3DN.%26aulast%3DPilotte%26aufirst%3DL.%26aulast%3DMoulin%26aufirst%3DP.%26aulast%3DLarrieu%26aufirst%3DP.%26aulast%3DRenauld%26aufirst%3DJ.-C.%26aulast%3DHerv%25C3%25A9%26aufirst%3DC.%26aulast%3DGutierrez-Roelens%26aufirst%3DI.%26aulast%3DMarbaix%26aufirst%3DE.%26aulast%3DSempoux%26aufirst%3DC.%26aulast%3DVan%2Bden%2BEynde%26aufirst%3DB.%2BJ.%26atitle%3DExtensive%2520Profiling%2520Of%2520The%2520Expression%2520Of%2520The%2520Indoleamine%25202%252C3-Dioxygenase%25201%2520Protein%2520In%2520Normal%2520And%2520Tumoral%2520Human%2520Tissues.%2520Cancer%2520Immunology%2520Research%25202014%252C%25203%2520%25282%2529%252C%2520161-172%26jtitle%3DCancer%2520Immunol.%2520Res.%26date%3D2015%26volume%3D3%26spage%3D161%26epage%3D172%26doi%3D10.1158%2F2326-6066.cir-14-0137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roszik, J.</span>; <span class="NLM_string-name">Tanese, K.</span>; <span class="NLM_string-name">Ekmekcioglu, S.</span></span> <span> </span><span class="NLM_article-title">Editorial: Targeting Metabolism In Cancer Immunotherapy</span>.  <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume">9</span>.2029 <span class="refDoi"> DOI: 10.3389/fimmu.2018.02029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.3389%2Ffimmu.2018.02029" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&author=J.+Roszik&author=K.+Tanese&author=S.+Ekmekcioglu&title=Editorial%3A+Targeting+Metabolism+In+Cancer+Immunotherapy&doi=10.3389%2Ffimmu.2018.02029"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2018.02029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2018.02029%26sid%3Dliteratum%253Aachs%26aulast%3DRoszik%26aufirst%3DJ.%26atitle%3DEditorial%253A%2520Targeting%2520Metabolism%2520In%2520Cancer%2520Immunotherapy%26jtitle%3DFront.%2520Immunol.%26date%3D2018%26volume%3D9%26doi%3D10.3389%2Ffimmu.2018.02029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span> <span> </span><span class="NLM_article-title">Upregulated Expression Of Indoleamine 2, 3-Dioxygenase In Primary Breast Cancer Correlates With Increase Of Infiltrated Regulatory T Cellsin Situand Lymph Node Metastasis</span>. <i>Clin. Dev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2011</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.1155/2011/469135</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1155%2F2011%2F469135" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2011&publication_year=2011&pages=1-10&author=J.+Yuauthor=J.+Sunauthor=S.+E.+Wangauthor=H.+Liauthor=S.+Caoauthor=Y.+Congauthor=J.+Liuauthor=X.+Ren&title=Upregulated+Expression+Of+Indoleamine+2%2C+3-Dioxygenase+In+Primary+Breast+Cancer+Correlates+With+Increase+Of+Infiltrated+Regulatory+T+Cellsin+Situand+Lymph+Node+Metastasis&doi=10.1155%2F2011%2F469135"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1155%2F2011%2F469135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2011%252F469135%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DS.%2BE.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DCao%26aufirst%3DS.%26aulast%3DCong%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DRen%26aufirst%3DX.%26atitle%3DUpregulated%2520Expression%2520Of%2520Indoleamine%25202%252C%25203-Dioxygenase%2520In%2520Primary%2520Breast%2520Cancer%2520Correlates%2520With%2520Increase%2520Of%2520Infiltrated%2520Regulatory%2520T%2520Cellsin%2520Situand%2520Lymph%2520Node%2520Metastasis%26jtitle%3DClin.%2520Dev.%2520Immunol.%26date%3D2011%26volume%3D2011%26spage%3D1%26epage%3D10%26doi%3D10.1155%2F2011%2F469135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ino, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kajiyama, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terauchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nawa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takikawa, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kikkawa, F.</span></span> <span> </span><span class="NLM_article-title">Inverse Correlation Between Tumoral Indoleamine 2,3-Dioxygenase Expression And Tumor-Infiltrating Lymphocytes In Endometrial Cancer: Its Association With Disease Progression And Survival</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">2310</span>– <span class="NLM_lpage">2317</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.ccr-07-4144</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1158%2F1078-0432.CCR-07-4144" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=18413819" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BD1cXkvFGmtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=2310-2317&author=K.+Inoauthor=E.+Yamamotoauthor=K.+Shibataauthor=H.+Kajiyamaauthor=N.+Yoshidaauthor=M.+Terauchiauthor=A.+Nawaauthor=T.+Nagasakaauthor=O.+Takikawaauthor=F.+Kikkawa&title=Inverse+Correlation+Between+Tumoral+Indoleamine+2%2C3-Dioxygenase+Expression+And+Tumor-Infiltrating+Lymphocytes+In+Endometrial+Cancer%3A+Its+Association+With+Disease+Progression+And+Survival&doi=10.1158%2F1078-0432.ccr-07-4144"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Inverse Correlation between Tumoral Indoleamine 2,3-Dioxygenase Expression and Tumor-Infiltrating Lymphocytes in Endometrial Cancer: Its Association with Disease Progression and Survival</span></div><div class="casAuthors">Ino, Kazuhiko; Yamamoto, Eiko; Shibata, Kiyosumi; Kajiyama, Hiroaki; Yoshida, Norio; Terauchi, Mikio; Nawa, Akihiro; Nagasaka, Tetsuro; Takikawa, Osamu; Kikkawa, Fumitaka</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2310-2317</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Tumor escape from host immune systems is a crucial mechanism for disease progression.  We recently showed that the immunosuppressive enzyme indoleamine 2,3-dioxygenase (IDO) is a prognostic indicator for endometrial cancer.  The purpose of the present study was to investigate the relationship between IDO expression and tumor-infiltrating lymphocytes (TIL) or natural killer (NK) cells and to clarify their prognostic effect in endometrial cancer.  Exptl. Design: Immunohistochem. staining for IDO expression in endometrial cancer tissues (n = 65) was done.  Tumor-infiltrating CD3+ and CD8+ lymphocytes, as well as CD57+ NK cells, were counted in serial tissue sections.  RESULTS: High IDO expression in tumor cells was found in 32 of 65 cases and was pos. correlated with myometrial invasion, nodal metastasis, and lymph-vascular space involvement.  We also found a significant correlation between high IDO expression and reduced nos. of CD3+, CD8+, and CD57+ cells infiltrating into both the tumor epithelium and stroma.  Patients with high IDO expression, a low no. of stromal CD3 (<60), low intraepithelial CD8 (<25), or low stromal CD8 (<40) had significantly impaired progression-free survival.  On multivariate anal., IDO expression and the no. of stromal CD3+ TILs were independent prognostic factors for impaired progression-free survival.  CONCLUSIONS: Tumoral IDO expression correlated with a reduced no. of TILs and NK cells in endometrial cancer, possibly contributing to disease progression and impaired clin. outcome.  These findings suggest that targeting IDO to restore host antitumor immunity may be a therapeutic strategy for endometrial cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZZtHpmlR407Vg90H21EOLACvtfcHk0ljt4InjaRQOCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXkvFGmtL0%253D&md5=6baa8848c1ba82c24fd749f907c4acef</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-4144&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-4144%26sid%3Dliteratum%253Aachs%26aulast%3DIno%26aufirst%3DK.%26aulast%3DYamamoto%26aufirst%3DE.%26aulast%3DShibata%26aufirst%3DK.%26aulast%3DKajiyama%26aufirst%3DH.%26aulast%3DYoshida%26aufirst%3DN.%26aulast%3DTerauchi%26aufirst%3DM.%26aulast%3DNawa%26aufirst%3DA.%26aulast%3DNagasaka%26aufirst%3DT.%26aulast%3DTakikawa%26aufirst%3DO.%26aulast%3DKikkawa%26aufirst%3DF.%26atitle%3DInverse%2520Correlation%2520Between%2520Tumoral%2520Indoleamine%25202%252C3-Dioxygenase%2520Expression%2520And%2520Tumor-Infiltrating%2520Lymphocytes%2520In%2520Endometrial%2520Cancer%253A%2520Its%2520Association%2520With%2520Disease%2520Progression%2520And%2520Survival%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26spage%3D2310%26epage%3D2317%26doi%3D10.1158%2F1078-0432.ccr-07-4144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galli, F.</span>; <span class="NLM_string-name">Aguilera, J.</span>; <span class="NLM_string-name">Palermo, B.</span>; <span class="NLM_string-name">Markovic, S.</span>; <span class="NLM_string-name">Nisticò, P.</span>; <span class="NLM_string-name">Signore, A.</span></span> <span> </span><span class="NLM_article-title">Relevance Of Immune Cell And Tumor Microenvironment Imaging In The New Era Of Immunotherapy</span>.  <i>J. Exp. Clin. Canc. Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume">39</span>.89 <span class="refDoi"> DOI: 10.1186/s13046-020-01586-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1186%2Fs13046-020-01586-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=32423420" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2020&author=F.+Galli&author=J.+Aguilera&author=B.+Palermo&author=S.+Markovic&author=P.+Nistic%C3%B2&author=A.+Signore&title=Relevance+Of+Immune+Cell+And+Tumor+Microenvironment+Imaging+In+The+New+Era+Of+Immunotherapy&doi=10.1186%2Fs13046-020-01586-y"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1186%2Fs13046-020-01586-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13046-020-01586-y%26sid%3Dliteratum%253Aachs%26aulast%3DGalli%26aufirst%3DF.%26atitle%3DRelevance%2520Of%2520Immune%2520Cell%2520And%2520Tumor%2520Microenvironment%2520Imaging%2520In%2520The%2520New%2520Era%2520Of%2520Immunotherapy%26jtitle%3DJ.%2520Exp.%2520Clin.%2520Canc.%2520Res.%26date%3D2020%26volume%3D39%26doi%3D10.1186%2Fs13046-020-01586-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladomersky, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenzen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauing, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wainwright, D. A.</span></span> <span> </span><span class="NLM_article-title">IDO1 In Cancer: A Gemini Of Immune Checkpoints</span>. <i>Cell. Mol. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">447</span>– <span class="NLM_lpage">457</span>, <span class="refDoi"> DOI: 10.1038/cmi.2017.143</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1038%2Fcmi.2017.143" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=29375124" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVWqsbbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2018&pages=447-457&author=L.+Zhaiauthor=E.+Ladomerskyauthor=A.+Lenzenauthor=B.+Nguyenauthor=R.+Patelauthor=K.+L.+Lauingauthor=M.+Wuauthor=D.+A.+Wainwright&title=IDO1+In+Cancer%3A+A+Gemini+Of+Immune+Checkpoints&doi=10.1038%2Fcmi.2017.143"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">IDO1 in cancer: a Gemini of immune checkpoints</span></div><div class="casAuthors">Zhai, Lijie; Ladomersky, Erik; Lenzen, Alicia; Nguyen, Brenda; Patel, Ricky; Lauing, Kristen L.; Wu, Meijing; Wainwright, Derek A.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular & Molecular Immunology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">447-457</span>CODEN:
                <span class="NLM_cas:coden">CMIEAO</span>;
        ISSN:<span class="NLM_cas:issn">1672-7681</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Indoleamine 2, 3-dioxygenase 1 (IDO1) is a rate-limiting metabolic enzyme that converts the essential amino acid tryptophan (Trp) into downstream catabolites known as kynurenines.  Coincidently, numerous studies have demonstrated that IDO1 is highly expressed in multiple types of human cancer.  Preclin. studies have further introduced an interesting paradox: while single-agent treatment with IDO1 enzyme inhibitor has a negligible effect on decreasing the established cancer burden, approaches combining select therapies with IDO1 blockade tend to yield a synergistic benefit against tumor growth and/or animal subject survival.  Given the high expression of IDO1 among multiple cancer types along with the lack of monotherapeutic efficacy, these data suggest that there is a more complex mechanism of action than previously appreciated.  Similar to the dual faces of the astrol. Gemini, we highlight the multiple roles of IDO1 and review its canonical assocn. with IDO1-dependent tryptophan metab., as well as documented evidence confirming the dispensability of enzyme activity for its immunosuppressive effects.  The gene transcript levels for IDO1 highlight its strong assocn. with T-cell infiltration, but the lack of a universal prognostic significance among all cancer subtypes.  Finally, ongoing clin. trials are discussed with consideration of IDO1-targeting strategies that enhance the efficacy of immunotherapy for cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvVLMCOcWWorVg90H21EOLACvtfcHk0ljt4InjaRQOCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVWqsbbP&md5=cf75d557eed8dc2b131f4eefe178b7d1</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fcmi.2017.143&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcmi.2017.143%26sid%3Dliteratum%253Aachs%26aulast%3DZhai%26aufirst%3DL.%26aulast%3DLadomersky%26aufirst%3DE.%26aulast%3DLenzen%26aufirst%3DA.%26aulast%3DNguyen%26aufirst%3DB.%26aulast%3DPatel%26aufirst%3DR.%26aulast%3DLauing%26aufirst%3DK.%2BL.%26aulast%3DWu%26aufirst%3DM.%26aulast%3DWainwright%26aufirst%3DD.%2BA.%26atitle%3DIDO1%2520In%2520Cancer%253A%2520A%2520Gemini%2520Of%2520Immune%2520Checkpoints%26jtitle%3DCell.%2520Mol.%2520Immunol.%26date%3D2018%26volume%3D15%26spage%3D447%26epage%3D457%26doi%3D10.1038%2Fcmi.2017.143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueng, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, C.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, M.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, F.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsiao, W.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsueh, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shia, K.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.-Y.</span></span> <span> </span><span class="NLM_article-title">Important Hydrogen Bond Networks In Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Design Revealed By Crystal Structures Of Imidazoleisoindole Derivatives With IDO1</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">282</span>– <span class="NLM_lpage">293</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01390</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01390" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFKjtLnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=282-293&author=Y.-H.+Pengauthor=S.-H.+Uengauthor=C.-T.+Tsengauthor=M.-S.+Hungauthor=J.-S.+Songauthor=J.-S.+Wuauthor=F.-Y.+Liaoauthor=Y.-S.+Fanauthor=M.-H.+Wuauthor=W.-C.+Hsiaoauthor=C.-C.+Hsuehauthor=S.-Y.+Linauthor=C.-Y.+Chengauthor=C.-H.+Tuauthor=L.-C.+Leeauthor=M.-F.+Chengauthor=K.-S.+Shiaauthor=C.+Shihauthor=S.-Y.+Wu&title=Important+Hydrogen+Bond+Networks+In+Indoleamine+2%2C3-Dioxygenase+1+%28IDO1%29+Inhibitor+Design+Revealed+By+Crystal+Structures+Of+Imidazoleisoindole+Derivatives+With+IDO1&doi=10.1021%2Facs.jmedchem.5b01390"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Important Hydrogen Bond Networks in Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Design Revealed by Crystal Structures of Imidazoleisoindole Derivatives with IDO1</span></div><div class="casAuthors">Peng, Yi-Hui; Ueng, Shau-Hua; Tseng, Chen-Tso; Hung, Ming-Shiu; Song, Jen-Shin; Wu, Jian-Sung; Liao, Fang-Yu; Fan, Yu-Shiou; Wu, Mine-Hsine; Hsiao, Wen-Chi; Hsueh, Ching-Cheng; Lin, Shu-Yu; Cheng, Chia-Yi; Tu, Chih-Hsiang; Lee, Lung-Chun; Cheng, Ming-Fu; Shia, Kak-Shan; Shih, Chuan; Wu, Su-Ying</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">282-293</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1), promoting immune escape of tumors, is a therapeutic target for the cancer immunotherapy.  A no. of IDO1 inhibitors have been identified, but only limited structural biol. studies of IDO1 inhibitors are available to provide insights on the binding mechanism of IDO1.  In this study, we present the structure of IDO1 in complex with 24, a NLG919 analog with potent activity.  The complex structure revealed the imidazole nitrogen atom of 24 to coordinate with the heme iron, and the imidazoleisoindole core situated in pocket A with the 1-cyclohexylethanol moiety extended to pocket B to interact with the surrounding residues.  Most interestingly, 24 formed an extensive hydrogen bond network with IDO1, which is a distinct feature of IDO1/24 complex structure and is not obsd. in the other IDO1 complex structures.  Further structure-activity relationship, UV spectra, and structural biol. studies of several analogs of 24 demonstrated that extensive hydrophobic interactions and the unique hydrogen bonding network contribute to the great potency of imidazoleisoindole derivs.  These results are expected to facilitate the structure-based drug design of new IDO inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodJqtuECqcsrVg90H21EOLACvtfcHk0lhlxfbKZyNhlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFKjtLnJ&md5=2258be36595a3fa8e6c9064b2f15e1de</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01390&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01390%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DY.-H.%26aulast%3DUeng%26aufirst%3DS.-H.%26aulast%3DTseng%26aufirst%3DC.-T.%26aulast%3DHung%26aufirst%3DM.-S.%26aulast%3DSong%26aufirst%3DJ.-S.%26aulast%3DWu%26aufirst%3DJ.-S.%26aulast%3DLiao%26aufirst%3DF.-Y.%26aulast%3DFan%26aufirst%3DY.-S.%26aulast%3DWu%26aufirst%3DM.-H.%26aulast%3DHsiao%26aufirst%3DW.-C.%26aulast%3DHsueh%26aufirst%3DC.-C.%26aulast%3DLin%26aufirst%3DS.-Y.%26aulast%3DCheng%26aufirst%3DC.-Y.%26aulast%3DTu%26aufirst%3DC.-H.%26aulast%3DLee%26aufirst%3DL.-C.%26aulast%3DCheng%26aufirst%3DM.-F.%26aulast%3DShia%26aufirst%3DK.-S.%26aulast%3DShih%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DS.-Y.%26atitle%3DImportant%2520Hydrogen%2520Bond%2520Networks%2520In%2520Indoleamine%25202%252C3-Dioxygenase%25201%2520%2528IDO1%2529%2520Inhibitor%2520Design%2520Revealed%2520By%2520Crystal%2520Structures%2520Of%2520Imidazoleisoindole%2520Derivatives%2520With%2520IDO1%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D282%26epage%3D293%26doi%3D10.1021%2Facs.jmedchem.5b01390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yue, E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douty, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wayland, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bower, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leffet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansbury, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wynn, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burn, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koblish, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridman, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metcalf, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherle, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Combs, A. P.</span></span> <span> </span><span class="NLM_article-title">Discovery Of Potent Competitive Inhibitors Of Indoleamine 2,3-Dioxygenase With In Vivo Pharmacodynamic Activity and Efficacy In A Mouse Melanoma Model</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">7364</span>– <span class="NLM_lpage">7367</span>, <span class="refDoi"> DOI: 10.1021/jm900518f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900518f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BD1MXntVSksb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=7364-7367&author=E.+W.+Yueauthor=B.+Doutyauthor=B.+Waylandauthor=M.+Bowerauthor=X.+Liuauthor=L.+Leffetauthor=Q.+Wangauthor=K.+J.+Bowmanauthor=M.+J.+Hansburyauthor=C.+Liuauthor=M.+Weiauthor=Y.+Liauthor=R.+Wynnauthor=T.+C.+Burnauthor=H.+K.+Koblishauthor=J.+S.+Fridmanauthor=B.+Metcalfauthor=P.+A.+Scherleauthor=A.+P.+Combs&title=Discovery+Of+Potent+Competitive+Inhibitors+Of+Indoleamine+2%2C3-Dioxygenase+With+In+Vivo+Pharmacodynamic+Activity+and+Efficacy+In+A+Mouse+Melanoma+Model&doi=10.1021%2Fjm900518f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent Competitive Inhibitors of Indoleamine 2,3-Dioxygenase with in Vivo Pharmacodynamic Activity and Efficacy in a Mouse Melanoma Model</span></div><div class="casAuthors">Yue, Eddy W.; Douty, Brent; Wayland, Brian; Bower, Michael; Liu, Xiangdong; Leffet, Lynn; Wang, Qian; Bowman, Kevin J.; Hansbury, Michael J.; Liu, Changnian; Wei, Min; Li, Yanlong; Wynn, Richard; Burn, Timothy C.; Koblish, Holly K.; Fridman, Jordan S.; Metcalf, Brian; Scherle, Peggy A.; Combs, Andrew P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7364-7367</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A hydroxyamidine chemotype has been discovered as a key pharmacophore in novel inhibitors of indoleamine 2,3-dioxygenase (IDO).  Optimization led to the identification of (I), which is a potent (HeLa IC50 = 19 nM) competitive inhibitor of IDO.  Testing of I in mice demonstrated pharmacodynamic inhibition of IDO, as measured by decreased kynurenine levels (>50%) in plasma and dose dependent efficacy in mice bearing GM-CSF-secreting B16 melanoma tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZsq88hx0J77Vg90H21EOLACvtfcHk0lhlxfbKZyNhlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXntVSksb8%253D&md5=328d92bffb88a86da030c31eff707dc6</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjm900518f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900518f%26sid%3Dliteratum%253Aachs%26aulast%3DYue%26aufirst%3DE.%2BW.%26aulast%3DDouty%26aufirst%3DB.%26aulast%3DWayland%26aufirst%3DB.%26aulast%3DBower%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLeffet%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DBowman%26aufirst%3DK.%2BJ.%26aulast%3DHansbury%26aufirst%3DM.%2BJ.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DWei%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWynn%26aufirst%3DR.%26aulast%3DBurn%26aufirst%3DT.%2BC.%26aulast%3DKoblish%26aufirst%3DH.%2BK.%26aulast%3DFridman%26aufirst%3DJ.%2BS.%26aulast%3DMetcalf%26aufirst%3DB.%26aulast%3DScherle%26aufirst%3DP.%2BA.%26aulast%3DCombs%26aufirst%3DA.%2BP.%26atitle%3DDiscovery%2520Of%2520Potent%2520Competitive%2520Inhibitors%2520Of%2520Indoleamine%25202%252C3-Dioxygenase%2520With%2520In%2520Vivo%2520Pharmacodynamic%2520Activity%2520and%2520Efficacy%2520In%2520A%2520Mouse%2520Melanoma%2520Model%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D7364%26epage%3D7367%26doi%3D10.1021%2Fjm900518f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crosignani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bingham, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottemanne, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cannelle, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cauwenberghs, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cordonnier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalvie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deroose, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomes, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greasley, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaiser, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraus, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Négrerie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maegley, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soloweij, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torti, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Den Eynde, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wythes, M.</span></span> <span> </span><span class="NLM_article-title">Discovery Of A Novel And Selective Indoleamine 2,3-Dioxygenase (IDO-1) Inhibitor 3-(5-Fluoro-1H-Indol-3-Yl)Pyrrolidine-2,5-Dione (EOS200271/PF-06840003) And Its Characterization As A Potential Clinical Candidate</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">9617</span>– <span class="NLM_lpage">9629</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00974</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00974" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslOns7%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=9617-9629&author=S.+Crosignaniauthor=P.+Binghamauthor=P.+Bottemanneauthor=H.+Cannelleauthor=S.+Cauwenberghsauthor=M.+Cordonnierauthor=D.+Dalvieauthor=F.+Derooseauthor=J.+L.+Fengauthor=B.+Gomesauthor=S.+Greasleyauthor=S.+E.+Kaiserauthor=M.+Krausauthor=M.+N%C3%A9grerieauthor=K.+Maegleyauthor=N.+Millerauthor=B.+W.+Murrayauthor=M.+Schneiderauthor=J.+Soloweijauthor=A.+E.+Stewartauthor=J.+Tumangauthor=V.+R.+Tortiauthor=B.+Van+Den+Eyndeauthor=M.+Wythes&title=Discovery+Of+A+Novel+And+Selective+Indoleamine+2%2C3-Dioxygenase+%28IDO-1%29+Inhibitor+3-%285-Fluoro-1H-Indol-3-Yl%29Pyrrolidine-2%2C5-Dione+%28EOS200271%2FPF-06840003%29+And+Its+Characterization+As+A+Potential+Clinical+Candidate&doi=10.1021%2Facs.jmedchem.7b00974"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Novel and Selective Indoleamine 2,3-Dioxygenase (IDO-1) Inhibitor 3-(5-Fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione (EOS200271/PF-06840003) and Its Characterization as a Potential Clinical Candidate</span></div><div class="casAuthors">Crosignani, Stefano; Bingham, Patrick; Bottemanne, Pauline; Cannelle, Helene; Cauwenberghs, Sandra; Cordonnier, Marie; Dalvie, Deepak; Deroose, Frederik; Feng, Jun Li; Gomes, Bruno; Greasley, Samantha; Kaiser, Stephen E.; Kraus, Manfred; Negrerie, Michel; Maegley, Karen; Miller, Nichol; Murray, Brion W.; Schneider, Manfred; Soloweij, James; Stewart, Albert E.; Tumang, Joseph; Torti, Vince R.; Van Den Eynde, Benoit; Wythes, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9617-9629</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tumors use tryptophan-catabolizing enzymes such as indoleamine 2,3-dioxygenase (IDO-1) to induce an immunosuppressive environment.  IDO-1 is induced in response to inflammatory stimuli and promotes immune tolerance through effector T-cell anergy and enhanced Treg function.  As such, IDO-1 is a nexus for the induction of a key immunosuppressive mechanism and represents an important immunotherapeutic target in oncol.  Starting from HTS hit I, IDO-1 inhibitor II has been developed.  The structure-activity relationship around II is described and rationalized using the x-ray crystal structure of II bound to human IDO-1, which shows that II, differently from most of the IDO-1 inhibitors described so far, does not bind to the heme iron atom and has a novel binding mode.  Clin. candidate II shows good potency in an IDO-1 human whole blood assay and also shows a very favorable ADME profile leading to favorable predicted human pharmacokinetic properties, including a predicted half-life of 16-19 h.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogfHmZRAC-dLVg90H21EOLACvtfcHk0lhlxfbKZyNhlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslOns7%252FK&md5=dc2e45c243aa22c100ccc39db9b5918a</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00974&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00974%26sid%3Dliteratum%253Aachs%26aulast%3DCrosignani%26aufirst%3DS.%26aulast%3DBingham%26aufirst%3DP.%26aulast%3DBottemanne%26aufirst%3DP.%26aulast%3DCannelle%26aufirst%3DH.%26aulast%3DCauwenberghs%26aufirst%3DS.%26aulast%3DCordonnier%26aufirst%3DM.%26aulast%3DDalvie%26aufirst%3DD.%26aulast%3DDeroose%26aufirst%3DF.%26aulast%3DFeng%26aufirst%3DJ.%2BL.%26aulast%3DGomes%26aufirst%3DB.%26aulast%3DGreasley%26aufirst%3DS.%26aulast%3DKaiser%26aufirst%3DS.%2BE.%26aulast%3DKraus%26aufirst%3DM.%26aulast%3DN%25C3%25A9grerie%26aufirst%3DM.%26aulast%3DMaegley%26aufirst%3DK.%26aulast%3DMiller%26aufirst%3DN.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26aulast%3DSchneider%26aufirst%3DM.%26aulast%3DSoloweij%26aufirst%3DJ.%26aulast%3DStewart%26aufirst%3DA.%2BE.%26aulast%3DTumang%26aufirst%3DJ.%26aulast%3DTorti%26aufirst%3DV.%2BR.%26aulast%3DVan%2BDen%2BEynde%26aufirst%3DB.%26aulast%3DWythes%26aufirst%3DM.%26atitle%3DDiscovery%2520Of%2520A%2520Novel%2520And%2520Selective%2520Indoleamine%25202%252C3-Dioxygenase%2520%2528IDO-1%2529%2520Inhibitor%25203-%25285-Fluoro-1H-Indol-3-Yl%2529Pyrrolidine-2%252C5-Dione%2520%2528EOS200271%252FPF-06840003%2529%2520And%2520Its%2520Characterization%2520As%2520A%2520Potential%2520Clinical%2520Candidate%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D9617%26epage%3D9629%26doi%3D10.1021%2Facs.jmedchem.7b00974" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beck, H.</span>; <span class="NLM_string-name">Carlos, J.</span>; <span class="NLM_string-name">Osipov, M.</span>; <span class="NLM_string-name">Powers, J.</span>; <span class="NLM_string-name">Reilly, M.</span>; <span class="NLM_string-name">Shunatona, H.</span>; <span class="NLM_string-name">Walker, J.</span>; <span class="NLM_string-name">Zibinsky, M.</span>; <span class="NLM_string-name">Balog, J.</span>; <span class="NLM_string-name">Williams, D.</span>; <span class="NLM_string-name">Guo, W.</span></span> <span> </span><span class="NLM_article-title">Immunoregulatory agents</span>. <span class="NLM_patent">WO 2016073738 A2</span>, May 12, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=H.+Beck&author=J.+Carlos&author=M.+Osipov&author=J.+Powers&author=M.+Reilly&author=H.+Shunatona&author=J.+Walker&author=M.+Zibinsky&author=J.+Balog&author=D.+Williams&author=W.+Guo&title=Immunoregulatory+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBeck%26aufirst%3DH.%26atitle%3DImmunoregulatory%2520agents%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beck, H.</span>; <span class="NLM_string-name">Carlos, J.</span>; <span class="NLM_string-name">Osiprov, J.</span>; <span class="NLM_string-name">Powers, J.</span>; <span class="NLM_string-name">Reilly, M.</span>; <span class="NLM_string-name">Shunatona, H.</span>; <span class="NLM_string-name">Walker, J.</span>; <span class="NLM_string-name">Zibrinsky, M.</span>; <span class="NLM_string-name">Balog, J.</span>; <span class="NLM_string-name">Williams, D.</span>; <span class="NLM_string-name">Markwalder, J.</span>; <span class="NLM_string-name">Cherney, E.</span>; <span class="NLM_string-name">Shan, W.</span>; <span class="NLM_string-name">Huang, A.</span></span> <span> </span><span class="NLM_article-title">Immunoregulatory agents</span>. <span class="NLM_patent">WO 2016073770 A1</span>, May 12, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=H.+Beck&author=J.+Carlos&author=J.+Osiprov&author=J.+Powers&author=M.+Reilly&author=H.+Shunatona&author=J.+Walker&author=M.+Zibrinsky&author=J.+Balog&author=D.+Williams&author=J.+Markwalder&author=E.+Cherney&author=W.+Shan&author=A.+Huang&title=Immunoregulatory+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBeck%26aufirst%3DH.%26atitle%3DImmunoregulatory%2520agents%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seliger, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Q.</span></span> <span> </span><span class="NLM_article-title">What Is The Prospect Of Indoleamine 2,3-Dioxygenase 1 Inhibition In Cancer? Extrapolation From The Past</span>. <i>J. Exp. Clin. Canc. Res.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">60</span>, <span class="refDoi"> DOI: 10.1186/s13046-021-01847-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1186%2Fs13046-021-01847-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=33557876" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BB3MXktFymtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2021&pages=60&author=Y.+Yaoauthor=H.+Liangauthor=X.+Fangauthor=S.+Zhangauthor=Z.+Xingauthor=L.+Shiauthor=C.+Kuangauthor=B.+Seligerauthor=Q.+Yang&title=What+Is+The+Prospect+Of+Indoleamine+2%2C3-Dioxygenase+1+Inhibition+In+Cancer%3F+Extrapolation+From+The+Past&doi=10.1186%2Fs13046-021-01847-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">What is the prospect of indoleamine 2,3-dioxygenase 1 inhibition in cancer? Extrapolation from the past</span></div><div class="casAuthors">Yao, Yu; Liang, Heng; Fang, Xin; Zhang, Shengnan; Xing, Zikang; Shi, Lei; Kuang, Chunxiang; Seliger, Barbara; Yang, Qing</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental & Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">60</span>CODEN:
                <span class="NLM_cas:coden">JECRDN</span>;
        ISSN:<span class="NLM_cas:issn">1756-9966</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Indoleamine 2,3-dioxygenase 1 (IDO1), a monomeric heme-contg. enzyme, catalyzes the first and rate-limiting step in the kynurenine pathway of tryptophan metab., which plays an important role in immunity and neuronal function.  Its implication in different pathophysiol. processes including cancer and neurodegenerative diseases has inspired the development of IDO1 inhibitors in the past decades.  However, the neg. results of the phase III clin. trial of the would-be first-in-class IDO1 inhibitor (epacadostat) in combination with an anti-PD1 antibody (pembrolizumab) in patients with advanced malignant melanoma call for a better understanding of the role of IDO1 inhibition.  In this review, the current status of the clin. development of IDO1 inhibitors will be introduced and the key pre-clin. and clin. data of epacadostat will be summarized.  Moreover, based on the cautionary notes obtained from the clin. readout of epacadostat, strategies for the identification of reliable predictive biomarkers and pharmacodynamic markers as well as for the selection of the tumor types to be treated with IDO1inhibitors will be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1kT2hGzb3XbVg90H21EOLACvtfcHk0lhjYqIwyghxsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXktFymtbg%253D&md5=6b3da80ac25d07222ed7a70d9162d3ee</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1186%2Fs13046-021-01847-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13046-021-01847-4%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DY.%26aulast%3DLiang%26aufirst%3DH.%26aulast%3DFang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DXing%26aufirst%3DZ.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DKuang%26aufirst%3DC.%26aulast%3DSeliger%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DQ.%26atitle%3DWhat%2520Is%2520The%2520Prospect%2520Of%2520Indoleamine%25202%252C3-Dioxygenase%25201%2520Inhibition%2520In%2520Cancer%253F%2520Extrapolation%2520From%2520The%2520Past%26jtitle%3DJ.%2520Exp.%2520Clin.%2520Canc.%2520Res.%26date%3D2021%26volume%3D40%26spage%3D60%26doi%3D10.1186%2Fs13046-021-01847-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ping, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bian, J.</span></span> <span> </span><span class="NLM_article-title">Development Of Indoleamine 2,3-Dioxygenase 1 Inhibitors For Cancer Therapy And Beyond: A Recent Perspective</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">15115</span>– <span class="NLM_lpage">15139</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00925</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00925" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitlKrs7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=15115-15139&author=X.+Fengauthor=D.+Liaoauthor=D.+Liuauthor=A.+Pingauthor=Z.+Liauthor=J.+Bian&title=Development+Of+Indoleamine+2%2C3-Dioxygenase+1+Inhibitors+For+Cancer+Therapy+And+Beyond%3A+A+Recent+Perspective&doi=10.1021%2Facs.jmedchem.0c00925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Indoleamine 2,3-Dioxygenase 1 Inhibitors for Cancer Therapy and Beyond: A Recent Perspective</span></div><div class="casAuthors">Feng, Xi; Liao, Dongdong; Liu, Dongyu; Ping, An; Li, Zhiyu; Bian, Jinlei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">15115-15139</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1) has received increasing attention due to its immunosuppressive function in connection with various diseases, including cancer.  A recent increase in the understanding of IDO1 has significantly contributed to the discovery of numerous novel inhibitors, but the latest clin. outcomes raised questions and have indicated a future direction of IDO1 inhibition for therapeutic approaches.  Herein, we present a comprehensive review of IDO1, discussing the latest advances in understanding the IDO1 structure and mechanism, an overview of recent IDO1 inhibitor discoveries and potential therapeutic applications to provide helpful information for medicinal chemists investigating IDO1 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMlqxJwtbFQ7Vg90H21EOLACvtfcHk0lhjYqIwyghxsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitlKrs7rL&md5=b08b669f697bb0473e94710257890460</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00925%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DX.%26aulast%3DLiao%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DPing%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DBian%26aufirst%3DJ.%26atitle%3DDevelopment%2520Of%2520Indoleamine%25202%252C3-Dioxygenase%25201%2520Inhibitors%2520For%2520Cancer%2520Therapy%2520And%2520Beyond%253A%2520A%2520Recent%2520Perspective%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D15115%26epage%3D15139%26doi%3D10.1021%2Facs.jmedchem.0c00925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beatty, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Dwyer, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherle, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newton, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaub, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maleski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leopold, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gajewski, T. F.</span></span> <span> </span><span class="NLM_article-title">First-In-Human Phase I Study Of The Oral Inhibitor Of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) In Patients With Advanced Solid Malignancies</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">3269</span>– <span class="NLM_lpage">3276</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.ccr-16-2272</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1158%2F1078-0432.CCR-16-2272" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=28053021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFSnurfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=3269-3276&author=G.+L.+Beattyauthor=P.+J.+O%E2%80%99Dwyerauthor=J.+Clarkauthor=J.+G.+Shiauthor=K.+J.+Bowmanauthor=P.+A.+Scherleauthor=R.+C.+Newtonauthor=R.+Schaubauthor=J.+Maleskiauthor=L.+Leopoldauthor=T.+F.+Gajewski&title=First-In-Human+Phase+I+Study+Of+The+Oral+Inhibitor+Of+Indoleamine+2%2C3-Dioxygenase-1+Epacadostat+%28INCB024360%29+In+Patients+With+Advanced+Solid+Malignancies&doi=10.1158%2F1078-0432.ccr-16-2272"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies</span></div><div class="casAuthors">Beatty, Gregory L.; O'Dwyer, Peter J.; Clark, Jason; Shi, Jack G.; Bowman, Kevin J.; Scherle, Peggy A.; Newton, Robert C.; Schaub, Richard; Maleski, Janet; Leopold, Lance; Gajewski, Thomas F.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3269-3276</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase-1 (IDO1) catalyzes the degrdn. of tryptophan to N-formyl-kynurenine.  Overexpressed in many solid malignancies, IDO1 can promote tumor escape from host immunosurveillance.  This first-in-human phase I study investigated the max. tolerated dose, safety, pharmacokinetics, pharmacodynamics, and antitumor activity of epacadostat (INCB024360), a potent and selective inhibitor of IDO1.  Fifty-two patients with advanced solid malignancies were treated with epacadostat [50 mg once daily or 50, 100, 300, 400, 500, 600, or 700 mg twice daily (BID)] in a dose-escalation 3 + 3 design and evaluated in 28-day cycles.  Treatment was continued until disease progression or unacceptable toxicity.  One dose-limiting toxicity (DLT) occurred at the dose of 300 mg BID (grade 3, radiation pneumonitis); another DLT occurred at 400 mg BID (grade 3, fatigue).  The most common adverse events in >20% of patients overall were fatigue, nausea, decreased appetite, vomiting, constipation, abdominal pain, diarrhea, dyspnea, back pain, and cough.  Treatment produced significant dose-dependent redns. in plasma kynurenine levels and in the plasma kynurenine/tryptophan ratio at all doses and in all patients.  Near maximal changes were obsd. at doses of ≥100 mg BID with >80% to 90% inhibition of IDO1 achieved throughout the dosing period.  Although no objective responses were detected, stable disease lasting ≥16 wk was obsd. in 7 of 52 patients.  Epacadostat was generally well tolerated, effectively normalized kynurenine levels, and produced maximal inhibition of IDO1 activity at doses of ≥100 mg BID.  Studies investigating epacadostat in combination with other immunomodulatory drugs are ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLdL__p3Q7B7Vg90H21EOLACvtfcHk0lhlH5tmqtQOtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFSnurfP&md5=dee4464e680b476ebe0dbad7f5ec8d46</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-16-2272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-16-2272%26sid%3Dliteratum%253Aachs%26aulast%3DBeatty%26aufirst%3DG.%2BL.%26aulast%3DO%25E2%2580%2599Dwyer%26aufirst%3DP.%2BJ.%26aulast%3DClark%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DJ.%2BG.%26aulast%3DBowman%26aufirst%3DK.%2BJ.%26aulast%3DScherle%26aufirst%3DP.%2BA.%26aulast%3DNewton%26aufirst%3DR.%2BC.%26aulast%3DSchaub%26aufirst%3DR.%26aulast%3DMaleski%26aufirst%3DJ.%26aulast%3DLeopold%26aufirst%3DL.%26aulast%3DGajewski%26aufirst%3DT.%2BF.%26atitle%3DFirst-In-Human%2520Phase%2520I%2520Study%2520Of%2520The%2520Oral%2520Inhibitor%2520Of%2520Indoleamine%25202%252C3-Dioxygenase-1%2520Epacadostat%2520%2528INCB024360%2529%2520In%2520Patients%2520With%2520Advanced%2520Solid%2520Malignancies%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2017%26volume%3D23%26spage%3D3269%26epage%3D3276%26doi%3D10.1158%2F1078-0432.ccr-16-2272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Long, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dummer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamid, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gajewski, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caglevic, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arance, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlino, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grob, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demidov, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larkin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maleski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diede, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, T. C.</span></span> <span> </span><span class="NLM_article-title">Epacadostat Plus Pembrolizumab Versus Placebo Plus Pembrolizumab In Patients With Unresectable Or Metastatic Melanoma (ECHO-301/KEYNOTE-252): A Phase 3, Randomised, Double-Blind Study</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1083</span>– <span class="NLM_lpage">1097</span>, <span class="refDoi"> DOI: 10.1016/s1470-2045(19)30274-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1016%2FS1470-2045%2819%2930274-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=31221619" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtF2kurbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=1083-1097&author=G.+V.+Longauthor=R.+Dummerauthor=O.+Hamidauthor=T.+F.+Gajewskiauthor=C.+Caglevicauthor=S.+Dalleauthor=A.+Aranceauthor=M.+S.+Carlinoauthor=J.-J.+Grobauthor=T.+M.+Kimauthor=L.+Demidovauthor=C.+Robertauthor=J.+Larkinauthor=J.+R.+Andersonauthor=J.+Maleskiauthor=M.+Jonesauthor=S.+J.+Diedeauthor=T.+C.+Mitchell&title=Epacadostat+Plus+Pembrolizumab+Versus+Placebo+Plus+Pembrolizumab+In+Patients+With+Unresectable+Or+Metastatic+Melanoma+%28ECHO-301%2FKEYNOTE-252%29%3A+A+Phase+3%2C+Randomised%2C+Double-Blind+Study&doi=10.1016%2Fs1470-2045%2819%2930274-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomized, double-blind study</span></div><div class="casAuthors">Long, Georgina V.; Dummer, Reinhard; Hamid, Omid; Gajewski, Thomas F.; Caglevic, Christian; Dalle, Stephane; Arance, Ana; Carlino, Matteo S.; Grob, Jean-Jacques; Kim, Tae Min; Demidov, Lev; Robert, Caroline; Larkin, James; Anderson, James R.; Maleski, Janet; Jones, Mark; Diede, Scott J.; Mitchell, Tara C.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1083-1097</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Immunotherapy combination treatments can improve patient outcomes.  Epacadostat, an IDO1 selective inhibitor, and pembrolizumab, a PD-1 inhibitor, showed promising antitumor activity in the phase 1-2 ECHO-202/KEYNOTE-037 study in advanced melanoma.  In this trial, we aimed to compare progression-free survival and overall survival in patients with unresectable stage III or IV melanoma receiving epacadostat plus pembrolizumab vs. placebo plus pembrolizumab.  In this international, randomized, placebo-controlled, double-blind, parallel-group, phase 3 trial, eligible participants were aged 18 years or older, with unresectable stage III or IV melanoma previously untreated with PD-1 or PD-L1 checkpoint inhibitors, an ECOG performance status of 0 or 1, and had a known BRAFV600 mutant status or consented to BRAFV600 mutation testing during screening.  Patients were stratified by PD-L1 expression and BRAFV600 mutation status and randomly assigned (1:1) through a central interactive voice and integrated web response system to receive epacadostat 100 mg orally twice daily plus pembrolizumab 200 mg i.v. every 3 wk or placebo plus pembrolizumab for up to 2 years.  We used block randomization with a block size of four in each stratum.  Primary endpoints were progression-free survival and overall survival in the intention-to-treat population.  The safety anal. population included randomly assigned patients who received at least one dose of study treatment.  The study was stopped after the second interim anal.; follow-up for safety is ongoing.  This study is registered with ClinicalTrials.gov, no. NCT02752074.  Between June 21, 2016, and Aug 7, 2017, 928 patients were screened and 706 patients were randomly assigned to receive epacadostat plus pembrolizumab (n=354) or placebo plus pembrolizumab (n=352).  Median follow-up was 12·4 mo (IQR 10·3-14·5).  No significant differences were found between the treatment groups for progression-free survival (median 4·7 mo, 95% CI 2·9-6·8, for epacadostat plus pembrolizumab vs 4·9 mo, 2·9-6·8, for placebo plus pembrolizumab; hazard ratio [HR] 1·00, 95% CI 0·83-1·21; one-sided p=0·52) or overall survival (median not reached in either group; epacadostat plus pembrolizumab vs placebo plus pembrolizumab: HR 1·13, 0·86-1·49; one-sided p=0·81).  The most common grade 3 or worse treatment-related adverse event was lipase increase, which occurred in 14 (4%) of 353 patients receiving epacadostat plus pembrolizumab and 11 (3%) of 352 patients receiving placebo plus pembrolizumab.  Treatment-related serious adverse events were reported in 37 (10%) of 353 patients receiving epacadostat plus pembrolizumab and 32 (9%) of 352 patients receiving placebo plus pembrolizumab.  There were no treatment-related deaths in either treatment group.  Epacadostat 100 mg twice daily plus pembrolizumab did not improve progression-free survival or overall survival compared with placebo plus pembrolizumab in patients with unresectable or metastatic melanoma.  The usefulness of IDO1 inhibition as a strategy to enhance anti-PD-1 therapy activity in cancer remains uncertain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8j2WQ35JqjbVg90H21EOLACvtfcHk0lhlH5tmqtQOtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtF2kurbM&md5=f1dce1f431d2650fe4f8b8e46677e03d</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2819%2930274-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252819%252930274-8%26sid%3Dliteratum%253Aachs%26aulast%3DLong%26aufirst%3DG.%2BV.%26aulast%3DDummer%26aufirst%3DR.%26aulast%3DHamid%26aufirst%3DO.%26aulast%3DGajewski%26aufirst%3DT.%2BF.%26aulast%3DCaglevic%26aufirst%3DC.%26aulast%3DDalle%26aufirst%3DS.%26aulast%3DArance%26aufirst%3DA.%26aulast%3DCarlino%26aufirst%3DM.%2BS.%26aulast%3DGrob%26aufirst%3DJ.-J.%26aulast%3DKim%26aufirst%3DT.%2BM.%26aulast%3DDemidov%26aufirst%3DL.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DAnderson%26aufirst%3DJ.%2BR.%26aulast%3DMaleski%26aufirst%3DJ.%26aulast%3DJones%26aufirst%3DM.%26aulast%3DDiede%26aufirst%3DS.%2BJ.%26aulast%3DMitchell%26aufirst%3DT.%2BC.%26atitle%3DEpacadostat%2520Plus%2520Pembrolizumab%2520Versus%2520Placebo%2520Plus%2520Pembrolizumab%2520In%2520Patients%2520With%2520Unresectable%2520Or%2520Metastatic%2520Melanoma%2520%2528ECHO-301%252FKEYNOTE-252%2529%253A%2520A%2520Phase%25203%252C%2520Randomised%252C%2520Double-Blind%2520Study%26jtitle%3DLancet%2520Oncol.%26date%3D2019%26volume%3D20%26spage%3D1083%26epage%3D1097%26doi%3D10.1016%2Fs1470-2045%2819%2930274-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nayak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobbins, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vahanian, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mautino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Link, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Royer-Joo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrissey, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahrus, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCall, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirzkall, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janik, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khleif, S.</span></span> <span> </span><span class="NLM_article-title">346 Phase 1A Study Of The Safety, Pharmacokinetics, And Pharmacodynamics Of GDC-0919 In Patients With Recurrent/Advanced Solid Tumors</span>. <i>Eur. J. Canc.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">S69</span>, <span class="refDoi"> DOI: 10.1016/s0959-8049(16)30209-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1016%2FS0959-8049%2816%2930209-X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2015&pages=S69&author=A.+Nayakauthor=Z.+Haoauthor=R.+Sadekauthor=R.+Dobbinsauthor=L.+Marshallauthor=N.+Vahanianauthor=J.+Ramseyauthor=E.+Kennedyauthor=M.+Mautinoauthor=C.+Linkauthor=R.+Linauthor=S.+Royer-Jooauthor=K.+Morrisseyauthor=S.+Mahrusauthor=B.+McCallauthor=A.+Pirzkallauthor=D.+Munnauthor=J.+Janikauthor=S.+Khleif&title=346+Phase+1A+Study+Of+The+Safety%2C+Pharmacokinetics%2C+And+Pharmacodynamics+Of+GDC-0919+In+Patients+With+Recurrent%2FAdvanced+Solid+Tumors&doi=10.1016%2Fs0959-8049%2816%2930209-x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2FS0959-8049%2816%2930209-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0959-8049%252816%252930209-X%26sid%3Dliteratum%253Aachs%26aulast%3DNayak%26aufirst%3DA.%26aulast%3DHao%26aufirst%3DZ.%26aulast%3DSadek%26aufirst%3DR.%26aulast%3DDobbins%26aufirst%3DR.%26aulast%3DMarshall%26aufirst%3DL.%26aulast%3DVahanian%26aufirst%3DN.%26aulast%3DRamsey%26aufirst%3DJ.%26aulast%3DKennedy%26aufirst%3DE.%26aulast%3DMautino%26aufirst%3DM.%26aulast%3DLink%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DR.%26aulast%3DRoyer-Joo%26aufirst%3DS.%26aulast%3DMorrissey%26aufirst%3DK.%26aulast%3DMahrus%26aufirst%3DS.%26aulast%3DMcCall%26aufirst%3DB.%26aulast%3DPirzkall%26aufirst%3DA.%26aulast%3DMunn%26aufirst%3DD.%26aulast%3DJanik%26aufirst%3DJ.%26aulast%3DKhleif%26aufirst%3DS.%26atitle%3D346%2520Phase%25201A%2520Study%2520Of%2520The%2520Safety%252C%2520Pharmacokinetics%252C%2520And%2520Pharmacodynamics%2520Of%2520GDC-0919%2520In%2520Patients%2520With%2520Recurrent%252FAdvanced%2520Solid%2520Tumors%26jtitle%3DEur.%2520J.%2520Canc.%26date%3D2015%26volume%3D51%26spage%3DS69%26doi%3D10.1016%2Fs0959-8049%2816%2930209-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nelp, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kates, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newitt, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balog, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allentoff, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borzilleri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seitz, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groves, J. T.</span></span> <span> </span><span class="NLM_article-title">Immune-Modulating Enzyme Indoleamine 2,3-Dioxygenase Is Effectively Inhibited By Targeting Its Apo-Form</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">3249</span>– <span class="NLM_lpage">3254</span>, <span class="refDoi"> DOI: 10.1073/pnas.1719190115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1073%2Fpnas.1719190115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=29531094" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1Ckur7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2018&pages=3249-3254&author=M.+T.+Nelpauthor=P.+A.+Katesauthor=J.+T.+Huntauthor=J.+A.+Newittauthor=A.+Balogauthor=D.+Maleyauthor=X.+Zhuauthor=L.+Abellauthor=A.+Allentoffauthor=R.+Borzilleriauthor=H.+A.+Lewisauthor=Z.+Linauthor=S.+P.+Seitzauthor=C.+Yanauthor=J.+T.+Groves&title=Immune-Modulating+Enzyme+Indoleamine+2%2C3-Dioxygenase+Is+Effectively+Inhibited+By+Targeting+Its+Apo-Form&doi=10.1073%2Fpnas.1719190115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Immune-modulating enzyme indoleamine 2,3-dioxygenase is effectively inhibited by targeting its apo-form</span></div><div class="casAuthors">Nelp, Micah T.; Kates, Patrick A.; Hunt, John T.; Newitt, John A.; Balog, Aaron; Maley, Derrick; Zhu, Xiao; Abelle, Lynn; Allentoff, Alban; Borzilleri, Robert; Lewis, Hal A.; Lin, Zeyu; Seitz, Steven P.; Yan, Chunhong; Groves, John T.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3249-3254</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">For cancer cells to survive and proliferate, they must escape normal immune destruction.  One mechanism by which this is accomplished is through immune suppression effected by up-regulation of indole- amine 2,3-dioxygenase (IDO1), a heme enzyme that catalyzes the oxidn. of tryptophan to N-formylkynurenine.  On deformylation, kynurenine and downstream metabolites suppress T cell function.  The importance of this immunosuppressive mechanism has spurred intense interest in the development of clin. IDO1 inhibitors.  Herein, we describe the mechanism by which a class of compds. effectively and specifically inhibits IDO1 by targeting its apo- form.  We show that the in vitro kinetics of inhibition coincide with an unusually high rate of intrinsic enzyme-heme dissocn., esp. in the ferric form.  X-ray crystal structures of the inhibitor-enzyme complexes show that heme is displaced from the enzyme and blocked from rebinding by these compds.  The results reveal that apo-IDO1 serves as a unique target for inhibition and that heme lability plays an important role in posttranslational regulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoqG51BFbfm7Vg90H21EOLACvtfcHk0ljwlYQsfsdMng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1Ckur7I&md5=b44352b022692d150053696bb984665f</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1719190115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1719190115%26sid%3Dliteratum%253Aachs%26aulast%3DNelp%26aufirst%3DM.%2BT.%26aulast%3DKates%26aufirst%3DP.%2BA.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DNewitt%26aufirst%3DJ.%2BA.%26aulast%3DBalog%26aufirst%3DA.%26aulast%3DMaley%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DAbell%26aufirst%3DL.%26aulast%3DAllentoff%26aufirst%3DA.%26aulast%3DBorzilleri%26aufirst%3DR.%26aulast%3DLewis%26aufirst%3DH.%2BA.%26aulast%3DLin%26aufirst%3DZ.%26aulast%3DSeitz%26aufirst%3DS.%2BP.%26aulast%3DYan%26aufirst%3DC.%26aulast%3DGroves%26aufirst%3DJ.%2BT.%26atitle%3DImmune-Modulating%2520Enzyme%2520Indoleamine%25202%252C3-Dioxygenase%2520Is%2520Effectively%2520Inhibited%2520By%2520Targeting%2520Its%2520Apo-Form%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2018%26volume%3D115%26spage%3D3249%26epage%3D3254%26doi%3D10.1073%2Fpnas.1719190115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Balog, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T.-a.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gullo-Brown, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kandoussi, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. T.</span></span> <span> </span><span class="NLM_article-title">Preclinical Characterization Of Linrodostat Mesylate, A Novel, Potent, And Selective Oral Indoleamine 2,3-Dioxygenase 1 Inhibitor</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">467</span>– <span class="NLM_lpage">476</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.mct-20-0251</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1158%2F1535-7163.MCT-20-0251" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=33298590" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2020&pages=467-476&author=A.+Balogauthor=T.-a.+Linauthor=D.+Maleyauthor=J.+Gullo-Brownauthor=E.+H.+Kandoussiauthor=J.+Zengauthor=J.+T.+Hunt&title=Preclinical+Characterization+Of+Linrodostat+Mesylate%2C+A+Novel%2C+Potent%2C+And+Selective+Oral+Indoleamine+2%2C3-Dioxygenase+1+Inhibitor&doi=10.1158%2F1535-7163.mct-20-0251"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-20-0251&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-20-0251%26sid%3Dliteratum%253Aachs%26aulast%3DBalog%26aufirst%3DA.%26aulast%3DLin%26aufirst%3DT.-a.%26aulast%3DMaley%26aufirst%3DD.%26aulast%3DGullo-Brown%26aufirst%3DJ.%26aulast%3DKandoussi%26aufirst%3DE.%2BH.%26aulast%3DZeng%26aufirst%3DJ.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26atitle%3DPreclinical%2520Characterization%2520Of%2520Linrodostat%2520Mesylate%252C%2520A%2520Novel%252C%2520Potent%252C%2520And%2520Selective%2520Oral%2520Indoleamine%25202%252C3-Dioxygenase%25201%2520Inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2020%26volume%3D20%26spage%3D467%26epage%3D476%26doi%3D10.1158%2F1535-7163.mct-20-0251" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, M. M. T.</span>; <span class="NLM_string-name">Dancsok, A. R.</span>; <span class="NLM_string-name">Nielsen, T. O.</span></span> <span> </span><span class="NLM_article-title">Indoleamine Dioxygenase Inhibitors: Clinical Rationale And Current Development</span>.  <i>Curr. Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume">21</span>.2 <span class="refDoi"> DOI: 10.1007/s11912-019-0750-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1007%2Fs11912-019-0750-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=30659394" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2019&author=M.+M.+T.+Zhu&author=A.+R.+Dancsok&author=T.+O.+Nielsen&title=Indoleamine+Dioxygenase+Inhibitors%3A+Clinical+Rationale+And+Current+Development&doi=10.1007%2Fs11912-019-0750-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1007%2Fs11912-019-0750-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11912-019-0750-1%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DM.%2BM.%2BT.%26atitle%3DIndoleamine%2520Dioxygenase%2520Inhibitors%253A%2520Clinical%2520Rationale%2520And%2520Current%2520Development%26jtitle%3DCurr.%2520Oncol.%2520Rep.%26date%3D2019%26volume%3D21%26doi%3D10.1007%2Fs11912-019-0750-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lewis-Ballester, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pham, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batabyal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karkashon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonanno, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulos, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, S. R.</span></span> <span> </span><span class="NLM_article-title">Structural Insights Into Substrate And Inhibitor Binding Sites In Human Indoleamine 2,3-Dioxygenase 1</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1693</span>, <span class="refDoi"> DOI: 10.1038/s41467-017-01725-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1038%2Fs41467-017-01725-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=29167421" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A280%3ADC%252BC1M3ktFOhtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1693&author=A.+Lewis-Ballesterauthor=K.+N.+Phamauthor=D.+Batabyalauthor=S.+Karkashonauthor=J.+B.+Bonannoauthor=T.+L.+Poulosauthor=S.+R.+Yeh&title=Structural+Insights+Into+Substrate+And+Inhibitor+Binding+Sites+In+Human+Indoleamine+2%2C3-Dioxygenase+1&doi=10.1038%2Fs41467-017-01725-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Structural insights into substrate and inhibitor binding sites in human indoleamine 2,3-dioxygenase 1</span></div><div class="casAuthors">Lewis-Ballester Ariel; Pham Khoa N; Karkashon Shay; Yeh Syun-Ru; Batabyal Dipanwita; Poulos Thomas L; Batabyal Dipanwita; Poulos Thomas L; Batabyal Dipanwita; Poulos Thomas L; Bonanno Jeffrey B</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1693</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Human indoleamine 2,3-dioxygenase 1 (hIDO1) is an attractive cancer immunotherapeutic target owing to its role in promoting tumoral immune escape.  However, drug development has been hindered by limited structural information.  Here, we report the crystal structures of hIDO1 in complex with its substrate, Trp, an inhibitor, epacadostat, and/or an effector, indole ethanol (IDE).  The data reveal structural features of the active site (Sa) critical for substrate activation; in addition, they disclose a new inhibitor-binding mode and a distinct small molecule binding site (Si).  Structure-guided mutation of a critical residue, F270, to glycine perturbs the Si site, allowing structural determination of an inhibitory complex, where both the Sa and Si sites are occupied by Trp.  The Si site offers a novel target site for allosteric inhibitors and a molecular explanation for the previously baffling substrate-inhibition behavior of the enzyme.  Taken together, the data open exciting new avenues for structure-based drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQI81SqDTDg0dbHMBt0mMIXfW6udTcc2eb9Gqq9MWPTorntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M3ktFOhtQ%253D%253D&md5=36b0221b0726c73a6c4345e4cf2ec8be</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fs41467-017-01725-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-017-01725-8%26sid%3Dliteratum%253Aachs%26aulast%3DLewis-Ballester%26aufirst%3DA.%26aulast%3DPham%26aufirst%3DK.%2BN.%26aulast%3DBatabyal%26aufirst%3DD.%26aulast%3DKarkashon%26aufirst%3DS.%26aulast%3DBonanno%26aufirst%3DJ.%2BB.%26aulast%3DPoulos%26aufirst%3DT.%2BL.%26aulast%3DYeh%26aufirst%3DS.%2BR.%26atitle%3DStructural%2520Insights%2520Into%2520Substrate%2520And%2520Inhibitor%2520Binding%2520Sites%2520In%2520Human%2520Indoleamine%25202%252C3-Dioxygenase%25201%26jtitle%3DNat.%2520Commun.%26date%3D2017%26volume%3D8%26spage%3D1693%26doi%3D10.1038%2Fs41467-017-01725-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Röhrig, U. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynaud, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majjigapu, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pojer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoete, V.</span></span> <span> </span><span class="NLM_article-title">Inhibition Mechanisms Of Indoleamine 2,3-Dioxygenase 1 (IDO1)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">8784</span>– <span class="NLM_lpage">8795</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00942</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00942" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslOqu7%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=8784-8795&author=U.+F.+R%C3%B6hrigauthor=A.+Reynaudauthor=S.+R.+Majjigapuauthor=P.+Vogelauthor=F.+Pojerauthor=V.+Zoete&title=Inhibition+Mechanisms+Of+Indoleamine+2%2C3-Dioxygenase+1+%28IDO1%29&doi=10.1021%2Facs.jmedchem.9b00942"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition Mechanisms of Indoleamine 2,3-Dioxygenase 1 (IDO1)</span></div><div class="casAuthors">Rohrig, Ute F.; Reynaud, Aline; Majjigapu, Somi Reddy; Vogel, Pierre; Pojer, Florence; Zoete, Vincent</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8784-8795</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1) catalyzes the rate-limiting step in the kynurenine pathway of tryptophan metab., which is involved in immunity, neuronal function, and aging.  Its implication in pathologies such as cancer and neurodegenerative diseases has stimulated the development of IDO1 inhibitors.  However, neg. phase III clin. trial results of the IDO1 inhibitor epacadostat in cancer immunotherapy call for a better understanding of the role and the mechanisms of IDO1 inhibition.  In this work, we investigate the mol. inhibition mechanisms of four known IDO1 inhibitors and of two quinones in detail, using different exptl. and computational approaches.  We also det. for the first time the X-ray structure of the highly efficient 1,2,3-triazole inhibitor MMG-0358.  Based on our results and a comprehensive literature overview, we propose a classification scheme for IDO1 inhibitors according to their inhibition mechanism, which will be useful for further developments in the field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTZnLePiNWE7Vg90H21EOLACvtfcHk0lhYVqTmV9j-8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslOqu7%252FP&md5=01919796d4821743975fe01a5527008c</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00942&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00942%26sid%3Dliteratum%253Aachs%26aulast%3DR%25C3%25B6hrig%26aufirst%3DU.%2BF.%26aulast%3DReynaud%26aufirst%3DA.%26aulast%3DMajjigapu%26aufirst%3DS.%2BR.%26aulast%3DVogel%26aufirst%3DP.%26aulast%3DPojer%26aufirst%3DF.%26aulast%3DZoete%26aufirst%3DV.%26atitle%3DInhibition%2520Mechanisms%2520Of%2520Indoleamine%25202%252C3-Dioxygenase%25201%2520%2528IDO1%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D8784%26epage%3D8795%26doi%3D10.1021%2Facs.jmedchem.9b00942" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pham, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, S.-R.</span></span> <span> </span><span class="NLM_article-title">Mapping The Binding Trajectory Of A Suicide Inhibitor In Human Indoleamine 2,3-Dioxygenase 1</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>140</i></span>,  <span class="NLM_fpage">14538</span>– <span class="NLM_lpage">14541</span>, <span class="refDoi"> DOI: 10.1021/jacs.8b07994</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.8b07994" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFygsbfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2018&pages=14538-14541&author=K.+N.+Phamauthor=S.-R.+Yeh&title=Mapping+The+Binding+Trajectory+Of+A+Suicide+Inhibitor+In+Human+Indoleamine+2%2C3-Dioxygenase+1&doi=10.1021%2Fjacs.8b07994"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Mapping the Binding Trajectory of a Suicide Inhibitor in Human Indoleamine 2,3-Dioxygenase 1</span></div><div class="casAuthors">Pham, Khoa N.; Yeh, Syun-Ru</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">14538-14541</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Human indoleamine 2,3-dioxygenase 1 (hIDO1) is an important heme-contg. enzyme that is a key drug target for cancer immunotherapy.  Several hIDO1 inhibitors have entered clin. trials, among which BMS-986205 (BMS) stands out as the only suicide inhibitor.  Despite its "best-in-class" activity, the action mechanism of BMS remains elusive.  Here, we report three crystal structures of hIDO1-BMS complexes that define the complete binding trajectory of the inhibitor.  BMS first binds in a solvent exposed surface cleft near the active site in an extended conformation.  The initial binding partially unfolds the active site, which triggers heme release, thereby exposing a new binding pocket.  The inhibitor then undergoes a large scale movement to this new binding pocket, where it binds by adopting a high energy kinked conformation.  Finally, the inhibitor relaxes to a bent conformation, via an addnl. large scale rearrangement, culminating in the energy min. state.  The structural data offer a mol. explanation for the remarkable efficacy and suicide inhibition activity of the inhibitor.  They also suggest a novel strategy that can be applied for drug development targeting hIDO1 and related enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo49tBUq_145rVg90H21EOLACvtfcHk0lhYVqTmV9j-8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFygsbfJ&md5=833164c8276bd3b8d9d93df197cf4780</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjacs.8b07994&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.8b07994%26sid%3Dliteratum%253Aachs%26aulast%3DPham%26aufirst%3DK.%2BN.%26aulast%3DYeh%26aufirst%3DS.-R.%26atitle%3DMapping%2520The%2520Binding%2520Trajectory%2520Of%2520A%2520Suicide%2520Inhibitor%2520In%2520Human%2520Indoleamine%25202%252C3-Dioxygenase%25201%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2018%26volume%3D140%26spage%3D14538%26epage%3D14541%26doi%3D10.1021%2Fjacs.8b07994" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Serafini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torre, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aprile, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosso, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gesù, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griglio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colombo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Travelli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paiella, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adamo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orecchini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coletti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallotta, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ugel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massarotti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirali, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fallarini, S.</span></span> <span> </span><span class="NLM_article-title">Discovery Of Highly Potent Benzimidazole Derivatives As Indoleamine 2,3-Dioxygenase-1 (IDO1) Inhibitors: From Structure-Based Virtual Screening To In Vivo Pharmacodynamic Activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">3047</span>– <span class="NLM_lpage">3065</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01809</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01809" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BB3cXksFaitbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=3047-3065&author=M.+Serafiniauthor=E.+Torreauthor=S.+Aprileauthor=E.+D.+Grossoauthor=A.+Ges%C3%B9author=A.+Griglioauthor=G.+Colomboauthor=C.+Travelliauthor=S.+Paiellaauthor=A.+Adamoauthor=E.+Orecchiniauthor=A.+Colettiauthor=M.+T.+Pallottaauthor=S.+Ugelauthor=A.+Massarottiauthor=T.+Piraliauthor=S.+Fallarini&title=Discovery+Of+Highly+Potent+Benzimidazole+Derivatives+As+Indoleamine+2%2C3-Dioxygenase-1+%28IDO1%29+Inhibitors%3A+From+Structure-Based+Virtual+Screening+To+In+Vivo+Pharmacodynamic+Activity&doi=10.1021%2Facs.jmedchem.9b01809"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Highly Potent Benzimidazole Derivatives as Indoleamine 2,3-Dioxygenase-1 (IDO1) Inhibitors: From Structure-Based Virtual Screening to in Vivo Pharmacodynamic Activity</span></div><div class="casAuthors">Serafini, Marta; Torre, Enza; Aprile, Silvio; Grosso, Erika Del; Gesu, Alessandro; Griglio, Alessia; Colombo, Giorgia; Travelli, Cristina; Paiella, Salvatore; Adamo, Annalisa; Orecchini, Elena; Coletti, Alice; Pallotta, Maria Teresa; Ugel, Stefano; Massarotti, Alberto; Pirali, Tracey; Fallarini, Silvia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">3047-3065</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this study, a successful medicinal chem. campaign that exploited virtual, biophys., and biol. investigations led to the identification of a novel class of IDO1 inhibitors based on a benzimidazole substructure.  This family of compds. is endowed with an extensive bonding network in the protein active site, including the interaction with pocket C, a region not commonly exploited by previously reported IDO1 inhibitors.  The tight packing of selected compds. within the enzyme contributes to the strong binding interaction with IDO1, to the inhibitory potency at the low nanomolar level in several tumoral settings, and to the selectivity toward IDO1 over TDO and CYPs.  Notably, a significant redn. of L-Kyn levels in plasma, together with a potent effect on abrogating immunosuppressive properties of MDSC-like cells isolated from patients affected by pancreatic ductal adenocarcinoma, was obsd., pointing to this class of mols. as a valuable template for boosting the antitumor immune system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSfZttD9qaarVg90H21EOLACvtfcHk0lhYVqTmV9j-8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXksFaitbs%253D&md5=118293cb0e185b77b209568fa4c151a2</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01809&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01809%26sid%3Dliteratum%253Aachs%26aulast%3DSerafini%26aufirst%3DM.%26aulast%3DTorre%26aufirst%3DE.%26aulast%3DAprile%26aufirst%3DS.%26aulast%3DGrosso%26aufirst%3DE.%2BD.%26aulast%3DGes%25C3%25B9%26aufirst%3DA.%26aulast%3DGriglio%26aufirst%3DA.%26aulast%3DColombo%26aufirst%3DG.%26aulast%3DTravelli%26aufirst%3DC.%26aulast%3DPaiella%26aufirst%3DS.%26aulast%3DAdamo%26aufirst%3DA.%26aulast%3DOrecchini%26aufirst%3DE.%26aulast%3DColetti%26aufirst%3DA.%26aulast%3DPallotta%26aufirst%3DM.%2BT.%26aulast%3DUgel%26aufirst%3DS.%26aulast%3DMassarotti%26aufirst%3DA.%26aulast%3DPirali%26aufirst%3DT.%26aulast%3DFallarini%26aufirst%3DS.%26atitle%3DDiscovery%2520Of%2520Highly%2520Potent%2520Benzimidazole%2520Derivatives%2520As%2520Indoleamine%25202%252C3-Dioxygenase-1%2520%2528IDO1%2529%2520Inhibitors%253A%2520From%2520Structure-Based%2520Virtual%2520Screening%2520To%2520In%2520Vivo%2520Pharmacodynamic%2520Activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D3047%26epage%3D3065%26doi%3D10.1021%2Facs.jmedchem.9b01809" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, F.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, C.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuppusamy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, A.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsueh, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shia, K.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, T.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, M.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueng, S.-H.</span></span> <span> </span><span class="NLM_article-title">Unique Sulfur–Aromatic Interactions Contribute To The Binding Of Potent Imidazothiazole Indoleamine 2,3-Dioxygenase Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">1642</span>– <span class="NLM_lpage">1659</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01549</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01549" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsFSmu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=1642-1659&author=Y.-H.+Pengauthor=F.-Y.+Liaoauthor=C.-T.+Tsengauthor=R.+Kuppusamyauthor=A.-S.+Liauthor=C.-H.+Chenauthor=Y.-S.+Fanauthor=S.-Y.+Wangauthor=M.-H.+Wuauthor=C.-C.+Hsuehauthor=J.-Y.+Changauthor=L.-C.+Leeauthor=C.+Shihauthor=K.-S.+Shiaauthor=T.-K.+Yehauthor=M.-S.+Hungauthor=C.-C.+Kuoauthor=J.-S.+Songauthor=S.-Y.+Wuauthor=S.-H.+Ueng&title=Unique+Sulfur%E2%80%93Aromatic+Interactions+Contribute+To+The+Binding+Of+Potent+Imidazothiazole+Indoleamine+2%2C3-Dioxygenase+Inhibitors&doi=10.1021%2Facs.jmedchem.9b01549"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Unique Sulfur-Aromatic Interactions Contribute to the Binding of Potent Imidazothiazole Indoleamine 2,3-Dioxygenase Inhibitors</span></div><div class="casAuthors">Peng, Yi-Hui; Liao, Fang-Yu; Tseng, Chen-Tso; Kuppusamy, Ramajayam; Li, An-Siou; Chen, Chi-Han; Fan, Yu-Shiou; Wang, Sing-Yi; Wu, Mine-Hsine; Hsueh, Ching-Cheng; Chang, Jia-Yu; Lee, Lung-Chun; Shih, Chuan; Shia, Kak-Shan; Yeh, Teng-Kuang; Hung, Ming-Shiu; Kuo, Ching-Chuan; Song, Jen-Shin; Wu, Su-Ying; Ueng, Shau-Hua</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1642-1659</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase (IDO1) inhibitors are speculated to be useful in cancer immunotherapy, but a phase III clin. trial of the most advanced IDO1 inhibitor, epacadostat, did not meet its primary endpoint and was abandoned.  In previous work we identified the novel IDO1 inhibitor N-(4-chlorophenyl)-2-((5-phenylthiazolo[2,3-c][1,2,4]triazol-3-yl)thio)acetamide 1 through high-throughput screening (HTS).  Herein, we report a structure-activity relationship (SAR) study of this compd., which resulted in the potent IDO1 inhibitor 1-(4-cyanophenyl)-3-(3-(cyclopropylethynyl)imidazo[2,1-b]thiazol-5-yl)thiourea 47 (hIDO IC50 = 16.4 nM).  X-ray co-crystal structural anal. revealed that the basis for this high potency is a unique sulfur-arom. interaction network formed by the thiourea moiety of 47 with the F163 and F226.  This finding is expected to inspire new approaches towards the discovery of potent IDO1 inhibitors in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLdRgatLF0JLVg90H21EOLACvtfcHk0ljKLdt5JWR2kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsFSmu7s%253D&md5=fa171b57b2e03f46d1658ba29419a150</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01549&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01549%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DY.-H.%26aulast%3DLiao%26aufirst%3DF.-Y.%26aulast%3DTseng%26aufirst%3DC.-T.%26aulast%3DKuppusamy%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DA.-S.%26aulast%3DChen%26aufirst%3DC.-H.%26aulast%3DFan%26aufirst%3DY.-S.%26aulast%3DWang%26aufirst%3DS.-Y.%26aulast%3DWu%26aufirst%3DM.-H.%26aulast%3DHsueh%26aufirst%3DC.-C.%26aulast%3DChang%26aufirst%3DJ.-Y.%26aulast%3DLee%26aufirst%3DL.-C.%26aulast%3DShih%26aufirst%3DC.%26aulast%3DShia%26aufirst%3DK.-S.%26aulast%3DYeh%26aufirst%3DT.-K.%26aulast%3DHung%26aufirst%3DM.-S.%26aulast%3DKuo%26aufirst%3DC.-C.%26aulast%3DSong%26aufirst%3DJ.-S.%26aulast%3DWu%26aufirst%3DS.-Y.%26aulast%3DUeng%26aufirst%3DS.-H.%26atitle%3DUnique%2520Sulfur%25E2%2580%2593Aromatic%2520Interactions%2520Contribute%2520To%2520The%2520Binding%2520Of%2520Potent%2520Imidazothiazole%2520Indoleamine%25202%252C3-Dioxygenase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D1642%26epage%3D1659%26doi%3D10.1021%2Facs.jmedchem.9b01549" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, L.-h.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis, And Biological Evaluation Of 1,2,5-Oxadiazole-3-Carboximidamide Derivatives As Novel Indoleamine-2,3-Dioxygenase 1 Inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>189</i></span>,  <span class="NLM_fpage">112059</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1016%2Fj.ejmech.2020.112059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=31981851" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslSgtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=189&publication_year=2020&pages=112059&author=X.+Songauthor=P.+Sunauthor=J.+Wangauthor=W.+Guoauthor=Y.+Wangauthor=L.-h.+Mengauthor=H.+Liu&title=Design%2C+Synthesis%2C+And+Biological+Evaluation+Of+1%2C2%2C5-Oxadiazole-3-Carboximidamide+Derivatives+As+Novel+Indoleamine-2%2C3-Dioxygenase+1+Inhibitors&doi=10.1016%2Fj.ejmech.2020.112059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, and biological evaluation of 1,2,5-oxadiazole-3-carboximidamide derivatives as novel indoleamine-2,3-dioxygenase 1 inhibitors</span></div><div class="casAuthors">Song, Xiaohan; Sun, Pu; Wang, Jiang; Guo, Wei; Wang, Yi; Meng, Ling-hua; Liu, Hong</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">189</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112059</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A novel series of 1,2,5-oxadiazole-3-carboximidamide derivs. I [R = (1-sulfamoylpyrrolidin-3-yl)methyl, (1-methanesulfonylpyrrolidin-3-yl)methyl, [1-(cyclopropanesulfonyl)piperidin-3-yl]methyl, etc] bearing cycle in the side chain were designed, synthesized, and biol. evaluated for their anti-tumor activity.  Most of them exhibited potent activity against hIDO1 in enzymic assays and in HEK293T cells over-expressing hIDO1.  Among them, compd. I [R = [(3R)-1-sulfamoylpyrrolidin-3-yl]methyl, [(3R)-1-sulfamoylpiperidin-3-yl]methyl, [(3S)-1-sulfamoylpiperidin-3-yl]methyl] showed significant inhibitory activity against hIDO1 (IC50 = 108.7, 178.1 and 139.1 nM resp.) and in HEK293T cells expressing hIDO1 (cellular IC50 = 19.88, 68.59 and 57.76 nM resp.).  Moreover, compd. I [R = [(3R)-1-sulfamoylpiperidin-3-yl]methyl] displayed improved PK property with longer half-life (t1/2 = 3.81 h in CD-1 mice) and better oral bioavailability (F = 33.6%) compared with epacadostat.  In addn., compd. I [R = [(3R)-1-sulfamoylpiperidin-3-yl]methyl] showed similar potency to inhibit the growth of CT-26 syngeneic xenograft compared to epacadostat, making it justifiable for further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOVCKyiy04nLVg90H21EOLACvtfcHk0ljKLdt5JWR2kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslSgtrc%253D&md5=eaacdbc7d1498bc8644774d4ae1ff3d0</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112059%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DX.%26aulast%3DSun%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DGuo%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DMeng%26aufirst%3DL.-h.%26aulast%3DLiu%26aufirst%3DH.%26atitle%3DDesign%252C%2520Synthesis%252C%2520And%2520Biological%2520Evaluation%2520Of%25201%252C2%252C5-Oxadiazole-3-Carboximidamide%2520Derivatives%2520As%2520Novel%2520Indoleamine-2%252C3-Dioxygenase%25201%2520Inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D189%26spage%3D112059%26doi%3D10.1016%2Fj.ejmech.2020.112059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cowley, P.</span>; <span class="NLM_string-name">McGowan, M.</span>; <span class="NLM_string-name">Brown, T.</span>; <span class="NLM_string-name">Han, Y.</span>; <span class="NLM_string-name">Liu, K.</span>; <span class="NLM_string-name">Pu, Q.</span>; <span class="NLM_string-name">Wise, A.</span>; <span class="NLM_string-name">Zhang, H.</span>; <span class="NLM_string-name">Zhou, H.</span></span> <span> </span><span class="NLM_article-title">Novel substituted imidazopyridine compounds as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan-2,3-dioxygenase</span>. <span class="NLM_patent">WO 2017189386 A1</span>, Nov 2, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=P.+Cowley&author=M.+McGowan&author=T.+Brown&author=Y.+Han&author=K.+Liu&author=Q.+Pu&author=A.+Wise&author=H.+Zhang&author=H.+Zhou&title=Novel+substituted+imidazopyridine+compounds+as+inhibitors+of+indoleamine+2%2C3-dioxygenase+and%2For+tryptophan-2%2C3-dioxygenase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCowley%26aufirst%3DP.%26atitle%3DNovel%2520substituted%2520imidazopyridine%2520compounds%2520as%2520inhibitors%2520of%2520indoleamine%25202%252C3-dioxygenase%2520and%252For%2520tryptophan-2%252C3-dioxygenase%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, R.</span>; <span class="NLM_string-name">Jones, P.</span>; <span class="NLM_string-name">Petrocchi, A.</span>; <span class="NLM_string-name">Reyna, N.</span>; <span class="NLM_string-name">Hamilton, M.</span>; <span class="NLM_string-name">Cross, J.</span>; <span class="NLM_string-name">Tremblay, M.</span>; <span class="NLM_string-name">Leonard, P.</span></span> Compounds. <span class="NLM_patent">WO 2018136887 A1</span>, July 26, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Lewis%2C+R.%3B+Jones%2C+P.%3B+Petrocchi%2C+A.%3B+Reyna%2C+N.%3B+Hamilton%2C+M.%3B+Cross%2C+J.%3B+Tremblay%2C+M.%3B+Leonard%2C+P.+Compounds.+WO+2018136887+A1%2C+July+26%2C+2018."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLewis%26aufirst%3DR.%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cherney, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gullo-Brown, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darienzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Discenza, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranasinghe, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grubb, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziemba, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traeger, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopcho, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fereshteh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefanski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fargnoli, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swanson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delpy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seitz, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borzilleri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vite, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balog, A.</span></span> <span> </span><span class="NLM_article-title">Discovery And Preclinical Evaluation Of BMS-986242, A Potent, Selective Inhibitor Of Indoleamine-2,3-Dioxygenase 1</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">288</span>– <span class="NLM_lpage">294</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.0c00668</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.0c00668" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BB3MXitFyis7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2021&pages=288-294&author=E.+C.+Cherneyauthor=L.+Zhangauthor=S.+Naraauthor=X.+Zhuauthor=J.+Gullo-Brownauthor=D.+Maleyauthor=T.-A.+Linauthor=J.+T.+Huntauthor=C.+Huangauthor=Z.+Yangauthor=C.+Darienzoauthor=L.+Discenzaauthor=A.+Ranasingheauthor=M.+Grubbauthor=T.+Ziembaauthor=S.+C.+Traegerauthor=X.+Liauthor=K.+Johnstonauthor=L.+Kopchoauthor=M.+Fereshtehauthor=K.+Fosterauthor=K.+Stefanskiauthor=J.+Fargnoliauthor=J.+Swansonauthor=J.+Brownauthor=D.+Delpyauthor=S.+P.+Seitzauthor=R.+Borzilleriauthor=G.+Viteauthor=A.+Balog&title=Discovery+And+Preclinical+Evaluation+Of+BMS-986242%2C+A+Potent%2C+Selective+Inhibitor+Of+Indoleamine-2%2C3-Dioxygenase+1&doi=10.1021%2Facsmedchemlett.0c00668"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Preclinical Evaluation of BMS-986242, a Potent, Selective Inhibitor of Indoleamine-2,3-dioxygenase 1</span></div><div class="casAuthors">Cherney, Emily C.; Zhang, Liping; Nara, Susheel; Zhu, Xiao; Gullo-Brown, Johnni; Maley, Derrick; Lin, Tai-An; Hunt, John T.; Huang, Christine; Yang, Zheng; Darienzo, Celia; Discenza, Lorell; Ranasinghe, Asoka; Grubb, Mary; Ziemba, Theresa; Traeger, Sarah C.; Li, Xin; Johnston, Kathy; Kopcho, Lisa; Fereshteh, Mark; Foster, Kimberly; Stefanski, Kevin; Fargnoli, Joseph; Swanson, Jesse; Brown, Jennifer; Delpy, Diane; Seitz, Steven P.; Borzilleri, Robert; Vite, Gregory; Balog, Aaron</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">288-294</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1) is a heme-contg. dioxygenase enzyme implicated in cancer immune response.  This account details the discovery of BMS-986242, a novel IDO1 inhibitor designed for the treatment of a variety of cancers including metastatic melanoma and renal cell carcinoma.  Given the substantial interest around this target for cancer immunotherapy, we sought to identify a structurally differentiated clin. candidate that performs comparably to linrodostat (BMS-986205) in terms of both in vitro potency and in vivo pharmacodynamic effect in a mouse xenograft model.  On the basis of its preclin. profile, BMS-986242 was selected as a candidate for clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMG8_qVFwyi7Vg90H21EOLACvtfcHk0ljKLdt5JWR2kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXitFyis7w%253D&md5=49574830c2c45c4e778f8be9ebd18879</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.0c00668&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.0c00668%26sid%3Dliteratum%253Aachs%26aulast%3DCherney%26aufirst%3DE.%2BC.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DNara%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DGullo-Brown%26aufirst%3DJ.%26aulast%3DMaley%26aufirst%3DD.%26aulast%3DLin%26aufirst%3DT.-A.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DHuang%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DDarienzo%26aufirst%3DC.%26aulast%3DDiscenza%26aufirst%3DL.%26aulast%3DRanasinghe%26aufirst%3DA.%26aulast%3DGrubb%26aufirst%3DM.%26aulast%3DZiemba%26aufirst%3DT.%26aulast%3DTraeger%26aufirst%3DS.%2BC.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DJohnston%26aufirst%3DK.%26aulast%3DKopcho%26aufirst%3DL.%26aulast%3DFereshteh%26aufirst%3DM.%26aulast%3DFoster%26aufirst%3DK.%26aulast%3DStefanski%26aufirst%3DK.%26aulast%3DFargnoli%26aufirst%3DJ.%26aulast%3DSwanson%26aufirst%3DJ.%26aulast%3DBrown%26aufirst%3DJ.%26aulast%3DDelpy%26aufirst%3DD.%26aulast%3DSeitz%26aufirst%3DS.%2BP.%26aulast%3DBorzilleri%26aufirst%3DR.%26aulast%3DVite%26aufirst%3DG.%26aulast%3DBalog%26aufirst%3DA.%26atitle%3DDiscovery%2520And%2520Preclinical%2520Evaluation%2520Of%2520BMS-986242%252C%2520A%2520Potent%252C%2520Selective%2520Inhibitor%2520Of%2520Indoleamine-2%252C3-Dioxygenase%25201%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2021%26volume%3D12%26spage%3D288%26epage%3D294%26doi%3D10.1021%2Facsmedchemlett.0c00668" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherney, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T.-a.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gullo-Brown, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston-Allegretto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopcho, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fereshteh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traeger, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhar, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anandam, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahankali, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padmanabhan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajanna, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murali, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mariappan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borzilleri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vite, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balog, A.</span></span> <span> </span><span class="NLM_article-title">Discovery Of Imidazopyridines As Potent Inhibitors Of Indoleamine 2,3-Dioxygenase 1 For Cancer Immunotherapy</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">494</span>– <span class="NLM_lpage">501</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.1c00014</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.1c00014" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BB3MXltlyhsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2021&pages=494-501&author=L.+Zhangauthor=E.+C.+Cherneyauthor=X.+Zhuauthor=T.-a.+Linauthor=J.+Gullo-Brownauthor=D.+Maleyauthor=K.+Johnston-Allegrettoauthor=L.+Kopchoauthor=M.+Fereshtehauthor=C.+Huangauthor=X.+Liauthor=S.+C.+Traegerauthor=G.+Dharauthor=A.+Anandamauthor=S.+Mahankaliauthor=S.+Padmanabhanauthor=P.+Rajannaauthor=V.+Muraliauthor=T.+Mariappanauthor=R.+Borzilleriauthor=G.+Viteauthor=J.+T.+Huntauthor=A.+Balog&title=Discovery+Of+Imidazopyridines+As+Potent+Inhibitors+Of+Indoleamine+2%2C3-Dioxygenase+1+For+Cancer+Immunotherapy&doi=10.1021%2Facsmedchemlett.1c00014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Imidazopyridines as Potent Inhibitors of Indoleamine 2,3-Dioxygenase 1 for Cancer Immunotherapy</span></div><div class="casAuthors">Zhang, Liping; Cherney, Emily C.; Zhu, Xiao; Lin, Tai-an; Gullo-Brown, Johnni; Maley, Derrick; Johnston-Allegretto, Kathy; Kopcho, Lisa; Fereshteh, Mark; Huang, Christine; Li, Xin; Traeger, Sarah C.; Dhar, Gopal; Anandam, Aravind; Mahankali, Sandeep; Padmanabhan, Shweta; Rajanna, Prabhakar; Murali, Venkata; Mariappan, Thanga; Borzilleri, Robert; Vite, Gregory; Hunt, John T.; Balog, Aaron</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">494-501</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1) has been identified as a target for small-mol. immunotherapy for the treatment of a variety of cancers including renal cell carcinoma and metastatic melanoma.  This work focuses on the identification of IDO1 inhibitors contg. replacements or isosteres for the amide found in BMS-986205, an amide-contg., IDO1-selective inhibitor currently in phase III clin. trials.  Detailed subsequently are efforts to identify a structurally differentiated IDO1 inhibitor via the pursuit of a variety of heterocyclic isosteres, leading to the discovery of highly potent, imidazopyridine-contg. IDO1 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofhLoepiTzULVg90H21EOLACvtfcHk0lj738hqJElYwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXltlyhsLY%253D&md5=479921e0eb4ee4b4e644eed31bccd331</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.1c00014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.1c00014%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DCherney%26aufirst%3DE.%2BC.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DLin%26aufirst%3DT.-a.%26aulast%3DGullo-Brown%26aufirst%3DJ.%26aulast%3DMaley%26aufirst%3DD.%26aulast%3DJohnston-Allegretto%26aufirst%3DK.%26aulast%3DKopcho%26aufirst%3DL.%26aulast%3DFereshteh%26aufirst%3DM.%26aulast%3DHuang%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DTraeger%26aufirst%3DS.%2BC.%26aulast%3DDhar%26aufirst%3DG.%26aulast%3DAnandam%26aufirst%3DA.%26aulast%3DMahankali%26aufirst%3DS.%26aulast%3DPadmanabhan%26aufirst%3DS.%26aulast%3DRajanna%26aufirst%3DP.%26aulast%3DMurali%26aufirst%3DV.%26aulast%3DMariappan%26aufirst%3DT.%26aulast%3DBorzilleri%26aufirst%3DR.%26aulast%3DVite%26aufirst%3DG.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DBalog%26aufirst%3DA.%26atitle%3DDiscovery%2520Of%2520Imidazopyridines%2520As%2520Potent%2520Inhibitors%2520Of%2520Indoleamine%25202%252C3-Dioxygenase%25201%2520For%2520Cancer%2520Immunotherapy%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2021%26volume%3D12%26spage%3D494%26epage%3D501%26doi%3D10.1021%2Facsmedchemlett.1c00014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doty, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fradera, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesburg, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGowan, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geda, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otte, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sciammetta, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solban, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sloman, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lammens, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neumann, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasternak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery Of Potent And Orally Available Bicyclo[1.1.1]Pentane-Derived Indoleamine-2,3-Dioxygenase 1 (IDO1) Inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1548</span>– <span class="NLM_lpage">1554</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.0c00195</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.0c00195" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtl2jtLbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=1548-1554&author=Q.+Puauthor=H.+Zhangauthor=L.+Guoauthor=M.+Chengauthor=A.+C.+Dotyauthor=H.+Fergusonauthor=X.+Fraderaauthor=C.+A.+Lesburgauthor=M.+A.+McGowanauthor=J.+R.+Millerauthor=P.+Gedaauthor=X.+Songauthor=K.+Otteauthor=N.+Sciammettaauthor=N.+Solbanauthor=W.+Yuauthor=D.+L.+Slomanauthor=H.+Zhouauthor=A.+Lammensauthor=L.+Neumannauthor=D.+J.+Bennettauthor=A.+Pasternakauthor=Y.+Han&title=Discovery+Of+Potent+And+Orally+Available+Bicyclo%5B1.1.1%5DPentane-Derived+Indoleamine-2%2C3-Dioxygenase+1+%28IDO1%29+Inhibitors&doi=10.1021%2Facsmedchemlett.0c00195"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent and Orally Available Bicyclo[1.1.1]pentane-Derived Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitors</span></div><div class="casAuthors">Pu, Qinglin; Zhang, Hongjun; Guo, Liangqin; Cheng, Mangeng; Doty, Amy C.; Ferguson, Heidi; Fradera, Xavier; Lesburg, Charles A.; McGowan, Meredeth A.; Miller, J. Richard; Geda, Prasanthi; Song, Xuelei; Otte, Karin; Sciammetta, Nunzio; Solban, Nicolas; Yu, Wensheng; Sloman, David L.; Zhou, Hua; Lammens, Alfred; Neumann, Lars; Bennett, David Jonathan; Pasternak, Alexander; Han, Yongxin</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1548-1554</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indoleamine-2,3-dioxygenase 1 (IDO1) inhibition and its combination with immune checkpoint inhibitors like pembrolizumab have drawn considerable attention from both academia and the pharmaceutical industry.  Here, we describe the discovery of a novel class of highly potent IDO1 heme-displacing inhibitors featuring a unique bicyclo[1.1.1]pentane motif.  Compd. 1, evolving from an ALIS (automated ligand identification system) hit, exhibited excellent potency but lacked the desired pharmacokinetic profile due to extensive amide hydrolysis of the benzamide moiety.  Replacing the central Ph ring in 1 with a bicyclo[1.1.1]pentane bioisostere effectively circumvented the amide hydrolysis issue, resulting in the discovery of compd. 2(I) with a favorable overall profile such as excellent potency, selectivity, pharmacokinetics, and a low predicted human dose.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCRMnzRWR18LVg90H21EOLACvtfcHk0lj738hqJElYwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtl2jtLbI&md5=d55b05877e5ee16eeaa7937ef0b83cef</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.0c00195&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.0c00195%26sid%3Dliteratum%253Aachs%26aulast%3DPu%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DGuo%26aufirst%3DL.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DDoty%26aufirst%3DA.%2BC.%26aulast%3DFerguson%26aufirst%3DH.%26aulast%3DFradera%26aufirst%3DX.%26aulast%3DLesburg%26aufirst%3DC.%2BA.%26aulast%3DMcGowan%26aufirst%3DM.%2BA.%26aulast%3DMiller%26aufirst%3DJ.%2BR.%26aulast%3DGeda%26aufirst%3DP.%26aulast%3DSong%26aufirst%3DX.%26aulast%3DOtte%26aufirst%3DK.%26aulast%3DSciammetta%26aufirst%3DN.%26aulast%3DSolban%26aufirst%3DN.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DSloman%26aufirst%3DD.%2BL.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DLammens%26aufirst%3DA.%26aulast%3DNeumann%26aufirst%3DL.%26aulast%3DBennett%26aufirst%3DD.%2BJ.%26aulast%3DPasternak%26aufirst%3DA.%26aulast%3DHan%26aufirst%3DY.%26atitle%3DDiscovery%2520Of%2520Potent%2520And%2520Orally%2520Available%2520Bicyclo%255B1.1.1%255DPentane-Derived%2520Indoleamine-2%252C3-Dioxygenase%25201%2520%2528IDO1%2529%2520Inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26spage%3D1548%26epage%3D1554%26doi%3D10.1021%2Facsmedchemlett.0c00195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">White, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGowan, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sciammetta, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fradera, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nickbarg, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trewick, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Augustin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Köenig, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesburg, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otte, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knemeyer, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spacciapoli, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geda, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smotrov, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curran, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heo, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abeywickrema, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span></span> <span> </span><span class="NLM_article-title">Strategic Incorporation Of Polarity In Heme-Displacing Inhibitors Of Indoleamine-2,3-Dioxygenase-1 (IDO1)</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">550</span>– <span class="NLM_lpage">557</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.0c00010</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.0c00010" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkslWksbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=550-557&author=C.+Whiteauthor=M.+A.+McGowanauthor=H.+Zhouauthor=N.+Sciammettaauthor=X.+Fraderaauthor=J.+Limauthor=E.+M.+Joshiauthor=C.+Andrewsauthor=E.+B.+Nickbargauthor=P.+Cowleyauthor=S.+Trewickauthor=M.+Augustinauthor=K.+von+K%C3%B6enigauthor=C.+A.+Lesburgauthor=K.+Otteauthor=I.+Knemeyerauthor=H.+Wooauthor=W.+Yuauthor=M.+Chengauthor=P.+Spacciapoliauthor=P.+Gedaauthor=X.+Songauthor=N.+Smotrovauthor=P.+Curranauthor=M.+R.+Heoauthor=P.+Abeywickremaauthor=J.+R.+Millerauthor=D.+J.+Bennettauthor=Y.+Han&title=Strategic+Incorporation+Of+Polarity+In+Heme-Displacing+Inhibitors+Of+Indoleamine-2%2C3-Dioxygenase-1+%28IDO1%29&doi=10.1021%2Facsmedchemlett.0c00010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Strategic Incorporation of Polarity in Heme-Displacing Inhibitors of Indoleamine-2,3-dioxygenase-1 (IDO1)</span></div><div class="casAuthors">White, Catherine; McGowan, Meredeth A.; Zhou, Hua; Sciammetta, Nunzio; Fradera, Xavier; Lim, Jongwon; Joshi, Elizabeth M.; Andrews, Christine; Nickbarg, Elliott B.; Cowley, Phillip; Trewick, Sarah; Augustin, Martin; von Koenig, Konstanze; Lesburg, Charles A.; Otte, Karin; Knemeyer, Ian; Woo, Hyun; Yu, Wensheng; Cheng, Mangeng; Spacciapoli, Peter; Geda, Prasanthi; Song, Xuelei; Smotrov, Nadya; Curran, Patrick; Heo, Mee Ra; Abeywickrema, Pravien; Miller, J. Richard; Bennett, David Jonathan; Han, Yongxin</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">550-557</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indoleamine-2,3-dioxygenase-1 (IDO1) has emerged as a target of significant interest to the field of cancer immunotherapy, as the upregulation of IDO1 in certain cancers has been linked to host immune evasion and poor prognosis for patients.  In particular, IDO1 inhibition is of interest as a combination therapy with immune checkpoint inhibition.  Through an Automated Ligand Identification System (ALIS) screen, a diamide class of compds. was identified as a promising lead for the inhibition of IDO1.  While hit 1() possessed attractive cell-based potency, it suffered from a significant right-shift in a whole blood assay, poor soly., and poor pharmacokinetic properties.  Through a physicochem. property-based approach, including a focus on lowering AlogP98 via the strategic introduction of polar substitution, compd. 13 was identified bearing a pyridyl oxetane core.  Compd. 13() demonstrated improved whole blood potency and soly., and an improved pharmacokinetic profile resulting in a low predicted human dose.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnzfQfxAahcbVg90H21EOLACvtfcHk0liFgHUOzkT6GQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkslWksbc%253D&md5=cad9d7aa1db10d920c558cd4ba4af9cd</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.0c00010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.0c00010%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DC.%26aulast%3DMcGowan%26aufirst%3DM.%2BA.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DSciammetta%26aufirst%3DN.%26aulast%3DFradera%26aufirst%3DX.%26aulast%3DLim%26aufirst%3DJ.%26aulast%3DJoshi%26aufirst%3DE.%2BM.%26aulast%3DAndrews%26aufirst%3DC.%26aulast%3DNickbarg%26aufirst%3DE.%2BB.%26aulast%3DCowley%26aufirst%3DP.%26aulast%3DTrewick%26aufirst%3DS.%26aulast%3DAugustin%26aufirst%3DM.%26aulast%3Dvon%2BK%25C3%25B6enig%26aufirst%3DK.%26aulast%3DLesburg%26aufirst%3DC.%2BA.%26aulast%3DOtte%26aufirst%3DK.%26aulast%3DKnemeyer%26aufirst%3DI.%26aulast%3DWoo%26aufirst%3DH.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DSpacciapoli%26aufirst%3DP.%26aulast%3DGeda%26aufirst%3DP.%26aulast%3DSong%26aufirst%3DX.%26aulast%3DSmotrov%26aufirst%3DN.%26aulast%3DCurran%26aufirst%3DP.%26aulast%3DHeo%26aufirst%3DM.%2BR.%26aulast%3DAbeywickrema%26aufirst%3DP.%26aulast%3DMiller%26aufirst%3DJ.%2BR.%26aulast%3DBennett%26aufirst%3DD.%2BJ.%26aulast%3DHan%26aufirst%3DY.%26atitle%3DStrategic%2520Incorporation%2520Of%2520Polarity%2520In%2520Heme-Displacing%2520Inhibitors%2520Of%2520Indoleamine-2%252C3-Dioxygenase-1%2520%2528IDO1%2529%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26spage%3D550%26epage%3D557%26doi%3D10.1021%2Facsmedchemlett.0c00010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dorsey, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benhadji, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sams, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schindler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huss, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolayev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpenito, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clawson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faber, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haney, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMillen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sall, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geeganage, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, J.</span></span> <span> </span><span class="NLM_article-title">Identification And Characterization Of The IDO1 Inhibitor LY3381916. Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA) AACR</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">5245</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=5245&author=F.+C.+Dorseyauthor=K.+Benhadjiauthor=L.+Samsauthor=D.+Youngauthor=J.+Schindlerauthor=K.+Hussauthor=A.+Nikolayevauthor=C.+Carpenitoauthor=D.+Clawsonauthor=B.+Jonesauthor=A.+Faberauthor=J.+Thomasauthor=S.+Haneyauthor=G.+Zhaoauthor=W.+McMillenauthor=T.+Smealauthor=D.+Sallauthor=M.+Kalosauthor=S.+Geeganageauthor=J.+Henry&title=Identification+And+Characterization+Of+The+IDO1+Inhibitor+LY3381916.+Proceedings+of+the+American+Association+for+Cancer+Research+Annual+Meeting+2018%3B+2018+Apr+14-18%3B+Chicago%2C+IL.+Philadelphia+%28PA%29+AACR"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDorsey%26aufirst%3DF.%2BC.%26aulast%3DBenhadji%26aufirst%3DK.%26aulast%3DSams%26aufirst%3DL.%26aulast%3DYoung%26aufirst%3DD.%26aulast%3DSchindler%26aufirst%3DJ.%26aulast%3DHuss%26aufirst%3DK.%26aulast%3DNikolayev%26aufirst%3DA.%26aulast%3DCarpenito%26aufirst%3DC.%26aulast%3DClawson%26aufirst%3DD.%26aulast%3DJones%26aufirst%3DB.%26aulast%3DFaber%26aufirst%3DA.%26aulast%3DThomas%26aufirst%3DJ.%26aulast%3DHaney%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DG.%26aulast%3DMcMillen%26aufirst%3DW.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DSall%26aufirst%3DD.%26aulast%3DKalos%26aufirst%3DM.%26aulast%3DGeeganage%26aufirst%3DS.%26aulast%3DHenry%26aufirst%3DJ.%26atitle%3DIdentification%2520And%2520Characterization%2520Of%2520The%2520IDO1%2520Inhibitor%2520LY3381916.%2520Proceedings%2520of%2520the%2520American%2520Association%2520for%2520Cancer%2520Research%2520Annual%2520Meeting%25202018%253B%25202018%2520Apr%252014-18%253B%2520Chicago%252C%2520IL.%2520Philadelphia%2520%2528PA%2529%2520AACR%26jtitle%3DCancer%2520Res.%26date%3D2018%26volume%3D78%26spage%3D5245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Achab, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bharathan, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanyal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fradera, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesburg, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lammens, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinot, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doty, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nickbarg, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spacciapoli, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geda, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smotrov, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abeywickrema, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mabrouk, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curran, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richards, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saradjian, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knemeyer, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otte, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sciammetta, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasternak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span></span> <span> </span><span class="NLM_article-title">Carbamate And N-Pyrimidine Mitigate Amide Hydrolysis: Structure-Based Drug Design Of Tetrahydroquinoline IDO1 Inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">389</span>– <span class="NLM_lpage">396</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.0c00525</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.0c00525" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BB3MXltFSks7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2021&pages=389-396&author=D.+Liauthor=Y.+Dengauthor=A.+Achabauthor=I.+Bharathanauthor=B.+A.+Hopkinsauthor=W.+Yuauthor=H.+Zhangauthor=S.+Sanyalauthor=Q.+Puauthor=H.+Zhouauthor=K.+Liuauthor=J.+Limauthor=X.+Fraderaauthor=C.+A.+Lesburgauthor=A.+Lammensauthor=T.+A.+Martinotauthor=R.+D.+Cohenauthor=A.+C.+Dotyauthor=H.+Fergusonauthor=E.+B.+Nickbargauthor=M.+Chengauthor=P.+Spacciapoliauthor=P.+Gedaauthor=X.+Songauthor=N.+Smotrovauthor=P.+Abeywickremaauthor=C.+Andrewsauthor=C.+Chamberlinauthor=O.+Mabroukauthor=P.+Curranauthor=M.+Richardsauthor=P.+Saradjianauthor=J.+R.+Millerauthor=I.+Knemeyerauthor=K.+M.+Otteauthor=S.+Vincentauthor=N.+Sciammettaauthor=A.+Pasternakauthor=D.+J.+Bennettauthor=Y.+Han&title=Carbamate+And+N-Pyrimidine+Mitigate+Amide+Hydrolysis%3A+Structure-Based+Drug+Design+Of+Tetrahydroquinoline+IDO1+Inhibitors&doi=10.1021%2Facsmedchemlett.0c00525"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Carbamate and N-Pyrimidine Mitigate Amide Hydrolysis: Structure-Based Drug Design of Tetrahydroquinoline IDO1 Inhibitors</span></div><div class="casAuthors">Li, Derun; Deng, Yongqi; Achab, Abdelghani; Bharathan, Indu; Hopkins, Brett Andrew; Yu, Wensheng; Zhang, Hongjun; Sanyal, Sulagna; Pu, Qinglin; Zhou, Hua; Liu, Kun; Lim, Jongwon; Fradera, Xavier; Lesburg, Charles A.; Lammens, Alfred; Martinot, Theodore A.; Cohen, Ryan D.; Doty, Amy C.; Ferguson, Heidi; Nickbarg, Elliott B.; Cheng, Mangeng; Spacciapoli, Peter; Geda, Prasanthi; Song, Xuelei; Smotrov, Nadya; Abeywickrema, Pravien; Andrews, Christine; Chamberlin, Chad; Mabrouk, Omar; Curran, Patrick; Richards, Matthew; Saradjian, Peter; Miller, J. Richard; Knemeyer, Ian; Otte, Karin M.; Vincent, Stella; Sciammetta, Nunzio; Pasternak, Alexander; Bennett, David Jonathan; Han, Yongxin</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">389-396</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indoleamine-2,3-dioxygenase-1 (IDO1) has emerged as an attractive target for cancer immunotherapy.  An automated ligand identification system screen afforded the tetrahydroquinoline class of novel IDO1 inhibitors.  Potency and pharmacokinetic (PK) were key issues with this class of compds.  Structure-based drug design and strategic incorporation of polarity enabled the rapid improvement on potency, soly., and oxidative metabolic stability.  Metabolite identification studies revealed that amide hydrolysis in the D-pocket was the key clearance mechanism for this class.  Strategic survey of amide isosteres revealed that carbamates and N-pyrimidines, which maintained exquisite potencies, mitigated the amide hydrolysis issue and led to an improved rat PK profile.  The lead compd. 28 is a potent IDO1 inhibitor, with clean off-target profiles and the potential for quaque die dosing in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJaibKNJjuVrVg90H21EOLACvtfcHk0lg6yIKQ8Cq9qQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXltFSks7Y%253D&md5=a2bbc31ff1de8f8aa6668a7079dcf905</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.0c00525&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.0c00525%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DD.%26aulast%3DDeng%26aufirst%3DY.%26aulast%3DAchab%26aufirst%3DA.%26aulast%3DBharathan%26aufirst%3DI.%26aulast%3DHopkins%26aufirst%3DB.%2BA.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DSanyal%26aufirst%3DS.%26aulast%3DPu%26aufirst%3DQ.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DK.%26aulast%3DLim%26aufirst%3DJ.%26aulast%3DFradera%26aufirst%3DX.%26aulast%3DLesburg%26aufirst%3DC.%2BA.%26aulast%3DLammens%26aufirst%3DA.%26aulast%3DMartinot%26aufirst%3DT.%2BA.%26aulast%3DCohen%26aufirst%3DR.%2BD.%26aulast%3DDoty%26aufirst%3DA.%2BC.%26aulast%3DFerguson%26aufirst%3DH.%26aulast%3DNickbarg%26aufirst%3DE.%2BB.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DSpacciapoli%26aufirst%3DP.%26aulast%3DGeda%26aufirst%3DP.%26aulast%3DSong%26aufirst%3DX.%26aulast%3DSmotrov%26aufirst%3DN.%26aulast%3DAbeywickrema%26aufirst%3DP.%26aulast%3DAndrews%26aufirst%3DC.%26aulast%3DChamberlin%26aufirst%3DC.%26aulast%3DMabrouk%26aufirst%3DO.%26aulast%3DCurran%26aufirst%3DP.%26aulast%3DRichards%26aufirst%3DM.%26aulast%3DSaradjian%26aufirst%3DP.%26aulast%3DMiller%26aufirst%3DJ.%2BR.%26aulast%3DKnemeyer%26aufirst%3DI.%26aulast%3DOtte%26aufirst%3DK.%2BM.%26aulast%3DVincent%26aufirst%3DS.%26aulast%3DSciammetta%26aufirst%3DN.%26aulast%3DPasternak%26aufirst%3DA.%26aulast%3DBennett%26aufirst%3DD.%2BJ.%26aulast%3DHan%26aufirst%3DY.%26atitle%3DCarbamate%2520And%2520N-Pyrimidine%2520Mitigate%2520Amide%2520Hydrolysis%253A%2520Structure-Based%2520Drug%2520Design%2520Of%2520Tetrahydroquinoline%2520IDO1%2520Inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2021%26volume%3D12%26spage%3D389%26epage%3D396%26doi%3D10.1021%2Facsmedchemlett.0c00525" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kinzel, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steeneck, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderhub, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hornberger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morschhaeuser, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonnek, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallinger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czekańska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, T.</span></span> <span> </span><span class="NLM_article-title">Discovery Of Highly Potent Heme-Displacing IDO1 Inhibitors Based On A Spirofused Bicyclic Scaffold</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">127738</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2020.127738</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1016%2Fj.bmcl.2020.127738" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=33316404" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BB3MXks1Oguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2021&pages=127738&author=O.+Kinzelauthor=C.+Steeneckauthor=S.+Anderhubauthor=M.+Hornbergerauthor=S.+Pintoauthor=B.+Morschhaeuserauthor=M.+Albersauthor=C.+Sonnekauthor=Y.+Wangauthor=A.+Mallingerauthor=M.+Czeka%C5%84skaauthor=T.+Hoffmann&title=Discovery+Of+Highly+Potent+Heme-Displacing+IDO1+Inhibitors+Based+On+A+Spirofused+Bicyclic+Scaffold&doi=10.1016%2Fj.bmcl.2020.127738"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of highly potent heme-displacing IDO1 inhibitors based on a spirofused bicyclic scaffold</span></div><div class="casAuthors">Kinzel, Olaf; Steeneck, Christoph; Anderhub, Simon; Hornberger, Martin; Pinto, Sheena; Morschhaeuser, Barbara; Albers, Michael; Sonnek, Christina; Wang, Yansong; Mallinger, Aurelie; Czekanska, Marta; Hoffmann, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">127738</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Through structural modification of an oxalamide derived chemotype, a novel class of highly potent, orally bioavailable IDO1-specific inhibitors was identified.  Representative compd. 18 inhibited human IDO1 with IC50 values of 3.9 nM and 52 nM in a cellular and human whole blood assay, resp.  In vitro assessment of the ADME properties of 18 demonstrated very high metabolic stability.  Pharmacokinetic profiling in mice showed a significantly reduced clearance compared to the oxalamides.  In a mouse pharmacodynamic model 18 nearly completely suppressed lipopolysaccharide-induced kynurenine prodn.  Hepatocyte data of 18 suggest the human clearance to be in a similar range to linrodostat (1).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonffyAQcOpG7Vg90H21EOLACvtfcHk0lg6yIKQ8Cq9qQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXks1Oguw%253D%253D&md5=913fcc9195925ccaecc22108a06731f8</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2020.127738&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2020.127738%26sid%3Dliteratum%253Aachs%26aulast%3DKinzel%26aufirst%3DO.%26aulast%3DSteeneck%26aufirst%3DC.%26aulast%3DAnderhub%26aufirst%3DS.%26aulast%3DHornberger%26aufirst%3DM.%26aulast%3DPinto%26aufirst%3DS.%26aulast%3DMorschhaeuser%26aufirst%3DB.%26aulast%3DAlbers%26aufirst%3DM.%26aulast%3DSonnek%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DMallinger%26aufirst%3DA.%26aulast%3DCzeka%25C5%2584ska%26aufirst%3DM.%26aulast%3DHoffmann%26aufirst%3DT.%26atitle%3DDiscovery%2520Of%2520Highly%2520Potent%2520Heme-Displacing%2520IDO1%2520Inhibitors%2520Based%2520On%2520A%2520Spirofused%2520Bicyclic%2520Scaffold%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2021%26volume%3D33%26spage%3D127738%26doi%3D10.1016%2Fj.bmcl.2020.127738" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><a href="http://ClinicalTrials.gov/ct2/show/NCT03351231" class="extLink">ClinicalTrials.gov/ct2/show/NCT03351231</a> (accessed March 21,
2021).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=ClinicalTrials.gov%2Fct2%2Fshow%2FNCT03351231+%28accessed+March+21%2C%0A2021%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hutchinson, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leveridge, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heathcote, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gee, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munoz-Muriedas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leavens, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shillings, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Homes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baddeley, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, C.-w.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bridges, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Argyrou, A.</span></span> <span> </span><span class="NLM_article-title">Enabling Lead Discovery For Histone Lysine Demethylases By High-Throughput Rapidfire Mass Spectrometry</span>. <i>J. Biomol. Screen</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">39</span>– <span class="NLM_lpage">48</span>, <span class="refDoi"> DOI: 10.1177/1087057111416660</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1177%2F1087057111416660" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=21859681" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=39-48&author=S.+E.+Hutchinsonauthor=M.+V.+Leveridgeauthor=M.+L.+Heathcoteauthor=P.+Francisauthor=L.+Williamsauthor=M.+Geeauthor=J.+Munoz-Muriedasauthor=B.+Leavensauthor=A.+Shillingsauthor=E.+Jonesauthor=P.+Homesauthor=S.+Baddeleyauthor=C.-w.+Chungauthor=A.+Bridgesauthor=A.+Argyrou&title=Enabling+Lead+Discovery+For+Histone+Lysine+Demethylases+By+High-Throughput+Rapidfire+Mass+Spectrometry&doi=10.1177%2F1087057111416660"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1177%2F1087057111416660&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1087057111416660%26sid%3Dliteratum%253Aachs%26aulast%3DHutchinson%26aufirst%3DS.%2BE.%26aulast%3DLeveridge%26aufirst%3DM.%2BV.%26aulast%3DHeathcote%26aufirst%3DM.%2BL.%26aulast%3DFrancis%26aufirst%3DP.%26aulast%3DWilliams%26aufirst%3DL.%26aulast%3DGee%26aufirst%3DM.%26aulast%3DMunoz-Muriedas%26aufirst%3DJ.%26aulast%3DLeavens%26aufirst%3DB.%26aulast%3DShillings%26aufirst%3DA.%26aulast%3DJones%26aufirst%3DE.%26aulast%3DHomes%26aufirst%3DP.%26aulast%3DBaddeley%26aufirst%3DS.%26aulast%3DChung%26aufirst%3DC.-w.%26aulast%3DBridges%26aufirst%3DA.%26aulast%3DArgyrou%26aufirst%3DA.%26atitle%3DEnabling%2520Lead%2520Discovery%2520For%2520Histone%2520Lysine%2520Demethylases%2520By%2520High-Throughput%2520Rapidfire%2520Mass%2520Spectrometry%26jtitle%3DJ.%2520Biomol.%2520Screen%26date%3D2011%26volume%3D17%26spage%3D39%26epage%3D48%26doi%3D10.1177%2F1087057111416660" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marquez, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comin, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russ, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huleihel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ben-Kasus, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agbaria, R.</span></span> <span> </span><span class="NLM_article-title">Understanding How The Herpes Thymidine Kinase Orchestrates Optimal Sugar And Nucleobase Conformations To Accommodate Its Substrate At The Active Site: A Chemical Approach</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">15145</span>– <span class="NLM_lpage">15150</span>, <span class="refDoi"> DOI: 10.1021/ja053789s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja053789s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVKmtLjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2005&pages=15145-15150&author=V.+E.+Marquezauthor=Y.+Choiauthor=M.+J.+Cominauthor=P.+Russauthor=C.+Georgeauthor=M.+Huleihelauthor=T.+Ben-Kasusauthor=R.+Agbaria&title=Understanding+How+The+Herpes+Thymidine+Kinase+Orchestrates+Optimal+Sugar+And+Nucleobase+Conformations+To+Accommodate+Its+Substrate+At+The+Active+Site%3A+A+Chemical+Approach&doi=10.1021%2Fja053789s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Understanding How the Herpes Thymidine Kinase Orchestrates Optimal Sugar and Nucleobase Conformations To Accommodate Its Substrate at the Active Site: A Chemical Approach</span></div><div class="casAuthors">Marquez, Victor E.; Choi, Yongseok; Comin, Maria Julieta; Russ, Pamela; George, Clifford; Huleihel, Mahmoud; Ben-Kasus, Tsipi; Agbaria, Riad</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">15145-15150</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The herpes virus thymidine kinase (HSV-tk) is a crit. enzyme for the activation of anti-HSV nucleosides.  However, a successful therapeutic outcome depends not only on the activity of this enzyme but also on the ability of the compd.(s) to interact effectively with cellular kinases and with the target viral or cellular DNA polymerases.  Herein, we describe the synthesis and study of two nucleoside analogs built on a conformationally locked bicyclo[3.1.0]hexane template designed to investigate the conformational preferences of HSV-tk for the 2'-deoxyribose ring.  Intimately assocd. with the conformation of the 2'-deoxyribose ring is the value of the C-N torsion angle χ, which positions the nucleobase into two different domains (syn or anti).  The often-conflicting sugar and nucleobase conformational parameters were studied using North and South methanocarbadeoxythymidine analogs (6 and 7), which forced HSV-tk to make a clear choice in the conformation of the substrate.  The results provide new insights into the mechanism of action of this enzyme, which cannot be gleaned from a static X-ray crystal structure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTI23V1P863bVg90H21EOLACvtfcHk0lhWXFqgUQPb5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVKmtLjO&md5=f4d4192e81bf6fb821d41c34827b7cc2</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Fja053789s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja053789s%26sid%3Dliteratum%253Aachs%26aulast%3DMarquez%26aufirst%3DV.%2BE.%26aulast%3DChoi%26aufirst%3DY.%26aulast%3DComin%26aufirst%3DM.%2BJ.%26aulast%3DRuss%26aufirst%3DP.%26aulast%3DGeorge%26aufirst%3DC.%26aulast%3DHuleihel%26aufirst%3DM.%26aulast%3DBen-Kasus%26aufirst%3DT.%26aulast%3DAgbaria%26aufirst%3DR.%26atitle%3DUnderstanding%2520How%2520The%2520Herpes%2520Thymidine%2520Kinase%2520Orchestrates%2520Optimal%2520Sugar%2520And%2520Nucleobase%2520Conformations%2520To%2520Accommodate%2520Its%2520Substrate%2520At%2520The%2520Active%2520Site%253A%2520A%2520Chemical%2520Approach%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2005%26volume%3D127%26spage%3D15145%26epage%3D15150%26doi%3D10.1021%2Fja053789s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowary, T. L.</span></span> <span> </span><span class="NLM_article-title">Synthesis Of Bicyclo[3.1.0]Hexane Derivatives As Conformationally Restricted Analogues Of Β-Arabinofuranosyl And Α-Galactofuranosyl Rings</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">881</span>– <span class="NLM_lpage">884</span>, <span class="refDoi"> DOI: 10.1021/ol703041y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol703041y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFCitLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2008&pages=881-884&author=J.+Liauthor=T.+L.+Lowary&title=Synthesis+Of+Bicyclo%5B3.1.0%5DHexane+Derivatives+As+Conformationally+Restricted+Analogues+Of+%CE%92-Arabinofuranosyl+And+%CE%91-Galactofuranosyl+Rings&doi=10.1021%2Fol703041y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of Bicyclo[3.1.0]hexane Derivatives as Conformationally Restricted Analogues of β-Arabinofuranosyl and α-Galactofuranosyl Rings</span></div><div class="casAuthors">Li, Jing; Lowary, Todd L.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">881-884</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A route for the synthesis of bicyclo[3.1.0]hexane-derived conformationally restricted analogs I and II of β-arabinofuranosyl and α-galactofuranosyl rings is described.  Advantage is taken of the pseudo-enantiomeric relationship between the two ring systems to develop a route that provides both targets from a single precursor.  Key steps include a base-promoted ring contraction of an epoxy ketone obtained from cyclohexane-1,4-dione to give the bicyclo[3.1.0]hexane ring system and a late stage resoln. involving esterification with O-acetyl-(S)-mandelic acid.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYv7Hc-GPmt7Vg90H21EOLACvtfcHk0lhWXFqgUQPb5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFCitLk%253D&md5=b226ad723ec550dfbe8a9fd3d155d3ed</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fol703041y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol703041y%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLowary%26aufirst%3DT.%2BL.%26atitle%3DSynthesis%2520Of%2520Bicyclo%255B3.1.0%255DHexane%2520Derivatives%2520As%2520Conformationally%2520Restricted%2520Analogues%2520Of%2520%25CE%2592-Arabinofuranosyl%2520And%2520%25CE%2591-Galactofuranosyl%2520Rings%26jtitle%3DOrg.%2520Lett.%26date%3D2008%26volume%3D10%26spage%3D881%26epage%3D884%26doi%3D10.1021%2Fol703041y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Colombo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernardi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennet, A. J.</span></span> <span> </span><span class="NLM_article-title">Synthesis And Evaluation Of Influenza A Viral Neuraminidase Candidate Inhibitors Based On A Bicyclo[3.1.0]Hexane Scaffold</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">6539</span>– <span class="NLM_lpage">6553</span>, <span class="refDoi"> DOI: 10.1039/c6ob00999a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1039%2FC6OB00999A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=27305457" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BC28Xptl2qtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2016&pages=6539-6553&author=C.+Colomboauthor=B.+M.+Pintoauthor=A.+Bernardiauthor=A.+J.+Bennet&title=Synthesis+And+Evaluation+Of+Influenza+A+Viral+Neuraminidase+Candidate+Inhibitors+Based+On+A+Bicyclo%5B3.1.0%5DHexane+Scaffold&doi=10.1039%2Fc6ob00999a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of influenza A viral neuraminidase candidate inhibitors based on a bicyclo[3.1.0]hexane scaffold</span></div><div class="casAuthors">Colombo, Cinzia; Pinto, B. Mario; Bernardi, Anna; Bennet, Andrew J.</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">6539-6553</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">This manuscript describes a novel class of derivs. based on a bicyclo[3.1.0]hexane scaffold, proposed as mimics of sialic acid in a distorted boat conformation that is on the catalytic pathway of neuraminidases (sialidases).  A general synthetic route for these constrained-ring mols. was developed using a photochem. reaction followed by a Johnson-Corey-Chaykovsky cyclopropanation.  Functionalization with the goal of occupying the 150-cavity was also exploited.  Inhibition assays demonstrated low micromolar inhibition against both group-1 (H5N1) and group-2 (H9N2) influenza neuraminidase subtypes, indicating good affinity for the alpha and beta sialic acid mimics and 150-cavity-targeted derivs.  These results provide a validation of a bicyclo[3.1.0]hexane scaffold as a mimic of a distorted sialic acid bound in the neuraminidase active site during catalysis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgDJ0TA7VUqbVg90H21EOLACvtfcHk0lhWXFqgUQPb5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xptl2qtbg%253D&md5=30a40819786fd77b8d1b5c698ac62c82</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1039%2FC6OB00999A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6OB00999A%26sid%3Dliteratum%253Aachs%26aulast%3DColombo%26aufirst%3DC.%26aulast%3DPinto%26aufirst%3DB.%2BM.%26aulast%3DBernardi%26aufirst%3DA.%26aulast%3DBennet%26aufirst%3DA.%2BJ.%26atitle%3DSynthesis%2520And%2520Evaluation%2520Of%2520Influenza%2520A%2520Viral%2520Neuraminidase%2520Candidate%2520Inhibitors%2520Based%2520On%2520A%2520Bicyclo%255B3.1.0%255DHexane%2520Scaffold%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2016%26volume%3D14%26spage%3D6539%26epage%3D6553%26doi%3D10.1039%2Fc6ob00999a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bentzien, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickey, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemper, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brewer, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyekjær, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">East, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittaker, M.</span></span> <span> </span><span class="NLM_article-title">An In Silico Method For Predicting Ames Activities Of Primary Aromatic Amines By Calculating The Stabilities Of Nitrenium Ions</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">274</span>– <span class="NLM_lpage">297</span>, <span class="refDoi"> DOI: 10.1021/ci900378x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci900378x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlvFWgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2010&pages=274-297&author=J.+Bentzienauthor=E.+R.+Hickeyauthor=R.+A.+Kemperauthor=M.+L.+Brewerauthor=J.+D.+Dyekj%C3%A6rauthor=S.+P.+Eastauthor=M.+Whittaker&title=An+In+Silico+Method+For+Predicting+Ames+Activities+Of+Primary+Aromatic+Amines+By+Calculating+The+Stabilities+Of+Nitrenium+Ions&doi=10.1021%2Fci900378x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">An in Silico Method for Predicting Ames Activities of Primary Aromatic Amines by Calculating the Stabilities of Nitrenium Ions</span></div><div class="casAuthors">Bentzien, Joerg; Hickey, Eugene R.; Kemper, Raymond A.; Brewer, Mark L.; Dyekjaer, Jane D.; East, Stephen P.; Whittaker, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">274-297</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this paper, the authors describe an in silico first principal approach to predict the mutagenic potential of primary arom. amines.  This approach is based on the so-called "nitrenium hypothesis", which was developed by Ford et al. in the early 1990s.  This hypothesis asserts that the mutagenic effect for this class of mols. is mediated through the transient formation of a nitrenium ion and that the stability of this cation is correlated with the mutagenic potential.  Here the authors use quantum mech. calcns. at different levels of theory (semiempirical AM1, ab initio HF/3-21G, HF/6-311G(d,p), and DFT/B3LYP/6-311G(d,p)) to compute the stability of nitrenium ions.  When applied to a test set of 257 primary arom. amines, the authors show that this method can correctly differentiate between Ames active and inactive compds., and furthermore that it is able to rationalize and predict SAR trends within structurally related chem. series.  For this test set, the AM1 nitrenium stability calcns. are found to provide a good balance between speed and accuracy, resulting in an overall accuracy of 85%, and sensitivity and specificity of 91% and 72%, resp.  The nitrenium-based predictions are also compared to the com. software packages DEREK, MULTICASE, and the MOE-Toxicophore descriptor.  One advantage of the approach presented here is that the calcn. of relative stabilities results in a continuous spectrum of activities and not a simple yes/no answer.  This allows the authors to observe and rationalize subtle trends due to the different electrostatic properties of the org. mols.  The authors' results strongly indicate that nitrenium ion stability calcns. should be used as a complementary approach to assist the medicinal chemist in prioritizing and selecting nonmutagenic primary arom. amines during preclin. drug discovery programs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkMtrGYCOK9rVg90H21EOLACvtfcHk0lhWXFqgUQPb5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlvFWgug%253D%253D&md5=ded91291e2d099e1f333f66170f6be3b</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Fci900378x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci900378x%26sid%3Dliteratum%253Aachs%26aulast%3DBentzien%26aufirst%3DJ.%26aulast%3DHickey%26aufirst%3DE.%2BR.%26aulast%3DKemper%26aufirst%3DR.%2BA.%26aulast%3DBrewer%26aufirst%3DM.%2BL.%26aulast%3DDyekj%25C3%25A6r%26aufirst%3DJ.%2BD.%26aulast%3DEast%26aufirst%3DS.%2BP.%26aulast%3DWhittaker%26aufirst%3DM.%26atitle%3DAn%2520In%2520Silico%2520Method%2520For%2520Predicting%2520Ames%2520Activities%2520Of%2520Primary%2520Aromatic%2520Amines%2520By%2520Calculating%2520The%2520Stabilities%2520Of%2520Nitrenium%2520Ions%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2010%26volume%3D50%26spage%3D274%26epage%3D297%26doi%3D10.1021%2Fci900378x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shamovsky, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ripa, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Börjesson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nordén, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasselgren, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donovan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sjö, P.</span></span> <span> </span><span class="NLM_article-title">Explanation For Main Features Of Structure–Genotoxicity Relationships Of Aromatic Amines By Theoretical Studies Of Their Activation Pathways In CYP1A2</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>133</i></span>,  <span class="NLM_fpage">16168</span>– <span class="NLM_lpage">16185</span>, <span class="refDoi"> DOI: 10.1021/ja206427u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja206427u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1SrsrvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2011&pages=16168-16185&author=I.+Shamovskyauthor=L.+Ripaauthor=L.+B%C3%B6rjessonauthor=C.+Meeauthor=B.+Nord%C3%A9nauthor=P.+Hansenauthor=C.+Hasselgrenauthor=M.+O%E2%80%99Donovanauthor=P.+Sj%C3%B6&title=Explanation+For+Main+Features+Of+Structure%E2%80%93Genotoxicity+Relationships+Of+Aromatic+Amines+By+Theoretical+Studies+Of+Their+Activation+Pathways+In+CYP1A2&doi=10.1021%2Fja206427u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Explanation for Main Features of Structure-Genotoxicity Relationships of Aromatic Amines by Theoretical Studies of Their Activation Pathways in CYP1A2</span></div><div class="casAuthors">Shamovsky, Igor; Ripa, Lena; Borjesson, Lena; Mee, Christine; Norden, Bo; Hansen, Peter; Hasselgren, Catrin; O'Donovan, Mike; Sjo, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">16168-16185</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Arom. and heteroarom. amines (ArNH2) represent a class of potential mutagens that after being metabolically activated covalently modify DNA.  Activation of ArNH2 in many cases starts with N-hydroxylation by P 450 enzymes, primarily CYP1A2.  Poor understanding of structure-mutagenicity relationships of ArNH2 limits their use in drug discovery programs.  Key factors that facilitate activation of ArNH2 are revealed by exploring their reaction intermediates in CYP1A2 using DFT calcns.  On the basis of these calcns. and extensive anal. of structure-mutagenicity data, we suggest that mutagenic metabolites are generated by ferric peroxo intermediate, (CYP1A2)FeIII-OO-, in a three-step heterolytic mechanism.  First, the distal oxygen of the oxidant abstrs. proton from H-bonded ArNH2.  The subsequent proximal protonation of the resulting (CYP1A2)FeIII-OOH weakens both the O-O and the O-H bonds of the oxidant.  Heterolytic cleavage of the O-O bond leads to N-hydroxylation of ArNH- via SN2 mechanism, whereas cleavage of the O-H bond results in release of hydroperoxy radical.  Thus, our proposed reaction offers a mechanistic explanation for previous observations that metab. of arom. amines could cause oxidative stress.  The primary drivers for mutagenic potency of ArNH2 are (i) binding affinity of ArNH2 in the productive binding mode within the CYP1A2 substrate cavity, (ii) resonance stabilization of the anionic forms of ArNH2, and (iii) exothermicity of proton-assisted heterolytic cleavage of N-O bonds of hydroxylamines and their bioconjugates.  This leads to a strategy for designing mutagenicity free ArNH2: Structural alterations in ArNH2, which disrupt geometric compatibility with CYP1A2, hinder proton abstraction, or strongly destabilize the nitrenium ion, in this order of priority, prevent genotoxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrctr81IIN2trVg90H21EOLACvtfcHk0lid-OsGsWcRIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1SrsrvI&md5=9447ee2144a899b65e9350b712ca2a46</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fja206427u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja206427u%26sid%3Dliteratum%253Aachs%26aulast%3DShamovsky%26aufirst%3DI.%26aulast%3DRipa%26aufirst%3DL.%26aulast%3DB%25C3%25B6rjesson%26aufirst%3DL.%26aulast%3DMee%26aufirst%3DC.%26aulast%3DNord%25C3%25A9n%26aufirst%3DB.%26aulast%3DHansen%26aufirst%3DP.%26aulast%3DHasselgren%26aufirst%3DC.%26aulast%3DO%25E2%2580%2599Donovan%26aufirst%3DM.%26aulast%3DSj%25C3%25B6%26aufirst%3DP.%26atitle%3DExplanation%2520For%2520Main%2520Features%2520Of%2520Structure%25E2%2580%2593Genotoxicity%2520Relationships%2520Of%2520Aromatic%2520Amines%2520By%2520Theoretical%2520Studies%2520Of%2520Their%2520Activation%2520Pathways%2520In%2520CYP1A2%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2011%26volume%3D133%26spage%3D16168%26epage%3D16185%26doi%3D10.1021%2Fja206427u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Teasdale, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elder, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, S.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez Flores, I. H.</span></span> <span> </span><span class="NLM_article-title">Risk Assessment Of Genotoxic Impurities In New Chemical Entities: Strategies To Demonstrate Control</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">221</span>– <span class="NLM_lpage">230</span>, <span class="refDoi"> DOI: 10.1021/op300268u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/op300268u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntVWiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2013&pages=221-230&author=A.+Teasdaleauthor=D.+Elderauthor=S.-J.+Changauthor=S.+Wangauthor=R.+Thompsonauthor=N.+Benzauthor=I.+H.+Sanchez+Flores&title=Risk+Assessment+Of+Genotoxic+Impurities+In+New+Chemical+Entities%3A+Strategies+To+Demonstrate+Control&doi=10.1021%2Fop300268u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Risk Assessment of Genotoxic Impurities in New Chemical Entities: Strategies To Demonstrate Control</span></div><div class="casAuthors">Teasdale, Andrew; Elder, David; Chang, Sou-Jen; Wang, Sophie; Thompson, Richard; Benz, Nancy; Sanchez Flores, Ignacio H.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">221-230</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The control of genotoxic impurities (GTIs) is a crucial activity that is performed for any new chem. entity intended for clin. use.  A key element of this is the quality risk assessment.  This article seeks to examine the primary components of such a strategy, focusing specifically on the effective use of in silico assessment tools to augment this process, in particular the calcn. of theor. purge factors based on the physicochem. properties of a specific GTI and its interrelationship to the process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphCkprmUbIMLVg90H21EOLACvtfcHk0lid-OsGsWcRIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntVWiuw%253D%253D&md5=0c78ffdb8527c57ce278e7625ab559c0</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fop300268u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop300268u%26sid%3Dliteratum%253Aachs%26aulast%3DTeasdale%26aufirst%3DA.%26aulast%3DElder%26aufirst%3DD.%26aulast%3DChang%26aufirst%3DS.-J.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DThompson%26aufirst%3DR.%26aulast%3DBenz%26aufirst%3DN.%26aulast%3DSanchez%2BFlores%26aufirst%3DI.%2BH.%26atitle%3DRisk%2520Assessment%2520Of%2520Genotoxic%2520Impurities%2520In%2520New%2520Chemical%2520Entities%253A%2520Strategies%2520To%2520Demonstrate%2520Control%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2013%26volume%3D17%26spage%3D221%26epage%3D230%26doi%3D10.1021%2Fop300268u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Teffera, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brake, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saffran, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span> <span> </span><span class="NLM_article-title">Impact Of Hydrolysis-Mediated Clearance On The Pharmacokinetics Of Novel Anaplastic Lymphoma Kinase Inhibitors</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">238</span>– <span class="NLM_lpage">247</span>, <span class="refDoi"> DOI: 10.1124/dmd.112.047993</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1124%2Fdmd.112.047993" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=23118327" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlt1OntA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2013&pages=238-247&author=Y.+Tefferaauthor=L.+M.+Berryauthor=R.+L.+Brakeauthor=R.+T.+Lewisauthor=D.+C.+Saffranauthor=E.+Mooreauthor=J.+Liuauthor=Z.+Zhao&title=Impact+Of+Hydrolysis-Mediated+Clearance+On+The+Pharmacokinetics+Of+Novel+Anaplastic+Lymphoma+Kinase+Inhibitors&doi=10.1124%2Fdmd.112.047993"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of hydrolysis-mediated clearance on the pharmacokinetics of novel anaplastic lymphoma kinase inhibitors</span></div><div class="casAuthors">Teffera, Yohannes; Berry, Loren M.; Brake, Rachael L.; Lewis, Richard T.; Saffran, Douglas C.; Moore, Earl; Liu, Jingzhou; Zhao, Zhiyang</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">238-247</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Compd. 1 [(E)-4-fluoro-N-(6-((4-(2-hydroxypropan-2-yl)piperidin-1-yl)methyl)-1-((1S,4S)-4-(isopropylcarbamoyl)cyclohexyl)-1H-benzo[d]imidazol-2(3H)-ylidene)benzamide], a new, potent, selective anaplastic lymphoma kinase (ALK) inhibitor with potential application for the treatment of cancer, was selected as candidate to advance into efficacy studies in mice.  However, the compd. underwent mouse-specific enzymic hydrolysis in plasma to a primary amine product (M1).  Subsequent i.v. pharmacokinetics studies in mice showed that compd. 1 had high clearance (CL) and a short half-life.  Oral dose escalation studies in mice indicated that elimination of compd. 1 was saturable, with higher doses achieving sufficient exposures above in vitro IC50.  Chem. efforts to minimize hydrolysis resulted in the discovery of several analogs that were stable in mouse plasma.  Three were taken in vivo into mice and showed decreased CL corresponding to increased in vitro stability in plasma.  However, the more stable compds. also showed reduced potency against ALK.  Kinetic studies in NADPH-fortified and unfortified microsomes and plasma produced submicromolar Km values and could help explain the satn. of elimination obsd. in vivo.  Predictions of CL based on kinetics from hydrolysis and NADPH-dependent pathways produced predicted hepatic CL values of 3.8, 3.0, 1.6, and 1.2 l/h·kg for compd. 1, compd. 2 [(E)-3,5-difluoro-N-(6-((4-(2-hydroxypropan-2-yl)piperidin-1-yl)methyl)-1-((1s,4s)-4-(isopropylcarbamoyl)cyclohexyl)-1H-benzo[d]imidazo-2(3H)-ylidene)benzamide], compd. 3 [(E)-3-chloro-5-fluoro-N-(6-((4-(2-hydroxypropan-2-yl)piperidin-1-yl)methyl)-1-((1s,4s)-4-(isopropylcarbamoyl)cyclohexyl)-1H-benzo[d]imidazol-2(3H)-ylidene)benzamide], and compd. 4 [(E)-N-(6-((4-(2-hydroxypropan-2-yl)piperidin-1-yl)methyl)-1-((1s,4s)-4-(isopropylcarbamoyl)cyclohexyl)-1H-benzo[d]imidazol-2(3H)-ylidene)-3-(trifluoromethyl)benzamide], resp.  The in vivo obsd. CLs for compds. 1, 2, 3, and 4 were 5.52, 3.51, 2.14, and 2.66 l/h kg, resp.  These results indicate that in vitro metab. kinetic data, incorporating contributions from both hydrolysis and NADPH-dependent metab., could be used to predict the systemic CL of compds. cleared via hydrolytic pathways provided that the in vitro assays thoroughly investigate the processes, including the contribution of other metabolic pathways and the possibility of satn. kinetics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokHx1C0KZVi7Vg90H21EOLACvtfcHk0lid-OsGsWcRIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlt1OntA%253D%253D&md5=a46b21704e0ecab631a6048ca947fe01</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1124%2Fdmd.112.047993&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.112.047993%26sid%3Dliteratum%253Aachs%26aulast%3DTeffera%26aufirst%3DY.%26aulast%3DBerry%26aufirst%3DL.%2BM.%26aulast%3DBrake%26aufirst%3DR.%2BL.%26aulast%3DLewis%26aufirst%3DR.%2BT.%26aulast%3DSaffran%26aufirst%3DD.%2BC.%26aulast%3DMoore%26aufirst%3DE.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DZ.%26atitle%3DImpact%2520Of%2520Hydrolysis-Mediated%2520Clearance%2520On%2520The%2520Pharmacokinetics%2520Of%2520Novel%2520Anaplastic%2520Lymphoma%2520Kinase%2520Inhibitors%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2013%26volume%3D41%26spage%3D238%26epage%3D247%26doi%3D10.1124%2Fdmd.112.047993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="note"><p class="first last">Compound <b>21</b>: permeability MDCK-MDR1 cell line assay (<i>P</i><sub>app</sub> × 10<sup>–6</sup> cm/s, wt A–B/B–A, ratio; MDR1 A–B/B–A, ratio) 5.53/5.61, 1.02; 3.70/2.07, 0.56. Compound <b>22</b>: mouse plasma stability, 12.8 h. permeability (<i>P</i><sub>app</sub> × 10<sup>-6</sup> cm/s, wt A–B/B–A, ratio; MDR1 A–B/B–A, ratio) 3.63/1.73, 0.48; 1.86/1.40, 0.75.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, A. W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terentis, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, N. J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, S. R.</span></span> <span> </span><span class="NLM_article-title">Role Of Indoleamine 2,3-Dioxygenase In Health And Disease</span>. <i>Clin. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">601</span>– <span class="NLM_lpage">672</span>, <span class="refDoi"> DOI: 10.1042/cs20140392</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1042%2FCS20140392" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslKqtLnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2015&pages=601-672&author=A.+W.+S.+Yeungauthor=A.+C.+Terentisauthor=N.+J.+C.+Kingauthor=S.+R.+Thomas&title=Role+Of+Indoleamine+2%2C3-Dioxygenase+In+Health+And+Disease&doi=10.1042%2Fcs20140392"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Role of indoleamine 2,3-dioxygenase in health and disease</span></div><div class="casAuthors">Yeung, Amanda W. S.; Terentis, Andrew C.; King, Nicholas J. C.; Thomas, Shane R.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Science</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">601-672</span>CODEN:
                <span class="NLM_cas:coden">CSCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1470-8736</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">IDO1 (indoleamine 2,3-dioxygenase 1) is a member of a unique class of mammalian heme dioxygenases that catalyze the oxidative catabolism of the least-abundant essential amino acid, L-Trp (L-tryptophan), along the kynurenine pathway.  Significant increases in knowledge have been recently gained with respect to understanding the fundamental biochem. of IDO1 including its catalytic reaction mechanism, the scope of enzyme reactions it catalyzes, the biochem. mechanisms controlling IDO1 expression and enzyme activity, and the discovery of enzyme inhibitors.  Major advances in understanding the roles of IDO1 in physiol. and disease have also been realized.  IDO1 is recognized as a prominent immune regulatory enzyme capable of modulating immune cell activation status and phenotype via several mol. mechanisms including enzyme-dependent deprivation of L-Trp and its conversion into the aryl hydrocarbon receptor ligand kynurenine and other bioactive kynurenine pathway metabolites, or non-enzymic cell signalling actions involving tyrosine phosphorylation of IDO1.  Through these different modes of biochem. signalling, IDO1 regulates certain physiol. functions (e.g. pregnancy) and modulates the pathogenesis and severity of diverse conditions including chronic inflammation, infectious disease, allergic and autoimmune disorders, transplantation, neuropathol. and cancer.  In the present review, we detail the current understanding of IDO1's catalytic actions and the biochem. mechanisms regulating IDO1 expression and activity.  We also discuss the biol. functions of IDO1 with a focus on the enzyme's immune-modulatory function, its medical implications in diverse pathol. settings and its utility as a therapeutic target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpK04GKaRGhtrVg90H21EOLACvtfcHk0lh-nQa59ymBwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslKqtLnN&md5=86a912483bbe5504a07011513059aa95</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1042%2FCS20140392&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FCS20140392%26sid%3Dliteratum%253Aachs%26aulast%3DYeung%26aufirst%3DA.%2BW.%2BS.%26aulast%3DTerentis%26aufirst%3DA.%2BC.%26aulast%3DKing%26aufirst%3DN.%2BJ.%2BC.%26aulast%3DThomas%26aufirst%3DS.%2BR.%26atitle%3DRole%2520Of%2520Indoleamine%25202%252C3-Dioxygenase%2520In%2520Health%2520And%2520Disease%26jtitle%3DClin.%2520Sci.%26date%3D2015%26volume%3D129%26spage%3D601%26epage%3D672%26doi%3D10.1042%2Fcs20140392" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Badawy, A. A.-B.</span></span> <span> </span><span class="NLM_article-title">Kynurenine Pathway Of Tryptophan Metabolism: Regulatory And Functional Aspects</span>. <i>Int. J. Tryptophan Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">117864691769193</span>, <span class="refDoi"> DOI: 10.1177/1178646917691938</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1177%2F1178646917691938" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2017&pages=117864691769193&author=A.+A.-B.+Badawy&title=Kynurenine+Pathway+Of+Tryptophan+Metabolism%3A+Regulatory+And+Functional+Aspects&doi=10.1177%2F1178646917691938"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1177%2F1178646917691938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1178646917691938%26sid%3Dliteratum%253Aachs%26aulast%3DBadawy%26aufirst%3DA.%2BA.-B.%26atitle%3DKynurenine%2520Pathway%2520Of%2520Tryptophan%2520Metabolism%253A%2520Regulatory%2520And%2520Functional%2520Aspects%26jtitle%3DInt.%2520J.%2520Tryptophan%2520Res.%26date%3D2017%26volume%3D10%26spage%3D117864691769193%26doi%3D10.1177%2F1178646917691938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirey, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlin, J. M.</span></span> <span> </span><span class="NLM_article-title">Synergistic Transcriptional Activation Of Indoleamine Dioxygenase By IFN-Γ And Tumor Necrosis Factor-Α</span>. <i>J. Interferon Cytokine Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">413</span>– <span class="NLM_lpage">421</span>, <span class="refDoi"> DOI: 10.1089/107999003322277829</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1089%2F107999003322277829" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=13678429" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmvVOmsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2003&pages=413-421&author=C.+M.+Robinsonauthor=K.+A.+Shireyauthor=J.+M.+Carlin&title=Synergistic+Transcriptional+Activation+Of+Indoleamine+Dioxygenase+By+IFN-%CE%93+And+Tumor+Necrosis+Factor-%CE%91&doi=10.1089%2F107999003322277829"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic Transcriptional Activation of Indoleamine Dioxygenase by IFNγ and Tumor Necrosis Factor-α</span></div><div class="casAuthors">Robinson, Cory M.; Shirey, Kari Ann; Carlin, Joseph M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Interferon and Cytokine Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">413-421</span>CODEN:
                <span class="NLM_cas:coden">JICRFJ</span>;
        ISSN:<span class="NLM_cas:issn">1079-9907</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">Interferon-γ (IFN-γ)-induced indoleamine 2,3-dioxygenase (IDO) activity inhibits the growth of susceptible intracellular pathogens by catalyzing the oxidative cleavage of the indole ring of L-tryptophan and depleting pools of the essential amino acid.  Tumor necrosis factor-α (TNF-α) synergistically enhances the IDO activity induced by IFN-γ at the level of transcription in human epithelial cells.  The purpose here was to characterize the mol. mechanisms responsible for synergistic gene expression in response to IFN-γ and TNF α.  It was found that IFN-γ-induced mechanisms, such as the binding of Stat1 to gamma activation sequences (GAS) and IFN regulatory factor-1 (IRF-1) to IFN-stimulated response elements (ISREs), are more highly activated following treatment with IFN and TNF-α.  This enhanced signal transduction may be due to the increase in IFN-γ receptor (IFNGR) expression following combined cytokine stimulation and is a likely contributor to the synergy.  Addnl., the contribution of a third previously uncharacterized GAS element that forms a complex with Stat1 was investigated using a plasmid reporter system that controls for copy no.  When the GAS-3 sequence was included in the regulatory region, gene expression was increased relative to a region contg. the mutated GAS-3.  This suggests that GAS-3 is transcriptionally active and contributes to IFN-γ-induced regulation of the IDO gene.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJev_oK-00RLVg90H21EOLACvtfcHk0lh-nQa59ymBwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmvVOmsrg%253D&md5=cd0fc93db235c0938650bb96bdb1a00d</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1089%2F107999003322277829&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252F107999003322277829%26sid%3Dliteratum%253Aachs%26aulast%3DRobinson%26aufirst%3DC.%2BM.%26aulast%3DShirey%26aufirst%3DK.%2BA.%26aulast%3DCarlin%26aufirst%3DJ.%2BM.%26atitle%3DSynergistic%2520Transcriptional%2520Activation%2520Of%2520Indoleamine%2520Dioxygenase%2520By%2520IFN-%25CE%2593%2520And%2520Tumor%2520Necrosis%2520Factor-%25CE%2591%26jtitle%3DJ.%2520Interferon%2520Cytokine%2520Res.%26date%3D2003%26volume%3D23%26spage%3D413%26epage%3D421%26doi%3D10.1089%2F107999003322277829" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salahifar, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mashima, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stocker, R.</span></span> <span> </span><span class="NLM_article-title">Antioxidants Inhibit Indoleamine 2,3-Dioxygenase In IFN-Γ-Activated Human Macrophages: Posttranslational Regulation By Pyrrolidine Dithiocarbamate</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>166</i></span>,  <span class="NLM_fpage">6332</span>– <span class="NLM_lpage">6340</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.166.10.6332</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.4049%2Fjimmunol.166.10.6332" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=11342657" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjsFCqtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=166&publication_year=2001&pages=6332-6340&author=S.+R.+Thomasauthor=H.+Salahifarauthor=R.+Mashimaauthor=N.+H.+Huntauthor=D.+R.+Richardsonauthor=R.+Stocker&title=Antioxidants+Inhibit+Indoleamine+2%2C3-Dioxygenase+In+IFN-%CE%93-Activated+Human+Macrophages%3A+Posttranslational+Regulation+By+Pyrrolidine+Dithiocarbamate&doi=10.4049%2Fjimmunol.166.10.6332"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Antioxidants inhibit indoleamine 2,3-dioxygenase in IFN-γ-activated human macrophages: posttranslational regulation by pyrrolidine dithiocarbamate</span></div><div class="casAuthors">Thomas, Shane R.; Salahifar, Houta; Mashima, Ryuichi; Hunt, Nicholas H.; Richardson, Des R.; Stocker, Roland</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">166</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">6332-6340</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Induction of the heme-contg. indoleamine 2,3-dioxygenase (IDO) by IFN-γ is implicated in anti-microbial and pro-inflammatory activities of human macrophages.  Antioxidants can modulate the expression of immune and inflammatory genes, and pyrrolidine dithiocarbamate (PDTC) is a frequently used antioxidant to inhibit the transcription factor NF-κB.  Here the authors show that IFN-γ treatment of human monocyte-derived macrophages (hMDMs) increased the proportion of oxidized glutathione.  PDTC attenuated this increase and inhibited IDO activity, although it increased IDO protein expression and did not affect IDO mRNA expression and enzyme activity directly.  Other antioxidants, 2-ME, ebselen, and t-Bu hydroquinone, inhibited IDO protein expression.  Similar to PDTC, the heme biosynthesis inhibitor succinylacetone (SA) and the iron-chelator pyridoxal isonicotinoyl hydrazone inhibited cellular IDO activity without affecting protein expression, whereas addn. of hemin or the heme precursor δ-aminolevulinic acid increased IDO activity.  Also, incubation of IFN-γ-activated hMDM with δ-[14C]-aminolevulinic acid resulted in the incorporation of label into immunopptd. IDO, a process inhibited by PDTC and SA.  Furthermore, supplementation of lysates from PDTC- or SA-treated hMDM with hemin fully restored IDO activity to control levels, and hemin also reversed the inhibitory action of SA but not PDTC in intact cells.  Together these results establish a requirement for de novo heme synthesis for IDO activity in IFN-γ-activated hMDM.  They show that, similar to other pro-inflammatory proteins, the activity of IDO is modulated by antioxidants though in the case of PDTC this takes place posttranslationally, in part by limiting the availability of heme for the formation of holo-IDO.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorX-KrrnzpGbVg90H21EOLACvtfcHk0lh-nQa59ymBwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjsFCqtL4%253D&md5=5f56a998c930c1d0858d37a2635e7c5a</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.166.10.6332&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.166.10.6332%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DS.%2BR.%26aulast%3DSalahifar%26aufirst%3DH.%26aulast%3DMashima%26aufirst%3DR.%26aulast%3DHunt%26aufirst%3DN.%2BH.%26aulast%3DRichardson%26aufirst%3DD.%2BR.%26aulast%3DStocker%26aufirst%3DR.%26atitle%3DAntioxidants%2520Inhibit%2520Indoleamine%25202%252C3-Dioxygenase%2520In%2520IFN-%25CE%2593-Activated%2520Human%2520Macrophages%253A%2520Posttranslational%2520Regulation%2520By%2520Pyrrolidine%2520Dithiocarbamate%26jtitle%3DJ.%2520Immunol.%26date%3D2001%26volume%3D166%26spage%3D6332%26epage%3D6340%26doi%3D10.4049%2Fjimmunol.166.10.6332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Orabona, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallotta, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volpi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fallarino, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacca, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bianchi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belladonna, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fioretti, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grohmann, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puccetti, P.</span></span> <span> </span><span class="NLM_article-title">SOCS3 Drives Proteasomal Degradation Of Indoleamine 2,3-Dioxygenase (IDO) And Antagonizes IDO-Dependent Tolerogenesis</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">20828</span>– <span class="NLM_lpage">20833</span>, <span class="refDoi"> DOI: 10.1073/pnas.0810278105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1073%2Fpnas.0810278105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=19088199" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BD1MXksFSnsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=20828-20833&author=C.+Orabonaauthor=M.+T.+Pallottaauthor=C.+Volpiauthor=F.+Fallarinoauthor=C.+Vaccaauthor=R.+Bianchiauthor=M.+L.+Belladonnaauthor=M.+C.+Fiorettiauthor=U.+Grohmannauthor=P.+Puccetti&title=SOCS3+Drives+Proteasomal+Degradation+Of+Indoleamine+2%2C3-Dioxygenase+%28IDO%29+And+Antagonizes+IDO-Dependent+Tolerogenesis&doi=10.1073%2Fpnas.0810278105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">SOCS3 drives proteasomal degradation of indoleamine 2,3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis</span></div><div class="casAuthors">Orabona, Ciriana; Pallotta, Maria T.; Volpi, Claudia; Fallarino, Francesca; Vacca, Carmine; Bianchi, Roberta; Belladonna, Maria L.; Fioretti, Maria C.; Grohmann, Ursula; Puccetti, Paolo</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">52</span>),
    <span class="NLM_cas:pages">20828-20833</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Despite their common ability to activate intracellular signaling through CD80/CD86 mols., cytotoxic T lymphocyte antigen 4 (CTLA-4)-Ig and CD28-Ig bias the downstream response in opposite directions, the latter promoting immunity, and CTLA-4-Ig tolerance, in dendritic cells (DCs) with opposite but flexible programs of antigen presentation.  Nevertheless, in the absence of suppressor of cytokine signaling 3 (SOCS3), CD28-Ig - and the assocd., dominant IL-6 response-become immunosuppressive and mimic the effect of CTLA-4-Ig, including a high functional expression of the tolerogenic enzyme indoleamine 2,3-dioxygenase (IDO).  Here we show that forced SOCS3 expression antagonized CTLA-4-Ig activity in a proteasome-dependent fashion.  Unrecognized by previous studies, IDO appeared to possess two tyrosine residues within two distinct putative immunoreceptor tyrosine-based inhibitory motifs, VPY115CEL and LLY253EGV.  We found that SOCS3 - known to interact with phosphotyrosine-contg. peptides and be selectively induced by CD28-Ig/IL-6 - would bind IDO and target the IDO/SOCS3 complex for ubiquitination and subsequent proteasomal degrdn.  This event accounted for the ability of CD28-Ig and IL-6 to convert otherwise tolerogenic, IDO-competent DCs into immunogenic cells.  Thus onset of immunity in response to antigen within an early inflammatory context requires that IDO be degraded in tolerogenic DCs.  In addn. to identifying SOCS3 as a candidate signature for mouse DC subsets programmed to direct immunity, this study demonstrates that IDO undergoes regulatory proteolysis in response to immunogenic stimuli.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX7Y39qFDWH7Vg90H21EOLACvtfcHk0lj7qobD4UDQBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXksFSnsw%253D%253D&md5=31aa780e675a4e11490f79a329ca2e01</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0810278105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0810278105%26sid%3Dliteratum%253Aachs%26aulast%3DOrabona%26aufirst%3DC.%26aulast%3DPallotta%26aufirst%3DM.%2BT.%26aulast%3DVolpi%26aufirst%3DC.%26aulast%3DFallarino%26aufirst%3DF.%26aulast%3DVacca%26aufirst%3DC.%26aulast%3DBianchi%26aufirst%3DR.%26aulast%3DBelladonna%26aufirst%3DM.%2BL.%26aulast%3DFioretti%26aufirst%3DM.%2BC.%26aulast%3DGrohmann%26aufirst%3DU.%26aulast%3DPuccetti%26aufirst%3DP.%26atitle%3DSOCS3%2520Drives%2520Proteasomal%2520Degradation%2520Of%2520Indoleamine%25202%252C3-Dioxygenase%2520%2528IDO%2529%2520And%2520Antagonizes%2520IDO-Dependent%2520Tolerogenesis%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2008%26volume%3D105%26spage%3D20828%26epage%3D20833%26doi%3D10.1073%2Fpnas.0810278105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poncelet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ait-Belkacem, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marillier, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomes, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stauber, J.</span></span> <span> </span><span class="NLM_article-title">Target Exposure and Pharmacodynamics Study Of The Indoleamine 2,3-Dioxygenase-1 (IDO-1) Inhibitor Epacadostat In The CT26 Mouse Tumor Model</span>. <i>J. Pharm. Biomed. Anal.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>170</i></span>,  <span class="NLM_fpage">220</span>– <span class="NLM_lpage">227</span>, <span class="refDoi"> DOI: 10.1016/j.jpba.2019.02.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1016%2Fj.jpba.2019.02.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=30933897" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmtlyhsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=170&publication_year=2019&pages=220-227&author=L.+Ponceletauthor=R.+Ait-Belkacemauthor=R.+Marillierauthor=B.+Gomesauthor=J.+Stauber&title=Target+Exposure+and+Pharmacodynamics+Study+Of+The+Indoleamine+2%2C3-Dioxygenase-1+%28IDO-1%29+Inhibitor+Epacadostat+In+The+CT26+Mouse+Tumor+Model&doi=10.1016%2Fj.jpba.2019.02.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Target exposure and pharmacodynamics study of the indoleamine 2,3-dioxygenase-1 (IDO-1) inhibitor epacadostat in the CT26 mouse tumor model</span></div><div class="casAuthors">Poncelet, Lauranne; Ait-Belkacem, Rima; Marillier, Reece; Gomes, Bruno; Stauber, Jonathan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical and Biomedical Analysis</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">170</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">220-227</span>CODEN:
                <span class="NLM_cas:coden">JPBADA</span>;
        ISSN:<span class="NLM_cas:issn">0731-7085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Indoleamine-2,3-dioxygenase (IDO1) is an enzyme which converts tryptophan (Trp) into kynurenine (Kyn).  Having a crit. role in tumor immune escape by decreasing Trp and increasing Kyn levels in the microenvironment, IDO1 was one of the first targets for small mols. drug discovery in the field of immuno-oncol.  A potent and selective IDO1 inhibitor such as Epacadostat (EPA) was shown to enhance the antitumor activity by restoring the immune system fitness.  As exposure at the site of action and to its specific target are identified as the most important factors for success in drug discovery, the objective of this study was to explore the target exposure and intra-tumor pharmacodynamics effects of EPA drug on the tumor metab.  To do so, we used both Quant. Mass Spectrometry Imaging (QMSI) and liq. chromatog. coupled with tandem mass spectrometry (LC-MS/MS) technologies in order to monitor drug and metabolites distribution and their endogenous quantity in the CT26 mouse tumor model.  Target exposure anal. showed that almost 61% of EPA signal (26 μg/g) was concd. within 38% of the entire tumor surface.  Semi quant. anal. of this region confirmed a pos. correlation between IDO1 expression and EPA concn.  In parallel, pharmacodynamics anal. highlighted a response efficacy through Kyn/Trp ratio calcn. that was shown decreasing after EPA treatment as noticed in treated CT26 tumors (-82%), plasma (-63%) and blood (-62%) compared to control samples.  Finally, 15% and 85% of Kyn signal was found in regions with high and low EPA, resp.  In this study, using QMSI, we went further than only quantifying the metabolites and the drug, by estg. the pharmacol. effect efficacy of the drug through a target exposure study handled in different regions of the tumor either expressing IDO1 or Kyn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYWZJdqzRfj7Vg90H21EOLACvtfcHk0lj7qobD4UDQBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmtlyhsbk%253D&md5=3187f470111997d1761f259628694c00</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2Fj.jpba.2019.02.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jpba.2019.02.038%26sid%3Dliteratum%253Aachs%26aulast%3DPoncelet%26aufirst%3DL.%26aulast%3DAit-Belkacem%26aufirst%3DR.%26aulast%3DMarillier%26aufirst%3DR.%26aulast%3DGomes%26aufirst%3DB.%26aulast%3DStauber%26aufirst%3DJ.%26atitle%3DTarget%2520Exposure%2520and%2520Pharmacodynamics%2520Study%2520Of%2520The%2520Indoleamine%25202%252C3-Dioxygenase-1%2520%2528IDO-1%2529%2520Inhibitor%2520Epacadostat%2520In%2520The%2520CT26%2520Mouse%2520Tumor%2520Model%26jtitle%3DJ.%2520Pharm.%2520Biomed.%2520Anal.%26date%3D2019%26volume%3D170%26spage%3D220%26epage%3D227%26doi%3D10.1016%2Fj.jpba.2019.02.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, E.</span></span> <span> </span><span class="NLM_article-title">Subcutaneous Inoculation Position Affects The Immune Environment In CT26 Carcinomas</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>512</i></span>,  <span class="NLM_fpage">244</span>– <span class="NLM_lpage">249</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2019.03.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1016%2Fj.bbrc.2019.03.042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=30879760" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BC1MXltVSgt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=512&publication_year=2019&pages=244-249&author=X.+Fuauthor=Y.+Yangauthor=J.+Xieauthor=X.+Panauthor=X.+Yangauthor=Z.+Duauthor=E.+Hao&title=Subcutaneous+Inoculation+Position+Affects+The+Immune+Environment+In+CT26+Carcinomas&doi=10.1016%2Fj.bbrc.2019.03.042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Subcutaneous inoculation position affects the immune environment in CT26 carcinomas</span></div><div class="casAuthors">Fu, Xiaocong; Yang, Yeguo; Xie, Jinling; Pan, Xianglong; Yang, Xue; Du, Zhengcai; Hao, Erwei</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">512</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">244-249</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Comprehensive knowledge on the murine CT26 colon carcinoma line is a classic model used in the pharmacodynamic expts. involving IDO-1 inhibitors, immune-related checkpoint antibodies and immune related mechanisms.  In this study, we detd. the impact of different s.c. inoculation locations on tumor growth and immune factor expression.  CT26 cells were treated with the IDO-1 inhibitor, INCB024360, following INF-γ stimulation and analyzed for kynurenine concn.  Female Balb/c mice were inoculated with CT26 cells in either or both the right upper flank or the right lower flank.  Isolated tumors were evaluated for changes in tumor vol. following treatment with anti-PD-1, anti-CTLA-4, or no treatment.  Isolated tumors were also evaluated for changes in immune cell subpopulations and expression of key immune factors using FACS.  Treatment of two CT26 cell lines with INCB024360 produced similar results.  IC50 values were 222.5 and 276.0, and the peak inhibitory rates were 97.99% and 91.85% resp.  Anal. of tumor growth revealed that tumor vols. were larger (1925 mm3 vs. 767 mm3), and the anti-tumor effects of both anti-PD-1 and anti-CTLA-4 were different in mice inoculated in the right lower flank than in those inoculated in the upper flank.  FACS anal. revealed that the CD8+T subpopulation in the right upper flank was higher than that in the lower flank (*P < 0.05).  By contrast, the myeloid cell populations was lower in the right upper flank than it was in the right lower flank (*P < 0.05).  The INF-γ populations in CD8+T (*P < 0.05) and regulatory T (Treg) cell subpopulation (*P < 0.05) were also more abundant in the right upper flank than in the right lower flank.  In contrast to the uniform of the results from the in vitro expt., the anti-CTLA-4 and anti-PD-1 antibodies had different efficacies depending on the location of the s.c. inoculation of CT26 in mice.  The differences in the percentages of CD8+T, myeloid cells, INF-γ in CD8+T, and Treg subpopulations indicated that the tumor microenvironment was affected by inoculation position.  Taken together, these results suggest that tumors isolated from same cell line with different inoculation positions are different enough to be considered different models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq44q9XBHhcprVg90H21EOLACvtfcHk0lj7qobD4UDQBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXltVSgt74%253D&md5=ce5877da2f6ef22b54e6139c771b358d</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2019.03.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2019.03.042%26sid%3Dliteratum%253Aachs%26aulast%3DFu%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DPan%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DDu%26aufirst%3DZ.%26aulast%3DHao%26aufirst%3DE.%26atitle%3DSubcutaneous%2520Inoculation%2520Position%2520Affects%2520The%2520Immune%2520Environment%2520In%2520CT26%2520Carcinomas%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2019%26volume%3D512%26spage%3D244%26epage%3D249%26doi%3D10.1016%2Fj.bbrc.2019.03.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tuntland, T.</span>; <span class="NLM_string-name">Ethell, B.</span>; <span class="NLM_string-name">Kosaka, T.</span>; <span class="NLM_string-name">Blasco, F.</span>; <span class="NLM_string-name">Zang, R. X.</span>; <span class="NLM_string-name">Jain, M.</span>; <span class="NLM_string-name">Gould, T.</span>; <span class="NLM_string-name">Hoffmaster, K.</span></span> <span> </span><span class="NLM_article-title">Implementation Of Pharmacokinetic And Pharmacodynamic Strategies In Early Research Phases Of Drug Discovery And Development At Novartis Institute Of Biomedical Research</span>.  <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume">5</span>.174 <span class="refDoi"> DOI: 10.3389/fphar.2014.00174</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.3389%2Ffphar.2014.00174" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=25120485" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&author=T.+Tuntland&author=B.+Ethell&author=T.+Kosaka&author=F.+Blasco&author=R.+X.+Zang&author=M.+Jain&author=T.+Gould&author=K.+Hoffmaster&title=Implementation+Of+Pharmacokinetic+And+Pharmacodynamic+Strategies+In+Early+Research+Phases+Of+Drug+Discovery+And+Development+At+Novartis+Institute+Of+Biomedical+Research&doi=10.3389%2Ffphar.2014.00174"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2014.00174&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2014.00174%26sid%3Dliteratum%253Aachs%26aulast%3DTuntland%26aufirst%3DT.%26atitle%3DImplementation%2520Of%2520Pharmacokinetic%2520And%2520Pharmacodynamic%2520Strategies%2520In%2520Early%2520Research%2520Phases%2520Of%2520Drug%2520Discovery%2520And%2520Development%2520At%2520Novartis%2520Institute%2520Of%2520Biomedical%2520Research%26jtitle%3DFront.%2520Pharmacol.%26date%3D2014%26volume%3D5%26doi%3D10.3389%2Ffphar.2014.00174" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jamieson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moir, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wishart, G.</span></span> <span> </span><span class="NLM_article-title">Medicinal Chemistry Of Herg Optimizations: Highlights And Hang-Ups</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">5029</span>– <span class="NLM_lpage">5046</span>, <span class="refDoi"> DOI: 10.1021/jm060379l</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060379l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BD28Xns1WqsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=5029-5046&author=C.+Jamiesonauthor=E.+M.+Moirauthor=Z.+Rankovicauthor=G.+Wishart&title=Medicinal+Chemistry+Of+Herg+Optimizations%3A+Highlights+And+Hang-Ups&doi=10.1021%2Fjm060379l"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Medicinal chemistry of hERG optimizations: Highlights and hang-ups</span></div><div class="casAuthors">Jamieson, Craig; Moir, Elizabeth M.; Rankovic, Zoran; Wishart, Grant</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5029-5046</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  A brief summary of the in silico, in vitro, and in vivo approaches employed to measure blockade of hERG and QT prolongation is detailed.  The discussion aims to summarize the approaches engaged to circumvent activity at hERG, identified through an extensive literature survey.  The optimizations are recorded as pairs of compds., which have been categorized in terms of the tactics employed to diminish hERG activity. Examn. of the properties of the compds. within each category has enabled formulation os some empirical guidelines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqv6eM5w53KebVg90H21EOLACvtfcHk0lg0UlMLDoL9XQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xns1WqsL8%253D&md5=117c84a010f877c835b7dbc945996b92</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1021%2Fjm060379l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060379l%26sid%3Dliteratum%253Aachs%26aulast%3DJamieson%26aufirst%3DC.%26aulast%3DMoir%26aufirst%3DE.%2BM.%26aulast%3DRankovic%26aufirst%3DZ.%26aulast%3DWishart%26aufirst%3DG.%26atitle%3DMedicinal%2520Chemistry%2520Of%2520Herg%2520Optimizations%253A%2520Highlights%2520And%2520Hang-Ups%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D5029%26epage%3D5046%26doi%3D10.1021%2Fjm060379l" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Redfern, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlsson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackenzie, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palethorpe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegl, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strang, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallis, R.</span></span> <span> </span><span class="NLM_article-title">Relationships Between Preclinical Cardiac Electrophysiology, Clinical QT Interval Prolongation And Torsade De Pointes For A Broad Range Of Drugs: Evidence For A Provisional Safety Margin In Drug Development</span>. <i>Cardiovasc. Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">45</span>, <span class="refDoi"> DOI: 10.1016/s0008-6363(02)00846-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1016%2FS0008-6363%2802%2900846-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=12667944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BD3sXit12gsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2003&pages=32-45&author=W.+Redfernauthor=L.+Carlssonauthor=A.+Davisauthor=W.+Lynchauthor=I.+Mackenzieauthor=S.+Palethorpeauthor=P.+Sieglauthor=I.+Strangauthor=A.+Sullivanauthor=R.+Wallis&title=Relationships+Between+Preclinical+Cardiac+Electrophysiology%2C+Clinical+QT+Interval+Prolongation+And+Torsade+De+Pointes+For+A+Broad+Range+Of+Drugs%3A+Evidence+For+A+Provisional+Safety+Margin+In+Drug+Development&doi=10.1016%2Fs0008-6363%2802%2900846-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development</span></div><div class="casAuthors">Redfern, W. S.; Carlsson, L.; Davis, A. S.; Lynch, W. G.; MacKenzie, I.; Palethorpe, S.; Siegl, P. K. S.; Strang, I.; Sullivan, A. T.; Wallis, R.; Camm, A. J.; Hammond, T. G.</div><div class="citationInfo"><span class="NLM_cas:title">Cardiovascular Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32-45</span>CODEN:
                <span class="NLM_cas:coden">CVREAU</span>;
        ISSN:<span class="NLM_cas:issn">0008-6363</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review discussing attempts to det. the relative value of preclin. cardiac electrophysiol. data (in vitro and in vivo) for predicting risk of torsades de pointes (TdP) in clin. use.  Published data on human ether-a-go-go-related gene-encoded voltage-dependent potassium channel (hERG) (or IKr) activity, cardiac action potential duration (at 90% repolarization; APD90), and QT prolongation in dogs were compared against QT effects and reports of TdP in humans for 100 drugs.  These data were set against the free plasma concns. attained during clin. use (effective therapeutic plasma concns.; ETPCunbound).  The drugs were divided into five categories: (1) Class Ia and III antiarrhythmics; (2) withdrawn from market due to TdP; (3) measurable incidence/numerous reports of TdP in humans; (4) isolated reports of TdP in humans; (5) no reports of TdP in humans.  Data from hERG (or IKr) assays in addn. to ETPCunbound data were available for 52 drugs.  For Category 1 drugs, data for hERG/IKr IC50, APD90, QTc in animals and QTc in humans were generally close to or superimposed on the ETPCunbound values.  This relationship was uncoupled in the other categories, with more complex relationships between the data.  In Category 1 (except amiodarone), the ratios between hERG/IKr IC50 and ETPCunbound (max) ranged 0.1-31-fold.  Similar ranges were obtained for drugs in Category 2 (0.31-13-fold) and Category 3 (0.03-35-fold).  A large spread was found for Category 4 drugs (0.13-35,700-fold); this category embraced an assortment of mechanisms ranging from drugs which may well be affecting IKr currents in clin. use (e.g., sparfloxacin) to others such as nifedipine (35,700-fold) where channel block is not involved.  Finally, for the majority of Category 5 drugs there was a >30-fold sepn. between hERG/IKr activity and ETPCunbound values, with the notable exception of verapamil (1.7-fold), which is free from QT prolongation in man; this is probably explained by its multiple interactions with cardiac ion channels.  The dataset confirms the widely held belief that most drugs assocd. with TdP in humans are also assocd. with hERG K+ channel block at concns. close to or superimposed upon the free plasma concns. found in clin. use.  A 30-fold margin between Cmax and hERG IC50 may suffice for drugs currently undergoing clin. evaluation, but for future drug discovery programs, pharmaceutical companies should consider increasing this margin, particularly for drugs aimed at nondebilitating diseases.  However, interactions with multiple cardiac ion channels can either mitigate or exacerbate the prolongation of APD and QT that would ensue from block of IKr currents alone, and delay of repolarization per se is not necessarily torsadogenic.  Clearly, an integrated assessment of in vitro and in vivo data is required in order to predict the torsadogenic risk of a new candidate drug in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkpRDUH0rhyrVg90H21EOLACvtfcHk0lg0UlMLDoL9XQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXit12gsb8%253D&md5=a236c07febd2e05fe70e61604619bf2e</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2FS0008-6363%2802%2900846-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0008-6363%252802%252900846-5%26sid%3Dliteratum%253Aachs%26aulast%3DRedfern%26aufirst%3DW.%26aulast%3DCarlsson%26aufirst%3DL.%26aulast%3DDavis%26aufirst%3DA.%26aulast%3DLynch%26aufirst%3DW.%26aulast%3DMackenzie%26aufirst%3DI.%26aulast%3DPalethorpe%26aufirst%3DS.%26aulast%3DSiegl%26aufirst%3DP.%26aulast%3DStrang%26aufirst%3DI.%26aulast%3DSullivan%26aufirst%3DA.%26aulast%3DWallis%26aufirst%3DR.%26atitle%3DRelationships%2520Between%2520Preclinical%2520Cardiac%2520Electrophysiology%252C%2520Clinical%2520QT%2520Interval%2520Prolongation%2520And%2520Torsade%2520De%2520Pointes%2520For%2520A%2520Broad%2520Range%2520Of%2520Drugs%253A%2520Evidence%2520For%2520A%2520Provisional%2520Safety%2520Margin%2520In%2520Drug%2520Development%26jtitle%3DCardiovasc.%2520Res.%26date%3D2003%26volume%3D58%26spage%3D32%26epage%3D45%26doi%3D10.1016%2Fs0008-6363%2802%2900846-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selvaggio, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearlstein, R. A.</span></span> <span> </span><span class="NLM_article-title">Toward In Vivo-Relevant Herg Safety Assessment And Mitigation Strategies Based On Relationships Between Non-Equilibrium Blocker Binding, Three-Dimensional Channel-Blocker Interactions, Dynamic Occupancy, Dynamic Exposure, And Cellular Arrhythmia</span>. <i>PloS One</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>15</i></span>, <span class="NLM_elocation-id">e0234946</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0234946</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1371%2Fjournal.pone.0234946" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=33147278" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitlWisb3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2020&author=H.+Wanauthor=G.+Selvaggioauthor=R.+A.+Pearlstein&title=Toward+In+Vivo-Relevant+Herg+Safety+Assessment+And+Mitigation+Strategies+Based+On+Relationships+Between+Non-Equilibrium+Blocker+Binding%2C+Three-Dimensional+Channel-Blocker+Interactions%2C+Dynamic+Occupancy%2C+Dynamic+Exposure%2C+And+Cellular+Arrhythmia&doi=10.1371%2Fjournal.pone.0234946"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Toward in vivo-relevant hERG safety assessment and mitigation strategies based on relationships between non-equilibrium blocker binding, three-dimensional channel-blocker interactions, dynamic occupancy, dynamic exposure, and cellular arrhythmia</span></div><div class="casAuthors">Wan, Hongbin; Selvaggio, Gianluca; Pearlstein, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">e0234946</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">We propose a two-step blocker binding process consisting of: The initial capture step: diffusion of a single fully solvated blocker copy into a large cavity lined by the intra-cellular cyclic nucleotide binding homol. domain (CNBHD).  Occupation of this cavity is necessary but insufficient condition for ion current disruption.  The IKr disruption step: translocation of the captured blocker along channel axis, such that: head group, consisting of quasi-rod-shaped moiety, projects into open pore, accompanied by partial de-solvation of binding interface.  One tail moiety packs along kink between S6 helix and proximal C-linker helix adjacent to intra-cellular entrance of pore, likewise accompanied by mutual de-solvation of binding interface.  Blockers contg. highly planar moiety that projects into a putative constriction zone within the closed channel become trapped upon closing, as do blockers terminating prior to this region.  A single captured blocker copy may conceivably assoc. and dissoc. to/from the pore many times before exiting the CNBHD cavity.  The predicted arrhythmogenic fractional hERG occupancy (based on action potential (AP) simulations of the undiseased human ventricular cardiomyocyte).  Risk of exposure escalation toward the predicted arrhythmic limit due to patient-to-patient pharmacokinetic (PK) variability, drug-drug interactions, overdose, and use for off-label indications in which the hERG safety parameters may differ from their on-label counterparts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp08X5mSqeNQrVg90H21EOLACvtfcHk0lg0UlMLDoL9XQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitlWisb3J&md5=0e15f6b5cf1751443b27773a679b5e47</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0234946&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0234946%26sid%3Dliteratum%253Aachs%26aulast%3DWan%26aufirst%3DH.%26aulast%3DSelvaggio%26aufirst%3DG.%26aulast%3DPearlstein%26aufirst%3DR.%2BA.%26atitle%3DToward%2520In%2520Vivo-Relevant%2520Herg%2520Safety%2520Assessment%2520And%2520Mitigation%2520Strategies%2520Based%2520On%2520Relationships%2520Between%2520Non-Equilibrium%2520Blocker%2520Binding%252C%2520Three-Dimensional%2520Channel-Blocker%2520Interactions%252C%2520Dynamic%2520Occupancy%252C%2520Dynamic%2520Exposure%252C%2520And%2520Cellular%2520Arrhythmia%26jtitle%3DPloS%2520One%26date%3D2020%26volume%3D15%26doi%3D10.1371%2Fjournal.pone.0234946" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kongsamut, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roehr, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rampe, D.</span></span> <span> </span><span class="NLM_article-title">A Comparison Of The Receptor Binding And HERG Channel Affinities For A Series Of Antipsychotic Drugs</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>450</i></span>,  <span class="NLM_fpage">37</span>– <span class="NLM_lpage">41</span>, <span class="refDoi"> DOI: 10.1016/s0014-2999(02)02074-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1016%2FS0014-2999%2802%2902074-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=12176106" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BD38XmtlKjsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=450&publication_year=2002&pages=37-41&author=S.+Kongsamutauthor=J.+Kangauthor=X.-L.+Chenauthor=J.+Roehrauthor=D.+Rampe&title=A+Comparison+Of+The+Receptor+Binding+And+HERG+Channel+Affinities+For+A+Series+Of+Antipsychotic+Drugs&doi=10.1016%2Fs0014-2999%2802%2902074-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs</span></div><div class="casAuthors">Kongsamut, Sathapana; Kang, Jiesheng; Chen, Xiao-Liang; Roehr, Joachim; Rampe, David</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">450</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">37-41</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">Many antipsychotic drugs produce QT interval prolongation on the ECG.  Blockade of the human cardiac K+ channel known as human ether-a-go-go-related gene (HERG) often underlies such clin. findings.  In fact, HERG channel inhibition is now commonly used as a screen to predict the ability of a drug to prolong QT interval.  However, the exact relation between HERG channel blockade, target receptor binding affinity and clin. QT prolongation is not known.  Using patch-clamp electrophysiol., the authors examd. a series of seven antipsychotic drugs for their ability to block HERG, and detd. their IC50 values.  The authors then compared these results to their binding affinities (Ki values) for the dopamine D2 receptor, the 5-HT2A receptor and, where available, to clin. QT prolongation data.  The authors found that sertindole, pimozide and thioridazine displayed little (<10-fold) or no selectivity for dopamine D2 or 5-HT2A receptors relative to their HERG channel affinities.  This lack of selectivity likely underlies the significant QT interval prolongation obsd. with administration of these drugs.  Of the other drugs tested (ziprasidone, quetiapine, risperidone and olanzapine), olanzapine displayed the greatest selectivity for dopamine D2 and 5-HT2A receptor binding (100-1000-fold) compared to its HERG channel IC50.  The authors also compared these HERG channel IC50 values to QT interval prolongation and plasma drug levels obtained in a recent clin. study.  The authors found that the ratio of total plasma drug concn. to HERG IC50 value was indicative of the degree of QT prolongation obsd.  Target receptor affinity and expected clin. plasma levels are important parameters to consider for the interpretation of HERG channel data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1PPyFCa8xyrVg90H21EOLACvtfcHk0ljzZ-zFdeTQSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmtlKjsbo%253D&md5=8b5879e5d59e01dcd490e71d57844fdf</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2FS0014-2999%2802%2902074-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-2999%252802%252902074-5%26sid%3Dliteratum%253Aachs%26aulast%3DKongsamut%26aufirst%3DS.%26aulast%3DKang%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DX.-L.%26aulast%3DRoehr%26aufirst%3DJ.%26aulast%3DRampe%26aufirst%3DD.%26atitle%3DA%2520Comparison%2520Of%2520The%2520Receptor%2520Binding%2520And%2520HERG%2520Channel%2520Affinities%2520For%2520A%2520Series%2520Of%2520Antipsychotic%2520Drugs%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2002%26volume%3D450%26spage%3D37%26epage%3D41%26doi%3D10.1016%2Fs0014-2999%2802%2902074-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shahripour, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jesus, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teumelsan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Priest, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swensen, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alonso-Galicia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felix, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brochu, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas-Fowlkes, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pai, L.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hampton, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehrhart, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaczorowski, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasternak, A.</span></span> <span> </span><span class="NLM_article-title">Differentiation Of ROMK Potency From Herg Potency In The Phenacetyl Piperazine Series Through Heterocycle Incorporation</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">2339</span>– <span class="NLM_lpage">2343</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.03.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1016%2Fj.bmcl.2016.03.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=27017115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BC28XkvVCms7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=2339-2343&author=S.+P.+Walshauthor=A.+Shahripourauthor=H.+Tangauthor=R.+K.+de+Jesusauthor=N.+Teumelsanauthor=Y.+Zhuauthor=J.+Frieauthor=B.+T.+Priestauthor=A.+M.+Swensenauthor=M.+Alonso-Galiciaauthor=J.+P.+Felixauthor=R.+M.+Brochuauthor=T.+Baileyauthor=B.+Thomas-Fowlkesauthor=X.+Zhouauthor=L.-Y.+Paiauthor=C.+Hamptonauthor=M.+Hernandezauthor=K.+Owensauthor=J.+Ehrhartauthor=S.+Royauthor=G.+J.+Kaczorowskiauthor=L.+Yangauthor=M.+L.+Garciaauthor=A.+Pasternak&title=Differentiation+Of+ROMK+Potency+From+Herg+Potency+In+The+Phenacetyl+Piperazine+Series+Through+Heterocycle+Incorporation&doi=10.1016%2Fj.bmcl.2016.03.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Differentiation of ROMK potency from hERG potency in the phenacetyl piperazine series through heterocycle incorporation</span></div><div class="casAuthors">Walsh, Shawn P.; Shahripour, Aurash; Tang, Haifeng; de Jesus, Reynalda K.; Teumelsan, Nardos; Zhu, Yuping; Frie, Jessica; Priest, Birgit T.; Swensen, Andrew M.; Alonso-Galicia, Magdalena; Felix, John P.; Brochu, Richard M.; Bailey, Timothy; Thomas-Fowlkes, Brande; Zhou, Xiaoyan; Pai, Lee-Yuh; Hampton, Caryn; Hernandez, Melba; Owens, Karen; Ehrhart, Juliann; Roy, Sophie; Kaczorowski, Gregory J.; Yang, Lihu; Garcia, Maria L.; Pasternak, Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2339-2343</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Following the discovery of small mol. acyl piperazine ROMK inhibitors and their initial preclin. validation as a novel diuretic agent, the authors' group set out to discover new ROMK inhibitors with reduced risk for QT effects, suitable for further pharmacol. expts. in addnl. species.  Several strategies for decreasing hERG affinity while maintaining ROMK inhibition were investigated and are described herein.  The most promising candidate, derived from the newly discovered 4-N-heteroaryl acetyl series, improved functional hERG/ROMK ratio by >10× over the previous lead.  In vivo evaluation demonstrated comparable diuretic effects in rat with no detectable QT effects at the doses evaluated in an in vivo dog model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLmiCSrRXlP7Vg90H21EOLACvtfcHk0ljzZ-zFdeTQSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XkvVCms7c%253D&md5=e38c26bd27012f90c551c56469ef86db</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.03.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.03.035%26sid%3Dliteratum%253Aachs%26aulast%3DWalsh%26aufirst%3DS.%2BP.%26aulast%3DShahripour%26aufirst%3DA.%26aulast%3DTang%26aufirst%3DH.%26aulast%3Dde%2BJesus%26aufirst%3DR.%2BK.%26aulast%3DTeumelsan%26aufirst%3DN.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DFrie%26aufirst%3DJ.%26aulast%3DPriest%26aufirst%3DB.%2BT.%26aulast%3DSwensen%26aufirst%3DA.%2BM.%26aulast%3DAlonso-Galicia%26aufirst%3DM.%26aulast%3DFelix%26aufirst%3DJ.%2BP.%26aulast%3DBrochu%26aufirst%3DR.%2BM.%26aulast%3DBailey%26aufirst%3DT.%26aulast%3DThomas-Fowlkes%26aufirst%3DB.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DPai%26aufirst%3DL.-Y.%26aulast%3DHampton%26aufirst%3DC.%26aulast%3DHernandez%26aufirst%3DM.%26aulast%3DOwens%26aufirst%3DK.%26aulast%3DEhrhart%26aufirst%3DJ.%26aulast%3DRoy%26aufirst%3DS.%26aulast%3DKaczorowski%26aufirst%3DG.%2BJ.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DGarcia%26aufirst%3DM.%2BL.%26aulast%3DPasternak%26aufirst%3DA.%26atitle%3DDifferentiation%2520Of%2520ROMK%2520Potency%2520From%2520Herg%2520Potency%2520In%2520The%2520Phenacetyl%2520Piperazine%2520Series%2520Through%2520Heterocycle%2520Incorporation%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D2339%26epage%3D2343%26doi%3D10.1016%2Fj.bmcl.2016.03.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, J.</span></span> <span> </span><span class="NLM_article-title">Pre-Clinical Murine Models: Syngeneic Models For Immuno-Oncology</span>.  <i>MOJ Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume">2</span>()00052 .<span class="refDoi"> DOI: 10.15406/moji.2015.02.00052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.15406%2Fmoji.2015.02.00052" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2015&author=J.+Murphy&title=Pre-Clinical+Murine+Models%3A+Syngeneic+Models+For+Immuno-Oncology&doi=10.15406%2Fmoji.2015.02.00052"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.15406%2Fmoji.2015.02.00052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.15406%252Fmoji.2015.02.00052%26sid%3Dliteratum%253Aachs%26aulast%3DMurphy%26aufirst%3DJ.%26atitle%3DPre-Clinical%2520Murine%2520Models%253A%2520Syngeneic%2520Models%2520For%2520Immuno-Oncology%26jtitle%3DMOJ%2520Immunol.%26date%3D2015%26volume%3D2%26doi%3D10.15406%2Fmoji.2015.02.00052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saito, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashima, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, O.</span></span> <span> </span><span class="NLM_article-title">Faithful Preclinical Mouse Models For Better Translation To Bedside In The Field Of Immuno-Oncology</span>. <i>Int. J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">831</span>– <span class="NLM_lpage">841</span>, <span class="refDoi"> DOI: 10.1007/s10147-019-01520-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1007%2Fs10147-019-01520-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=31407168" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2019&pages=831-841&author=R.+Saitoauthor=T.+Kobayashiauthor=S.+Kashimaauthor=K.+Matsumotoauthor=O.+Ogawa&title=Faithful+Preclinical+Mouse+Models+For+Better+Translation+To+Bedside+In+The+Field+Of+Immuno-Oncology&doi=10.1007%2Fs10147-019-01520-z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1007%2Fs10147-019-01520-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10147-019-01520-z%26sid%3Dliteratum%253Aachs%26aulast%3DSaito%26aufirst%3DR.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DKashima%26aufirst%3DS.%26aulast%3DMatsumoto%26aufirst%3DK.%26aulast%3DOgawa%26aufirst%3DO.%26atitle%3DFaithful%2520Preclinical%2520Mouse%2520Models%2520For%2520Better%2520Translation%2520To%2520Bedside%2520In%2520The%2520Field%2520Of%2520Immuno-Oncology%26jtitle%3DInt.%2520J.%2520Clin.%2520Oncol.%26date%3D2019%26volume%3D25%26spage%3D831%26epage%3D841%26doi%3D10.1007%2Fs10147-019-01520-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, R.</span>; <span class="NLM_string-name">Hamilton, M.</span>; <span class="NLM_string-name">Jones, P.</span>; <span class="NLM_string-name">Petrocchi, A.</span>; <span class="NLM_string-name">Reyna, N.</span>; <span class="NLM_string-name">McAfoos, T.</span>; <span class="NLM_string-name">Cross, J.</span>; <span class="NLM_string-name">Soth, M.</span></span> <span> </span><span class="NLM_article-title">Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase</span>. <span class="NLM_patent">WO 2020018670 A1</span>, Janurary 23, <span class="NLM_year">2020</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=R.+Lewis&author=M.+Hamilton&author=P.+Jones&author=A.+Petrocchi&author=N.+Reyna&author=T.+McAfoos&author=J.+Cross&author=M.+Soth&title=Compounds+useful+as+inhibitors+of+indoleamine+2%2C3-dioxygenase+and%2For+tryptophan+dioxygenase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLewis%26aufirst%3DR.%26atitle%3DCompounds%2520useful%2520as%2520inhibitors%2520of%2520indoleamine%25202%252C3-dioxygenase%2520and%252For%2520tryptophan%2520dioxygenase%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sonpavde, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Necchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinberg, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gschwend, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Der Heijden, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garzon, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raybold, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liaw, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutstein, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galsky, M. D.</span></span> <span> </span><span class="NLM_article-title">ENERGIZE: A Phase III Study Of Neoadjuvant Chemotherapy Alone Or With Nivolumab With/Without Linrodostat Mesylate For Muscle-Invasive Bladder Cancer</span>. <i>Future Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">4359</span>– <span class="NLM_lpage">4368</span>, <span class="refDoi"> DOI: 10.2217/fon-2019-0611</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.2217%2Ffon-2019-0611" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=31823654" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVSntr3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2020&pages=4359-4368&author=G.+Sonpavdeauthor=A.+Necchiauthor=S.+Guptaauthor=G.+D.+Steinbergauthor=J.+E.+Gschwendauthor=M.+S.+Van+Der+Heijdenauthor=N.+Garzonauthor=M.+Ibrahimauthor=B.+Rayboldauthor=D.+Liawauthor=M.+Rutsteinauthor=M.+D.+Galsky&title=ENERGIZE%3A+A+Phase+III+Study+Of+Neoadjuvant+Chemotherapy+Alone+Or+With+Nivolumab+With%2FWithout+Linrodostat+Mesylate+For+Muscle-Invasive+Bladder+Cancer&doi=10.2217%2Ffon-2019-0611"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">ENERGIZE: a Phase III study of neoadjuvant chemotherapy alone or with nivolumab with/without linrodostat mesylate for muscle-invasive bladder cancer</span></div><div class="casAuthors">Sonpavde, Guru; Necchi, Andrea; Gupta, Shilpa; Steinberg, Gary D.; Gschwend, Juergen E.; Van Der Heijden, Michiel Simon; Garzon, Nathalie; Ibrahim, Mohammed; Raybold, Bradley; Liaw, Danny; Rutstein, Mark; Galsky, Matt D.</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">4359-4368</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1744-8301</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">Immune checkpoint inhibitors have revolutionized the treatment of patients with metastatic urothelial carcinoma.  In cisplatin-eligible muscle-invasive bladder cancer (MIBC), cisplatin-based neoadjuvant chemotherapy (NAC) before radical cystectomy improves overall survival.  Tumor PD-L1 expression increases in MIBC after NAC, suggesting potential synergy in combining PD1/PD-L1 inhibitors with NAC.  IDO1 is overexpressed in bladder cancer and is assocd. with poor outcomes.  Linrodostat mesylate (BMS-986205) a selective, potent, oral IDO1 inhibitor combined with nivolumab has demonstrated safety and preliminary evidence of clin. activity in metastatic urothelial carcinoma.  Here, we discuss the rationale and trial design of the ENERGIZE, a Phase III trial investigating the efficacy of NAC in combination with nivolumab with or without linrodostat followed by postsurgery nivolumab or nivolumab with linrodostat in cisplatin-eligible patients with MIBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3VxHx2k7HEbVg90H21EOLACvtfcHk0ljXrz5te2M6OQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVSntr3N&md5=68ce0cc3472d7958423c4b0f57b75c78</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.2217%2Ffon-2019-0611&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffon-2019-0611%26sid%3Dliteratum%253Aachs%26aulast%3DSonpavde%26aufirst%3DG.%26aulast%3DNecchi%26aufirst%3DA.%26aulast%3DGupta%26aufirst%3DS.%26aulast%3DSteinberg%26aufirst%3DG.%2BD.%26aulast%3DGschwend%26aufirst%3DJ.%2BE.%26aulast%3DVan%2BDer%2BHeijden%26aufirst%3DM.%2BS.%26aulast%3DGarzon%26aufirst%3DN.%26aulast%3DIbrahim%26aufirst%3DM.%26aulast%3DRaybold%26aufirst%3DB.%26aulast%3DLiaw%26aufirst%3DD.%26aulast%3DRutstein%26aufirst%3DM.%26aulast%3DGalsky%26aufirst%3DM.%2BD.%26atitle%3DENERGIZE%253A%2520A%2520Phase%2520III%2520Study%2520Of%2520Neoadjuvant%2520Chemotherapy%2520Alone%2520Or%2520With%2520Nivolumab%2520With%252FWithout%2520Linrodostat%2520Mesylate%2520For%2520Muscle-Invasive%2520Bladder%2520Cancer%26jtitle%3DFuture%2520Oncol.%26date%3D2020%26volume%3D16%26spage%3D4359%26epage%3D4368%26doi%3D10.2217%2Ffon-2019-0611" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lyssikatos, J. P.</span>; <span class="NLM_string-name">Liu, W.</span>; <span class="NLM_string-name">Siu, M.</span>; <span class="NLM_string-name">Estrada, A.</span>; <span class="NLM_string-name">Patel, S.</span>; <span class="NLM_string-name">Liang, G.</span>; <span class="NLM_string-name">Huestis, M.</span>; <span class="NLM_string-name">Chen, K.</span></span> <span> </span><span class="NLM_article-title">Pyrazole derivatives and uses thereof as inhibitors of dlk</span>. <span class="NLM_patent">WO 2015091889 A1</span>, June 25, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=J.+P.+Lyssikatos&author=W.+Liu&author=M.+Siu&author=A.+Estrada&author=S.+Patel&author=G.+Liang&author=M.+Huestis&author=K.+Chen&title=Pyrazole+derivatives+and+uses+thereof+as+inhibitors+of+dlk"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLyssikatos%26aufirst%3DJ.%2BP.%26atitle%3DPyrazole%2520derivatives%2520and%2520uses%2520thereof%2520as%2520inhibitors%2520of%2520dlk%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrada, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shore, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyssikatos, J.</span></span> <span> </span><span class="NLM_article-title">Mild And General One-Pot Reduction And Cyclization Of Aromatic And Heteroaromatic 2-Nitroamines To Bicyclic 2H-Imidazoles</span>. <i>Synlett</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>2010</i></span>,  <span class="NLM_fpage">2759</span>– <span class="NLM_lpage">2764</span>, <span class="refDoi"> DOI: 10.1055/s-0030-1259007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1055%2Fs-0030-1259007" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2010&publication_year=2010&pages=2759-2764&author=E.+Hananauthor=B.+Chanauthor=A.+Estradaauthor=D.+Shoreauthor=J.+Lyssikatos&title=Mild+And+General+One-Pot+Reduction+And+Cyclization+Of+Aromatic+And+Heteroaromatic+2-Nitroamines+To+Bicyclic+2H-Imidazoles&doi=10.1055%2Fs-0030-1259007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1055%2Fs-0030-1259007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0030-1259007%26sid%3Dliteratum%253Aachs%26aulast%3DHanan%26aufirst%3DE.%26aulast%3DChan%26aufirst%3DB.%26aulast%3DEstrada%26aufirst%3DA.%26aulast%3DShore%26aufirst%3DD.%26aulast%3DLyssikatos%26aufirst%3DJ.%26atitle%3DMild%2520And%2520General%2520One-Pot%2520Reduction%2520And%2520Cyclization%2520Of%2520Aromatic%2520And%2520Heteroaromatic%25202-Nitroamines%2520To%2520Bicyclic%25202H-Imidazoles%26jtitle%3DSynlett%26date%3D2010%26volume%3D2010%26spage%3D2759%26epage%3D2764%26doi%3D10.1055%2Fs-0030-1259007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ellman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, T. P.</span></span> <span> </span><span class="NLM_article-title">N-Tert-Butanesulfinyl Imines: Versatile Intermediates For The Asymmetric Synthesis Of Amines</span>. <i>Acc. Chem. Res.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">984</span>– <span class="NLM_lpage">995</span>, <span class="refDoi"> DOI: 10.1021/ar020066u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ar020066u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BD38XmtVShsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2002&pages=984-995&author=J.+A.+Ellmanauthor=T.+D.+Owensauthor=T.+P.+Tang&title=N-Tert-Butanesulfinyl+Imines%3A+Versatile+Intermediates+For+The+Asymmetric+Synthesis+Of+Amines&doi=10.1021%2Far020066u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">N-tert-Butanesulfinyl Imines: Versatile Intermediates for the Asymmetric Synthesis of Amines</span></div><div class="casAuthors">Ellman, Jonathan A.; Owens, Timothy D.; Tang, Tony P.</div><div class="citationInfo"><span class="NLM_cas:title">Accounts of Chemical Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">984-995</span>CODEN:
                <span class="NLM_cas:coden">ACHRE4</span>;
        ISSN:<span class="NLM_cas:issn">0001-4842</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  N-tert-Butanesulfinyl aldimines and ketimines are exceedingly versatile intermediates for the asym. synthesis of amines.  The N-tert-butanesulfinyl imines are prepd. in high yields by condensing enantiomerically pure tert-butanesulfinamide, which is readily available in either configuration, with a wide range of aldehydes and ketones.  The tert-butanesulfinyl group activates the imines for the addn. of many different classes of nucleophiles, serves as a powerful chiral directing group, and after nucleophilic addn. is readily cleaved by treatment of the product with acid.  A wide range of highly enantioenriched amines, including α-branched and α,α-dibranched amines, α- and β-amino acids, 1,2- and 1,3-amino alcs., and α-trifluoromethyl amines, are efficiently synthesized using this methodol.  In addn., N-tert-butanesulfinyl imine derivs. provide a new family of ligands for asym. catalysis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIvB8xHaLharVg90H21EOLACvtfcHk0liJA2ZK0lLsVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmtVShsb8%253D&md5=7eb60c0d6e186f6ac10c874f9b34989f</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1021%2Far020066u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Far020066u%26sid%3Dliteratum%253Aachs%26aulast%3DEllman%26aufirst%3DJ.%2BA.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26aulast%3DTang%26aufirst%3DT.%2BP.%26atitle%3DN-Tert-Butanesulfinyl%2520Imines%253A%2520Versatile%2520Intermediates%2520For%2520The%2520Asymmetric%2520Synthesis%2520Of%2520Amines%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D2002%26volume%3D35%26spage%3D984%26epage%3D995%26doi%3D10.1021%2Far020066u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoye, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffrey, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, F.</span></span> <span> </span><span class="NLM_article-title">Mosher Ester Analysis For The Determination Of Absolute Configuration Of Stereogenic (Chiral) Carbinol Carbons</span>. <i>Nat. Protoc.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">2451</span>– <span class="NLM_lpage">2458</span>, <span class="refDoi"> DOI: 10.1038/nprot.2007.354</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1038%2Fnprot.2007.354" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=17947986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFOksL3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=2451-2458&author=T.+R.+Hoyeauthor=C.+S.+Jeffreyauthor=F.+Shao&title=Mosher+Ester+Analysis+For+The+Determination+Of+Absolute+Configuration+Of+Stereogenic+%28Chiral%29+Carbinol+Carbons&doi=10.1038%2Fnprot.2007.354"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Mosher ester analysis for the determination of absolute configuration of stereogenic (chiral) carbinol carbons</span></div><div class="casAuthors">Hoye, Thomas R.; Jeffrey, Christopher S.; Shao, Feng</div><div class="citationInfo"><span class="NLM_cas:title">Nature Protocols</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2451-2458</span>CODEN:
                <span class="NLM_cas:coden">NPARDW</span>;
        ISSN:<span class="NLM_cas:issn">1750-2799</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">This protocol details the most commonly used NMR-based method for deducing the configuration of otherwise unknown stereogenic, secondary carbinol (alc.) centers (R1R2CHOH (or the analogous amines where OH is replaced by NH2)).  This 'Mosher ester anal.' relies on the fact that the protons in diastereomeric α-methoxy-α-trifluoromethylphenylacetic acid (MTPA) esters (i.e., those derived from conjugation of the carbinol under interrogation with MTPA) display different arrays of chem. shifts (δs) in their 1H NMR spectra.  The protocol consists of the following: (i) prepn. of each of the diastereomeric S- and R-MTPA esters and (ii) comparative (ΔδSR) anal. of the 1H NMR spectral data of these two esters.  By analyzing the sign of the difference in chem. shifts for a no. of analogous pairs of protons (the set of ΔδSR values) in the diastereomeric esters (or amides), the abs. configuration of the original carbinol (or amino) stereocenter can be reliably deduced.  A typical Mosher ester anal. requires approx. 4-6 h of active effort over a 1- to 2-d period.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsdQys4JRj4LVg90H21EOLACvtfcHk0liVRVrAjV54BQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFOksL3E&md5=741bb9fd8eb7c18c310196f298e5ea3f</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1038%2Fnprot.2007.354&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnprot.2007.354%26sid%3Dliteratum%253Aachs%26aulast%3DHoye%26aufirst%3DT.%2BR.%26aulast%3DJeffrey%26aufirst%3DC.%2BS.%26aulast%3DShao%26aufirst%3DF.%26atitle%3DMosher%2520Ester%2520Analysis%2520For%2520The%2520Determination%2520Of%2520Absolute%2520Configuration%2520Of%2520Stereogenic%2520%2528Chiral%2529%2520Carbinol%2520Carbons%26jtitle%3DNat.%2520Protoc.%26date%3D2007%26volume%3D2%26spage%3D2451%26epage%3D2458%26doi%3D10.1038%2Fnprot.2007.354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomiyama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirata, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayaishi, O.</span></span> <span> </span><span class="NLM_article-title">Indoleamine 2,3-Dioxygenase. Purification And Some Properties</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1978</span>,  <span class="NLM_volume"><i>253</i></span>,  <span class="NLM_fpage">4700</span>– <span class="NLM_lpage">4706</span>, <span class="refDoi"> DOI: 10.1016/s0021-9258(17)30447-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=10.1016%2FS0021-9258%2817%2930447-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=26687" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;key=1%3ACAS%3A528%3ADyaE1cXkvVKgtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=253&publication_year=1978&pages=4700-4706&author=T.+Shimizuauthor=S.+Nomiyamaauthor=F.+Hirataauthor=O.+Hayaishi&title=Indoleamine+2%2C3-Dioxygenase.+Purification+And+Some+Properties&doi=10.1016%2Fs0021-9258%2817%2930447-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Indoleamine 2,3-dioxygenase.  Purification and some properties</span></div><div class="casAuthors">Shimizu, Takao; Nomiyama, Sumitsugu; Hirata, Fusao; Hayaishi, Osamu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1978</span>),
    <span class="NLM_cas:volume">253</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4700-6</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">Indoleamine 2,3-dioxygenase (I) was purified from rabbit small intestine to apparent homogeneity as judged by polyacrylamide gel electrophoresis and anal. ultracentrifugation.  Native I was a monomeric protein of mol. wt. 41,000 with sedimentation coeff. of 3.45 S.  It had a relative abundance of hydrophobic amino acids and contained ∼5% carbohydrate by wt.  One mol I had 0.8 mol protoheme IX as a prosthetic group.  However, Cu was not detected in significant amt. and the ratio of Cu to heme was <0.03.  EPR spectra of the NO complex of Fe2+-I indicated that a N atom, possibly in an imidazole group, might be coordinated as the 5th ligand of the heme coenzyme.  A single enzyme protein catalyzed the oxygenative ring cleavage of D- and L-tryptophan, D- and L-5-hydroxytryptophan, tryptamine, and serotonin.  In addn. purified I had peroxidase activity with guaiacol and KI as H-donors, but not catalase activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB_vYru3V9SLVg90H21EOLACvtfcHk0liVRVrAjV54BQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1cXkvVKgtrc%253D&md5=5e0a989a09b1c8243ff2e79db390851f</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1016%2FS0021-9258%2817%2930447-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0021-9258%252817%252930447-7%26sid%3Dliteratum%253Aachs%26aulast%3DShimizu%26aufirst%3DT.%26aulast%3DNomiyama%26aufirst%3DS.%26aulast%3DHirata%26aufirst%3DF.%26aulast%3DHayaishi%26aufirst%3DO.%26atitle%3DIndoleamine%25202%252C3-Dioxygenase.%2520Purification%2520And%2520Some%2520Properties%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1978%26volume%3D253%26spage%3D4700%26epage%3D4706%26doi%3D10.1016%2Fs0021-9258%2817%2930447-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7M7D" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7M7D','PDB','7M7D'); return false;">PDB: 7M7D</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7B1O" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7B1O','PDB','7B1O'); return false;">PDB: 7B1O</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6AZW" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6AZW','PDB','6AZW'); return false;">PDB: 6AZW</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6V52" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6V52','PDB','6V52'); return false;">PDB: 6V52</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6WJY" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6WJY','PDB','6WJY'); return false;">PDB: 6WJY</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7M63" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7M63','PDB','7M63'); return false;">PDB: 7M63</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i92"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00679">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_65711"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00679?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00679</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Preparation of compounds 18–20, 23–61, and 63–69; full western blot; procedures for microsomal stability; CYP inhibition; plasma protein binding; hERG assays; X-ray crystallography; sequence alignment of the binding site of IDO1; representative HeLa cellular assay and viability curves for <b>22</b> and <b>62</b>; and LCMS traces for <b>17</b>, <b>17R</b>, <b>21</b>, <b>22</b>, <b>24</b>, <b>31</b>, <b>34</b>, <b>38</b>, <b>56</b>, <b>57</b>, <b>58</b>, <b>59</b>, and <b>62</b> (IACS-9779), <b>63</b>, <b>64</b>, <b>65</b>, and <b>70</b> (IACS-70099), <b>71</b> (IACS-70465), and <b>72</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00679/suppl_file/jm1c00679_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00679/suppl_file/jm1c00679_si_003.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00679/suppl_file/jm1c00679_si_001.pdf">jm1c00679_si_001.pdf (3.58 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00679/suppl_file/jm1c00679_si_003.csv">jm1c00679_si_003.csv (11.57 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.1c00679&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.1c00679%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.1c00679" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679965fcae2f3d2a","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
